,direction,relation,relex_relcos,sentence,term1,term2
0,IM CEFTRIAXONE treats URETHRAL OR RECTAL GONORRHEA,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
1,URETHRAL OR RECTAL GONORRHEA treats IM CEFTRIAXONE,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
2,IM CEFTRIAXONE treats URETHRAL OR RECTAL GONORRHEA,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
3,URETHRAL OR RECTAL GONORRHEA treats IM CEFTRIAXONE,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
4,IM CEFTRIAXONE treats URETHRAL OR RECTAL GONORRHEA,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
5,IM CEFTRIAXONE treats URETHRAL OR RECTAL GONORRHEA,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
6,IM CEFTRIAXONE treats URETHRAL OR RECTAL GONORRHEA,treats,1.0,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
7,no_relation,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
8,OSTEOSARCOMA diagnosis RETINOBLASTOMA,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
9,no_relation,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
10,no_relation,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
11,no_relation,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
12,no_relation,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
13,no_relation,diagnosis,0.5303300858899109,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
14,ALLERGY contraindicates NON ALLERGY,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
15,no_relation,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
16,no_relation,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
17,ALLERGY contraindicates NON ALLERGY,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
18,no_relation,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
19,no_relation,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
20,ALLERGY contraindicates NON ALLERGY,contraindicates,0.471404520791032,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
21,SALMETEROL treats EXERCISE INDUCED ASTHMA,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
22,SALMETEROL treats EXERCISE INDUCED ASTHMA,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
23,SALMETEROL treats EXERCISE INDUCED ASTHMA,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
24,SALMETEROL treats EXERCISE INDUCED ASTHMA,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
25,SALMETEROL treats EXERCISE INDUCED ASTHMA,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
26,SALMETEROL treats EXERCISE INDUCED ASTHMA,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
27,no_relation,treats,0.99654575824488,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
28,no_relation,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
29,SYNOPHRYS causes CORNELIA DE LANGE SYNDROME,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
30,CORNELIA DE LANGE SYNDROME causes SYNOPHRYS,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
31,CORNELIA DE LANGE SYNDROME causes SYNOPHRYS,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
32,no_relation,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
33,CORNELIA DE LANGE SYNDROME causes SYNOPHRYS,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
34,CORNELIA DE LANGE SYNDROME causes SYNOPHRYS,causes,0.8834522085987719,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
35,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
36,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
37,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
38,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
39,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
40,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
41,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
42,ESCHERICHIA COLI ENDOTOXIN causes ENDOTOXEMIA,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
43,no_relation,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
44,ESCHERICHIA COLI ENDOTOXIN causes ENDOTOXEMIA,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
45,ESCHERICHIA COLI ENDOTOXIN causes ENDOTOXEMIA,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
46,ESCHERICHIA COLI ENDOTOXIN causes ENDOTOXEMIA,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
47,ESCHERICHIA COLI ENDOTOXIN causes ENDOTOXEMIA,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
48,ESCHERICHIA COLI ENDOTOXIN causes ENDOTOXEMIA,causes,0.948683298050514,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
49,OSTEOARTHRITIS location JOINTS,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
50,no_relation,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
51,OSTEOARTHRITIS location JOINTS,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
52,no_relation,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
53,no_relation,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
54,OSTEOARTHRITIS location JOINTS,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
55,no_relation,location,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
56,PRINZMETAL ANGINA diagnosis ERGONOVINE,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
57,PRINZMETAL ANGINA diagnosis ERGONOVINE,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
58,ERGONOVINE diagnosis PRINZMETAL ANGINA,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
59,PRINZMETAL ANGINA diagnosis ERGONOVINE,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
60,ERGONOVINE diagnosis PRINZMETAL ANGINA,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
61,no_relation,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
62,PRINZMETAL ANGINA diagnosis ERGONOVINE,diagnosis,0.9237604307034007,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
63,SEIZURES causes STATUS EPILEPTICUS,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
64,SEIZURES causes STATUS EPILEPTICUS,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
65,no_relation,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
66,SEIZURES causes STATUS EPILEPTICUS,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
67,no_relation,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
68,no_relation,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
69,SEIZURES causes STATUS EPILEPTICUS,causes,0.577350269189626,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
70,no_relation,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
71,no_relation,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
72,no_relation,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
73,no_relation,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
74,no_relation,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
75,OSTEOARTHRITIS treats JOINTS,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
76,JOINTS treats OSTEOARTHRITIS,treats,0.404519917477945,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
77,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
78,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
79,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
80,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
81,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
82,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
83,PREDNISOLONE ACETATE treats POSTOPERATIVE INFLAMMATION,treats,0.964901281354015,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
84,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
85,no_relation,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
86,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
87,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
88,no_relation,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
89,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
90,no_relation,causes,0.412081691846067,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
91,LIVER causes HEPATOCELLULAR CARCINOMA,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
92,no_relation,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
93,no_relation,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
94,LIVER causes HEPATOCELLULAR CARCINOMA,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
95,no_relation,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
96,no_relation,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
97,no_relation,causes,0.707106781186547,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
98,BRONCHIAL CARCINOMA diagnosis HEMOPTYSIS,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
99,HEMOPTYSIS diagnosis BRONCHIAL CARCINOMA,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
100,BRONCHIAL CARCINOMA diagnosis HEMOPTYSIS,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
101,HEMOPTYSIS diagnosis BRONCHIAL CARCINOMA,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
102,no_relation,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
103,no_relation,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
104,BRONCHIAL CARCINOMA diagnosis HEMOPTYSIS,diagnosis,0.308606699924184,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
105,MYASTHENIA GRAVIS diagnosis INTRAVENOUS EDROPHONIUM CHLORIDE,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
106,MYASTHENIA GRAVIS diagnosis INTRAVENOUS EDROPHONIUM CHLORIDE,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
107,MYASTHENIA GRAVIS diagnosis INTRAVENOUS EDROPHONIUM CHLORIDE,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
108,INTRAVENOUS EDROPHONIUM CHLORIDE diagnosis MYASTHENIA GRAVIS,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
109,INTRAVENOUS EDROPHONIUM CHLORIDE diagnosis MYASTHENIA GRAVIS,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
110,MYASTHENIA GRAVIS diagnosis INTRAVENOUS EDROPHONIUM CHLORIDE,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
111,MYASTHENIA GRAVIS diagnosis INTRAVENOUS EDROPHONIUM CHLORIDE,diagnosis,1.0,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
112,OPIOID OVERDOSE causes FLUMAZENIL,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
113,no_relation,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
114,FLUMAZENIL causes OPIOID OVERDOSE,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
115,no_relation,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
116,no_relation,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
117,OPIOID OVERDOSE causes FLUMAZENIL,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
118,OPIOID OVERDOSE causes FLUMAZENIL,causes,0.442325868464691,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
119,CEFACLOR treats PHARYNGITIS,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
120,CEFACLOR treats PHARYNGITIS,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
121,CEFACLOR treats PHARYNGITIS,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
122,CEFACLOR treats PHARYNGITIS,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
123,PHARYNGITIS treats CEFACLOR,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
124,CEFACLOR treats PHARYNGITIS,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
125,CEFACLOR treats PHARYNGITIS,treats,0.9760921603577252,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
126,HYPERTENSION diagnosis SPONTANEOUSLY ELEVATED BP,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
127,HYPERTENSION diagnosis SPONTANEOUSLY ELEVATED BP,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
128,HYPERTENSION diagnosis SPONTANEOUSLY ELEVATED BP,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
129,HYPERTENSION diagnosis SPONTANEOUSLY ELEVATED BP,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
130,no_relation,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
131,SPONTANEOUSLY ELEVATED BP diagnosis HYPERTENSION,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
132,no_relation,diagnosis,0.480384461415261,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
133,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
134,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
135,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
136,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
137,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
138,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
139,ADALIMUMAB treats RHEUMATOID ARTHRITIS,treats,0.981980506061966,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
140,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
141,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
142,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
143,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
144,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
145,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
146,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.975900072948533,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
147,no_relation,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
148,no_relation,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
149,HEPATOCELLULAR CARCINOMA treats HYPERTHERMIA,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
150,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
151,no_relation,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
152,no_relation,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
153,no_relation,treats,0.8090398349558909,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
154,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
155,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
156,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
157,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
158,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
159,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
160,CLOZAPINE treats SCHIZOPHRENIA,treats,0.923380516876639,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
161,no_relation,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
162,ATROPINE treats BRADYCARDIA,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
163,ATROPINE treats BRADYCARDIA,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
164,ATROPINE treats BRADYCARDIA,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
165,ATROPINE treats BRADYCARDIA,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
166,no_relation,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
167,ATROPINE treats BRADYCARDIA,treats,0.948683298050514,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
168,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
169,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
170,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
171,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
172,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
173,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
174,METHENAMINE HIPPURATE treats SYMPTOMATIC URINARY TRACT INFECTION,treats,0.964763821237732,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
175,GLUCOSAMINE SULPHATE treats OSTEOARTHRITIS OF THE KNEE,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
176,GLUCOSAMINE SULPHATE treats OSTEOARTHRITIS OF THE KNEE,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
177,GLUCOSAMINE SULPHATE treats OSTEOARTHRITIS OF THE KNEE,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
178,GLUCOSAMINE SULPHATE treats OSTEOARTHRITIS OF THE KNEE,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
179,no_relation,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
180,GLUCOSAMINE SULPHATE treats OSTEOARTHRITIS OF THE KNEE,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
181,GLUCOSAMINE SULPHATE treats OSTEOARTHRITIS OF THE KNEE,treats,0.9918365981341758,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
182,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
183,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
184,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
185,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
186,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
187,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
188,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9950371902099888,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
189,no_relation,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
190,no_relation,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
191,no_relation,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
192,OSTEOARTHRITIS causes JOINTS,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
193,no_relation,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
194,no_relation,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
195,no_relation,causes,0.8090398349558909,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
196,no_relation,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
197,no_relation,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
198,ERGONOVINE treats PRINZMETAL ANGINA,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
199,no_relation,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
200,ERGONOVINE treats PRINZMETAL ANGINA,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
201,PRINZMETAL ANGINA treats ERGONOVINE,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
202,no_relation,treats,0.346410161513775,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
203,YERSINIA PESTIS causes PLAGUE,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
204,YERSINIA PESTIS causes PLAGUE,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
205,YERSINIA PESTIS causes PLAGUE,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
206,YERSINIA PESTIS causes PLAGUE,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
207,YERSINIA PESTIS causes PLAGUE,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
208,YERSINIA PESTIS causes PLAGUE,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
209,no_relation,causes,1.0,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
210,no_relation,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
211,no_relation,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
212,no_relation,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
213,no_relation,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
214,no_relation,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
215,ATOPIC DISEASES diagnosis ATOPIC DERMATITIS,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
216,no_relation,diagnosis,0.486664263392288,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
217,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
218,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
219,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
220,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
221,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
222,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
223,no_relation,treats,0.9897433186107868,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
224,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
225,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
226,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
227,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
228,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
229,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
230,FLUTAMIDE treats HIRSUTISM,treats,0.99654575824488,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
231,RIBOFLAVIN DEFICIENCY causes RIBOFLAVIN,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
232,RIBOFLAVIN causes RIBOFLAVIN DEFICIENCY,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
233,no_relation,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
234,no_relation,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
235,no_relation,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
236,RIBOFLAVIN causes RIBOFLAVIN DEFICIENCY,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
237,RIBOFLAVIN causes RIBOFLAVIN DEFICIENCY,causes,0.8090398349558909,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
238,no_relation,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
239,SPONTANEOUSLY ELEVATED BP causes HYPERTENSION,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
240,HYPERTENSION causes SPONTANEOUSLY ELEVATED BP,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
241,no_relation,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
242,SPONTANEOUSLY ELEVATED BP causes HYPERTENSION,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
243,SPONTANEOUSLY ELEVATED BP causes HYPERTENSION,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
244,HYPERTENSION causes SPONTANEOUSLY ELEVATED BP,causes,0.640512615220348,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
245,HYPERSENSITIVITY REACTION causes BEESTING ALLERGY,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
246,no_relation,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
247,BEESTING ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
248,no_relation,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
249,BEESTING ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
250,no_relation,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
251,no_relation,causes,0.9,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
252,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
253,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
254,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
255,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
256,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
257,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
258,IMIPRAMINE treats DEPRESSION,treats,0.8834522085987719,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
259,no_relation,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
260,no_relation,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
261,no_relation,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
262,CLOZAPINE causes SCHIZOPHRENIA,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
263,no_relation,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
264,CLOZAPINE causes SCHIZOPHRENIA,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
265,CLOZAPINE causes SCHIZOPHRENIA,causes,0.307793505625546,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
266,no_relation,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
267,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
268,HYPERTENSION treats PHEOCHROMOCYTOMA,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
269,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
270,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
271,no_relation,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
272,no_relation,treats,0.911684611677103,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
273,no_relation,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
274,no_relation,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
275,no_relation,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
276,TUBERCULIN SENSITIVITY causes TUBERCULOSIS,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
277,TUBERCULOSIS causes TUBERCULIN SENSITIVITY,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
278,TUBERCULOSIS causes TUBERCULIN SENSITIVITY,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
279,TUBERCULOSIS causes TUBERCULIN SENSITIVITY,causes,0.474341649025257,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
280,FERTILITY causes ENDOMETRIAL HYPERPLASIA,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
281,ENDOMETRIAL HYPERPLASIA causes FERTILITY,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
282,no_relation,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
283,no_relation,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
284,no_relation,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
285,no_relation,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
286,FERTILITY causes ENDOMETRIAL HYPERPLASIA,causes,0.787838597158335,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
287,no_relation,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
288,no_relation,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
289,INFLAMMATORY BOWEL DISEASE causes GASTROINTESTINAL TRACT,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
290,no_relation,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
291,no_relation,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
292,INFLAMMATORY BOWEL DISEASE causes GASTROINTESTINAL TRACT,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
293,no_relation,causes,0.538815906080325,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
294,PHARMACOLOGIC MYDRIASIS diagnosis TOPICAL PILOCARPINE,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
295,PHARMACOLOGIC MYDRIASIS diagnosis TOPICAL PILOCARPINE,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
296,PHARMACOLOGIC MYDRIASIS diagnosis TOPICAL PILOCARPINE,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
297,TOPICAL PILOCARPINE diagnosis PHARMACOLOGIC MYDRIASIS,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
298,PHARMACOLOGIC MYDRIASIS diagnosis TOPICAL PILOCARPINE,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
299,PHARMACOLOGIC MYDRIASIS diagnosis TOPICAL PILOCARPINE,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
300,no_relation,diagnosis,0.845154254728516,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
301,MYOCLONIC SEIZURE causes KINDLED SEIZURES,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
302,MYOCLONIC SEIZURE causes KINDLED SEIZURES,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
303,MYOCLONIC SEIZURE causes KINDLED SEIZURES,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
304,MYOCLONIC SEIZURE causes KINDLED SEIZURES,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
305,KINDLED SEIZURES causes MYOCLONIC SEIZURE,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
306,MYOCLONIC SEIZURE causes KINDLED SEIZURES,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
307,no_relation,causes,0.845154254728516,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
308,OVARIES location OVARIAN ADENOCARCINOMA,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
309,no_relation,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
310,OVARIES location OVARIAN ADENOCARCINOMA,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
311,OVARIES location OVARIAN ADENOCARCINOMA,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
312,OVARIES location OVARIAN ADENOCARCINOMA,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
313,no_relation,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
314,no_relation,location,0.944911182523068,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
315,SKIN location PERSPIRATION,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
316,SKIN location PERSPIRATION,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
317,SKIN location PERSPIRATION,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
318,PERSPIRATION location SKIN,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
319,SKIN location PERSPIRATION,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
320,SKIN location PERSPIRATION,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
321,SKIN location PERSPIRATION,location,0.980196058819607,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
322,SMALL JOINTS OF THE HANDS location ARTHRITIS,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
323,ARTHRITIS location SMALL JOINTS OF THE HANDS,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
324,SMALL JOINTS OF THE HANDS location ARTHRITIS,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
325,SMALL JOINTS OF THE HANDS location ARTHRITIS,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
326,SMALL JOINTS OF THE HANDS location ARTHRITIS,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
327,SMALL JOINTS OF THE HANDS location ARTHRITIS,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
328,no_relation,location,0.8728715609439692,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
329,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
330,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
331,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
332,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
333,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
334,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
335,20 WEEK BINGE PROGRAMME treats BINGE EATING,treats,0.848528137423857,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
336,BONE location OSTEOMYELITIS,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
337,BONE location OSTEOMYELITIS,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
338,OSTEOMYELITIS location BONE,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
339,BONE location OSTEOMYELITIS,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
340,OSTEOMYELITIS location BONE,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
341,BONE location OSTEOMYELITIS,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
342,BONE location OSTEOMYELITIS,location,0.993883734673619,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
343,JOINT location JOINT EFFUSION,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
344,JOINT location JOINT EFFUSION,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
345,JOINT location JOINT EFFUSION,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
346,JOINT location JOINT EFFUSION,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
347,JOINT location JOINT EFFUSION,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
348,JOINT location JOINT EFFUSION,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
349,JOINT EFFUSION location JOINT,location,0.7947194142390258,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
350,PV causes GASTROINTESTINAL BLEEDING,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
351,PV causes GASTROINTESTINAL BLEEDING,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
352,PV causes GASTROINTESTINAL BLEEDING,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
353,no_relation,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
354,PV causes GASTROINTESTINAL BLEEDING,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
355,no_relation,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
356,PV causes GASTROINTESTINAL BLEEDING,causes,0.617213399848368,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
357,no_relation,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
358,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
359,no_relation,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
360,no_relation,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
361,PHARMACOLOGIC MYDRIASIS treats TOPICAL PILOCARPINE,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
362,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
363,no_relation,treats,0.50709255283711,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
364,ANGINA causes PAIN,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
365,PAIN causes ANGINA,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
366,PAIN causes ANGINA,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
367,no_relation,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
368,PAIN causes ANGINA,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
369,no_relation,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
370,ANGINA causes PAIN,causes,0.896258159530272,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
371,OSTEOARTHRITIS treats NAPROXEN,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
372,NAPROXEN treats OSTEOARTHRITIS,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
373,NAPROXEN treats OSTEOARTHRITIS,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
374,NAPROXEN treats OSTEOARTHRITIS,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
375,NAPROXEN treats OSTEOARTHRITIS,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
376,NAPROXEN treats OSTEOARTHRITIS,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
377,NAPROXEN treats OSTEOARTHRITIS,treats,0.9901475429766742,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
378,METHACHOLINE causes BRONCHIAL HYPERREACTIVITY,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
379,BRONCHIAL HYPERREACTIVITY causes METHACHOLINE,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
380,METHACHOLINE causes BRONCHIAL HYPERREACTIVITY,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
381,no_relation,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
382,BRONCHIAL HYPERREACTIVITY causes METHACHOLINE,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
383,no_relation,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
384,no_relation,causes,0.8944271909999159,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
385,no_relation,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
386,PRIMARY SKIN DISEASES causes PSORIASIS,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
387,no_relation,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
388,no_relation,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
389,PRIMARY SKIN DISEASES causes PSORIASIS,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
390,no_relation,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
391,no_relation,causes,0.342997170285018,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
392,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
393,no_relation,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
394,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
395,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
396,NEUROLOGICAL SYMPTOMS causes PRIMARY MENINGEAL MELANOMA,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
397,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
398,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,causes,0.970142500145332,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
399,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
400,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
401,OBSESSIVE COMPULSIVE DISORDER treats FLUOXETINE,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
402,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
403,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
404,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
405,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.987878339907213,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
406,ANTIANGINAL EFFICACY diagnosis ANGINA DIARES,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
407,ANTIANGINAL EFFICACY diagnosis ANGINA DIARES,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
408,no_relation,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
409,ANTIANGINAL EFFICACY diagnosis ANGINA DIARES,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
410,no_relation,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
411,ANTIANGINAL EFFICACY diagnosis ANGINA DIARES,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
412,no_relation,diagnosis,0.845154254728516,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
413,no_relation,causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
414,NEUROENDOCRINE DIFFERENTIATION causes LUNG CARCINOMAS (SCLC),causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
415,no_relation,causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
416,no_relation,causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
417,no_relation,causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
418,LUNG CARCINOMAS (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
419,no_relation,causes,0.5962847939999439,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
420,GASTROINTESTINAL TRACT location INFLAMMATORY BOWEL DISEASE,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
421,GASTROINTESTINAL TRACT location INFLAMMATORY BOWEL DISEASE,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
422,GASTROINTESTINAL TRACT location INFLAMMATORY BOWEL DISEASE,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
423,GASTROINTESTINAL TRACT location INFLAMMATORY BOWEL DISEASE,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
424,GASTROINTESTINAL TRACT location INFLAMMATORY BOWEL DISEASE,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
425,INFLAMMATORY BOWEL DISEASE location GASTROINTESTINAL TRACT,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
426,INFLAMMATORY BOWEL DISEASE location GASTROINTESTINAL TRACT,location,0.7184212081071,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
427,CORNEAL NERVES AND HYPERTENSION causes PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
428,CORNEAL NERVES AND HYPERTENSION causes PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
429,no_relation,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
430,no_relation,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
431,no_relation,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
432,CORNEAL NERVES AND HYPERTENSION causes PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
433,no_relation,causes,0.8219949365267859,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
434,PROBIOTIC BACTERIA treats CARIES,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
435,no_relation,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
436,PROBIOTIC BACTERIA treats CARIES,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
437,PROBIOTIC BACTERIA treats CARIES,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
438,no_relation,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
439,no_relation,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
440,PROBIOTIC BACTERIA treats CARIES,treats,0.625543242171224,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
441,CELIAC DISEASE treats GLUTEN FREE DIET,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
442,CELIAC DISEASE treats GLUTEN FREE DIET,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
443,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
444,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
445,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
446,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
447,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.984731927834662,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
448,FLUORIDE causes DENTAL FLUOROSIS,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
449,DENTAL FLUOROSIS causes FLUORIDE,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
450,FLUORIDE causes DENTAL FLUOROSIS,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
451,FLUORIDE causes DENTAL FLUOROSIS,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
452,FLUORIDE causes DENTAL FLUOROSIS,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
453,no_relation,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
454,FLUORIDE causes DENTAL FLUOROSIS,causes,0.898026510133875,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
455,HENOCH SCHONLEIN PURPURA causes NONTHROMBOCYTIC PURPURA,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
456,no_relation,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
457,HENOCH SCHONLEIN PURPURA causes NONTHROMBOCYTIC PURPURA,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
458,no_relation,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
459,HENOCH SCHONLEIN PURPURA causes NONTHROMBOCYTIC PURPURA,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
460,NONTHROMBOCYTIC PURPURA causes HENOCH SCHONLEIN PURPURA,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
461,no_relation,causes,0.919145030018058,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
462,no_relation,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
463,SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
464,no_relation,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
465,SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
466,no_relation,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
467,no_relation,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
468,no_relation,causes,0.320256307610174,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
469,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
470,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
471,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
472,no_relation,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
473,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
474,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
475,no_relation,causes,0.774596669241483,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
476,ENDOMETRIAL CARCINOMA causes METRORRHAGIA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
477,ENDOMETRIAL CARCINOMA causes METRORRHAGIA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
478,ENDOMETRIAL CARCINOMA causes METRORRHAGIA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
479,METRORRHAGIA causes ENDOMETRIAL CARCINOMA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
480,ENDOMETRIAL CARCINOMA causes METRORRHAGIA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
481,ENDOMETRIAL CARCINOMA causes METRORRHAGIA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
482,ENDOMETRIAL CARCINOMA causes METRORRHAGIA,causes,0.98058067569092,"The simple hyperplasia predominates in the perimenopause, while the ENDOMETRIAL CARCINOMA was the most frequent cause for METRORRHAGIA in the postmenopausal women.",METRORRHAGIA,ENDOMETRIAL CARCINOMA
483,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
484,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
485,ACUTE EMESIS treats ONDANSETRON,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
486,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
487,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
488,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
489,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
490,DEFICIENCY causes PROTEIN CALORIE MALNUTRITION,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
491,PROTEIN CALORIE MALNUTRITION causes DEFICIENCY,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
492,no_relation,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
493,no_relation,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
494,DEFICIENCY causes PROTEIN CALORIE MALNUTRITION,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
495,PROTEIN CALORIE MALNUTRITION causes DEFICIENCY,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
496,DEFICIENCY causes PROTEIN CALORIE MALNUTRITION,causes,0.911684611677103,"The types of malnutrition caused by DEFICIENCY and the most frequently encountered in the developing countries are PROTEIN CALORIE MALNUTRITION avitaminoses, and mineral and iron deficiencies.",PROTEIN CALORIE MALNUTRITION,DEFICIENCY
497,ALLERGIC REACTIONS causes HYPERSENSITIVITY,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
498,HYPERSENSITIVITY causes ALLERGIC REACTIONS,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
499,ALLERGIC REACTIONS causes HYPERSENSITIVITY,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
500,no_relation,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
501,HYPERSENSITIVITY causes ALLERGIC REACTIONS,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
502,HYPERSENSITIVITY causes ALLERGIC REACTIONS,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
503,ALLERGIC REACTIONS causes HYPERSENSITIVITY,causes,0.609994281330419,A combination of various kinds of ALLERGIC REACTIONS of both the specific immediate type and of the local reaction of HYPERSENSITIVITY of the slow type plays its role in the development of acute appendicitis.,HYPERSENSITIVITY,ALLERGIC REACTIONS
504,POSTOPERATIVE PAIN treats FENTANYL,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
505,FENTANYL treats POSTOPERATIVE PAIN,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
506,FENTANYL treats POSTOPERATIVE PAIN,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
507,no_relation,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
508,FENTANYL treats POSTOPERATIVE PAIN,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
509,no_relation,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
510,FENTANYL treats POSTOPERATIVE PAIN,treats,0.8838834764831841,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of POSTOPERATIVE PAIN: a double blind comparison of FENTANYL and placebo systems.",POSTOPERATIVE PAIN,FENTANYL
511,TUBERCULIN TESTING diagnosis TUBERCULOSIS,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
512,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
513,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
514,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
515,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
516,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
517,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9594032236002472,TUBERCULOSIS was excluded by TUBERCULIN TESTING and bronchoalveolar lavage in both cases.,TUBERCULOSIS,TUBERCULIN TESTING
518,RESPIRATORY ALKALOSIS causes MECHANICALLY INDUCED HYPERVENTILATION,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
519,MECHANICALLY INDUCED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
520,MECHANICALLY INDUCED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
521,MECHANICALLY INDUCED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
522,RESPIRATORY ALKALOSIS causes MECHANICALLY INDUCED HYPERVENTILATION,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
523,MECHANICALLY INDUCED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
524,no_relation,causes,0.643267520902677,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
525,DEPRESSION treats DOXEPIN,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
526,DEPRESSION treats DOXEPIN,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
527,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
528,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
529,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
530,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
531,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
532,no_relation,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
533,HEPATOCELLULAR CARCINOMA diagnosis ASCITES ALPHA FETOPROTEIN,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
534,HEPATOCELLULAR CARCINOMA diagnosis ASCITES ALPHA FETOPROTEIN,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
535,no_relation,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
536,no_relation,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
537,no_relation,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
538,HEPATOCELLULAR CARCINOMA diagnosis ASCITES ALPHA FETOPROTEIN,diagnosis,0.34815531191139604,Serum or ASCITES ALPHA FETOPROTEIN (AFP) from patients with HEPATOCELLULAR CARCINOMA and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA A) or of erythroagglutinating phytohemagglutinin (E PHA) and Allomyrina dichotoma lectin (allo A.,ASCITES ALPHA FETOPROTEIN,HEPATOCELLULAR CARCINOMA
539,ASCITES causes SUPERIMPOSED HEPATOCELLULAR CARCINOMA,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
540,ASCITES causes SUPERIMPOSED HEPATOCELLULAR CARCINOMA,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
541,no_relation,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
542,no_relation,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
543,no_relation,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
544,no_relation,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
545,no_relation,causes,0.6488856845230501,Sixteen cirrhotic patients with SUPERIMPOSED HEPATOCELLULAR CARCINOMA in whom ASCITES was of uncertain etiology were considered separately.,ASCITES,SUPERIMPOSED HEPATOCELLULAR CARCINOMA
546,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
547,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
548,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
549,no_relation,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
550,no_relation,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
551,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
552,no_relation,treats,0.9901475429766742,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE against HYPERTENSION was evaluated in 36 patients (26 men and 10 women) between 33 68 years old.,HYPERTENSION,HYDROCHLOROTHIAZIDE
553,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
554,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
555,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
556,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
557,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
558,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
559,CYTARABINE treats LEUKEMIA,treats,0.98058067569092,Eleven patients with LEUKEMIA refractory to conventional therapy were treated with high doses of CYTARABINE (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,LEUKEMIA,CYTARABINE
560,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
561,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
562,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
563,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
564,no_relation,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
565,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
566,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.938314863256836,The authors report a case of PHEOCHROMOCYTOMA revealed by a de novo appeared HYPERTENSION in a young female patient at her 3rd trimester of pregnancy.,HYPERTENSION,PHEOCHROMOCYTOMA
567,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
568,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
569,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
570,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
571,METASTATIC MALIGNANT MELANOMA treats DACARBAZINE,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
572,no_relation,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
573,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8888888888888891,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
574,TUBERCULOSIS treats TUBERCULIN,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
575,TUBERCULOSIS treats TUBERCULIN,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
576,TUBERCULIN treats TUBERCULOSIS,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
577,TUBERCULIN treats TUBERCULOSIS,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
578,TUBERCULIN treats TUBERCULOSIS,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
579,no_relation,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
580,no_relation,treats,0.462910049886276,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
581,TYPE I ALLERGIC REACTIONS causes VERNAL KERATOCONJUNCTIVITIS,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
582,VERNAL KERATOCONJUNCTIVITIS causes TYPE I ALLERGIC REACTIONS,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
583,no_relation,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
584,TYPE I ALLERGIC REACTIONS causes VERNAL KERATOCONJUNCTIVITIS,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
585,TYPE I ALLERGIC REACTIONS causes VERNAL KERATOCONJUNCTIVITIS,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
586,no_relation,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
587,VERNAL KERATOCONJUNCTIVITIS causes TYPE I ALLERGIC REACTIONS,causes,0.493196961916072,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
588,ALLERGY causes ALLERGIC ASTHMA,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
589,ALLERGY causes ALLERGIC ASTHMA,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
590,ALLERGY causes ALLERGIC ASTHMA,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
591,no_relation,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
592,ALLERGY causes ALLERGIC ASTHMA,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
593,no_relation,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
594,ALLERGIC ASTHMA causes ALLERGY,causes,0.8677218312746251,"In many aspects, respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent the hallmarks of ALLERGY",ALLERGIC ASTHMA,ALLERGY
595,RESPIRATORY ALKALOSIS treats MECHANICALLY INDUCED HYPERVENTILATION,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
596,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
597,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
598,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
599,no_relation,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
600,no_relation,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
601,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
602,PHEOCHROMOCYTOMA causes MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
603,no_relation,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
604,PHEOCHROMOCYTOMA causes MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
605,no_relation,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
606,PHEOCHROMOCYTOMA causes MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
607,no_relation,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
608,no_relation,causes,0.36115755925730697,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
609,IN SITU (DCIS) location MICROCALCIFICATIONS,location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
610,IN SITU (DCIS) location MICROCALCIFICATIONS,location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
611,no_relation,location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
612,no_relation,location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
613,no_relation,location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
614,no_relation,location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
615,MICROCALCIFICATIONS location IN SITU (DCIS),location,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
616,HAEMOPHILIA A causes FACTOR VIII GENE,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
617,FACTOR VIII GENE causes HAEMOPHILIA A,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
618,FACTOR VIII GENE causes HAEMOPHILIA A,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
619,FACTOR VIII GENE causes HAEMOPHILIA A,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
620,FACTOR VIII GENE causes HAEMOPHILIA A,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
621,FACTOR VIII GENE causes HAEMOPHILIA A,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
622,no_relation,causes,0.875,Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the FACTOR VIII GENE the recent description of X chromosome inversions as a cause of severe HAEMOPHILIA A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.,HAEMOPHILIA A,FACTOR VIII GENE
623,BONE MARROW causes MYELODYSPLASTIC SYNDROME,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
624,no_relation,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
625,no_relation,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
626,no_relation,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
627,no_relation,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
628,MYELODYSPLASTIC SYNDROME causes BONE MARROW,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
629,no_relation,causes,0.666666666666667,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
630,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
631,no_relation,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
632,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
633,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
634,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
635,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
636,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.875,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
637,(IODINE AND TROPOMYOSINE ALLERGY causes ALLERGIC REACTIONS,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
638,(IODINE AND TROPOMYOSINE ALLERGY causes ALLERGIC REACTIONS,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
639,(IODINE AND TROPOMYOSINE ALLERGY causes ALLERGIC REACTIONS,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
640,ALLERGIC REACTIONS causes (IODINE AND TROPOMYOSINE ALLERGY,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
641,(IODINE AND TROPOMYOSINE ALLERGY causes ALLERGIC REACTIONS,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
642,(IODINE AND TROPOMYOSINE ALLERGY causes ALLERGIC REACTIONS,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
643,(IODINE AND TROPOMYOSINE ALLERGY causes ALLERGIC REACTIONS,causes,0.995893206467704,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, ALLERGIC REACTIONS caused by iodine containing chemicals (IODINE AND TROPOMYOSINE ALLERGY",(IODINE AND TROPOMYOSINE ALLERGY,ALLERGIC REACTIONS
644,no_relation,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
645,EPITHELIAL OVARIAN CANCER causes OVARIES,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
646,OVARIES causes EPITHELIAL OVARIAN CANCER,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
647,no_relation,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
648,OVARIES causes EPITHELIAL OVARIAN CANCER,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
649,no_relation,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
650,no_relation,causes,0.34188172937891403,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
651,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
652,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
653,POSTOPERATIVE HYPERTENSION causes PHEOCHROMOCYTOMA RESECTION,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
654,POSTOPERATIVE HYPERTENSION causes PHEOCHROMOCYTOMA RESECTION,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
655,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
656,no_relation,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
657,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.749268649265355,"? According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
658,ALOPECIA AREATA causes HAIR LOSS,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
659,no_relation,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
660,ALOPECIA AREATA causes HAIR LOSS,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
661,ALOPECIA AREATA causes HAIR LOSS,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
662,ALOPECIA AREATA causes HAIR LOSS,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
663,ALOPECIA AREATA causes HAIR LOSS,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
664,no_relation,causes,0.979957887012223,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
665,S TYPHI causes ENTERIC FEVER,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
666,S TYPHI causes ENTERIC FEVER,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
667,ENTERIC FEVER causes S TYPHI,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
668,S TYPHI causes ENTERIC FEVER,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
669,no_relation,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
670,S TYPHI causes ENTERIC FEVER,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
671,ENTERIC FEVER causes S TYPHI,causes,0.650944554904119,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
672,JOINT location SEPTIC ARTHRITIS,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
673,JOINT location SEPTIC ARTHRITIS,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
674,no_relation,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
675,JOINT location SEPTIC ARTHRITIS,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
676,SEPTIC ARTHRITIS location JOINT,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
677,SEPTIC ARTHRITIS location JOINT,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
678,no_relation,location,0.919145030018058,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
679,PHEOCHROMOCYTOMA causes HEADACHE,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
680,PHEOCHROMOCYTOMA causes HEADACHE,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
681,PHEOCHROMOCYTOMA causes HEADACHE,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
682,PHEOCHROMOCYTOMA causes HEADACHE,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
683,no_relation,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
684,PHEOCHROMOCYTOMA causes HEADACHE,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
685,PHEOCHROMOCYTOMA causes HEADACHE,causes,0.90913729009699,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
686,no_relation,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
687,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
688,no_relation,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
689,no_relation,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
690,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
691,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
692,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
693,HYPOTHYROIDISM diagnosis THYROXIN,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
694,HYPOTHYROIDISM diagnosis THYROXIN,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
695,no_relation,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
696,THYROXIN diagnosis HYPOTHYROIDISM,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
697,THYROXIN diagnosis HYPOTHYROIDISM,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
698,THYROXIN diagnosis HYPOTHYROIDISM,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
699,HYPOTHYROIDISM diagnosis THYROXIN,diagnosis,0.589767824619588,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
700,HEADACHE causes MIGRAINE,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
701,no_relation,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
702,MIGRAINE causes HEADACHE,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
703,no_relation,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
704,MIGRAINE causes HEADACHE,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
705,no_relation,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
706,HEADACHE causes MIGRAINE,causes,0.5656854249492379,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
707,THYROXIN causes HYPOTHYROIDISM,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
708,THYROXIN causes HYPOTHYROIDISM,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
709,no_relation,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
710,no_relation,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
711,THYROXIN causes HYPOTHYROIDISM,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
712,no_relation,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
713,no_relation,causes,0.737209780774486,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
714,GANGLIOGLIOMA causes SEIZURES,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
715,GANGLIOGLIOMA causes SEIZURES,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
716,GANGLIOGLIOMA causes SEIZURES,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
717,no_relation,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
718,GANGLIOGLIOMA causes SEIZURES,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
719,no_relation,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
720,GANGLIOGLIOMA causes SEIZURES,causes,0.9000703207408192,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
721,TOBRAMYCIN 03%/LOTEPREDNOL 05% treats TOTAL OCULAR INFLAMMATION,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
722,no_relation,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
723,TOBRAMYCIN 03%/LOTEPREDNOL 05% treats TOTAL OCULAR INFLAMMATION,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
724,TOBRAMYCIN 03%/LOTEPREDNOL 05% treats TOTAL OCULAR INFLAMMATION,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
725,no_relation,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
726,no_relation,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
727,TOBRAMYCIN 03%/LOTEPREDNOL 05% treats TOTAL OCULAR INFLAMMATION,treats,0.848874687627165,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
728,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE treats INFLAMMATION,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
729,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE treats INFLAMMATION,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
730,INFLAMMATION treats ORAL PREDNISONE AND CYCLOPHOSPHAMIDE,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
731,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE treats INFLAMMATION,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
732,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE treats INFLAMMATION,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
733,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE treats INFLAMMATION,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
734,no_relation,treats,0.977355554850442,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
735,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
736,POSTMENOPAUSAL OSTEOPOROSIS treats SUBCUTANEOUS TERIPARATIDE,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
737,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
738,POSTMENOPAUSAL OSTEOPOROSIS treats SUBCUTANEOUS TERIPARATIDE,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
739,no_relation,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
740,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
741,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
742,MASTOCYTOSIS causes HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
743,MASTOCYTOSIS causes HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
744,HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH causes MASTOCYTOSIS,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
745,MASTOCYTOSIS causes HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
746,HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH causes MASTOCYTOSIS,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
747,MASTOCYTOSIS causes HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
748,no_relation,causes,0.9282791216329142,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
749,HUMAN BRAIN TISSUE treats SUSPECTED OR ATYPICAL PRION DISEASE,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
750,no_relation,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
751,no_relation,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
752,no_relation,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
753,no_relation,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
754,HUMAN BRAIN TISSUE treats SUSPECTED OR ATYPICAL PRION DISEASE,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
755,no_relation,treats,0.4200840252084029,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
756,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL TEST,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
757,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL TEST,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
758,no_relation,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
759,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL TEST,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
760,no_relation,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
761,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL TEST,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
762,no_relation,diagnosis,0.956182887467515,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
763,no_relation,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
764,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
765,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
766,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
767,no_relation,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
768,no_relation,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
769,no_relation,treats,0.609994281330419,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
770,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
771,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
772,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
773,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
774,no_relation,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
775,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
776,VASOVAGAL SYNCOPE diagnosis ISOPROTERENOL,diagnosis,0.9931270663228408,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
777,NORMAL PALMAR SKIN location PALMAR LICHEN NITIDUS,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
778,PALMAR LICHEN NITIDUS location NORMAL PALMAR SKIN,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
779,no_relation,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
780,NORMAL PALMAR SKIN location PALMAR LICHEN NITIDUS,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
781,NORMAL PALMAR SKIN location PALMAR LICHEN NITIDUS,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
782,no_relation,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
783,PALMAR LICHEN NITIDUS location NORMAL PALMAR SKIN,location,0.3779644730092271,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
784,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
785,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
786,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
787,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
788,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
789,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
790,HUMAN BRAIN TISSUE location SUSPECTED OR ATYPICAL PRION DISEASE,location,0.8401680504168059,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
791,DRUG causes ADVERSE DRUG REACTIONS,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
792,ADVERSE DRUG REACTIONS causes DRUG,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
793,no_relation,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
794,DRUG causes ADVERSE DRUG REACTIONS,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
795,no_relation,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
796,DRUG causes ADVERSE DRUG REACTIONS,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
797,no_relation,causes,0.629940788348712,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
798,HYPERTENSION treats DOXAZOSIN,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
799,no_relation,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
800,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
801,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
802,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
803,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
804,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
805,no_relation,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
806,no_relation,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
807,no_relation,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
808,no_relation,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
809,no_relation,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
810,TYPE 1 DIABETES causes INSULIN PEPTIDE B9 23,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
811,no_relation,causes,0.375,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
812,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
813,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
814,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
815,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
816,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
817,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
818,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
819,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
820,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
821,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
822,no_relation,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
823,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
824,PARKINSON'S SYNDROME treats L DOPA WITH PERIPHERAL DECARBOXYLASE,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
825,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
826,LUNGS location LUNG CANCER,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
827,LUNGS location LUNG CANCER,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
828,LUNGS location LUNG CANCER,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
829,no_relation,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
830,no_relation,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
831,LUNG CANCER location LUNGS,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
832,LUNGS location LUNG CANCER,location,0.8164965809277259,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
833,no_relation,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
834,SEVERE SUSTAINED HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
835,SEVERE SUSTAINED HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
836,no_relation,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
837,no_relation,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
838,no_relation,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
839,SEVERE SUSTAINED HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.762000762001143,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
840,DENTAL CARIES diagnosis SODIUM FLUORIDE,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
841,DENTAL CARIES diagnosis SODIUM FLUORIDE,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
842,SODIUM FLUORIDE diagnosis DENTAL CARIES,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
843,DENTAL CARIES diagnosis SODIUM FLUORIDE,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
844,SODIUM FLUORIDE diagnosis DENTAL CARIES,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
845,SODIUM FLUORIDE diagnosis DENTAL CARIES,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
846,no_relation,diagnosis,0.707106781186547,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
847,GLIOBLASTOMA MULTIFORME diagnosis MICROVASCULAR PROLIFERATION,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
848,MICROVASCULAR PROLIFERATION diagnosis GLIOBLASTOMA MULTIFORME,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
849,MICROVASCULAR PROLIFERATION diagnosis GLIOBLASTOMA MULTIFORME,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
850,MICROVASCULAR PROLIFERATION diagnosis GLIOBLASTOMA MULTIFORME,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
851,GLIOBLASTOMA MULTIFORME diagnosis MICROVASCULAR PROLIFERATION,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
852,GLIOBLASTOMA MULTIFORME diagnosis MICROVASCULAR PROLIFERATION,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
853,GLIOBLASTOMA MULTIFORME diagnosis MICROVASCULAR PROLIFERATION,diagnosis,0.6,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
854,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
855,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
856,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
857,SEIZURE treats EPILEPSY,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
858,SEIZURE treats EPILEPSY,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
859,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
860,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
861,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
862,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
863,BENIGN TERTIAN MALARIA treats PRIMAQUINE,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
864,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
865,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
866,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
867,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
868,no_relation,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
869,EPILEPSY causes SEIZURE,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
870,no_relation,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
871,EPILEPSY causes SEIZURE,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
872,EPILEPSY causes SEIZURE,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
873,SEIZURE causes EPILEPSY,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
874,no_relation,causes,0.918558653543692,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
875,no_relation,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
876,STOMACH causes GASTRIC CANCER,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
877,GASTRIC CANCER causes STOMACH,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
878,no_relation,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
879,no_relation,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
880,no_relation,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
881,no_relation,causes,0.4850712500726661,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
882,THROMBOCYTOPENIA diagnosis IDIOPATHIC THROMBOCYTOPENIC PURPURA,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
883,IDIOPATHIC THROMBOCYTOPENIC PURPURA diagnosis THROMBOCYTOPENIA,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
884,IDIOPATHIC THROMBOCYTOPENIC PURPURA diagnosis THROMBOCYTOPENIA,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
885,THROMBOCYTOPENIA diagnosis IDIOPATHIC THROMBOCYTOPENIC PURPURA,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
886,no_relation,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
887,THROMBOCYTOPENIA diagnosis IDIOPATHIC THROMBOCYTOPENIC PURPURA,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
888,IDIOPATHIC THROMBOCYTOPENIC PURPURA diagnosis THROMBOCYTOPENIA,diagnosis,0.458831467741123,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
889,HIGH GRADE DYSPLASIA location TUBULOVILLOUS ADENOMA,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
890,TUBULOVILLOUS ADENOMA location HIGH GRADE DYSPLASIA,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
891,HIGH GRADE DYSPLASIA location TUBULOVILLOUS ADENOMA,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
892,no_relation,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
893,TUBULOVILLOUS ADENOMA location HIGH GRADE DYSPLASIA,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
894,TUBULOVILLOUS ADENOMA location HIGH GRADE DYSPLASIA,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
895,no_relation,location,0.583459965991578,"A right hemicolectomy was performed, which revealed a TUBULOVILLOUS ADENOMA with HIGH GRADE DYSPLASIA located in the ascending colon, and a diffuse ischemic colitis.",HIGH GRADE DYSPLASIA,TUBULOVILLOUS ADENOMA
896,no_relation,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
897,no_relation,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
898,ISCHEMIA causes VESSELS,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
899,ISCHEMIA causes VESSELS,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
900,no_relation,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
901,no_relation,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
902,no_relation,causes,0.904194430179465,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
903,ACUTE PROMYELOCYTIC LEUKEMIA causes DISSEMINATED INTRAVASCULAR COAGULATION,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
904,no_relation,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
905,no_relation,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
906,ACUTE PROMYELOCYTIC LEUKEMIA causes DISSEMINATED INTRAVASCULAR COAGULATION,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
907,DISSEMINATED INTRAVASCULAR COAGULATION causes ACUTE PROMYELOCYTIC LEUKEMIA,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
908,ACUTE PROMYELOCYTIC LEUKEMIA causes DISSEMINATED INTRAVASCULAR COAGULATION,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
909,no_relation,causes,0.911684611677103,"Higuchi T, Shimizu T, Mori H, et al: Coagulation patterns of DISSEMINATED INTRAVASCULAR COAGULATION in ACUTE PROMYELOCYTIC LEUKEMIA",DISSEMINATED INTRAVASCULAR COAGULATION,ACUTE PROMYELOCYTIC LEUKEMIA
910,CHRONIC HEPATITIS diagnosis LIVER BIOPSY SPECIMEN,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
911,CHRONIC HEPATITIS diagnosis LIVER BIOPSY SPECIMEN,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
912,no_relation,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
913,CHRONIC HEPATITIS diagnosis LIVER BIOPSY SPECIMEN,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
914,LIVER BIOPSY SPECIMEN diagnosis CHRONIC HEPATITIS,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
915,CHRONIC HEPATITIS diagnosis LIVER BIOPSY SPECIMEN,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
916,CHRONIC HEPATITIS diagnosis LIVER BIOPSY SPECIMEN,diagnosis,0.923380516876639,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
917,no_relation,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
918,NEUROFIBROMATOSIS TYPE 1 diagnosis MPNSTS,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
919,no_relation,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
920,no_relation,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
921,no_relation,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
922,NEUROFIBROMATOSIS TYPE 1 diagnosis MPNSTS,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
923,NEUROFIBROMATOSIS TYPE 1 diagnosis MPNSTS,diagnosis,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
924,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
925,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
926,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
927,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
928,MICROCALCIFICATION causes DUCTAL CARCINOMA IN SITU,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
929,DUCTAL CARCINOMA IN SITU causes MICROCALCIFICATION,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
930,no_relation,causes,1.0,"DUCTAL CARCINOMA IN SITU (DCIS) usually manifests as MICROCALCIFICATION on mammography, but several other unusual forms of presentation on mammography are also described.",MICROCALCIFICATION,DUCTAL CARCINOMA IN SITU
931,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
932,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
933,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
934,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
935,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
936,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
937,FIBROMYALGIA SYNDROME causes PAIN,causes,0.986393923832143,The FIBROMYALGIA SYNDROME (FMS) is characterized by widespread PAIN and diffuse tenderness in specified locations.,PAIN,FIBROMYALGIA SYNDROME
938,WART treats HUMAN PAPILLOMA VIRUS,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
939,no_relation,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
940,WART treats HUMAN PAPILLOMA VIRUS,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
941,WART treats HUMAN PAPILLOMA VIRUS,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
942,no_relation,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
943,no_relation,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
944,no_relation,treats,0.328797974610715,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
945,BRAIN location ANENCEPHALY,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
946,ANENCEPHALY location BRAIN,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
947,BRAIN location ANENCEPHALY,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
948,BRAIN location ANENCEPHALY,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
949,no_relation,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
950,no_relation,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
951,no_relation,location,0.7504787743864558,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
952,STOMACH location GASTRIC CANCER,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
953,STOMACH location GASTRIC CANCER,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
954,STOMACH location GASTRIC CANCER,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
955,GASTRIC CANCER location STOMACH,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
956,STOMACH location GASTRIC CANCER,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
957,STOMACH location GASTRIC CANCER,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
958,STOMACH location GASTRIC CANCER,location,0.606339062590832,"However, the patients with extensive intestinal metaplasia of the STOMACH belong to the high risk group for the GASTRIC CANCER",STOMACH,GASTRIC CANCER
959,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
960,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
961,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
962,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
963,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
964,no_relation,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
965,no_relation,causes,0.9594032236002472,The case is presented of a 49 year old female who had had chronic renal insufficiency and HYPERTENSION for several years and who developed a HYPERTENSIVE CRISIS after cessation of therapy with clonidine and nadolol.,HYPERTENSION,HYPERTENSIVE CRISIS
966,no_relation,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
967,no_relation,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
968,no_relation,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
969,CADMIUM TOXICITY treats CADMIUM ION IN THE,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
970,no_relation,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
971,CADMIUM ION IN THE treats CADMIUM TOXICITY,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
972,no_relation,treats,0.412081691846067,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
973,no_relation,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
974,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
975,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
976,no_relation,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
977,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
978,no_relation,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
979,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.753778361444409,"The classic features of a patient with fully developed GRAVES' DISEASE are difficult to overlook, but the clinical features of THYROTOXICOSIS vary with the etiology of the disease and the sensitivity of the patient's peripheral tissues.",GRAVES' DISEASE,THYROTOXICOSIS
980,no_relation,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
981,no_relation,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
982,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
983,no_relation,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
984,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
985,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
986,no_relation,causes,0.8728715609439692,"? Screen all patients with MEN2 for pheochromocytoma before parathyroidectomy, and consider screening for pheochromocytoma in patients with primary hyperparathyroidism who have significant HYPERTENSION or symptoms suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
987,RHEUMATOID ARTHRITIS treats INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
988,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
989,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
990,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
991,no_relation,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
992,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
993,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS treats RHEUMATOID ARTHRITIS,treats,0.9931270663228408,"Sulfasalazine for rheumatoid arthritis  Penicillamine for treating rheumatoid arthritis  Moderate term, low dose corticosteroids for rheumatoid arthritis  Biologics for rheumatoid arthritis: an overview of Cochrane reviews  Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis  INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS  Herbal therapy for treating rheumatoid arthritis  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for RHEUMATOID ARTHRITIS  WITHDRAWN: Dynamic exercise therapy for rheumatoid arthritis  Cyclosporine for treating rheumatoid arthritis  Cyclophosphamide for treating rheumatoid arthritis  Balneotherapy for rheumatoid arthritis  Azathioprine for treating rheumatoid arthritis.",RHEUMATOID ARTHRITIS,INJECTABLE GOLD FOR RHEUMATOID ARTHRITIS
994,no_relation,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
995,DYSPLASIA causes CERVICAL CARCINOMA IN SITU,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
996,no_relation,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
997,no_relation,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
998,DYSPLASIA causes CERVICAL CARCINOMA IN SITU,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
999,CERVICAL CARCINOMA IN SITU causes DYSPLASIA,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
1000,no_relation,causes,0.329292779969071,"The high frequency of herpes simplex virus type 2 (HSV 2) antibodies in young women (21 years or younger) with CERVICAL CARCINOMA IN SITU and in women with DYSPLASIA or carcinoma in situ, matched for various sexual attributes to control women, provide support for a causal relation.",DYSPLASIA,CERVICAL CARCINOMA IN SITU
1001,FLUORIDE ION treats CARIES,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1002,no_relation,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1003,FLUORIDE ION treats CARIES,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1004,FLUORIDE ION treats CARIES,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1005,FLUORIDE ION treats CARIES,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1006,no_relation,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1007,no_relation,treats,0.9931270663228408,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
1008,no_relation,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1009,MYCOBACTERIUM TUBERCULOSIS causes TUBERCULOSIS,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1010,no_relation,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1011,no_relation,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1012,MYCOBACTERIUM TUBERCULOSIS causes TUBERCULOSIS,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1013,no_relation,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1014,no_relation,causes,0.640512615220348,Neither the impact of the HIV pandemic nor the occurrence of multiresistant strains of MYCOBACTERIUM TUBERCULOSIS has yet become a major problem in the care of TUBERCULOSIS patients in Sweden.,MYCOBACTERIUM TUBERCULOSIS,TUBERCULOSIS
1015,HUMAN PAPILLOMA VIRUS causes WART,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1016,WART causes HUMAN PAPILLOMA VIRUS,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1017,HUMAN PAPILLOMA VIRUS causes WART,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1018,HUMAN PAPILLOMA VIRUS causes WART,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1019,no_relation,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1020,HUMAN PAPILLOMA VIRUS causes WART,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1021,HUMAN PAPILLOMA VIRUS causes WART,causes,0.6575959492214289,These results support the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction in HUMAN PAPILLOMA VIRUS (HPV) load; to WART regression and to the normalisation of keratinocyte proliferation without evidence of scarring.,HUMAN PAPILLOMA VIRUS,WART
1022,CADMIUM ION IN THE causes CADMIUM TOXICITY,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1023,no_relation,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1024,no_relation,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1025,no_relation,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1026,CADMIUM ION IN THE causes CADMIUM TOXICITY,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1027,CADMIUM ION IN THE causes CADMIUM TOXICITY,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1028,no_relation,causes,0.6868028197434449,"The results suggest that cadmium thionein may play a paradoxical role, providing protection against the CADMIUM ION IN THE intracellular milieu, but promoting CADMIUM TOXICITY when it is present in sufficient amounts in the lumen of the intestine.",CADMIUM ION IN THE,CADMIUM TOXICITY
1029,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1030,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1031,SMALL CELL CARCINOMA causes NEUROENDOCRINE DIFFERENTIATION,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1032,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1033,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1034,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1035,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL CARCINOMA,causes,0.64699663922063,"In investigation on carcinogenesis the first reports were published on the use of antisense oligonucleotides during inhibition of the development of tumours by a humoral mechanism and on the gene based NEUROENDOCRINE DIFFERENTIATION of the lungs, perhaps associated with the basis for the development of SMALL CELL CARCINOMA",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA
1036,no_relation,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1037,LYME DISEASE causes BORRELIA BURGDORFERI,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1038,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1039,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1040,no_relation,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1041,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1042,no_relation,causes,0.741998516004452,"Of the 5,442 ticks collected, 90% (4,893) were the winter tick, Dermacentor albipictus, and 10% (549) were the deer tick, Ixodes dammini, the primary vector of the causative agent of LYME DISEASE BORRELIA BURGDORFERI",BORRELIA BURGDORFERI,LYME DISEASE
1043,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1044,no_relation,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1045,no_relation,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1046,PAPAVERINE diagnosis ERECTILE DYSFUNCTION,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1047,no_relation,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1048,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1049,no_relation,diagnosis,0.7559289460184542,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1050,ALLERGY causes VERNAL KERATOCONJUNCTIVITIS,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1051,no_relation,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1052,VERNAL KERATOCONJUNCTIVITIS causes ALLERGY,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1053,ALLERGY causes VERNAL KERATOCONJUNCTIVITIS,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1054,ALLERGY causes VERNAL KERATOCONJUNCTIVITIS,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1055,VERNAL KERATOCONJUNCTIVITIS causes ALLERGY,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1056,no_relation,causes,0.8427009716003839,"Allergic eye diseases are characterized by IgE mast cell mediated, as seen in allergic conjunctivitis; chronic mast cell activation and eosinophil/T lymphocyte mediated response, as seen in giant papillary conjunctivitis, VERNAL KERATOCONJUNCTIVITIS and atopic keratoconjunctivitis; or a T lymphocyte mediated response in contact ocular ALLERGY",VERNAL KERATOCONJUNCTIVITIS,ALLERGY
1057,DRASH SYNDROME contraindicates NEPHROPATHY,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1058,no_relation,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1059,NEPHROPATHY contraindicates DRASH SYNDROME,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1060,DRASH SYNDROME contraindicates NEPHROPATHY,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1061,NEPHROPATHY contraindicates DRASH SYNDROME,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1062,no_relation,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1063,NEPHROPATHY contraindicates DRASH SYNDROME,contraindicates,0.474341649025257,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1064,ESOPHAGUS treats ESOPHAGEAL CANCER,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1065,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1066,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1067,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1068,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1069,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1070,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
1071,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1072,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1073,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1074,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1075,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1076,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1077,no_relation,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
1078,WHIPPLE'S DISEASE causes BACTERIUM,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1079,BACTERIUM causes WHIPPLE'S DISEASE,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1080,no_relation,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1081,no_relation,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1082,no_relation,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1083,no_relation,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1084,no_relation,causes,0.64699663922063,This is in accordance with the phylogenetic relationship of this BACTERIUM as well as with known epidemiological aspects of WHIPPLE'S DISEASE,BACTERIUM,WHIPPLE'S DISEASE
1085,NEPHROPATHY diagnosis DRASH SYNDROME,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1086,NEPHROPATHY diagnosis DRASH SYNDROME,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1087,no_relation,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1088,NEPHROPATHY diagnosis DRASH SYNDROME,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1089,no_relation,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1090,no_relation,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1091,no_relation,diagnosis,0.31622776601683805,Gonadal dysgenesis and NEPHROPATHY are often indistinguishable from incomplete DRASH SYNDROME,NEPHROPATHY,DRASH SYNDROME
1092,BONE location PSEUDARTHROSIS,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1093,no_relation,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1094,BONE location PSEUDARTHROSIS,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1095,BONE location PSEUDARTHROSIS,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1096,BONE location PSEUDARTHROSIS,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1097,BONE location PSEUDARTHROSIS,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1098,no_relation,location,0.309529293013655,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
1099,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) causes ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1100,no_relation,causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1101,no_relation,causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1102,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR causes INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1103,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR causes INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME),causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1104,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) causes ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1105,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) causes ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,causes,0.933256525257383,We report on a 68 year old patient with complete androgen INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME) in whom an ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR developed in an intraabdominal testis.,ESTROGEN SECRETING MALIGNANT SEX CORD STROMAL TUMOR,INSENSITIVITY SYNDROME (TESTICULAR FEMINIZATION SYNDROME)
1106,MPNSTS causes NEUROFIBROMATOSIS TYPE 1,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1107,no_relation,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1108,no_relation,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1109,no_relation,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1110,NEUROFIBROMATOSIS TYPE 1 causes MPNSTS,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1111,NEUROFIBROMATOSIS TYPE 1 causes MPNSTS,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1112,no_relation,causes,0.301511344577764,"PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 NEUROFIBROMATOSIS TYPE 1 (NF1) related and 11 sporadic MPNSTS",MPNSTS,NEUROFIBROMATOSIS TYPE 1
1113,no_relation,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1114,STRABISMIC AMBLYOPIA diagnosis STRABISMUS,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1115,STRABISMUS diagnosis STRABISMIC AMBLYOPIA,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1116,STRABISMUS diagnosis STRABISMIC AMBLYOPIA,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1117,no_relation,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1118,no_relation,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1119,no_relation,diagnosis,0.33333333333333304,"Visual evoked potentials (VEPs) produced by pattern reversal were compared with those elicited by onset of motion in 37 amblyopic children (20 with anisometropic amblyopia, seven with STRABISMIC AMBLYOPIA and 10 with both anisometropia and STRABISMUS",STRABISMIC AMBLYOPIA,STRABISMUS
1120,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1121,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1122,HEPATITIS A VIRUS treats HEPATITIS A,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1123,HEPATITIS A treats HEPATITIS A VIRUS,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1124,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1125,HEPATITIS A VIRUS treats HEPATITIS A,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1126,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
1127,ALLERGIC CONTACT DERMATITIS diagnosis HYPERSENSITIVITY,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1128,no_relation,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1129,ALLERGIC CONTACT DERMATITIS diagnosis HYPERSENSITIVITY,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1130,ALLERGIC CONTACT DERMATITIS diagnosis HYPERSENSITIVITY,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1131,HYPERSENSITIVITY diagnosis ALLERGIC CONTACT DERMATITIS,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1132,ALLERGIC CONTACT DERMATITIS diagnosis HYPERSENSITIVITY,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1133,no_relation,diagnosis,0.549442255794756,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1134,no_relation,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1135,BONE MINERAL METABOLISM causes OSTEOPOROSIS,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1136,no_relation,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1137,OSTEOPOROSIS causes BONE MINERAL METABOLISM,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1138,OSTEOPOROSIS causes BONE MINERAL METABOLISM,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1139,no_relation,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1140,BONE MINERAL METABOLISM causes OSTEOPOROSIS,causes,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
1141,STEATORRHEA causes CELIAC DISEASE,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1142,CELIAC DISEASE causes STEATORRHEA,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1143,STEATORRHEA causes CELIAC DISEASE,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1144,CELIAC DISEASE causes STEATORRHEA,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1145,no_relation,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1146,CELIAC DISEASE causes STEATORRHEA,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1147,STEATORRHEA causes CELIAC DISEASE,causes,0.960768922830523,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
1148,NUTRITIONAL DEFICIENCIES causes PROTEIN CALORIE MALNUTRITION,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1149,PROTEIN CALORIE MALNUTRITION causes NUTRITIONAL DEFICIENCIES,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1150,no_relation,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1151,PROTEIN CALORIE MALNUTRITION causes NUTRITIONAL DEFICIENCIES,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1152,NUTRITIONAL DEFICIENCIES causes PROTEIN CALORIE MALNUTRITION,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1153,no_relation,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1154,no_relation,causes,0.753778361444409,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
1155,DIABETIC KETOACIDOSIS diagnosis DIABETES MELLITUS,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1156,no_relation,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1157,no_relation,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1158,no_relation,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1159,DIABETIC KETOACIDOSIS diagnosis DIABETES MELLITUS,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1160,DIABETIC KETOACIDOSIS diagnosis DIABETES MELLITUS,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1161,DIABETES MELLITUS diagnosis DIABETIC KETOACIDOSIS,diagnosis,0.31622776601683805,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
1162,ALLERGY causes HYPERSENSITIVITY,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1163,HYPERSENSITIVITY causes ALLERGY,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1164,ALLERGY causes HYPERSENSITIVITY,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1165,HYPERSENSITIVITY causes ALLERGY,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1166,HYPERSENSITIVITY causes ALLERGY,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1167,no_relation,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1168,ALLERGY causes HYPERSENSITIVITY,causes,0.898026510133875,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
1169,no_relation,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1170,LIVERS location CIRRHOSIS,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1171,CIRRHOSIS location LIVERS,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1172,no_relation,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1173,LIVERS location CIRRHOSIS,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1174,LIVERS location CIRRHOSIS,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1175,LIVERS location CIRRHOSIS,location,0.753778361444409,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1176,NEURAL TUBE DEFECTS treats FOLIC ACID,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1177,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1178,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1179,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1180,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1181,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1182,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.9733285267845748,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
1183,no_relation,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1184,no_relation,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1185,no_relation,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1186,OVERT PRIMARY THYROID FAILURE causes HYPOTHYROIDISM,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1187,OVERT PRIMARY THYROID FAILURE causes HYPOTHYROIDISM,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1188,OVERT PRIMARY THYROID FAILURE causes HYPOTHYROIDISM,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1189,HYPOTHYROIDISM causes OVERT PRIMARY THYROID FAILURE,causes,0.6575959492214289,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
1190,ATOPIC DERMATITIS causes RESPIRATORY ATOPY,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1191,ATOPIC DERMATITIS causes RESPIRATORY ATOPY,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1192,no_relation,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1193,no_relation,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1194,RESPIRATORY ATOPY causes ATOPIC DERMATITIS,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1195,no_relation,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1196,no_relation,causes,0.3651483716701111,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
1197,AGGRESSIVE CLINICAL COURSE treats BLASTOID MANTLE CELL LYMPHOMA (BV MCL),treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1198,AGGRESSIVE CLINICAL COURSE treats BLASTOID MANTLE CELL LYMPHOMA (BV MCL),treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1199,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) treats AGGRESSIVE CLINICAL COURSE,treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1200,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) treats AGGRESSIVE CLINICAL COURSE,treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1201,no_relation,treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1202,AGGRESSIVE CLINICAL COURSE treats BLASTOID MANTLE CELL LYMPHOMA (BV MCL),treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1203,no_relation,treats,0.458831467741123,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1204,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1205,no_relation,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1206,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1207,no_relation,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1208,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1209,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1210,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.9761870601839532,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
1211,DIPHTHERIA treats DIPHTHERIA TOXOID,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1212,DIPHTHERIA treats DIPHTHERIA TOXOID,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1213,DIPHTHERIA TOXOID treats DIPHTHERIA,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1214,DIPHTHERIA TOXOID treats DIPHTHERIA,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1215,DIPHTHERIA TOXOID treats DIPHTHERIA,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1216,DIPHTHERIA TOXOID treats DIPHTHERIA,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1217,no_relation,treats,0.984731927834662,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
1218,no_relation,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1219,OCULAR ALLERGY CONDITIONS causes PERENNIAL ALLERGIC CONJUNCTIVITIS,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1220,OCULAR ALLERGY CONDITIONS causes PERENNIAL ALLERGIC CONJUNCTIVITIS,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1221,no_relation,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1222,PERENNIAL ALLERGIC CONJUNCTIVITIS causes OCULAR ALLERGY CONDITIONS,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1223,no_relation,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1224,no_relation,causes,0.7715167498104591,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
1225,ANTIEMETICS treats VOMITING,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1226,VOMITING treats ANTIEMETICS,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1227,ANTIEMETICS treats VOMITING,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1228,ANTIEMETICS treats VOMITING,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1229,ANTIEMETICS treats VOMITING,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1230,ANTIEMETICS treats VOMITING,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1231,no_relation,treats,0.9950371902099888,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
1232,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1233,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1234,no_relation,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1235,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1236,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1237,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1238,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.937042571331636,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
1239,HYPERSENSITIVITY causes ALLERGIC CONTACT DERMATITIS,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1240,no_relation,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1241,HYPERSENSITIVITY causes ALLERGIC CONTACT DERMATITIS,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1242,ALLERGIC CONTACT DERMATITIS causes HYPERSENSITIVITY,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1243,no_relation,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1244,no_relation,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1245,no_relation,causes,0.824163383692134,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
1246,NEUROLOGICAL DISEASES location NERVOUS SYSTEM,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1247,NERVOUS SYSTEM location NEUROLOGICAL DISEASES,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1248,NERVOUS SYSTEM location NEUROLOGICAL DISEASES,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1249,NERVOUS SYSTEM location NEUROLOGICAL DISEASES,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1250,no_relation,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1251,no_relation,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1252,NERVOUS SYSTEM location NEUROLOGICAL DISEASES,location,0.889000889001333,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
1253,no_relation,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1254,PREGNANCY causes YELLOW FEVER,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1255,no_relation,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1256,no_relation,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1257,no_relation,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1258,YELLOW FEVER causes PREGNANCY,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1259,no_relation,causes,0.5,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
1260,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1261,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1262,ULCERATIVE COLITIS treats BALSALAZIDE,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1263,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1264,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1265,no_relation,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1266,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.992277876713668,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
1267,BENIGN EPILEPSY causes SEIZURE,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1268,BENIGN EPILEPSY causes SEIZURE,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1269,BENIGN EPILEPSY causes SEIZURE,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1270,BENIGN EPILEPSY causes SEIZURE,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1271,BENIGN EPILEPSY causes SEIZURE,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1272,no_relation,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1273,SEIZURE causes BENIGN EPILEPSY,causes,0.9045340337332908,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
1274,HYPERTENSION causes LOSARTAN INTERVENTION FOR ENDPOINT,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1275,no_relation,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1276,no_relation,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1277,LOSARTAN INTERVENTION FOR ENDPOINT causes HYPERTENSION,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1278,no_relation,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1279,no_relation,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1280,LOSARTAN INTERVENTION FOR ENDPOINT causes HYPERTENSION,causes,0.4472135954999579,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1281,TEETH location DENTAL PLAQUES,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1282,DENTAL PLAQUES location TEETH,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1283,no_relation,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1284,no_relation,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1285,TEETH location DENTAL PLAQUES,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1286,DENTAL PLAQUES location TEETH,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1287,TEETH location DENTAL PLAQUES,location,0.801783725737273,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
1288,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1289,POLIOMYELITIS treats TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1290,no_relation,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1291,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1292,no_relation,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1293,no_relation,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1294,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,1.0,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
1295,? MEDICATION OVERUSE HEADACHE causes TENSION TYPE HEADACHE,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1296,? MEDICATION OVERUSE HEADACHE causes TENSION TYPE HEADACHE,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1297,no_relation,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1298,no_relation,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1299,? MEDICATION OVERUSE HEADACHE causes TENSION TYPE HEADACHE,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1300,no_relation,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1301,TENSION TYPE HEADACHE causes ? MEDICATION OVERUSE HEADACHE,causes,0.8838834764831841,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
1302,no_relation,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1303,no_relation,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1304,ALLERGIC RHINITIS AR causes ATOPIC DISEASE,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1305,no_relation,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1306,no_relation,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1307,ALLERGIC RHINITIS AR causes ATOPIC DISEASE,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1308,ALLERGIC RHINITIS AR causes ATOPIC DISEASE,causes,0.43643578047198495,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
1309,DYSPLASIA location COLORECTAL ADENOMATOUS POLYPS,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1310,COLORECTAL ADENOMATOUS POLYPS location DYSPLASIA,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1311,no_relation,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1312,no_relation,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1313,no_relation,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1314,no_relation,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1315,COLORECTAL ADENOMATOUS POLYPS location DYSPLASIA,location,0.3651483716701111,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1316,FACTOR VIII treats HEMOPHILIA A,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1317,HEMOPHILIA A treats FACTOR VIII,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1318,FACTOR VIII treats HEMOPHILIA A,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1319,no_relation,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1320,FACTOR VIII treats HEMOPHILIA A,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1321,no_relation,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1322,FACTOR VIII treats HEMOPHILIA A,treats,0.960768922830523,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
1323,CUTANEOUS INVOLVEMENT causes URTICARIA PIGMENTOSA,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1324,no_relation,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1325,URTICARIA PIGMENTOSA causes CUTANEOUS INVOLVEMENT,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1326,URTICARIA PIGMENTOSA causes CUTANEOUS INVOLVEMENT,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1327,CUTANEOUS INVOLVEMENT causes URTICARIA PIGMENTOSA,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1328,URTICARIA PIGMENTOSA causes CUTANEOUS INVOLVEMENT,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1329,CUTANEOUS INVOLVEMENT causes URTICARIA PIGMENTOSA,causes,0.696310623822791,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
1330,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1331,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1332,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1333,no_relation,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1334,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1335,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1336,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.993883734673619,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
1337,DRUGS causes OVERDOSE,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1338,DRUGS causes OVERDOSE,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1339,DRUGS causes OVERDOSE,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1340,DRUGS causes OVERDOSE,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1341,DRUGS causes OVERDOSE,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1342,no_relation,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1343,DRUGS causes OVERDOSE,causes,0.845154254728516,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
1344,DYSPLASIA causes COLORECTAL ADENOMATOUS POLYPS,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1345,COLORECTAL ADENOMATOUS POLYPS causes DYSPLASIA,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1346,DYSPLASIA causes COLORECTAL ADENOMATOUS POLYPS,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1347,DYSPLASIA causes COLORECTAL ADENOMATOUS POLYPS,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1348,DYSPLASIA causes COLORECTAL ADENOMATOUS POLYPS,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1349,no_relation,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1350,no_relation,causes,0.7302967433402209,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
1351,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) causes AGGRESSIVE CLINICAL COURSE,causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1352,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) causes AGGRESSIVE CLINICAL COURSE,causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1353,AGGRESSIVE CLINICAL COURSE causes BLASTOID MANTLE CELL LYMPHOMA (BV MCL),causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1354,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) causes AGGRESSIVE CLINICAL COURSE,causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1355,no_relation,causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1356,no_relation,causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1357,no_relation,causes,0.688247201611685,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
1358,no_relation,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1359,ATOPY causes ALLERGIC DERMATITIS,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1360,ATOPY causes ALLERGIC DERMATITIS,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1361,no_relation,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1362,no_relation,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1363,no_relation,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1364,ATOPY causes ALLERGIC DERMATITIS,causes,0.857492925712544,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
1365,NEURALGIA causes PAIN,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1366,no_relation,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1367,NEURALGIA causes PAIN,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1368,NEURALGIA causes PAIN,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1369,no_relation,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1370,no_relation,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1371,NEURALGIA causes PAIN,causes,0.948683298050514,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
1372,no_relation,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1373,no_relation,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1374,LIVERS causes CIRRHOSIS,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1375,no_relation,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1376,no_relation,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1377,no_relation,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1378,CIRRHOSIS causes LIVERS,causes,0.452267016866645,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
1379,SPECTINOMYCIN treats UNCOMPLICATED GONORRHEA,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1380,UNCOMPLICATED GONORRHEA treats SPECTINOMYCIN,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1381,SPECTINOMYCIN treats UNCOMPLICATED GONORRHEA,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1382,UNCOMPLICATED GONORRHEA treats SPECTINOMYCIN,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1383,no_relation,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1384,SPECTINOMYCIN treats UNCOMPLICATED GONORRHEA,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1385,no_relation,treats,0.514495755427526,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
1386,HYPERTENSION treats LOSARTAN INTERVENTION FOR ENDPOINT,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1387,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1388,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1389,HYPERTENSION treats LOSARTAN INTERVENTION FOR ENDPOINT,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1390,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1391,no_relation,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1392,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.8944271909999159,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
1393,CARIES causes BACTERIA,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1394,BACTERIA causes CARIES,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1395,no_relation,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1396,BACTERIA causes CARIES,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1397,no_relation,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1398,no_relation,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1399,no_relation,causes,0.583459965991578,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
1400,no_relation,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1401,ACETABULAR DYSPLASIA treats DEVELOPMENTAL DYSPLASIA OF THE HIP,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1402,no_relation,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1403,ACETABULAR DYSPLASIA treats DEVELOPMENTAL DYSPLASIA OF THE HIP,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1404,no_relation,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1405,no_relation,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1406,no_relation,treats,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1407,TUBERCULOSIS diagnosis PPD SKIN TEST,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1408,PPD SKIN TEST diagnosis TUBERCULOSIS,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1409,TUBERCULOSIS diagnosis PPD SKIN TEST,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1410,TUBERCULOSIS diagnosis PPD SKIN TEST,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1411,TUBERCULOSIS diagnosis PPD SKIN TEST,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1412,PPD SKIN TEST diagnosis TUBERCULOSIS,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1413,PPD SKIN TEST diagnosis TUBERCULOSIS,diagnosis,0.936329177569044,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
1414,no_relation,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1415,no_relation,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1416,MICROSCOPIC HEMATURIA causes GROSS HEMATURIA,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1417,no_relation,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1418,no_relation,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1419,MICROSCOPIC HEMATURIA causes GROSS HEMATURIA,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1420,no_relation,causes,0.768221279597376,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
1421,no_relation,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1422,no_relation,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1423,(CYA METHOTREXATE AND PREDNISONE (PDN treats GVHD PROPHYLAXIS,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1424,(CYA METHOTREXATE AND PREDNISONE (PDN treats GVHD PROPHYLAXIS,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1425,(CYA METHOTREXATE AND PREDNISONE (PDN treats GVHD PROPHYLAXIS,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1426,no_relation,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1427,no_relation,treats,0.8846517369293829,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
1428,no_relation,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1429,no_relation,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1430,no_relation,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1431,SINGLE METHACHOLINE STIMULATION causes BRONCHIAL HYPERREACTIVITY,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1432,no_relation,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1433,no_relation,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1434,SINGLE METHACHOLINE STIMULATION causes BRONCHIAL HYPERREACTIVITY,causes,0.6488856845230501,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
1435,INHERITED RICKETS causes VITAMIN D,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1436,no_relation,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1437,VITAMIN D causes INHERITED RICKETS,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1438,VITAMIN D causes INHERITED RICKETS,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1439,no_relation,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1440,no_relation,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1441,no_relation,causes,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1442,no_relation,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1443,HEPATOMA causes ASCITES FLUID,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1444,no_relation,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1445,ASCITES FLUID causes HEPATOMA,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1446,no_relation,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1447,no_relation,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1448,HEPATOMA causes ASCITES FLUID,causes,0.676123403782813,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
1449,LEFT VENTRICULAR HYPERTROPHY treats RAMIPRIL,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1450,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1451,no_relation,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1452,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1453,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1454,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1455,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,1.0,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
1456,BONE MARROW CELLS causes CHRONIC GRANULOCYTIC LEUKEMIA CELLS,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1457,no_relation,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1458,no_relation,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1459,BONE MARROW CELLS causes CHRONIC GRANULOCYTIC LEUKEMIA CELLS,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1460,CHRONIC GRANULOCYTIC LEUKEMIA CELLS causes BONE MARROW CELLS,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1461,no_relation,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1462,no_relation,causes,0.3,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
1463,ACETABULAR DYSPLASIA causes DEVELOPMENTAL DYSPLASIA OF THE HIP,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1464,no_relation,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1465,ACETABULAR DYSPLASIA causes DEVELOPMENTAL DYSPLASIA OF THE HIP,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1466,ACETABULAR DYSPLASIA causes DEVELOPMENTAL DYSPLASIA OF THE HIP,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1467,DEVELOPMENTAL DYSPLASIA OF THE HIP causes ACETABULAR DYSPLASIA,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1468,no_relation,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1469,DEVELOPMENTAL DYSPLASIA OF THE HIP causes ACETABULAR DYSPLASIA,causes,0.693375245281537,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
1470,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1471,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1472,no_relation,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1473,no_relation,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1474,no_relation,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1475,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1476,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,causes,0.919145030018058,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
1477,no_relation,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1478,MULTIPLE POLYPS causes POLYP MASS,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1479,no_relation,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1480,no_relation,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1481,no_relation,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1482,no_relation,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1483,no_relation,causes,0.5,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
1484,JOINTS causes ARTHRITIS,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1485,ARTHRITIS causes JOINTS,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1486,no_relation,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1487,no_relation,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1488,ARTHRITIS causes JOINTS,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1489,ARTHRITIS causes JOINTS,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1490,JOINTS causes ARTHRITIS,causes,0.43301270189221897,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
1491,INHERITED RICKETS treats VITAMIN D,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1492,VITAMIN D treats INHERITED RICKETS,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1493,VITAMIN D treats INHERITED RICKETS,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1494,VITAMIN D treats INHERITED RICKETS,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1495,no_relation,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1496,VITAMIN D treats INHERITED RICKETS,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1497,VITAMIN D treats INHERITED RICKETS,treats,0.6859943405700349,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
1498,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1499,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1500,NICOTINE DEPENDENCE causes NICOTINE AND COTININE LEVELS,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1501,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1502,no_relation,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1503,no_relation,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1504,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,causes,0.42426406871192895,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
1505,DRUG SIDE EFFECTS causes DRUG REGIMENS,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1506,DRUG REGIMENS causes DRUG SIDE EFFECTS,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1507,no_relation,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1508,DRUG REGIMENS causes DRUG SIDE EFFECTS,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1509,DRUG REGIMENS causes DRUG SIDE EFFECTS,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1510,no_relation,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1511,no_relation,causes,0.833333333333333,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
1512,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA treats RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1513,no_relation,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1514,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1515,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1516,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1517,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1518,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.9615239476408228,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
1519,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1520,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1521,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1522,no_relation,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1523,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1524,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1525,MALIGNANT HYPERTHERMIA treats INTRAVENOUS DANTROLENE,treats,0.557086014531156,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1526,MALIGNANT HYPERTHERMIA diagnosis INTRAVENOUS DANTROLENE,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1527,INTRAVENOUS DANTROLENE diagnosis MALIGNANT HYPERTHERMIA,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1528,no_relation,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1529,MALIGNANT HYPERTHERMIA diagnosis INTRAVENOUS DANTROLENE,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1530,INTRAVENOUS DANTROLENE diagnosis MALIGNANT HYPERTHERMIA,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1531,MALIGNANT HYPERTHERMIA diagnosis INTRAVENOUS DANTROLENE,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1532,no_relation,diagnosis,0.7427813527082071,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
1533,no_relation,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1534,no_relation,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1535,no_relation,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1536,no_relation,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1537,no_relation,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1538,no_relation,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1539,OVARIAN CARCINOMA causes UNFAVORABLE CLINICAL OUTCOME,causes,0.7947194142390258,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
1540,APL treats DIC,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1541,APL treats DIC,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1542,no_relation,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1543,APL treats DIC,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1544,APL treats DIC,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1545,DIC treats APL,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1546,APL treats DIC,treats,0.6575959492214289,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
1547,CUTANEOUS PHOTOSENSITIVITY causes PORPHYRIA CUTANEA TARDA,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1548,PORPHYRIA CUTANEA TARDA causes CUTANEOUS PHOTOSENSITIVITY,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1549,CUTANEOUS PHOTOSENSITIVITY causes PORPHYRIA CUTANEA TARDA,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1550,PORPHYRIA CUTANEA TARDA causes CUTANEOUS PHOTOSENSITIVITY,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1551,PORPHYRIA CUTANEA TARDA causes CUTANEOUS PHOTOSENSITIVITY,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1552,no_relation,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1553,PORPHYRIA CUTANEA TARDA causes CUTANEOUS PHOTOSENSITIVITY,causes,1.0,The mutual clinical symptom was a CUTANEOUS PHOTOSENSITIVITY which is a major symptom in PORPHYRIA CUTANEA TARDA and a facultative one in porphyria variegata.,CUTANEOUS PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
1554,HUMAN IMMUNODEFICIENCY VIRUS diagnosis HUMAN IMMUNODEFICIENCY VIRUS (HIV),diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1555,no_relation,diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1556,HUMAN IMMUNODEFICIENCY VIRUS diagnosis HUMAN IMMUNODEFICIENCY VIRUS (HIV),diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1557,no_relation,diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1558,no_relation,diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1559,no_relation,diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1560,HUMAN IMMUNODEFICIENCY VIRUS (HIV) diagnosis HUMAN IMMUNODEFICIENCY VIRUS,diagnosis,0.34815531191139604,Ten patients were positive for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS and ten refused testing.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN IMMUNODEFICIENCY VIRUS
1561,DIETHYLENETRIAMINEPENTAACETIC ACID treats TUMORS,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1562,no_relation,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1563,DIETHYLENETRIAMINEPENTAACETIC ACID treats TUMORS,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1564,DIETHYLENETRIAMINEPENTAACETIC ACID treats TUMORS,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1565,DIETHYLENETRIAMINEPENTAACETIC ACID treats TUMORS,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1566,DIETHYLENETRIAMINEPENTAACETIC ACID treats TUMORS,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1567,DIETHYLENETRIAMINEPENTAACETIC ACID treats TUMORS,treats,0.9258200997725508,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine 125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111 localize into target TUMORS more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID
1568,ERGONOVINE treats VARIANT ANGINA,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1569,ERGONOVINE treats VARIANT ANGINA,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1570,ERGONOVINE treats VARIANT ANGINA,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1571,VARIANT ANGINA treats ERGONOVINE,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1572,ERGONOVINE treats VARIANT ANGINA,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1573,ERGONOVINE treats VARIANT ANGINA,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1574,VARIANT ANGINA treats ERGONOVINE,treats,0.914991421995628,"However, in patients with VARIANT ANGINA a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/  15.3% at the site of spastic occlusion included by a larger dose of ERGONOVINE, compared with that of 7.0 +/  11.9% in the remaining non spastic coronary arteries (p less than 0.05.",VARIANT ANGINA,ERGONOVINE
1575,PROMETHAZINE causes VOMITING,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1576,no_relation,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1577,PROMETHAZINE causes VOMITING,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1578,no_relation,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1579,VOMITING causes PROMETHAZINE,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1580,PROMETHAZINE causes VOMITING,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1581,no_relation,causes,0.308606699924184,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1582,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1583,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1584,BIPOLAR DISORDER treats LITHIUM,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1585,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1586,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1587,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1588,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
1589,no_relation,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1590,no_relation,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1591,no_relation,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1592,no_relation,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1593,MILD DYSPLASIA/CIN 1 causes MODERATE DYSPLASIA/CIN 2,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1594,no_relation,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1595,no_relation,causes,0.38490017945975,Forty one (30.1%) women had MILD DYSPLASIA/CIN 1 21 (15.4%) had MODERATE DYSPLASIA/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.,MODERATE DYSPLASIA/CIN 2,MILD DYSPLASIA/CIN 1
1596,no_relation,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1597,no_relation,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1598,NODULAR MELANOMAS causes VERTICAL GROWTH PHASE,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1599,no_relation,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1600,VERTICAL GROWTH PHASE causes NODULAR MELANOMAS,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1601,NODULAR MELANOMAS causes VERTICAL GROWTH PHASE,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1602,no_relation,causes,0.547722557505166,"Fifty non selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a VERTICAL GROWTH PHASE ten primary NODULAR MELANOMAS 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP 2alpha and c kit genes and by immunohistochemistry for the respective proteins.",VERTICAL GROWTH PHASE,NODULAR MELANOMAS
1603,PATHOLOGICAL FRACTURES causes BONE METASTASES,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1604,BONE METASTASES causes PATHOLOGICAL FRACTURES,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1605,no_relation,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1606,BONE METASTASES causes PATHOLOGICAL FRACTURES,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1607,BONE METASTASES causes PATHOLOGICAL FRACTURES,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1608,BONE METASTASES causes PATHOLOGICAL FRACTURES,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1609,BONE METASTASES causes PATHOLOGICAL FRACTURES,causes,1.0,"BONE METASTASES cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and thus are a significant clinical problem.",PATHOLOGICAL FRACTURES,BONE METASTASES
1610,no_relation,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1611,INFANTILE SPASMS causes SEIZURES,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1612,INFANTILE SPASMS causes SEIZURES,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1613,no_relation,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1614,SEIZURES causes INFANTILE SPASMS,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1615,INFANTILE SPASMS causes SEIZURES,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1616,no_relation,causes,0.493196961916072,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) INFANTILE SPASMS are usually generalized SEIZURES.,SEIZURES,INFANTILE SPASMS
1617,OSTEOARTHRITIS THAT INVOLVES JOINTS causes OSTEOARTHRITIS,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1618,no_relation,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1619,no_relation,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1620,no_relation,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1621,no_relation,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1622,no_relation,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1623,no_relation,causes,0.8006407690254359,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
1624,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1625,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1626,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1627,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1628,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1629,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1630,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE treats ACNE VULGARIS,treats,0.98058067569092,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE mainly used in the treatment of ACNE VULGARIS in young persons.,ACNE VULGARIS,MINOCYCLINE IS A TETRACYCLINE DERIVATIVE
1631,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE (ESRD),causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1632,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE (ESRD),causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1633,END STAGE RENAL DISEASE (ESRD) causes RENAL OSTEODYSTROPHY,causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1634,no_relation,causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1635,no_relation,causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1636,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE (ESRD),causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1637,END STAGE RENAL DISEASE (ESRD) causes RENAL OSTEODYSTROPHY,causes,0.7715167498104591,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of RENAL OSTEODYSTROPHY between Asian and Western countries in END STAGE RENAL DISEASE (ESRD) patients.,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE (ESRD)
1638,no_relation,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1639,no_relation,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1640,NIACIN causes PELLAGRA,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1641,PELLAGRA causes NIACIN,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1642,no_relation,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1643,no_relation,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1644,no_relation,causes,0.8006407690254359,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); PELLAGRA (lack of NIACIN); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,PELLAGRA,NIACIN
1645,DEMENTIA WITH LEWY BODIES causes PARKINSONISM,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1646,DEMENTIA WITH LEWY BODIES causes PARKINSONISM,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1647,no_relation,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1648,no_relation,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1649,no_relation,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1650,no_relation,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1651,no_relation,causes,0.7559289460184542,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1652,ASCITES location OVARIAN MUCINOUS ADENOCARCINOMAS,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1653,OVARIAN MUCINOUS ADENOCARCINOMAS location ASCITES,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1654,OVARIAN MUCINOUS ADENOCARCINOMAS location ASCITES,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1655,no_relation,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1656,ASCITES location OVARIAN MUCINOUS ADENOCARCINOMAS,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1657,OVARIAN MUCINOUS ADENOCARCINOMAS location ASCITES,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1658,no_relation,location,0.707106781186547,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
1659,PROMETHAZINE treats VOMITING,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1660,PROMETHAZINE treats VOMITING,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1661,VOMITING treats PROMETHAZINE,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1662,PROMETHAZINE treats VOMITING,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1663,PROMETHAZINE treats VOMITING,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1664,PROMETHAZINE treats VOMITING,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1665,PROMETHAZINE treats VOMITING,treats,0.9258200997725508,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
1666,PARKINSONISM diagnosis DEMENTIA WITH LEWY BODIES,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1667,no_relation,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1668,PARKINSONISM diagnosis DEMENTIA WITH LEWY BODIES,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1669,no_relation,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1670,DEMENTIA WITH LEWY BODIES diagnosis PARKINSONISM,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1671,no_relation,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1672,DEMENTIA WITH LEWY BODIES diagnosis PARKINSONISM,diagnosis,0.3779644730092271,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of DEMENTIA WITH LEWY BODIES (&gt;75% sensitivity) Vascular PARKINSONISM  Also known as lower body parkinsonism.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
1673,DYSMENORRHEA causes PAIN,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1674,DYSMENORRHEA causes PAIN,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1675,DYSMENORRHEA causes PAIN,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1676,DYSMENORRHEA causes PAIN,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1677,DYSMENORRHEA causes PAIN,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1678,DYSMENORRHEA causes PAIN,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1679,no_relation,causes,0.811107105653813,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy for disabling central PAIN primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,PAIN,DYSMENORRHEA
1680,no_relation,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1681,IDIOPATHIC PULMONARY FIBROSIS location LUNGS,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1682,LUNGS location IDIOPATHIC PULMONARY FIBROSIS,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1683,LUNGS location IDIOPATHIC PULMONARY FIBROSIS,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1684,LUNGS location IDIOPATHIC PULMONARY FIBROSIS,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1685,IDIOPATHIC PULMONARY FIBROSIS location LUNGS,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1686,no_relation,location,0.960768922830523,"HDGF was more highly expressed in the lungs of IDIOPATHIC PULMONARY FIBROSIS chiefly in the epithelial cells, than in control nonfibrotic LUNGS.",LUNGS,IDIOPATHIC PULMONARY FIBROSIS
1687,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1688,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS treats CLINDAMYCIN,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1689,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1690,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1691,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1692,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1693,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.987878339907213,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
1694,PERSISTENT UNEXPLAINED PAIN causes OSTEOID OSTEOMA OF THE STYLOID,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1695,no_relation,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1696,OSTEOID OSTEOMA OF THE STYLOID causes PERSISTENT UNEXPLAINED PAIN,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1697,no_relation,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1698,OSTEOID OSTEOMA OF THE STYLOID causes PERSISTENT UNEXPLAINED PAIN,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1699,OSTEOID OSTEOMA OF THE STYLOID causes PERSISTENT UNEXPLAINED PAIN,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1700,PERSISTENT UNEXPLAINED PAIN causes OSTEOID OSTEOMA OF THE STYLOID,causes,0.970142500145332,"It is suggested that in any case of PERSISTENT UNEXPLAINED PAIN of the wrist or clinical symptoms resembling those of tenosynovitis, OSTEOID OSTEOMA OF THE STYLOID process of the radius or of the carpal bones should also be included in the differential diagnosis.",PERSISTENT UNEXPLAINED PAIN,OSTEOID OSTEOMA OF THE STYLOID
1701,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1702,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1703,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1704,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1705,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1706,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1707,IBUPROFEN treats INFLAMMATION,treats,1.0,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
1708,LUNG location LUNG CANCER,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1709,LUNG location LUNG CANCER,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1710,LUNG location LUNG CANCER,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1711,LUNG location LUNG CANCER,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1712,LUNG CANCER location LUNG,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1713,LUNG location LUNG CANCER,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1714,LUNG location LUNG CANCER,location,0.9733285267845748,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
1715,no_relation,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1716,no_relation,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1717,no_relation,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1718,no_relation,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1719,HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA treats DIABETIC KETOACIDOSIS,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1720,DIABETIC KETOACIDOSIS treats HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1721,HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA treats DIABETIC KETOACIDOSIS,treats,0.9438798074485388,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
1722,no_relation,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1723,SKIN causes DERMATITIS,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1724,no_relation,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1725,no_relation,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1726,no_relation,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1727,no_relation,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1728,no_relation,causes,0.34874291623145803,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1729,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1730,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1731,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1732,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1733,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1734,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1735,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
1736,COLONIC ISCHEMIA causes SPONTANEOUS ISCHEMIC COLITIS,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1737,COLONIC ISCHEMIA causes SPONTANEOUS ISCHEMIC COLITIS,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1738,no_relation,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1739,no_relation,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1740,COLONIC ISCHEMIA causes SPONTANEOUS ISCHEMIC COLITIS,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1741,SPONTANEOUS ISCHEMIC COLITIS causes COLONIC ISCHEMIA,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1742,SPONTANEOUS ISCHEMIC COLITIS causes COLONIC ISCHEMIA,causes,0.304997140665209,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
1743,INDUCED NAUSEA AND VOMITING causes ANTIEMETICS,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1744,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1745,no_relation,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1746,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1747,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1748,INDUCED NAUSEA AND VOMITING causes ANTIEMETICS,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1749,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,causes,0.6030226891555269,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
1750,LIVER location HEPATOCELLULAR NECROSIS,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1751,LIVER location HEPATOCELLULAR NECROSIS,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1752,LIVER location HEPATOCELLULAR NECROSIS,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1753,LIVER location HEPATOCELLULAR NECROSIS,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1754,LIVER location HEPATOCELLULAR NECROSIS,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1755,HEPATOCELLULAR NECROSIS location LIVER,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1756,LIVER location HEPATOCELLULAR NECROSIS,location,0.964901281354015,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
1757,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1758,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1759,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1760,TAMOXIFEN ASSOCIATED HOT FLASHES treats CLONIDINE,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1761,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1762,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1763,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.9918365981341758,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
1764,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosis ADMINISTRATION OF THE DRUG AFTER THE TEST,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1765,no_relation,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1766,ADMINISTRATION OF THE DRUG AFTER THE TEST diagnosis AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1767,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosis ADMINISTRATION OF THE DRUG AFTER THE TEST,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1768,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosis ADMINISTRATION OF THE DRUG AFTER THE TEST,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1769,no_relation,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1770,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosis ADMINISTRATION OF THE DRUG AFTER THE TEST,diagnosis,0.7427813527082071,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1771,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1772,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1773,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1774,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1775,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1776,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1777,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
1778,BONE MARROW location LEUKEMIA,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1779,BONE MARROW location LEUKEMIA,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1780,BONE MARROW location LEUKEMIA,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1781,no_relation,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1782,no_relation,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1783,BONE MARROW location LEUKEMIA,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1784,BONE MARROW location LEUKEMIA,location,0.977355554850442,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
1785,no_relation,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1786,BRAIN location EPILEPSY,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1787,BRAIN location EPILEPSY,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1788,EPILEPSY location BRAIN,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1789,EPILEPSY location BRAIN,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1790,no_relation,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1791,BRAIN location EPILEPSY,location,0.529812942826018,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
1792,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1793,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1794,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1795,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1796,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1797,no_relation,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1798,ROBUST REDUCTION IN PAIN treats THE TREATMENT OF VULVODYNIA FOUND THAT 17,treats,0.848528137423857,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
1799,INSULIN treats TYPE 2 DIABETES,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1800,INSULIN treats TYPE 2 DIABETES,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1801,no_relation,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1802,INSULIN treats TYPE 2 DIABETES,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1803,no_relation,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1804,INSULIN treats TYPE 2 DIABETES,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1805,no_relation,treats,0.7559289460184542,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1806,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1807,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1808,TYPE 1 DIABETES treats INSULIN GLARGINE,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1809,TYPE 1 DIABETES treats INSULIN GLARGINE,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1810,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1811,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1812,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.985329278164293,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
1813,ROCKY MOUNTAIN SPOTTED FEVER causes RICKETTSIA RICKETTSII,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1814,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1815,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1816,no_relation,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1817,no_relation,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1818,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1819,no_relation,causes,0.589767824619588,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
1820,no_relation,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1821,no_relation,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1822,no_relation,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1823,ASCITES causes ADENOCARCINOMA OF THE OVARY,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1824,no_relation,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1825,ASCITES causes ADENOCARCINOMA OF THE OVARY,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1826,ASCITES causes ADENOCARCINOMA OF THE OVARY,causes,0.992277876713668,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
1827,no_relation,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1828,POLYCYSTIC KIDNEY DISEASE causes KIDNEY FAILURE,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1829,POLYCYSTIC KIDNEY DISEASE causes KIDNEY FAILURE,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1830,KIDNEY FAILURE causes POLYCYSTIC KIDNEY DISEASE,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1831,no_relation,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1832,POLYCYSTIC KIDNEY DISEASE causes KIDNEY FAILURE,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1833,KIDNEY FAILURE causes POLYCYSTIC KIDNEY DISEASE,causes,0.848528137423857,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
1834,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1835,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1836,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1837,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1838,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1839,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1840,URSODIOL treats GALLSTONES,treats,0.971285862357264,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
1841,CARCINOMA IN SITU causes SEVERE DYSPLASIA,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1842,no_relation,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1843,no_relation,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1844,no_relation,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1845,SEVERE DYSPLASIA causes CARCINOMA IN SITU,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1846,SEVERE DYSPLASIA causes CARCINOMA IN SITU,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1847,no_relation,causes,0.471404520791032,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
1848,no_relation,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1849,no_relation,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1850,no_relation,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1851,ADMINISTRATION OF THE DRUG AFTER THE TEST treats AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1852,ADMINISTRATION OF THE DRUG AFTER THE TEST treats AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1853,no_relation,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1854,ADMINISTRATION OF THE DRUG AFTER THE TEST treats AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,treats,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
1855,SKIN location DERMATITIS,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1856,SKIN location DERMATITIS,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1857,SKIN location DERMATITIS,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1858,DERMATITIS location SKIN,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1859,SKIN location DERMATITIS,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1860,SKIN location DERMATITIS,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1861,SKIN location DERMATITIS,location,0.929981109950554,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
1862,no_relation,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1863,no_relation,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1864,no_relation,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1865,FOLLICULAR DIFFERENTIATION causes TRICHOFOLLICULOMA,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1866,TRICHOFOLLICULOMA causes FOLLICULAR DIFFERENTIATION,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1867,TRICHOFOLLICULOMA causes FOLLICULAR DIFFERENTIATION,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1868,FOLLICULAR DIFFERENTIATION causes TRICHOFOLLICULOMA,causes,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
1869,COMPLICATION OF PREGNANCY causes PREECLAMPSIA,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1870,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1871,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1872,no_relation,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1873,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1874,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1875,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.549442255794756,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1876,NICOTINE causes DEPENDENT SMOKERS,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1877,no_relation,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1878,NICOTINE causes DEPENDENT SMOKERS,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1879,NICOTINE causes DEPENDENT SMOKERS,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1880,NICOTINE causes DEPENDENT SMOKERS,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1881,NICOTINE causes DEPENDENT SMOKERS,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1882,NICOTINE causes DEPENDENT SMOKERS,causes,0.8846517369293829,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
1883,ISCHEMIA diagnosis RAT FOUR VESSEL OCCLUSION MODEL,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1884,no_relation,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1885,ISCHEMIA diagnosis RAT FOUR VESSEL OCCLUSION MODEL,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1886,no_relation,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1887,no_relation,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1888,ISCHEMIA diagnosis RAT FOUR VESSEL OCCLUSION MODEL,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1889,no_relation,diagnosis,0.927172649945531,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
1890,no_relation,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1891,no_relation,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1892,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1893,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1894,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1895,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1896,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.964901281354015,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
1897,no_relation,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1898,no_relation,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1899,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1900,no_relation,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1901,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1902,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1903,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,causes,0.338061701891407,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
1904,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1905,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1906,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1907,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1908,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1909,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1910,DRUGS causes ADVERSE DRUG REACTION,causes,0.980196058819607,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
1911,no_relation,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1912,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1913,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1914,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1915,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1916,no_relation,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1917,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9258200997725508,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
1918,no_relation,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1919,EPINEPHRINE treats ANAPHYLAXIS,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1920,EPINEPHRINE treats ANAPHYLAXIS,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1921,EPINEPHRINE treats ANAPHYLAXIS,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1922,ANAPHYLAXIS treats EPINEPHRINE,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1923,EPINEPHRINE treats ANAPHYLAXIS,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1924,EPINEPHRINE treats ANAPHYLAXIS,treats,0.997458699830735,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
1925,GABAPENTIN treats PAIN,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1926,GABAPENTIN treats PAIN,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1927,GABAPENTIN treats PAIN,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1928,GABAPENTIN treats PAIN,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1929,no_relation,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1930,GABAPENTIN treats PAIN,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1931,PAIN treats GABAPENTIN,treats,0.98058067569092,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
1932,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1933,no_relation,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1934,no_relation,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1935,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1936,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1937,no_relation,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1938,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,causes,0.948683298050514,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
1939,ANTITUBERCULOSIS treats TB,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1940,ANTITUBERCULOSIS treats TB,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1941,ANTITUBERCULOSIS treats TB,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1942,no_relation,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1943,ANTITUBERCULOSIS treats TB,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1944,ANTITUBERCULOSIS treats TB,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1945,no_relation,treats,0.977355554850442,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
1946,no_relation,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1947,DRUG TOXICITY causes DRUG,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1948,DRUG causes DRUG TOXICITY,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1949,DRUG TOXICITY causes DRUG,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1950,DRUG causes DRUG TOXICITY,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1951,no_relation,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1952,DRUG causes DRUG TOXICITY,causes,0.7559289460184542,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
1953,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1954,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1955,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1956,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1957,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1958,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1959,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,treats,0.992277876713668,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
1960,EPOETIN ALFA treats ANEMIA,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1961,EPOETIN ALFA treats ANEMIA,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1962,EPOETIN ALFA treats ANEMIA,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1963,EPOETIN ALFA treats ANEMIA,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1964,no_relation,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1965,EPOETIN ALFA treats ANEMIA,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1966,EPOETIN ALFA treats ANEMIA,treats,0.981980506061966,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
1967,AMANTADINE treats PARKINSON'S DISEASE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1968,AMANTADINE treats PARKINSON'S DISEASE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1969,AMANTADINE treats PARKINSON'S DISEASE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1970,AMANTADINE treats PARKINSON'S DISEASE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1971,PARKINSON'S DISEASE treats AMANTADINE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1972,AMANTADINE treats PARKINSON'S DISEASE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1973,AMANTADINE treats PARKINSON'S DISEASE,treats,0.936329177569044,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
1974,no_relation,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1975,SKIN location URTICARIA,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1976,SKIN location URTICARIA,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1977,SKIN location URTICARIA,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1978,SKIN location URTICARIA,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1979,SKIN location URTICARIA,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1980,SKIN location URTICARIA,location,0.956182887467515,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
1981,no_relation,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1982,no_relation,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1983,no_relation,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1984,no_relation,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1985,no_relation,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1986,INSULIN causes TYPE 2 DIABETES,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1987,no_relation,causes,0.629940788348712,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
1988,no_relation,diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1989,L DOPA diagnosis UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1990,no_relation,diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1991,L DOPA diagnosis UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1992,L DOPA diagnosis UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1993,no_relation,diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1994,UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) diagnosis L DOPA,diagnosis,0.857492925712544,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
1995,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
1996,no_relation,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
1997,no_relation,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
1998,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
1999,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
2000,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
2001,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,treats,0.948683298050514,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
2002,ENDSTAGE RENAL FAILURE (ESRD causes ANEMIA OF CHRONIC RENAL FAILURE,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2003,no_relation,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2004,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2005,ENDSTAGE RENAL FAILURE (ESRD causes ANEMIA OF CHRONIC RENAL FAILURE,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2006,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2007,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2008,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,causes,0.452267016866645,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
2009,ERGOT ALKALOIDS causes ERGOTISM,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2010,ERGOTISM causes ERGOT ALKALOIDS,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2011,ERGOT ALKALOIDS causes ERGOTISM,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2012,ERGOT ALKALOIDS causes ERGOTISM,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2013,ERGOT ALKALOIDS causes ERGOTISM,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2014,ERGOT ALKALOIDS causes ERGOTISM,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2015,no_relation,causes,0.995893206467704,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
2016,JC VIRUS ISOLATES causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2017,JC VIRUS ISOLATES causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2018,JC VIRUS ISOLATES causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2019,MULTIFOCAL LEUKOENCEPHALOPATHY causes JC VIRUS ISOLATES,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2020,no_relation,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2021,JC VIRUS ISOLATES causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2022,JC VIRUS ISOLATES causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.811107105653813,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC VIRUS ISOLATES amplified from AIDS patients with and without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.",JC VIRUS ISOLATES,MULTIFOCAL LEUKOENCEPHALOPATHY
2023,FUNCTIONAL LIVER BLOOD FLOW treats LIVER ATROPHY,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2024,no_relation,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2025,FUNCTIONAL LIVER BLOOD FLOW treats LIVER ATROPHY,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2026,no_relation,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2027,FUNCTIONAL LIVER BLOOD FLOW treats LIVER ATROPHY,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2028,no_relation,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2029,FUNCTIONAL LIVER BLOOD FLOW treats LIVER ATROPHY,treats,0.943456353049726,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve FUNCTIONAL LIVER BLOOD FLOW and prevent LIVER ATROPHY and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",FUNCTIONAL LIVER BLOOD FLOW,LIVER ATROPHY
2030,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2031,no_relation,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2032,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2033,HYPERCORTISOLISM treats DEXAMETHASONE,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2034,HYPERCORTISOLISM treats DEXAMETHASONE,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2035,no_relation,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2036,no_relation,treats,0.547722557505166,In MDD there are two well documented biochemical abnormalities: HYPERCORTISOLISM and its resistance to DEXAMETHASONE suppression.,HYPERCORTISOLISM,DEXAMETHASONE
2037,no_relation,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2038,no_relation,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2039,no_relation,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2040,no_relation,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2041,WITH HEPATOCELLULAR CARC diagnosis STERILE CIRRHOTIC AS,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2042,WITH HEPATOCELLULAR CARC diagnosis STERILE CIRRHOTIC AS,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2043,no_relation,diagnosis,0.493196961916072,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with STERILE CIRRHOTIC AScites, 46 patients with spontaneous bacterial peritonitis, 123 patients WITH HEPATOCELLULAR CARCinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",STERILE CIRRHOTIC AS,WITH HEPATOCELLULAR CARC
2044,FORMALDEHYDE CONCENTRATION causes FORMALDEHYDE TOXICITY,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2045,FORMALDEHYDE TOXICITY causes FORMALDEHYDE CONCENTRATION,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2046,no_relation,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2047,FORMALDEHYDE TOXICITY causes FORMALDEHYDE CONCENTRATION,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2048,FORMALDEHYDE CONCENTRATION causes FORMALDEHYDE TOXICITY,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2049,FORMALDEHYDE CONCENTRATION causes FORMALDEHYDE TOXICITY,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2050,no_relation,causes,0.676123403782813,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
2051,DIC causes DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2052,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA causes DIC,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2053,no_relation,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2054,no_relation,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2055,DIC causes DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2056,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA causes DIC,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2057,no_relation,causes,0.320256307610174,? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.,DIC,DIC SECONDARY TO ACUTE PROMYELOCYTIC LEUKEMIA
2058,no_relation,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2059,no_relation,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2060,CUTANEOUS MELANOMA treats PRIMARY MELANOMA,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2061,no_relation,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2062,PRIMARY MELANOMA treats CUTANEOUS MELANOMA,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2063,no_relation,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2064,CUTANEOUS MELANOMA treats PRIMARY MELANOMA,treats,0.8219949365267859,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
2065,no_relation,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2066,no_relation,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2067,no_relation,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2068,no_relation,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2069,TACHYCARDIAS AND RECOGNITION OF THE SITE OF diagnosis AL DIAGNOSIS O,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2070,TACHYCARDIAS AND RECOGNITION OF THE SITE OF diagnosis AL DIAGNOSIS O,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2071,no_relation,diagnosis,0.802955068546966,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differentiAL DIAGNOSIS Of wide QRS complex TACHYCARDIAS AND RECOGNITION OF THE SITE OF origin of a ventricular tachycardia.,TACHYCARDIAS AND RECOGNITION OF THE SITE OF,AL DIAGNOSIS O
2072,NICOTINE treats NICOTINE ADDICTION,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2073,NICOTINE treats NICOTINE ADDICTION,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2074,NICOTINE ADDICTION treats NICOTINE,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2075,no_relation,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2076,no_relation,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2077,NICOTINE ADDICTION treats NICOTINE,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2078,no_relation,treats,0.3396831102433789,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
2079,RETINOBLASTOMA causes CALCIFICATION,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2080,RETINOBLASTOMA causes CALCIFICATION,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2081,no_relation,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2082,CALCIFICATION causes RETINOBLASTOMA,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2083,RETINOBLASTOMA causes CALCIFICATION,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2084,RETINOBLASTOMA causes CALCIFICATION,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2085,RETINOBLASTOMA causes CALCIFICATION,causes,0.970142500145332,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and CALCIFICATION on the echographic characteristics of RETINOBLASTOMA",CALCIFICATION,RETINOBLASTOMA
2086,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2087,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2088,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2089,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2090,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2091,GALLSTONE DISSOLUTION treats URSODEOXYCHOLIC ACID,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2092,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.997054485501582,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
2093,no_relation,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2094,TUBERCULIN causes TUBERCULOSIS,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2095,TUBERCULIN causes TUBERCULOSIS,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2096,TUBERCULIN causes TUBERCULOSIS,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2097,TUBERCULIN causes TUBERCULOSIS,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2098,no_relation,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2099,TUBERCULIN causes TUBERCULOSIS,causes,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
2100,DYSPLASIA causes LESION (LSIL),causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2101,no_relation,causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2102,no_relation,causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2103,no_relation,causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2104,no_relation,causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2105,LESION (LSIL) causes DYSPLASIA,causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2106,no_relation,causes,0.549442255794756,"Low grade squamous intraepithelial LESION (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High grade squamous intraepithelial lesion (HSIL) (moderate to severe DYSPLASIA CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",DYSPLASIA,LESION (LSIL)
2107,PIMECROLIMUS treats ATOPIC DERMATITIS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2108,PIMECROLIMUS treats ATOPIC DERMATITIS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2109,PIMECROLIMUS treats ATOPIC DERMATITIS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2110,PIMECROLIMUS treats ATOPIC DERMATITIS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2111,PIMECROLIMUS treats ATOPIC DERMATITIS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2112,ATOPIC DERMATITIS treats PIMECROLIMUS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2113,PIMECROLIMUS treats ATOPIC DERMATITIS,treats,1.0,PIMECROLIMUS has generated recognition as a topical non steroidal drug labeled for treatment of ATOPIC DERMATITIS,ATOPIC DERMATITIS,PIMECROLIMUS
2114,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2115,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2116,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2117,no_relation,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2118,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2119,no_relation,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2120,DIABETES INSIPIDUS treats VASOPRESSIN,treats,0.444444444444444,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2121,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2122,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2123,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2124,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2125,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2126,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2127,STOMACH location EARLY GASTRIC CANCER,location,0.9539980920057242,We studied the clinicopathological features of four EARLY GASTRIC CANCER patients with DSCs in the submucosal layer of the STOMACH,STOMACH,EARLY GASTRIC CANCER
2128,NEUROENDOCRINE DIFFERENTIATION causes CANCER (SCLC),causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2129,CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2130,CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2131,NEUROENDOCRINE DIFFERENTIATION causes CANCER (SCLC),causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2132,no_relation,causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2133,CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2134,CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.99654575824488,Small cell lung CANCER (SCLC) manifests a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic characteristics that distinguish the tumour from non small cell lung cancer (NSCLC.,NEUROENDOCRINE DIFFERENTIATION,CANCER (SCLC)
2135,no_relation,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2136,no_relation,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2137,no_relation,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2138,THROMBOCYTOSIS causes PRIMARY THROMBOCYTHEMIA,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2139,PRIMARY THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2140,PRIMARY THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2141,PRIMARY THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.34188172937891403,The results indicate that the 21q  marker chromosome may be due to a true deletion and that the marker is no specific for PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders associated with THROMBOCYTOSIS,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA
2142,NEUROFIBROMATOSIS causes NERVOUS SYSTEM,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2143,no_relation,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2144,NERVOUS SYSTEM causes NEUROFIBROMATOSIS,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2145,no_relation,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2146,no_relation,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2147,no_relation,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2148,NERVOUS SYSTEM causes NEUROFIBROMATOSIS,causes,0.629940788348712,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
2149,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2150,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2151,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2152,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2153,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2154,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2155,RABIES VIRUS causes RABIES,causes,0.927172649945531,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against RABIES a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of RABIES VIRUS into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",RABIES VIRUS,RABIES
2156,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2157,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2158,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2159,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2160,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2161,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2162,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.995893206467704,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
2163,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2164,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2165,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2166,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2167,no_relation,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2168,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2169,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.9918365981341758,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
2170,ISLET CELLS location DIABETES,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2171,ISLET CELLS location DIABETES,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2172,no_relation,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2173,ISLET CELLS location DIABETES,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2174,ISLET CELLS location DIABETES,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2175,ISLET CELLS location DIABETES,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2176,no_relation,location,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2177,DIABETES INSIPIDUS diagnosis VASOPRESSIN,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2178,DIABETES INSIPIDUS diagnosis VASOPRESSIN,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2179,VASOPRESSIN diagnosis DIABETES INSIPIDUS,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2180,DIABETES INSIPIDUS diagnosis VASOPRESSIN,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2181,DIABETES INSIPIDUS diagnosis VASOPRESSIN,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2182,DIABETES INSIPIDUS diagnosis VASOPRESSIN,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2183,no_relation,diagnosis,0.8888888888888891,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
2184,no_relation,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2185,no_relation,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2186,no_relation,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2187,no_relation,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2188,REFLUX TO THE STOMACH treats PATHOGENESIS OF RESIDUAL GASTRITIS,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2189,PATHOGENESIS OF RESIDUAL GASTRITIS treats REFLUX TO THE STOMACH,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2190,REFLUX TO THE STOMACH treats PATHOGENESIS OF RESIDUAL GASTRITIS,treats,0.493196961916072,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2191,no_relation,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2192,LOCAL PAIN causes NEURALGIA SYNDROME,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2193,no_relation,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2194,no_relation,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2195,NEURALGIA SYNDROME causes LOCAL PAIN,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2196,no_relation,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2197,no_relation,causes,0.468521285665818,"The principal symptoms were LOCAL PAIN in 8 patients, NEURALGIA SYNDROME in 3, and rupture in 2.",LOCAL PAIN,NEURALGIA SYNDROME
2198,KIDNEYS location PYELONEPHRITIS,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2199,KIDNEYS location PYELONEPHRITIS,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2200,KIDNEYS location PYELONEPHRITIS,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2201,KIDNEYS location PYELONEPHRITIS,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2202,no_relation,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2203,PYELONEPHRITIS location KIDNEYS,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2204,KIDNEYS location PYELONEPHRITIS,location,0.9237604307034007,"In the pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS and other diseases of the KIDNEYS oxygen radicals are involved.",KIDNEYS,PYELONEPHRITIS
2205,no_relation,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2206,EFFECT ON THE VOMITING CENTER OF THE causes NAUSEA AND VOMITING,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2207,NAUSEA AND VOMITING causes EFFECT ON THE VOMITING CENTER OF THE,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2208,no_relation,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2209,EFFECT ON THE VOMITING CENTER OF THE causes NAUSEA AND VOMITING,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2210,EFFECT ON THE VOMITING CENTER OF THE causes NAUSEA AND VOMITING,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2211,EFFECT ON THE VOMITING CENTER OF THE causes NAUSEA AND VOMITING,causes,0.9901475429766742,The most common immediate side effect is NAUSEA AND VOMITING due to direct central EFFECT ON THE VOMITING CENTER OF THE brain.,EFFECT ON THE VOMITING CENTER OF THE,NAUSEA AND VOMITING
2212,IPSID causes ABDOMINAL PAIN,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2213,IPSID causes ABDOMINAL PAIN,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2214,no_relation,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2215,no_relation,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2216,ABDOMINAL PAIN causes IPSID,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2217,IPSID causes ABDOMINAL PAIN,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2218,no_relation,causes,0.9594032236002472,"Among the lymphoma patients without IPSID 65% had ABDOMINAL PAIN weight loss, abdominal masses, obstruction, and perforation.",ABDOMINAL PAIN,IPSID
2219,no_relation,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2220,no_relation,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2221,no_relation,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2222,CENTRAL NEUROFIBROMATOSIS causes INVASIVE MENINGIOMA,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2223,INVASIVE MENINGIOMA causes CENTRAL NEUROFIBROMATOSIS,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2224,INVASIVE MENINGIOMA causes CENTRAL NEUROFIBROMATOSIS,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2225,CENTRAL NEUROFIBROMATOSIS causes INVASIVE MENINGIOMA,causes,0.452267016866645,"There were eight cases of meningiomas with aggressive characteristics, such as INVASIVE MENINGIOMA malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with CENTRAL NEUROFIBROMATOSIS",INVASIVE MENINGIOMA,CENTRAL NEUROFIBROMATOSIS
2226,no_relation,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2227,no_relation,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2228,DRUG NAIVE ANIMALS causes ACUTE TOLERANCE,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2229,DRUG NAIVE ANIMALS causes ACUTE TOLERANCE,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2230,no_relation,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2231,no_relation,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2232,ACUTE TOLERANCE causes DRUG NAIVE ANIMALS,causes,0.609994281330419,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
2233,ANTHRAX causes BACILLUS ANTHRACIS,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2234,no_relation,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2235,BACILLUS ANTHRACIS causes ANTHRAX,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2236,BACILLUS ANTHRACIS causes ANTHRAX,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2237,BACILLUS ANTHRACIS causes ANTHRAX,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2238,BACILLUS ANTHRACIS causes ANTHRAX,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2239,BACILLUS ANTHRACIS causes ANTHRAX,causes,1.0,BACILLUS ANTHRACIS is the causative agent of ANTHRAX and the spore form of the bacterium represents the infectious particle introduced into a host.,BACILLUS ANTHRACIS,ANTHRAX
2240,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2241,COMPLICATIONS OF PREGNANCY causes PREECLAMPSIA,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2242,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2243,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2244,COMPLICATIONS OF PREGNANCY causes PREECLAMPSIA,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2245,COMPLICATIONS OF PREGNANCY causes PREECLAMPSIA,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2246,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.953462589245592,"PREECLAMPSIA is one of the most frequent COMPLICATIONS OF PREGNANCY however, little is known about its etiology.",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
2247,CALCITONIN treats HYPERCALCEMIA OF MALIGNANCY,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2248,CALCITONIN treats HYPERCALCEMIA OF MALIGNANCY,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2249,HYPERCALCEMIA OF MALIGNANCY treats CALCITONIN,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2250,CALCITONIN treats HYPERCALCEMIA OF MALIGNANCY,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2251,CALCITONIN treats HYPERCALCEMIA OF MALIGNANCY,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2252,CALCITONIN treats HYPERCALCEMIA OF MALIGNANCY,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2253,CALCITONIN treats HYPERCALCEMIA OF MALIGNANCY,treats,0.9878291611472622,"Other agents used in the second line treatment of HYPERCALCEMIA OF MALIGNANCY include plicamycin, CALCITONIN gallium nitrate, and the glucocorticoids.",HYPERCALCEMIA OF MALIGNANCY,CALCITONIN
2254,BRAIN causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2255,BRAIN causes MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2256,no_relation,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2257,no_relation,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2258,no_relation,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2259,no_relation,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2260,no_relation,causes,0.314485451016576,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
2261,no_relation,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2262,PREECLAMPSIA causes COMPLICATED PREGNANCIES,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2263,no_relation,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2264,PREECLAMPSIA causes COMPLICATED PREGNANCIES,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2265,PREECLAMPSIA causes COMPLICATED PREGNANCIES,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2266,no_relation,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2267,COMPLICATED PREGNANCIES causes PREECLAMPSIA,causes,0.9494253265550828,The differences between uncomplicated and COMPLICATED PREGNANCIES offer new endpoints for an early identification of gestational hypertension and PREECLAMPSIA,COMPLICATED PREGNANCIES,PREECLAMPSIA
2268,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2269,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2270,no_relation,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2271,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2272,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2273,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2274,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2275,EPSTEIN BARR VIRUS causes INFECTIOUS MONONUCLEOSIS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2276,EPSTEIN BARR VIRUS causes INFECTIOUS MONONUCLEOSIS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2277,EPSTEIN BARR VIRUS causes INFECTIOUS MONONUCLEOSIS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2278,EPSTEIN BARR VIRUS causes INFECTIOUS MONONUCLEOSIS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2279,INFECTIOUS MONONUCLEOSIS causes EPSTEIN BARR VIRUS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2280,EPSTEIN BARR VIRUS causes INFECTIOUS MONONUCLEOSIS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2281,EPSTEIN BARR VIRUS causes INFECTIOUS MONONUCLEOSIS,causes,0.99654575824488,EPSTEIN BARR VIRUS is a herpesvirus that causes INFECTIOUS MONONUCLEOSIS carcinomas and immunoproliferative disease.,EPSTEIN BARR VIRUS,INFECTIOUS MONONUCLEOSIS
2282,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2283,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2284,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2285,no_relation,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2286,no_relation,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2287,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2288,no_relation,treats,0.9760921603577252,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
2289,HEADACHE TREATMENTS treats MIGRAINE DIAGNOSIS,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2290,no_relation,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2291,MIGRAINE DIAGNOSIS treats HEADACHE TREATMENTS,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2292,HEADACHE TREATMENTS treats MIGRAINE DIAGNOSIS,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2293,no_relation,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2294,MIGRAINE DIAGNOSIS treats HEADACHE TREATMENTS,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2295,MIGRAINE DIAGNOSIS treats HEADACHE TREATMENTS,treats,0.707106781186547,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2296,DEXTROSE causes HYPOGLYCEMIA,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2297,no_relation,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2298,no_relation,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2299,no_relation,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2300,no_relation,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2301,DEXTROSE causes HYPOGLYCEMIA,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2302,DEXTROSE causes HYPOGLYCEMIA,causes,0.375,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
2303,no_relation,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2304,no_relation,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2305,no_relation,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2306,INTESTINAL TYPE ADENOCARCINOMA location INTESTINAL METAPLASIA,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2307,no_relation,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2308,INTESTINAL METAPLASIA location INTESTINAL TYPE ADENOCARCINOMA,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2309,no_relation,location,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
2310,IRON causes HEMOCHROMATOSIS,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2311,no_relation,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2312,no_relation,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2313,IRON causes HEMOCHROMATOSIS,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2314,HEMOCHROMATOSIS causes IRON,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2315,no_relation,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2316,IRON causes HEMOCHROMATOSIS,causes,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
2317,WART VIRUS causes VERRUCA VULGARIS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2318,WART VIRUS causes VERRUCA VULGARIS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2319,WART VIRUS causes VERRUCA VULGARIS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2320,VERRUCA VULGARIS causes WART VIRUS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2321,WART VIRUS causes VERRUCA VULGARIS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2322,VERRUCA VULGARIS causes WART VIRUS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2323,WART VIRUS causes VERRUCA VULGARIS,causes,1.0,In 243 cases of VERRUCA VULGARIS about 85% of the epidermal efflorescences caused by the WART VIRUS were cured by two or more applications of Solcoderm in ambulant therapy.,WART VIRUS,VERRUCA VULGARIS
2324,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2325,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2326,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2327,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2328,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2329,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2330,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.981980506061966,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
2331,ESOPHAGEAL TUMOR location MIDDLE AND LOWER ESOPHAGUS,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2332,MIDDLE AND LOWER ESOPHAGUS location ESOPHAGEAL TUMOR,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2333,MIDDLE AND LOWER ESOPHAGUS location ESOPHAGEAL TUMOR,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2334,ESOPHAGEAL TUMOR location MIDDLE AND LOWER ESOPHAGUS,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2335,MIDDLE AND LOWER ESOPHAGUS location ESOPHAGEAL TUMOR,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2336,no_relation,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2337,MIDDLE AND LOWER ESOPHAGUS location ESOPHAGEAL TUMOR,location,0.9838699100999068,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the MIDDLE AND LOWER ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,MIDDLE AND LOWER ESOPHAGUS,ESOPHAGEAL TUMOR
2338,no_relation,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2339,HEADACHE TREATMENTS causes MIGRAINE DIAGNOSIS,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2340,MIGRAINE DIAGNOSIS causes HEADACHE TREATMENTS,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2341,no_relation,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2342,MIGRAINE DIAGNOSIS causes HEADACHE TREATMENTS,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2343,no_relation,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2344,MIGRAINE DIAGNOSIS causes HEADACHE TREATMENTS,causes,0.353553390593274,"Migraine patients underwent a structured direct interview about previous MIGRAINE DIAGNOSIS comorbidity, HEADACHE TREATMENTS and their side effects and healthcare utilization for migraine.",HEADACHE TREATMENTS,MIGRAINE DIAGNOSIS
2345,METASTATIC LESION OF THE SKULL causes BONE METASTASES,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2346,METASTATIC LESION OF THE SKULL causes BONE METASTASES,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2347,METASTATIC LESION OF THE SKULL causes BONE METASTASES,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2348,BONE METASTASES causes METASTATIC LESION OF THE SKULL,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2349,BONE METASTASES causes METASTATIC LESION OF THE SKULL,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2350,BONE METASTASES causes METASTATIC LESION OF THE SKULL,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2351,BONE METASTASES causes METASTATIC LESION OF THE SKULL,causes,0.5656854249492379,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
2352,INVOLVEMENT OF THE SKIN AND MUCOSA causes DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC),causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2353,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) causes INVOLVEMENT OF THE SKIN AND MUCOSA,causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2354,no_relation,causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2355,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) causes INVOLVEMENT OF THE SKIN AND MUCOSA,causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2356,INVOLVEMENT OF THE SKIN AND MUCOSA causes DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC),causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2357,no_relation,causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2358,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) causes INVOLVEMENT OF THE SKIN AND MUCOSA,causes,0.8834522085987719,Clinical and laboratory examinations of 250 patients with chronic DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC) have revealed secondary candidal INVOLVEMENT OF THE SKIN AND MUCOSA in 121 (46.6%.,INVOLVEMENT OF THE SKIN AND MUCOSA,DERMATOSES (ECZEMA NEURODERMATITIS PSORIASIS PEMPHIGUS ETC)
2359,ALCOHOLIC CIRRHOSIS causes END STAGE LIVER DISEASE,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2360,ALCOHOLIC CIRRHOSIS causes END STAGE LIVER DISEASE,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2361,ALCOHOLIC CIRRHOSIS causes END STAGE LIVER DISEASE,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2362,ALCOHOLIC CIRRHOSIS causes END STAGE LIVER DISEASE,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2363,no_relation,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2364,ALCOHOLIC CIRRHOSIS causes END STAGE LIVER DISEASE,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2365,ALCOHOLIC CIRRHOSIS causes END STAGE LIVER DISEASE,causes,0.995893206467704,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with END STAGE LIVER DISEASE whether it is caused by ALCOHOLIC CIRRHOSIS chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",END STAGE LIVER DISEASE,ALCOHOLIC CIRRHOSIS
2366,REFLUX TO THE STOMACH causes PATHOGENESIS OF RESIDUAL GASTRITIS,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2367,no_relation,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2368,no_relation,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2369,REFLUX TO THE STOMACH causes PATHOGENESIS OF RESIDUAL GASTRITIS,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2370,REFLUX TO THE STOMACH causes PATHOGENESIS OF RESIDUAL GASTRITIS,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2371,REFLUX TO THE STOMACH causes PATHOGENESIS OF RESIDUAL GASTRITIS,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2372,PATHOGENESIS OF RESIDUAL GASTRITIS causes REFLUX TO THE STOMACH,causes,0.6575959492214289,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
2373,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2374,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2375,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2376,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2377,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2378,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2379,BUSULPHAN treats POLYCYTHAEMIA VERA,treats,0.979957887012223,1]  Treatment of POLYCYTHAEMIA VERA by radiophosphorus or BUSULPHAN: a randomized trial.,POLYCYTHAEMIA VERA,BUSULPHAN
2380,REENTRANT ARRHYTHMIAS diagnosis ANTIARRHYTHMIC DRUGS,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2381,no_relation,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2382,no_relation,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2383,no_relation,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2384,REENTRANT ARRHYTHMIAS diagnosis ANTIARRHYTHMIC DRUGS,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2385,REENTRANT ARRHYTHMIAS diagnosis ANTIARRHYTHMIC DRUGS,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2386,REENTRANT ARRHYTHMIAS diagnosis ANTIARRHYTHMIC DRUGS,diagnosis,0.8626621856275071,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
2387,EDEMA diagnosis BUMETANIDE,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2388,no_relation,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2389,BUMETANIDE diagnosis EDEMA,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2390,no_relation,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2391,no_relation,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2392,EDEMA diagnosis BUMETANIDE,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2393,EDEMA diagnosis BUMETANIDE,diagnosis,0.375,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
2394,ATOPIC CONDITIONS causes ALLERGIC CONJUNCTIVITIS,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2395,no_relation,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2396,no_relation,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2397,ATOPIC CONDITIONS causes ALLERGIC CONJUNCTIVITIS,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2398,ATOPIC CONDITIONS causes ALLERGIC CONJUNCTIVITIS,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2399,no_relation,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2400,no_relation,causes,0.50709255283711,"ATOPIC CONDITIONS include allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",ALLERGIC CONJUNCTIVITIS,ATOPIC CONDITIONS
2401,no_relation,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2402,NEUROFIBROMATOSIS TYPE 1 causes CONGENITAL PSEUDARTHROSIS OF THE ULNA,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2403,no_relation,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2404,NEUROFIBROMATOSIS TYPE 1 causes CONGENITAL PSEUDARTHROSIS OF THE ULNA,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2405,NEUROFIBROMATOSIS TYPE 1 causes CONGENITAL PSEUDARTHROSIS OF THE ULNA,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2406,CONGENITAL PSEUDARTHROSIS OF THE ULNA causes NEUROFIBROMATOSIS TYPE 1,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2407,NEUROFIBROMATOSIS TYPE 1 causes CONGENITAL PSEUDARTHROSIS OF THE ULNA,causes,0.512147519731584,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at birth with CONGENITAL PSEUDARTHROSIS OF THE ULNA and radius are described.,CONGENITAL PSEUDARTHROSIS OF THE ULNA,NEUROFIBROMATOSIS TYPE 1
2408,LEFLUNOMIDE contraindicates PREGNANCY,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2409,PREGNANCY contraindicates LEFLUNOMIDE,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2410,no_relation,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2411,LEFLUNOMIDE contraindicates PREGNANCY,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2412,PREGNANCY contraindicates LEFLUNOMIDE,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2413,LEFLUNOMIDE contraindicates PREGNANCY,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2414,LEFLUNOMIDE contraindicates PREGNANCY,contraindicates,0.857142857142857,Discontinue LEFLUNOMIDE if the drug is administered inadvertently during PREGNANCY or if the patient becomes pregnant while receiving the drug.,PREGNANCY,LEFLUNOMIDE
2415,THIAMINE (VITAMIN B1 DEFICIENCY causes WERNICKE'S ENCEPHALOPATHY,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2416,no_relation,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2417,no_relation,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2418,no_relation,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2419,THIAMINE (VITAMIN B1 DEFICIENCY causes WERNICKE'S ENCEPHALOPATHY,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2420,WERNICKE'S ENCEPHALOPATHY causes THIAMINE (VITAMIN B1 DEFICIENCY,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2421,THIAMINE (VITAMIN B1 DEFICIENCY causes WERNICKE'S ENCEPHALOPATHY,causes,0.875189948987367,"Metabolic dysfunction as a consequence of THIAMINE (VITAMIN B1 DEFICIENCY (TD), a model of WERNICKE'S ENCEPHALOPATHY leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",WERNICKE'S ENCEPHALOPATHY,THIAMINE (VITAMIN B1 DEFICIENCY
2422,DYSENTERY causes DIARRHEA,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2423,no_relation,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2424,no_relation,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2425,no_relation,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2426,no_relation,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2427,DYSENTERY causes DIARRHEA,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2428,DIARRHEA causes DYSENTERY,causes,0.8090398349558909,"Each episode of DIARRHEA lasted a mean of 3 d, and those of DYSENTERY and ARI, 5 d.",DIARRHEA,DYSENTERY
2429,DIABETES causes ISLET CELLS,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2430,ISLET CELLS causes DIABETES,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2431,no_relation,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2432,DIABETES causes ISLET CELLS,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2433,no_relation,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2434,no_relation,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2435,no_relation,causes,0.308606699924184,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
2436,OBESITY causes SEVERE OBESITY,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2437,OBESITY causes SEVERE OBESITY,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2438,SEVERE OBESITY causes OBESITY,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2439,no_relation,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2440,OBESITY causes SEVERE OBESITY,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2441,no_relation,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2442,OBESITY causes SEVERE OBESITY,causes,0.42857142857142894,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of SEVERE OBESITY among young men is due to an increased persistence of OBESITY through adolescence, which parallels the development of welfare conditions in this country.",OBESITY,SEVERE OBESITY
2443,BRAIN location STROKE,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2444,BRAIN location STROKE,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2445,BRAIN location STROKE,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2446,BRAIN location STROKE,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2447,BRAIN location STROKE,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2448,BRAIN location STROKE,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2449,no_relation,location,0.8082903768654759,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the BRAIN (in STROKE",BRAIN,STROKE
2450,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2451,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2452,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2453,CUTANEOUS OR PULMONARY BLASTOMYCOSIS treats ORAL ANTIFUNGAL (EG KETOCONAZOLE),treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2454,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2455,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2456,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
2457,SKIN location ECZEMA,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2458,SKIN location ECZEMA,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2459,ECZEMA location SKIN,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2460,SKIN location ECZEMA,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2461,no_relation,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2462,SKIN location ECZEMA,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2463,SKIN location ECZEMA,location,0.964763821237732,"All patients had ECZEMA on their hands; in addition, 4 had SKIN symptoms on airborne areas, i.e., wrists, neck and face.",SKIN,ECZEMA
2464,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2465,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2466,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2467,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2468,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2469,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2470,OVERUSED JOINTS causes ARTHROSIS,causes,0.8838834764831841,"In each case, abnormal biomechanics were caused by or associated with arthritis or ARTHROSIS due to advanced age or OVERUSED JOINTS",OVERUSED JOINTS,ARTHROSIS
2471,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2472,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2473,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2474,DIABETIC NEUROPATHY causes DIABETES,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2475,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2476,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2477,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
2478,no_relation,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2479,CHRONIC NEUROGENIC BLADDERS diagnosis PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2480,CHRONIC NEUROGENIC BLADDERS diagnosis PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2481,no_relation,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2482,no_relation,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2483,CHRONIC NEUROGENIC BLADDERS diagnosis PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2484,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE diagnosis CHRONIC NEUROGENIC BLADDERS,diagnosis,0.7624928516630229,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
2485,no_relation,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2486,HEMORRHAGE causes CENTRAL NEUROCYTOMA,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2487,HEMORRHAGE causes CENTRAL NEUROCYTOMA,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2488,no_relation,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2489,no_relation,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2490,no_relation,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2491,no_relation,causes,0.461880215351701,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
2492,HEROIN USE causes HEROIN DEPENDENCE,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2493,HEROIN USE causes HEROIN DEPENDENCE,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2494,HEROIN USE causes HEROIN DEPENDENCE,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2495,HEROIN USE causes HEROIN DEPENDENCE,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2496,HEROIN USE causes HEROIN DEPENDENCE,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2497,HEROIN USE causes HEROIN DEPENDENCE,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2498,no_relation,causes,0.979957887012223,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
2499,HYDROCEPHALUS causes ATROPHIC BRAIN,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2500,HYDROCEPHALUS causes ATROPHIC BRAIN,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2501,ATROPHIC BRAIN causes HYDROCEPHALUS,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2502,ATROPHIC BRAIN causes HYDROCEPHALUS,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2503,ATROPHIC BRAIN causes HYDROCEPHALUS,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2504,no_relation,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2505,no_relation,causes,0.8846517369293829,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
2506,ACUTE CONTACT DERMATITIS causes SKIN,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2507,no_relation,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2508,no_relation,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2509,ACUTE CONTACT DERMATITIS causes SKIN,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2510,no_relation,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2511,no_relation,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2512,no_relation,causes,0.488677777425221,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
2513,no_relation,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2514,TIMOLOL causes MYOCARDIAL INFARCTION,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2515,no_relation,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2516,no_relation,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2517,TIMOLOL causes MYOCARDIAL INFARCTION,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2518,MYOCARDIAL INFARCTION causes TIMOLOL,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2519,no_relation,causes,0.5,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2520,CUSHING'S SYNDROME diagnosis METYRAPONE TESTING TESTING,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2521,CUSHING'S SYNDROME diagnosis METYRAPONE TESTING TESTING,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2522,no_relation,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2523,CUSHING'S SYNDROME diagnosis METYRAPONE TESTING TESTING,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2524,CUSHING'S SYNDROME diagnosis METYRAPONE TESTING TESTING,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2525,CUSHING'S SYNDROME diagnosis METYRAPONE TESTING TESTING,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2526,CUSHING'S SYNDROME diagnosis METYRAPONE TESTING TESTING,diagnosis,1.0,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
2527,HAEMATURIA causes CARCINOMA OF THE BLADDER,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2528,HAEMATURIA causes CARCINOMA OF THE BLADDER,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2529,CARCINOMA OF THE BLADDER causes HAEMATURIA,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2530,HAEMATURIA causes CARCINOMA OF THE BLADDER,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2531,HAEMATURIA causes CARCINOMA OF THE BLADDER,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2532,CARCINOMA OF THE BLADDER causes HAEMATURIA,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2533,CARCINOMA OF THE BLADDER causes HAEMATURIA,causes,0.34188172937891403,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
2534,KIDNEYS location RENAL CELL CARCINOMA,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2535,KIDNEYS location RENAL CELL CARCINOMA,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2536,KIDNEYS location RENAL CELL CARCINOMA,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2537,KIDNEYS location RENAL CELL CARCINOMA,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2538,KIDNEYS location RENAL CELL CARCINOMA,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2539,KIDNEYS location RENAL CELL CARCINOMA,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2540,no_relation,location,0.948683298050514,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2541,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2542,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2543,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2544,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2545,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2546,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2547,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
2548,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2549,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2550,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2551,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2552,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2553,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2554,CISPLATINUM treats OSTEOSARCOMA,treats,0.9950371902099888,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
2555,SEPSIS treats GENTAMYCIN,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2556,GENTAMYCIN treats SEPSIS,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2557,GENTAMYCIN treats SEPSIS,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2558,GENTAMYCIN treats SEPSIS,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2559,GENTAMYCIN treats SEPSIS,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2560,GENTAMYCIN treats SEPSIS,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2561,GENTAMYCIN treats SEPSIS,treats,0.981980506061966,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
2562,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2563,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2564,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2565,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2566,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2567,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2568,no_relation,causes,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2569,VIRUS diagnosis PROOF OF A VIRAL INFECTION OF SHML,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2570,VIRUS diagnosis PROOF OF A VIRAL INFECTION OF SHML,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2571,VIRUS diagnosis PROOF OF A VIRAL INFECTION OF SHML,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2572,no_relation,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2573,no_relation,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2574,PROOF OF A VIRAL INFECTION OF SHML diagnosis VIRUS,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2575,no_relation,diagnosis,0.33333333333333304,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2576,no_relation,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2577,no_relation,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2578,PHLEBITIS causes VARICES,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2579,PHLEBITIS causes VARICES,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2580,no_relation,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2581,VARICES causes PHLEBITIS,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2582,no_relation,causes,0.617213399848368,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
2583,HOST DISEASE (GVHD) PROPHYLAXIS treats MYCOPHENOLATE MOFETIL,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2584,HOST DISEASE (GVHD) PROPHYLAXIS treats MYCOPHENOLATE MOFETIL,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2585,MYCOPHENOLATE MOFETIL treats HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2586,MYCOPHENOLATE MOFETIL treats HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2587,MYCOPHENOLATE MOFETIL treats HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2588,MYCOPHENOLATE MOFETIL treats HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2589,no_relation,treats,0.9494253265550828,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
2590,MELPHALAN treats MULTIPLE MYELOMA,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2591,MELPHALAN treats MULTIPLE MYELOMA,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2592,MULTIPLE MYELOMA treats MELPHALAN,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2593,MULTIPLE MYELOMA treats MELPHALAN,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2594,MELPHALAN treats MULTIPLE MYELOMA,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2595,MELPHALAN treats MULTIPLE MYELOMA,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2596,MELPHALAN treats MULTIPLE MYELOMA,treats,0.9918365981341758,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
2597,MERCURY EXPOSURE causes MERCURY TOXICITY,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2598,MERCURY EXPOSURE causes MERCURY TOXICITY,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2599,MERCURY TOXICITY causes MERCURY EXPOSURE,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2600,MERCURY TOXICITY causes MERCURY EXPOSURE,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2601,MERCURY EXPOSURE causes MERCURY TOXICITY,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2602,no_relation,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2603,MERCURY EXPOSURE causes MERCURY TOXICITY,causes,0.881917103688197,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
2604,LYMPH VESSELS causes LYMPHANGIOMA,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2605,LYMPH VESSELS causes LYMPHANGIOMA,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2606,LYMPH VESSELS causes LYMPHANGIOMA,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2607,LYMPH VESSELS causes LYMPHANGIOMA,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2608,no_relation,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2609,no_relation,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2610,LYMPH VESSELS causes LYMPHANGIOMA,causes,0.43643578047198495,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
2611,ADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2612,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2613,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2614,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2615,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2616,no_relation,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2617,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.977355554850442,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
2618,no_relation,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2619,no_relation,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2620,no_relation,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2621,DELAYED TYPE HYPERSENSITIVITY LESIONS diagnosis EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2622,DELAYED TYPE HYPERSENSITIVITY LESIONS diagnosis EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2623,DELAYED TYPE HYPERSENSITIVITY LESIONS diagnosis EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2624,no_relation,diagnosis,0.308606699924184,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
2625,NICKEL ALLERGY causes DELAYED TYPE HYPERSENSITIVITY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2626,NICKEL ALLERGY causes DELAYED TYPE HYPERSENSITIVITY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2627,DELAYED TYPE HYPERSENSITIVITY causes NICKEL ALLERGY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2628,DELAYED TYPE HYPERSENSITIVITY causes NICKEL ALLERGY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2629,NICKEL ALLERGY causes DELAYED TYPE HYPERSENSITIVITY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2630,NICKEL ALLERGY causes DELAYED TYPE HYPERSENSITIVITY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2631,DELAYED TYPE HYPERSENSITIVITY causes NICKEL ALLERGY,causes,0.997054485501582,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
2632,no_relation,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2633,no_relation,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2634,no_relation,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2635,no_relation,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2636,no_relation,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2637,RENAL CELL CARCINOMA causes KIDNEYS,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2638,KIDNEYS causes RENAL CELL CARCINOMA,causes,0.31622776601683805,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
2639,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2640,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2641,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2642,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2643,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2644,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2645,CROHN'S DISEASE causes SIGMOIDO VESICAL FISTULA,causes,0.970142500145332,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
2646,no_relation,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2647,HYPERTENSIVE CRISIS diagnosis SECONDARY HYPERTENSION,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2648,HYPERTENSIVE CRISIS diagnosis SECONDARY HYPERTENSION,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2649,no_relation,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2650,SECONDARY HYPERTENSION diagnosis HYPERTENSIVE CRISIS,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2651,SECONDARY HYPERTENSION diagnosis HYPERTENSIVE CRISIS,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2652,no_relation,diagnosis,0.629940788348712,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
2653,HALOTHANE diagnosis MALIGNANT HYPERTHERMIA,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2654,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2655,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2656,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2657,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2658,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2659,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9901475429766742,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
2660,no_relation,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2661,no_relation,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2662,no_relation,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2663,no_relation,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2664,EVEN WHEN THE THYROID GLAND IS OUTSIDE OF location OF RADIATION INDUCED THYROID CANCER,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2665,no_relation,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2666,EVEN WHEN THE THYROID GLAND IS OUTSIDE OF location OF RADIATION INDUCED THYROID CANCER,location,0.514495755427526,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
2667,CHRONIC NEUTROPHILIC LEUKAEMIA causes SPLENOMEGALY,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2668,no_relation,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2669,no_relation,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2670,CHRONIC NEUTROPHILIC LEUKAEMIA causes SPLENOMEGALY,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2671,CHRONIC NEUTROPHILIC LEUKAEMIA causes SPLENOMEGALY,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2672,no_relation,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2673,SPLENOMEGALY causes CHRONIC NEUTROPHILIC LEUKAEMIA,causes,0.9918365981341758,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
2674,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2675,GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS treats CYCLOSPORINE,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2676,no_relation,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2677,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2678,GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS treats CYCLOSPORINE,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2679,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2680,no_relation,treats,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
2681,no_relation,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2682,no_relation,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2683,EXTRACTION OF BOTH LENSES causes SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2684,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS causes EXTRACTION OF BOTH LENSES,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2685,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS causes EXTRACTION OF BOTH LENSES,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2686,no_relation,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2687,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS causes EXTRACTION OF BOTH LENSES,causes,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
2688,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2689,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2690,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2691,no_relation,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2692,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2693,no_relation,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2694,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
2695,MENTAL RETARDATION causes TRISOMY 21,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2696,TRISOMY 21 causes MENTAL RETARDATION,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2697,TRISOMY 21 causes MENTAL RETARDATION,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2698,TRISOMY 21 causes MENTAL RETARDATION,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2699,TRISOMY 21 causes MENTAL RETARDATION,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2700,TRISOMY 21 causes MENTAL RETARDATION,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2701,TRISOMY 21 causes MENTAL RETARDATION,causes,0.987878339907213,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
2702,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2703,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2704,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2705,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2706,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2707,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2708,FIBROMYALGIA causes SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,causes,0.997054485501582,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
2709,BRONCHIAL HYPERREACTIVITY diagnosis METHACHOLINE CHLORIDE SOLUTIONS,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2710,no_relation,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2711,BRONCHIAL HYPERREACTIVITY diagnosis METHACHOLINE CHLORIDE SOLUTIONS,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2712,no_relation,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2713,METHACHOLINE CHLORIDE SOLUTIONS diagnosis BRONCHIAL HYPERREACTIVITY,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2714,BRONCHIAL HYPERREACTIVITY diagnosis METHACHOLINE CHLORIDE SOLUTIONS,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2715,BRONCHIAL HYPERREACTIVITY diagnosis METHACHOLINE CHLORIDE SOLUTIONS,diagnosis,1.0,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
2716,HEPATITIS B VIRUS causes ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2717,HEPATITIS B VIRUS causes ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2718,HEPATITIS B VIRUS causes ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2719,no_relation,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2720,HEPATITIS B VIRUS causes ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2721,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B causes HEPATITIS B VIRUS,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2722,HEPATITIS B VIRUS causes ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B,causes,1.0,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
2723,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS causes DYSPLASIA,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2724,DYSPLASIA causes 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2725,DYSPLASIA causes 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2726,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS causes DYSPLASIA,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2727,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS causes DYSPLASIA,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2728,no_relation,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2729,DYSPLASIA causes 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS,causes,0.461880215351701,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
2730,ECLAMPSIA causes NON LUPUS RELATED PREGNANCY COMPLICATIONS,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2731,NON LUPUS RELATED PREGNANCY COMPLICATIONS causes ECLAMPSIA,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2732,NON LUPUS RELATED PREGNANCY COMPLICATIONS causes ECLAMPSIA,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2733,no_relation,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2734,NON LUPUS RELATED PREGNANCY COMPLICATIONS causes ECLAMPSIA,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2735,ECLAMPSIA causes NON LUPUS RELATED PREGNANCY COMPLICATIONS,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2736,ECLAMPSIA causes NON LUPUS RELATED PREGNANCY COMPLICATIONS,causes,0.787838597158335,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
2737,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2738,BACTERIAL VAGINOSIS treats INTRAVAGINAL 0.75% METRONIDAZOLE GEL,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2739,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2740,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2741,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2742,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2743,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
2744,INTRAVASCULAR COAGULATION (DIC treats APL,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2745,no_relation,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2746,no_relation,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2747,no_relation,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2748,INTRAVASCULAR COAGULATION (DIC treats APL,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2749,no_relation,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2750,no_relation,treats,0.78086880944303,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
2751,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2752,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2753,no_relation,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2754,no_relation,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2755,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2756,no_relation,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2757,no_relation,causes,0.6324555320336761,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2758,FUNGUS causes FUNGAL INFECTION,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2759,FUNGUS causes FUNGAL INFECTION,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2760,FUNGUS causes FUNGAL INFECTION,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2761,FUNGUS causes FUNGAL INFECTION,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2762,FUNGUS causes FUNGAL INFECTION,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2763,FUNGUS causes FUNGAL INFECTION,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2764,no_relation,causes,0.975900072948533,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
2765,no_relation,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2766,CUTANEOUS VESSEL VASODILATION causes BLOOD FLOW INCREASED,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2767,CUTANEOUS VESSEL VASODILATION causes BLOOD FLOW INCREASED,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2768,CUTANEOUS VESSEL VASODILATION causes BLOOD FLOW INCREASED,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2769,CUTANEOUS VESSEL VASODILATION causes BLOOD FLOW INCREASED,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2770,no_relation,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2771,CUTANEOUS VESSEL VASODILATION causes BLOOD FLOW INCREASED,causes,0.9594032236002472,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
2772,SKIN location LICHENOID ERUPTION,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2773,SKIN location LICHENOID ERUPTION,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2774,no_relation,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2775,SKIN location LICHENOID ERUPTION,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2776,SKIN location LICHENOID ERUPTION,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2777,SKIN location LICHENOID ERUPTION,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2778,SKIN location LICHENOID ERUPTION,location,0.768349819927832,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
2779,TIMOLOL treats MYOCARDIAL INFARCTION,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2780,TIMOLOL treats MYOCARDIAL INFARCTION,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2781,no_relation,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2782,MYOCARDIAL INFARCTION treats TIMOLOL,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2783,no_relation,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2784,MYOCARDIAL INFARCTION treats TIMOLOL,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2785,TIMOLOL treats MYOCARDIAL INFARCTION,treats,0.666666666666667,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2786,MICRONUTRIENT DEFICITS causes PROTEIN CALORIE MALNUTRITION,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2787,MICRONUTRIENT DEFICITS causes PROTEIN CALORIE MALNUTRITION,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2788,PROTEIN CALORIE MALNUTRITION causes MICRONUTRIENT DEFICITS,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2789,MICRONUTRIENT DEFICITS causes PROTEIN CALORIE MALNUTRITION,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2790,MICRONUTRIENT DEFICITS causes PROTEIN CALORIE MALNUTRITION,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2791,PROTEIN CALORIE MALNUTRITION causes MICRONUTRIENT DEFICITS,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2792,MICRONUTRIENT DEFICITS causes PROTEIN CALORIE MALNUTRITION,causes,0.9901475429766742,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
2793,ESSENTIAL THROMBOCYTHEMIA diagnosis THROMBOCYTOSIS,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2794,ESSENTIAL THROMBOCYTHEMIA diagnosis THROMBOCYTOSIS,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2795,no_relation,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2796,THROMBOCYTOSIS diagnosis ESSENTIAL THROMBOCYTHEMIA,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2797,THROMBOCYTOSIS diagnosis ESSENTIAL THROMBOCYTHEMIA,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2798,no_relation,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2799,no_relation,diagnosis,0.381000381000572,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
2800,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2801,no_relation,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2802,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2803,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2804,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2805,no_relation,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2806,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.962250448649376,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
2807,PTLD diagnosis LYMPHADENOPATHY,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2808,LYMPHADENOPATHY diagnosis PTLD,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2809,no_relation,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2810,no_relation,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2811,PTLD diagnosis LYMPHADENOPATHY,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2812,LYMPHADENOPATHY diagnosis PTLD,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2813,no_relation,diagnosis,0.98058067569092,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
2814,no_relation,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2815,ACUTE LUPUS PNEUMONITIS causes SLE,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2816,no_relation,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2817,SLE causes ACUTE LUPUS PNEUMONITIS,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2818,ACUTE LUPUS PNEUMONITIS causes SLE,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2819,ACUTE LUPUS PNEUMONITIS causes SLE,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2820,no_relation,causes,0.342997170285018,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
2821,no_relation,causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2822,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES (MDS),causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2823,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES (MDS),causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2824,no_relation,causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2825,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES (MDS),causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2826,MYELODYSPLASTIC SYNDROMES (MDS) causes INEFFECTIVE HEMATOPOIESIS,causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2827,MYELODYSPLASTIC SYNDROMES (MDS) causes INEFFECTIVE HEMATOPOIESIS,causes,0.975900072948533,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
2828,SCHIZOPHRENIA treats OLANZAPINE,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2829,OLANZAPINE treats SCHIZOPHRENIA,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2830,OLANZAPINE treats SCHIZOPHRENIA,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2831,OLANZAPINE treats SCHIZOPHRENIA,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2832,OLANZAPINE treats SCHIZOPHRENIA,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2833,OLANZAPINE treats SCHIZOPHRENIA,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2834,OLANZAPINE treats SCHIZOPHRENIA,treats,0.970494958830946,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
2835,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2836,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2837,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2838,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2839,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2840,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2841,COBALAMIN DEFICIENCY causes SUBACUTE COMBINED DEGENERATION OF THE SPINAL,causes,0.9797958971132712,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
2842,LOW TURNOVER OSTEOMALACIA causes LOW BONE TURNOVER,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2843,LOW TURNOVER OSTEOMALACIA causes LOW BONE TURNOVER,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2844,LOW TURNOVER OSTEOMALACIA causes LOW BONE TURNOVER,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2845,LOW TURNOVER OSTEOMALACIA causes LOW BONE TURNOVER,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2846,LOW BONE TURNOVER causes LOW TURNOVER OSTEOMALACIA,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2847,LOW TURNOVER OSTEOMALACIA causes LOW BONE TURNOVER,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2848,no_relation,causes,0.9491579957524988,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
2849,no_relation,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2850,no_relation,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2851,VIRUS causes PROOF OF A VIRAL INFECTION OF SHML,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2852,no_relation,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2853,no_relation,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2854,no_relation,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2855,VIRUS causes PROOF OF A VIRAL INFECTION OF SHML,causes,0.5,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
2856,no_relation,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2857,no_relation,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2858,no_relation,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2859,UTERINE CARCINOSARCOMA contraindicates SARCOMATOUS COMPONENTS,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2860,UTERINE CARCINOSARCOMA contraindicates SARCOMATOUS COMPONENTS,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2861,SARCOMATOUS COMPONENTS contraindicates UTERINE CARCINOSARCOMA,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2862,no_relation,contraindicates,0.338061701891407,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
2863,no_relation,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2864,MYOCARDIAL INFARCTION diagnosis TIMOLOL,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2865,no_relation,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2866,TIMOLOL diagnosis MYOCARDIAL INFARCTION,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2867,no_relation,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2868,no_relation,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2869,no_relation,diagnosis,0.33333333333333304,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
2870,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2871,CUSHING'S SYNDROME treats AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2872,CUSHING'S SYNDROME treats AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2873,no_relation,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2874,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2875,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2876,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
2877,HYPERSENSITIVITY contraindicates ALLERGY,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2878,HYPERSENSITIVITY contraindicates ALLERGY,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2879,HYPERSENSITIVITY contraindicates ALLERGY,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2880,no_relation,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2881,no_relation,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2882,no_relation,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2883,ALLERGY contraindicates HYPERSENSITIVITY,contraindicates,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
2884,HEPATOMA causes ASCITES,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2885,HEPATOMA causes ASCITES,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2886,ASCITES causes HEPATOMA,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2887,no_relation,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2888,HEPATOMA causes ASCITES,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2889,no_relation,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2890,no_relation,causes,0.583459965991578,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA
2891,no_relation,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2892,FLUDARABINE THERAPY treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2893,FLUDARABINE THERAPY treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2894,no_relation,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2895,CHRONIC LYMPHOCYTIC LEUKEMIA treats FLUDARABINE THERAPY,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2896,FLUDARABINE THERAPY treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2897,no_relation,treats,0.979957887012223,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY
2898,PROSTATES location PROSTATIC CARCINOMAS,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2899,PROSTATES location PROSTATIC CARCINOMAS,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2900,PROSTATIC CARCINOMAS location PROSTATES,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2901,PROSTATES location PROSTATIC CARCINOMAS,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2902,PROSTATES location PROSTATIC CARCINOMAS,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2903,PROSTATES location PROSTATIC CARCINOMAS,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2904,no_relation,location,0.979957887012223,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS
2905,ONCOGENIC OSTEOMALACIA causes PHOSPHATURIA,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2906,no_relation,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2907,no_relation,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2908,PHOSPHATURIA causes ONCOGENIC OSTEOMALACIA,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2909,ONCOGENIC OSTEOMALACIA causes PHOSPHATURIA,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2910,no_relation,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2911,ONCOGENIC OSTEOMALACIA causes PHOSPHATURIA,causes,0.9830783046228492,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA
2912,no_relation,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2913,PEMPHIGUS VULGARIS causes DISEASE OF THE SKIN AND MUCOUS MEMBRANES,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2914,no_relation,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2915,no_relation,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2916,no_relation,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2917,PEMPHIGUS VULGARIS causes DISEASE OF THE SKIN AND MUCOUS MEMBRANES,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2918,PEMPHIGUS VULGARIS causes DISEASE OF THE SKIN AND MUCOUS MEMBRANES,causes,0.320256307610174,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
2919,no_relation,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2920,CALCIUM DEPOSITS causes EXTRASKELETAL OSTEOCHONDROMA,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2921,no_relation,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2922,EXTRASKELETAL OSTEOCHONDROMA causes CALCIUM DEPOSITS,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2923,CALCIUM DEPOSITS causes EXTRASKELETAL OSTEOCHONDROMA,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2924,EXTRASKELETAL OSTEOCHONDROMA causes CALCIUM DEPOSITS,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2925,no_relation,causes,0.7715167498104591,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
2926,ENDOTOXIN causes ENDOTOXIC SHOCK,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2927,ENDOTOXIC SHOCK causes ENDOTOXIN,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2928,ENDOTOXIC SHOCK causes ENDOTOXIN,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2929,ENDOTOXIN causes ENDOTOXIC SHOCK,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2930,no_relation,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2931,ENDOTOXIN causes ENDOTOXIC SHOCK,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2932,ENDOTOXIN causes ENDOTOXIC SHOCK,causes,0.956182887467515,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK
2933,no_relation,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2934,no_relation,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2935,NICKEL ALLERGY GROUP contraindicates NON ALLERGY GROUP,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2936,NON ALLERGY GROUP contraindicates NICKEL ALLERGY GROUP,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2937,no_relation,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2938,no_relation,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2939,NICKEL ALLERGY GROUP contraindicates NON ALLERGY GROUP,contraindicates,0.38490017945975,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP
2940,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2941,DELUSIONAL DEPRESSION treats TRICYCLIC ANTIDEPRESSANT,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2942,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2943,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2944,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2945,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2946,DELUSIONAL DEPRESSION treats TRICYCLIC ANTIDEPRESSANT,treats,1.0,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
2947,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2948,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2949,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2950,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2951,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2952,no_relation,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2953,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.9931270663228408,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE
2954,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2955,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2956,no_relation,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2957,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2958,GRAVES' THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2959,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2960,GRAVES' THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.737209780774486,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS
2961,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2962,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2963,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2964,no_relation,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2965,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2966,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2967,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.676123403782813,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
2968,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2969,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2970,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2971,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2972,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2973,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2974,KNEE JOINTS location CLINICAL ARTHRITIS,location,0.975900072948533,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS
2975,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2976,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2977,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2978,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2979,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2980,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2981,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
2982,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2983,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2984,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2985,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2986,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2987,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2988,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH
2989,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosis BILATERAL GROIN ADENOPATHY,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2990,no_relation,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2991,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosis BILATERAL GROIN ADENOPATHY,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2992,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosis BILATERAL GROIN ADENOPATHY,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2993,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosis BILATERAL GROIN ADENOPATHY,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2994,no_relation,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2995,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosis BILATERAL GROIN ADENOPATHY,diagnosis,0.784464540552736,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA
2996,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2997,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2998,no_relation,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2999,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
3000,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
3001,NEUROBLASTOMA causes SPONTANEOUS ADRENAL HEMORRHAGE,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
3002,NEUROBLASTOMA causes SPONTANEOUS ADRENAL HEMORRHAGE,causes,0.680413817439772,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
3003,CLOZAPINE treats SCHIZOPHRENIA,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3004,SCHIZOPHRENIA treats CLOZAPINE,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3005,CLOZAPINE treats SCHIZOPHRENIA,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3006,CLOZAPINE treats SCHIZOPHRENIA,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3007,CLOZAPINE treats SCHIZOPHRENIA,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3008,CLOZAPINE treats SCHIZOPHRENIA,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3009,CLOZAPINE treats SCHIZOPHRENIA,treats,1.0,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3010,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3011,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3012,PD treats IMMEDIATE RELEASE LEVODOPA,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3013,PD treats IMMEDIATE RELEASE LEVODOPA,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3014,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3015,PD treats IMMEDIATE RELEASE LEVODOPA,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3016,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
3017,SEIZURES causes EPILEPSY,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3018,SEIZURES causes EPILEPSY,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3019,no_relation,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3020,EPILEPSY causes SEIZURES,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3021,EPILEPSY causes SEIZURES,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3022,EPILEPSY causes SEIZURES,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3023,SEIZURES causes EPILEPSY,causes,0.668153104781061,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY
3024,HEMOPHAGOCYTOSIS causes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3025,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS causes HEMOPHAGOCYTOSIS,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3026,HEMOPHAGOCYTOSIS causes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3027,no_relation,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3028,no_relation,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3029,HEMOPHAGOCYTOSIS causes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3030,no_relation,causes,0.452267016866645,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
3031,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3032,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3033,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3034,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3035,no_relation,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3036,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3037,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,causes,0.462910049886276,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
3038,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3039,BACTERIA treats S PANAMA BACTEREMIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3040,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3041,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3042,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3043,no_relation,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3044,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3045,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3046,no_relation,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3047,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3048,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3049,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3050,no_relation,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3051,no_relation,treats,0.50709255283711,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3052,ASCITES location HEPATOMA,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3053,ASCITES location HEPATOMA,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3054,HEPATOMA location ASCITES,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3055,ASCITES location HEPATOMA,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3056,no_relation,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3057,ASCITES location HEPATOMA,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3058,HEPATOMA location ASCITES,location,0.78086880944303,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
3059,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3060,ARRHYTHMIAS treats ANTIARRHYTHMIC DRUG EFFICACY,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3061,no_relation,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3062,no_relation,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3063,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3064,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3065,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,treats,0.7624928516630229,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
3066,no_relation,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3067,LENSES location CATARACTS,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3068,CATARACTS location LENSES,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3069,CATARACTS location LENSES,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3070,LENSES location CATARACTS,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3071,LENSES location CATARACTS,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3072,CATARACTS location LENSES,location,0.9594032236002472,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS
3073,VERRUCA PLANA TYPE LESION causes HYPERKERATOSIS,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3074,VERRUCA PLANA TYPE LESION causes HYPERKERATOSIS,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3075,no_relation,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3076,VERRUCA PLANA TYPE LESION causes HYPERKERATOSIS,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3077,no_relation,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3078,no_relation,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3079,no_relation,causes,0.529812942826018,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION
3080,no_relation,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3081,no_relation,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3082,no_relation,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3083,ENALAPRIL causes CONGESTIVE HEART FAILURE,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3084,no_relation,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3085,ENALAPRIL causes CONGESTIVE HEART FAILURE,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3086,CONGESTIVE HEART FAILURE causes ENALAPRIL,causes,0.31622776601683805,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
3087,RISPERIDONE causes SCHIZOPHRENIA,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3088,SCHIZOPHRENIA causes RISPERIDONE,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3089,no_relation,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3090,no_relation,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3091,no_relation,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3092,RISPERIDONE causes SCHIZOPHRENIA,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3093,no_relation,causes,0.34188172937891403,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
3094,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3095,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3096,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3097,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3098,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3099,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3100,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
3101,no_relation,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3102,no_relation,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3103,no_relation,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3104,MICROCALCIFICATION CLUSTERS causes IN SITU (DCIS,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3105,no_relation,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3106,IN SITU (DCIS causes MICROCALCIFICATION CLUSTERS,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3107,MICROCALCIFICATION CLUSTERS causes IN SITU (DCIS,causes,0.547722557505166,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS
3108,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3109,no_relation,causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3110,no_relation,causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3111,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3112,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3113,no_relation,causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3114,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),causes,0.963086824686154,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA
3115,EPILEPSY causes SEIZURE,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3116,EPILEPSY causes SEIZURE,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3117,EPILEPSY causes SEIZURE,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3118,EPILEPSY causes SEIZURE,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3119,EPILEPSY causes SEIZURE,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3120,EPILEPSY causes SEIZURE,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3121,no_relation,causes,0.937042571331636,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY
3122,EDROPHONIUM (TENSILON) TEST diagnosis MYASTHENIA GRAVIS,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3123,MYASTHENIA GRAVIS diagnosis EDROPHONIUM (TENSILON) TEST,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3124,MYASTHENIA GRAVIS diagnosis EDROPHONIUM (TENSILON) TEST,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3125,MYASTHENIA GRAVIS diagnosis EDROPHONIUM (TENSILON) TEST,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3126,EDROPHONIUM (TENSILON) TEST diagnosis MYASTHENIA GRAVIS,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3127,MYASTHENIA GRAVIS diagnosis EDROPHONIUM (TENSILON) TEST,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3128,MYASTHENIA GRAVIS diagnosis EDROPHONIUM (TENSILON) TEST,diagnosis,1.0,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST
3129,BACTERIA causes S PANAMA BACTEREMIA,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3130,BACTERIA causes S PANAMA BACTEREMIA,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3131,BACTERIA causes S PANAMA BACTEREMIA,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3132,BACTERIA causes S PANAMA BACTEREMIA,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3133,no_relation,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3134,BACTERIA causes S PANAMA BACTEREMIA,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3135,S PANAMA BACTEREMIA causes BACTERIA,causes,0.7302967433402209,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
3136,NICOTINE DEPENDENCE causes NICOTINE,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3137,NICOTINE causes NICOTINE DEPENDENCE,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3138,NICOTINE causes NICOTINE DEPENDENCE,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3139,no_relation,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3140,NICOTINE causes NICOTINE DEPENDENCE,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3141,NICOTINE causes NICOTINE DEPENDENCE,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3142,NICOTINE causes NICOTINE DEPENDENCE,causes,0.975900072948533,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE
3143,ENDOMETRIOSIS causes PAIN,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3144,ENDOMETRIOSIS causes PAIN,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3145,ENDOMETRIOSIS causes PAIN,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3146,ENDOMETRIOSIS causes PAIN,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3147,ENDOMETRIOSIS causes PAIN,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3148,PAIN causes ENDOMETRIOSIS,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3149,ENDOMETRIOSIS causes PAIN,causes,0.99654575824488,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
3150,no_relation,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3151,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3152,MILD TO MODERATE INTELLECTUAL DISABILITY causes PART OF WAGR SYNDROME,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3153,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3154,MILD TO MODERATE INTELLECTUAL DISABILITY causes PART OF WAGR SYNDROME,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3155,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3156,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,causes,0.737209780774486,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME
3157,ALLERGY causes HYPERSENSITIVITY,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3158,no_relation,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3159,ALLERGY causes HYPERSENSITIVITY,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3160,ALLERGY causes HYPERSENSITIVITY,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3161,HYPERSENSITIVITY causes ALLERGY,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3162,HYPERSENSITIVITY causes ALLERGY,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3163,HYPERSENSITIVITY causes ALLERGY,causes,0.437594974493684,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY
3164,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) causes HEMOPHAGOCYTOSIS,causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3165,HEMOPHAGOCYTOSIS causes VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS),causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3166,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) causes HEMOPHAGOCYTOSIS,causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3167,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) causes HEMOPHAGOCYTOSIS,causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3168,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) causes HEMOPHAGOCYTOSIS,causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3169,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) causes HEMOPHAGOCYTOSIS,causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3170,no_relation,causes,0.8616404368553291,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
3171,no_relation,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3172,ULCERATIVE COLITIS causes INFLAMMATORY BOWEL DISEASES,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3173,ULCERATIVE COLITIS causes INFLAMMATORY BOWEL DISEASES,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3174,no_relation,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3175,ULCERATIVE COLITIS causes INFLAMMATORY BOWEL DISEASES,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3176,INFLAMMATORY BOWEL DISEASES causes ULCERATIVE COLITIS,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3177,no_relation,causes,0.6154574548966639,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
3178,PERIODIC ALTERNATING HYPERTENSION causes ADRENAL PHEOCHROMOCYTOMA,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3179,ADRENAL PHEOCHROMOCYTOMA causes PERIODIC ALTERNATING HYPERTENSION,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3180,no_relation,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3181,ADRENAL PHEOCHROMOCYTOMA causes PERIODIC ALTERNATING HYPERTENSION,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3182,ADRENAL PHEOCHROMOCYTOMA causes PERIODIC ALTERNATING HYPERTENSION,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3183,ADRENAL PHEOCHROMOCYTOMA causes PERIODIC ALTERNATING HYPERTENSION,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3184,ADRENAL PHEOCHROMOCYTOMA causes PERIODIC ALTERNATING HYPERTENSION,causes,0.843274042711568,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
3185,no_relation,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3186,CRANIOCEREBRAL TRAUMA causes POSTTRAUMATIC EPILEPSY,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3187,CRANIOCEREBRAL TRAUMA causes POSTTRAUMATIC EPILEPSY,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3188,CRANIOCEREBRAL TRAUMA causes POSTTRAUMATIC EPILEPSY,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3189,CRANIOCEREBRAL TRAUMA causes POSTTRAUMATIC EPILEPSY,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3190,no_relation,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3191,CRANIOCEREBRAL TRAUMA causes POSTTRAUMATIC EPILEPSY,causes,0.8006407690254359,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
3192,no_relation,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3193,AGGRESSIVE CLINICAL COURSE treats PLASMA CELL LEUKAEMIA,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3194,AGGRESSIVE CLINICAL COURSE treats PLASMA CELL LEUKAEMIA,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3195,PLASMA CELL LEUKAEMIA treats AGGRESSIVE CLINICAL COURSE,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3196,AGGRESSIVE CLINICAL COURSE treats PLASMA CELL LEUKAEMIA,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3197,no_relation,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3198,no_relation,treats,0.4574957109978139,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3199,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3200,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3201,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3202,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3203,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3204,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3205,STOMACH location GASTRIC CARCINOMA,location,0.984731927834662,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
3206,WARFARIN causes PREGNANCY,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3207,no_relation,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3208,no_relation,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3209,no_relation,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3210,no_relation,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3211,no_relation,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3212,no_relation,causes,0.855186110494136,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
3213,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3214,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3215,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3216,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3217,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3218,no_relation,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3219,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.6575959492214289,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
3220,no_relation,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3221,SUDDEN INFANT DEATHS treats SIDS,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3222,no_relation,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3223,no_relation,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3224,no_relation,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3225,SIDS treats SUDDEN INFANT DEATHS,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3226,SIDS treats SUDDEN INFANT DEATHS,treats,0.437594974493684,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
3227,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3228,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3229,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3230,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3231,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3232,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3233,ALL TRANS RETINOIC ACID (ATRA) treats ACUTE PROMYELOCYTIC LEUKEMIA (APL),treats,1.0,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
3234,IVIG treats IDIOPATHIC THROMBOCYTOPENIC PURPURA,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3235,no_relation,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3236,IDIOPATHIC THROMBOCYTOPENIC PURPURA treats IVIG,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3237,IVIG treats IDIOPATHIC THROMBOCYTOPENIC PURPURA,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3238,no_relation,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3239,IVIG treats IDIOPATHIC THROMBOCYTOPENIC PURPURA,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3240,IVIG treats IDIOPATHIC THROMBOCYTOPENIC PURPURA,treats,0.8846517369293829,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
3241,AL AMYLOIDOSIS causes MARKED HEPATOMEGALY,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3242,AL AMYLOIDOSIS causes MARKED HEPATOMEGALY,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3243,AL AMYLOIDOSIS causes MARKED HEPATOMEGALY,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3244,no_relation,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3245,AL AMYLOIDOSIS causes MARKED HEPATOMEGALY,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3246,no_relation,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3247,AL AMYLOIDOSIS causes MARKED HEPATOMEGALY,causes,0.9237604307034007,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3248,MMMT causes SARCOMATOUS COMPONENT,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3249,no_relation,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3250,SARCOMATOUS COMPONENT causes MMMT,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3251,no_relation,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3252,MMMT causes SARCOMATOUS COMPONENT,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3253,no_relation,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3254,no_relation,causes,0.5,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
3255,MEDICATIONS treats TOLERANCE,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3256,no_relation,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3257,no_relation,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3258,no_relation,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3259,MEDICATIONS treats TOLERANCE,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3260,no_relation,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3261,no_relation,treats,0.875189948987367,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
3262,HEMORRHAGIC FEVER WITH RENAL SYNDROME treats HANTAAN VIRUS,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3263,HANTAAN VIRUS treats HEMORRHAGIC FEVER WITH RENAL SYNDROME,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3264,HEMORRHAGIC FEVER WITH RENAL SYNDROME treats HANTAAN VIRUS,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3265,no_relation,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3266,no_relation,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3267,no_relation,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3268,HANTAAN VIRUS treats HEMORRHAGIC FEVER WITH RENAL SYNDROME,treats,0.753778361444409,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
3269,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3270,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3271,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3272,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3273,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3274,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3275,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
3276,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3277,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3278,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3279,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3280,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3281,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3282,ABSENCE EPILEPSY causes SEIZURES,causes,0.8867963503478641,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
3283,no_relation,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3284,ATOPIC DERMATITIS causes ASTHMA,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3285,no_relation,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3286,ATOPIC DERMATITIS causes ASTHMA,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3287,ASTHMA causes ATOPIC DERMATITIS,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3288,no_relation,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3289,no_relation,causes,0.38490017945975,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
3290,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3291,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3292,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3293,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3294,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3295,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3296,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.985329278164293,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
3297,VARICELLA causes CHICKENPOX,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3298,no_relation,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3299,no_relation,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3300,no_relation,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3301,no_relation,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3302,no_relation,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3303,no_relation,causes,0.566138517072298,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
3304,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3305,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3306,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3307,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3308,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3309,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3310,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.943456353049726,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3311,CALCIFICATIONS causes DCIS,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3312,no_relation,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3313,DCIS causes CALCIFICATIONS,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3314,no_relation,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3315,no_relation,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3316,CALCIFICATIONS causes DCIS,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3317,CALCIFICATIONS causes DCIS,causes,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
3318,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3319,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3320,DEPRESSION treats TRICYCLIC ANTIDEPRESSANTS,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3321,DEPRESSION treats TRICYCLIC ANTIDEPRESSANTS,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3322,no_relation,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3323,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3324,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.981980506061966,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
3325,BONE MARROW location MYELOGENOUS LEUKEMIA,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3326,BONE MARROW location MYELOGENOUS LEUKEMIA,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3327,BONE MARROW location MYELOGENOUS LEUKEMIA,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3328,BONE MARROW location MYELOGENOUS LEUKEMIA,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3329,BONE MARROW location MYELOGENOUS LEUKEMIA,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3330,no_relation,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3331,BONE MARROW location MYELOGENOUS LEUKEMIA,location,0.848528137423857,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
3332,CHRONIC DIARRHEA causes LOOSE STOOLS,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3333,CHRONIC DIARRHEA causes LOOSE STOOLS,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3334,LOOSE STOOLS causes CHRONIC DIARRHEA,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3335,CHRONIC DIARRHEA causes LOOSE STOOLS,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3336,CHRONIC DIARRHEA causes LOOSE STOOLS,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3337,CHRONIC DIARRHEA causes LOOSE STOOLS,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3338,no_relation,causes,0.9354143466934848,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
3339,VIRUS causes VIRAL INFECTION,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3340,no_relation,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3341,no_relation,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3342,VIRUS causes VIRAL INFECTION,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3343,VIRUS causes VIRAL INFECTION,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3344,VIRUS causes VIRAL INFECTION,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3345,VIRUS causes VIRAL INFECTION,causes,0.848874687627165,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
3346,MARKED HEPATOMEGALY diagnosis AL AMYLOIDOSIS,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3347,MARKED HEPATOMEGALY diagnosis AL AMYLOIDOSIS,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3348,AL AMYLOIDOSIS diagnosis MARKED HEPATOMEGALY,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3349,MARKED HEPATOMEGALY diagnosis AL AMYLOIDOSIS,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3350,MARKED HEPATOMEGALY diagnosis AL AMYLOIDOSIS,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3351,AL AMYLOIDOSIS diagnosis MARKED HEPATOMEGALY,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3352,MARKED HEPATOMEGALY diagnosis AL AMYLOIDOSIS,diagnosis,0.346410161513775,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
3353,no_relation,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3354,BLISTERING SKIN DISEASE PEMPHIGUS causes SKIN WOUNDS,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3355,BLISTERING SKIN DISEASE PEMPHIGUS causes SKIN WOUNDS,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3356,SKIN WOUNDS causes BLISTERING SKIN DISEASE PEMPHIGUS,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3357,SKIN WOUNDS causes BLISTERING SKIN DISEASE PEMPHIGUS,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3358,BLISTERING SKIN DISEASE PEMPHIGUS causes SKIN WOUNDS,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3359,BLISTERING SKIN DISEASE PEMPHIGUS causes SKIN WOUNDS,causes,0.790569415042095,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
3360,PLASMA GLUCOSE treats HYPOGLYCEMIA,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3361,no_relation,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3362,no_relation,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3363,no_relation,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3364,no_relation,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3365,no_relation,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3366,no_relation,treats,0.480384461415261,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3367,no_relation,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3368,GALLBLADDER diagnosis ACUTE CHOLECYSTITIS,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3369,ACUTE CHOLECYSTITIS diagnosis GALLBLADDER,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3370,GALLBLADDER diagnosis ACUTE CHOLECYSTITIS,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3371,ACUTE CHOLECYSTITIS diagnosis GALLBLADDER,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3372,GALLBLADDER diagnosis ACUTE CHOLECYSTITIS,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3373,ACUTE CHOLECYSTITIS diagnosis GALLBLADDER,diagnosis,0.970494958830946,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
3374,ARTERIAL OCCLUSION location BILATERAL INTERNAL CAROTID ARTERIES,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3375,ARTERIAL OCCLUSION location BILATERAL INTERNAL CAROTID ARTERIES,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3376,BILATERAL INTERNAL CAROTID ARTERIES location ARTERIAL OCCLUSION,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3377,BILATERAL INTERNAL CAROTID ARTERIES location ARTERIAL OCCLUSION,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3378,ARTERIAL OCCLUSION location BILATERAL INTERNAL CAROTID ARTERIES,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3379,BILATERAL INTERNAL CAROTID ARTERIES location ARTERIAL OCCLUSION,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3380,no_relation,location,0.8427009716003839,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
3381,FAMILIAL HYPERCHOLESTEROLEMIA causes EZETIMIBE,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3382,FAMILIAL HYPERCHOLESTEROLEMIA causes EZETIMIBE,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3383,EZETIMIBE causes FAMILIAL HYPERCHOLESTEROLEMIA,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3384,no_relation,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3385,no_relation,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3386,FAMILIAL HYPERCHOLESTEROLEMIA causes EZETIMIBE,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3387,no_relation,causes,0.707106781186547,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3388,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3389,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3390,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3391,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3392,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3393,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3394,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.948683298050514,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
3395,ACEBUTOLOL treats HYPERTENSION,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3396,ACEBUTOLOL treats HYPERTENSION,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3397,ACEBUTOLOL treats HYPERTENSION,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3398,ACEBUTOLOL treats HYPERTENSION,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3399,HYPERTENSION treats ACEBUTOLOL,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3400,ACEBUTOLOL treats HYPERTENSION,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3401,ACEBUTOLOL treats HYPERTENSION,treats,1.0,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
3402,no_relation,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3403,no_relation,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3404,no_relation,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3405,EPILEPTIC SEIZURES causes PSYCHOGENIC NON EPILEPTIC SEIZURES,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3406,no_relation,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3407,EPILEPTIC SEIZURES causes PSYCHOGENIC NON EPILEPTIC SEIZURES,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3408,no_relation,causes,0.3651483716701111,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
3409,no_relation,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3410,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3411,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3412,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3413,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3414,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3415,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,1.0,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
3416,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3417,no_relation,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3418,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3419,no_relation,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3420,no_relation,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3421,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3422,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.993883734673619,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
3423,L DOPA treats PARKINSON'S DISEASE,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3424,L DOPA treats PARKINSON'S DISEASE,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3425,PARKINSON'S DISEASE treats L DOPA,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3426,L DOPA treats PARKINSON'S DISEASE,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3427,L DOPA treats PARKINSON'S DISEASE,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3428,L DOPA treats PARKINSON'S DISEASE,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3429,L DOPA treats PARKINSON'S DISEASE,treats,0.9918365981341758,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
3430,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3431,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3432,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3433,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3434,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3435,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3436,GRAM NEGATIVE SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,causes,0.99654575824488,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
3437,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3438,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3439,REFRACTORY STATUS EPILEPTICUS treats PROPOFOL,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3440,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3441,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3442,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3443,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.995893206467704,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
3444,DRUG SIDE EFFECTS causes IMMUNOSUPPRESSIVE MEDICATIONS,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3445,IMMUNOSUPPRESSIVE MEDICATIONS causes DRUG SIDE EFFECTS,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3446,IMMUNOSUPPRESSIVE MEDICATIONS causes DRUG SIDE EFFECTS,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3447,IMMUNOSUPPRESSIVE MEDICATIONS causes DRUG SIDE EFFECTS,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3448,no_relation,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3449,DRUG SIDE EFFECTS causes IMMUNOSUPPRESSIVE MEDICATIONS,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3450,IMMUNOSUPPRESSIVE MEDICATIONS causes DRUG SIDE EFFECTS,causes,0.903696114115064,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
3451,no_relation,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3452,no_relation,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3453,AGGRESSIVE CLINICAL COURSE diagnosis PLASMA CELL LEUKAEMIA,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3454,no_relation,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3455,PLASMA CELL LEUKAEMIA diagnosis AGGRESSIVE CLINICAL COURSE,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3456,AGGRESSIVE CLINICAL COURSE diagnosis PLASMA CELL LEUKAEMIA,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3457,PLASMA CELL LEUKAEMIA diagnosis AGGRESSIVE CLINICAL COURSE,diagnosis,0.304997140665209,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
3458,no_relation,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3459,no_relation,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3460,no_relation,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3461,no_relation,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3462,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3463,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3464,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.353553390593274,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3465,DCIS causes BRANCHING (CASTING TYPE CALCIFICATIONS,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3466,BRANCHING (CASTING TYPE CALCIFICATIONS causes DCIS,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3467,no_relation,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3468,BRANCHING (CASTING TYPE CALCIFICATIONS causes DCIS,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3469,BRANCHING (CASTING TYPE CALCIFICATIONS causes DCIS,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3470,DCIS causes BRANCHING (CASTING TYPE CALCIFICATIONS,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3471,BRANCHING (CASTING TYPE CALCIFICATIONS causes DCIS,causes,0.956182887467515,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
3472,LEVODOPA treats PARKINSON'S DISEASE,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3473,no_relation,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3474,LEVODOPA treats PARKINSON'S DISEASE,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3475,no_relation,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3476,no_relation,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3477,LEVODOPA treats PARKINSON'S DISEASE,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3478,no_relation,treats,0.696310623822791,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3479,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3480,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3481,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3482,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3483,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3484,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3485,no_relation,diagnosis,0.387298334620742,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
3486,LAMELAR BONE location BONE PAIN,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3487,BONE PAIN location LAMELAR BONE,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3488,no_relation,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3489,LAMELAR BONE location BONE PAIN,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3490,no_relation,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3491,no_relation,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3492,LAMELAR BONE location BONE PAIN,location,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
3493,no_relation,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3494,CATARACT FORMATION causes LENS,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3495,LENS causes CATARACT FORMATION,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3496,no_relation,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3497,no_relation,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3498,CATARACT FORMATION causes LENS,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3499,no_relation,causes,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
3500,no_relation,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3501,PLASMA GLUCOSE causes HYPOGLYCEMIA,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3502,PLASMA GLUCOSE causes HYPOGLYCEMIA,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3503,no_relation,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3504,no_relation,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3505,PLASMA GLUCOSE causes HYPOGLYCEMIA,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3506,PLASMA GLUCOSE causes HYPOGLYCEMIA,causes,0.640512615220348,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
3507,MALT LYMPHOMAS causes LYMPHOEPITHELIAL LESIONS,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3508,no_relation,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3509,MALT LYMPHOMAS causes LYMPHOEPITHELIAL LESIONS,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3510,LYMPHOEPITHELIAL LESIONS causes MALT LYMPHOMAS,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3511,MALT LYMPHOMAS causes LYMPHOEPITHELIAL LESIONS,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3512,LYMPHOEPITHELIAL LESIONS causes MALT LYMPHOMAS,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3513,no_relation,causes,0.629940788348712,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
3514,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3515,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3516,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3517,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3518,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3519,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3520,PARACETAMOL treats PAIN,treats,0.997054485501582,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
3521,COMPLEX FEBRILE SEIZURES causes EPILEPSY,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3522,COMPLEX FEBRILE SEIZURES causes EPILEPSY,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3523,COMPLEX FEBRILE SEIZURES causes EPILEPSY,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3524,EPILEPSY causes COMPLEX FEBRILE SEIZURES,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3525,no_relation,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3526,EPILEPSY causes COMPLEX FEBRILE SEIZURES,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3527,COMPLEX FEBRILE SEIZURES causes EPILEPSY,causes,0.9438798074485388,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
3528,QUINIDINE treats VENTRICULAR TACHYCARDIA (VT),treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3529,QUINIDINE treats VENTRICULAR TACHYCARDIA (VT),treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3530,QUINIDINE treats VENTRICULAR TACHYCARDIA (VT),treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3531,VENTRICULAR TACHYCARDIA (VT) treats QUINIDINE,treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3532,QUINIDINE treats VENTRICULAR TACHYCARDIA (VT),treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3533,QUINIDINE treats VENTRICULAR TACHYCARDIA (VT),treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3534,QUINIDINE treats VENTRICULAR TACHYCARDIA (VT),treats,0.9838699100999068,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
3535,BLEPHAROSPASM treats TYPE A BOTULINUM TOXIN,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3536,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3537,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3538,BLEPHAROSPASM treats TYPE A BOTULINUM TOXIN,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3539,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3540,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3541,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3542,GENERALIZED HIVES location SKIN,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3543,SKIN location GENERALIZED HIVES,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3544,GENERALIZED HIVES location SKIN,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3545,SKIN location GENERALIZED HIVES,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3546,SKIN location GENERALIZED HIVES,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3547,SKIN location GENERALIZED HIVES,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3548,SKIN location GENERALIZED HIVES,location,0.9830783046228492,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
3549,no_relation,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3550,CENTRAL NERVOUS SYSTEM causes MEDULLOBLASTOMAS,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3551,no_relation,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3552,no_relation,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3553,no_relation,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3554,no_relation,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3555,no_relation,causes,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3556,CEREBELLUM location CEREBELLAR ATAXIA,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3557,CEREBELLUM location CEREBELLAR ATAXIA,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3558,CEREBELLUM location CEREBELLAR ATAXIA,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3559,CEREBELLAR ATAXIA location CEREBELLUM,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3560,no_relation,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3561,CEREBELLUM location CEREBELLAR ATAXIA,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3562,no_relation,location,0.855186110494136,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
3563,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3564,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3565,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3566,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3567,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3568,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3569,FLUORIDE treats DENTAL CARIES,treats,0.994134846772434,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
3570,MEDULLOBLASTOMAS location CENTRAL NERVOUS SYSTEM,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3571,CENTRAL NERVOUS SYSTEM location MEDULLOBLASTOMAS,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3572,CENTRAL NERVOUS SYSTEM location MEDULLOBLASTOMAS,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3573,MEDULLOBLASTOMAS location CENTRAL NERVOUS SYSTEM,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3574,MEDULLOBLASTOMAS location CENTRAL NERVOUS SYSTEM,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3575,no_relation,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3576,MEDULLOBLASTOMAS location CENTRAL NERVOUS SYSTEM,location,0.6868028197434449,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
3577,BREAST CANCER location BREAST EPITHELIAL STEM CELLS,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3578,BREAST EPITHELIAL STEM CELLS location BREAST CANCER,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3579,BREAST EPITHELIAL STEM CELLS location BREAST CANCER,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3580,BREAST CANCER location BREAST EPITHELIAL STEM CELLS,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3581,BREAST EPITHELIAL STEM CELLS location BREAST CANCER,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3582,BREAST EPITHELIAL STEM CELLS location BREAST CANCER,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3583,BREAST EPITHELIAL STEM CELLS location BREAST CANCER,location,0.9494253265550828,BREAST EPITHELIAL STEM CELLS are thought to be the primary targets in the aetiology of BREAST CANCER,BREAST EPITHELIAL STEM CELLS,BREAST CANCER
3584,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3585,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3586,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3587,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3588,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3589,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3590,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3591,ENDEMIC GOITER causes SELENIUM (SE) DEFICIENCY,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3592,SELENIUM (SE) DEFICIENCY causes ENDEMIC GOITER,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3593,SELENIUM (SE) DEFICIENCY causes ENDEMIC GOITER,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3594,SELENIUM (SE) DEFICIENCY causes ENDEMIC GOITER,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3595,ENDEMIC GOITER causes SELENIUM (SE) DEFICIENCY,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3596,no_relation,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3597,SELENIUM (SE) DEFICIENCY causes ENDEMIC GOITER,causes,0.943456353049726,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3598,PRINZMETAL VARIANT ANGINA diagnosis ERGOMETRINE,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3599,PRINZMETAL VARIANT ANGINA diagnosis ERGOMETRINE,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3600,PRINZMETAL VARIANT ANGINA diagnosis ERGOMETRINE,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3601,PRINZMETAL VARIANT ANGINA diagnosis ERGOMETRINE,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3602,PRINZMETAL VARIANT ANGINA diagnosis ERGOMETRINE,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3603,PRINZMETAL VARIANT ANGINA diagnosis ERGOMETRINE,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3604,no_relation,diagnosis,0.970142500145332,"ERGOMETRINE is currently used as a test for PRINZMETAL VARIANT ANGINA causing specifically a coronary artery spasm in these patients, even if the mechanism of this drug on coronaries is still unclear.",PRINZMETAL VARIANT ANGINA,ERGOMETRINE
3605,BLOOD PRESSURE ELEVATION causes HYPERTENSION,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3606,HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3607,BLOOD PRESSURE ELEVATION causes HYPERTENSION,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3608,HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3609,BLOOD PRESSURE ELEVATION causes HYPERTENSION,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3610,HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3611,no_relation,causes,0.7293249574894731,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3612,MALIGNANT MELANOMA causes MELANOMA PAN,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3613,no_relation,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3614,MELANOMA PAN causes MALIGNANT MELANOMA,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3615,no_relation,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3616,no_relation,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3617,no_relation,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3618,MELANOMA PAN causes MALIGNANT MELANOMA,causes,0.314485451016576,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3619,no_relation,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3620,ERGONOVINE causes VASOSPASTIC ANGINA PECTORIS,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3621,VASOSPASTIC ANGINA PECTORIS causes ERGONOVINE,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3622,ERGONOVINE causes VASOSPASTIC ANGINA PECTORIS,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3623,ERGONOVINE causes VASOSPASTIC ANGINA PECTORIS,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3624,ERGONOVINE causes VASOSPASTIC ANGINA PECTORIS,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3625,ERGONOVINE causes VASOSPASTIC ANGINA PECTORIS,causes,0.9578262852211508,"For clarification of the characteristic features of ventricular arrhythmias during acute myocardial ischemia, ventricular arrhythmias were studied in 81 patients with VASOSPASTIC ANGINA PECTORIS induced by ERGONOVINE",VASOSPASTIC ANGINA PECTORIS,ERGONOVINE
3626,FLUORIDES treats CARIES,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3627,FLUORIDES treats CARIES,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3628,FLUORIDES treats CARIES,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3629,FLUORIDES treats CARIES,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3630,no_relation,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3631,FLUORIDES treats CARIES,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3632,FLUORIDES treats CARIES,treats,0.953462589245592,In the past the inhibition of CARIES by FLUORIDES was ascribed to the reduced solubility of enamel due to the incorporation of F  into the enamel mineral.,CARIES,FLUORIDES
3633,no_relation,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3634,no_relation,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3635,DOG HYPERSENSITIVITY SYMPTOMS causes DOG HYPERSENSITIVITY,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3636,DOG HYPERSENSITIVITY causes DOG HYPERSENSITIVITY SYMPTOMS,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3637,DOG HYPERSENSITIVITY causes DOG HYPERSENSITIVITY SYMPTOMS,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3638,DOG HYPERSENSITIVITY causes DOG HYPERSENSITIVITY SYMPTOMS,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3639,DOG HYPERSENSITIVITY causes DOG HYPERSENSITIVITY SYMPTOMS,causes,0.964763821237732,"However, the children who were exposed to a dog at home during early childhood developed DOG HYPERSENSITIVITY SYMPTOMS significantly earlier and had DOG HYPERSENSITIVITY slightly more often than the subjects with a later exposure or no exposure to dog.",DOG HYPERSENSITIVITY SYMPTOMS,DOG HYPERSENSITIVITY
3640,GRADED PORTAL VEIN STENOSIS causes PORTAL HYPERTENSION,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3641,GRADED PORTAL VEIN STENOSIS causes PORTAL HYPERTENSION,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3642,PORTAL HYPERTENSION causes GRADED PORTAL VEIN STENOSIS,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3643,GRADED PORTAL VEIN STENOSIS causes PORTAL HYPERTENSION,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3644,GRADED PORTAL VEIN STENOSIS causes PORTAL HYPERTENSION,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3645,GRADED PORTAL VEIN STENOSIS causes PORTAL HYPERTENSION,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3646,GRADED PORTAL VEIN STENOSIS causes PORTAL HYPERTENSION,causes,0.970494958830946,PORTAL HYPERTENSION was induced by GRADED PORTAL VEIN STENOSIS whereas controls had a sham operation.,GRADED PORTAL VEIN STENOSIS,PORTAL HYPERTENSION
3647,no_relation,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3648,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3649,no_relation,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3650,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3651,no_relation,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3652,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3653,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.609994281330419,Rationale: ? A significant number of new cases of DIABETES MELLITUS begin as DIABETIC KETOACIDOSIS,DIABETIC KETOACIDOSIS,DIABETES MELLITUS
3654,AMYLOIDOSIS causes AMYLOID DEPOSITION,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3655,no_relation,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3656,no_relation,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3657,AMYLOIDOSIS causes AMYLOID DEPOSITION,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3658,no_relation,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3659,AMYLOID DEPOSITION causes AMYLOIDOSIS,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3660,AMYLOID DEPOSITION causes AMYLOIDOSIS,causes,0.338061701891407,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3661,LATENT HYPERCORTISOLISM diagnosis DEXAMETHASONE,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3662,DEXAMETHASONE diagnosis LATENT HYPERCORTISOLISM,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3663,no_relation,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3664,LATENT HYPERCORTISOLISM diagnosis DEXAMETHASONE,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3665,DEXAMETHASONE diagnosis LATENT HYPERCORTISOLISM,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3666,LATENT HYPERCORTISOLISM diagnosis DEXAMETHASONE,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3667,no_relation,diagnosis,0.99654575824488,"The crucial points of the French consensus are: the usefulness of CT scanning evaluation of adrenal incidentalomas, the systematic screening for pheochromocytoma, the usefulness of the 1mg overnight DEXAMETHASONE test to screen for LATENT HYPERCORTISOLISM the difficulty to interpret mild biological abnormalities of the HPA axis, the consensus to remove surgically most of tumours greater than 4cm, the necessity to follow clinically glucorticoid tissular targets in the follow up of non operated benign adrenocortical incidentalomas.",LATENT HYPERCORTISOLISM,DEXAMETHASONE
3668,BLADDER INJURY location BLADDER,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3669,BLADDER location BLADDER INJURY,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3670,BLADDER location BLADDER INJURY,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3671,BLADDER INJURY location BLADDER,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3672,BLADDER location BLADDER INJURY,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3673,BLADDER location BLADDER INJURY,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3674,BLADDER location BLADDER INJURY,location,1.0,Intraperitoneal rupture usually involves the bladder dome; it often occurs when the bladder is distended at the time of trauma and is the most common BLADDER INJURY in children because the BLADDER lies in the abdomen.,BLADDER,BLADDER INJURY
3675,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3676,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3677,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3678,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3679,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3680,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3681,no_relation,causes,0.707106781186547,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3682,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3683,HEPATOCELLULAR CARCINOMA treats HYPERTHERMIA,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3684,HEPATOCELLULAR CARCINOMA treats HYPERTHERMIA,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3685,no_relation,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3686,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3687,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3688,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.9578262852211508,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3689,no_relation,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3690,RISPERIDONE treats DEMENTIA,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3691,RISPERIDONE treats DEMENTIA,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3692,RISPERIDONE treats DEMENTIA,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3693,RISPERIDONE treats DEMENTIA,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3694,RISPERIDONE treats DEMENTIA,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3695,RISPERIDONE treats DEMENTIA,treats,0.997054485501582,"1]  Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al A randomized placebo controlled trial of RISPERIDONE for the treatment of aggression, agitation, and psychosis of DEMENTIA",DEMENTIA,RISPERIDONE
3696,VARIANT ANGINA PECTORIS treats ERGONOVINE,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3697,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3698,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3699,no_relation,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3700,no_relation,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3701,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3702,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9594032236002472,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3703,no_relation,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3704,GLIOBLASTOMA MULTIFORME location MICROVASCULAR PROLIFERATION,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3705,no_relation,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3706,GLIOBLASTOMA MULTIFORME location MICROVASCULAR PROLIFERATION,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3707,MICROVASCULAR PROLIFERATION location GLIOBLASTOMA MULTIFORME,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3708,no_relation,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3709,MICROVASCULAR PROLIFERATION location GLIOBLASTOMA MULTIFORME,location,0.508000508000762,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3710,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3711,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3712,no_relation,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3713,no_relation,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3714,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3715,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3716,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.4472135954999579,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3717,MAGNESIUM DEFICIENCY diagnosis MAGNESIUM TOLERANCE TEST,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3718,MAGNESIUM DEFICIENCY diagnosis MAGNESIUM TOLERANCE TEST,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3719,MAGNESIUM DEFICIENCY diagnosis MAGNESIUM TOLERANCE TEST,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3720,MAGNESIUM DEFICIENCY diagnosis MAGNESIUM TOLERANCE TEST,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3721,MAGNESIUM TOLERANCE TEST diagnosis MAGNESIUM DEFICIENCY,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3722,MAGNESIUM DEFICIENCY diagnosis MAGNESIUM TOLERANCE TEST,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3723,MAGNESIUM DEFICIENCY diagnosis MAGNESIUM TOLERANCE TEST,diagnosis,0.987878339907213,"The diagnosis of MAGNESIUM DEFICIENCY is usually made by a low serum magnesium concentration, although the MAGNESIUM TOLERANCE TEST may be more indicative of low magnesium states.",MAGNESIUM DEFICIENCY,MAGNESIUM TOLERANCE TEST
3724,ARSENIC TRIOXIDE treats PROMYELOCYTIC LEUKEMIA (APML),treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3725,PROMYELOCYTIC LEUKEMIA (APML) treats ARSENIC TRIOXIDE,treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3726,ARSENIC TRIOXIDE treats PROMYELOCYTIC LEUKEMIA (APML),treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3727,ARSENIC TRIOXIDE treats PROMYELOCYTIC LEUKEMIA (APML),treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3728,ARSENIC TRIOXIDE treats PROMYELOCYTIC LEUKEMIA (APML),treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3729,ARSENIC TRIOXIDE treats PROMYELOCYTIC LEUKEMIA (APML),treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3730,ARSENIC TRIOXIDE treats PROMYELOCYTIC LEUKEMIA (APML),treats,0.987878339907213,A total of 11 children (five males and six females) with hypergranular type of acute PROMYELOCYTIC LEUKEMIA (APML) were treated with intravenous ARSENIC TRIOXIDE (As(2)O(3)) between December 1998 and October 2003.,PROMYELOCYTIC LEUKEMIA (APML),ARSENIC TRIOXIDE
3731,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY treats ADRENALINE INDUCED ARRHYTHMIA,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3732,no_relation,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3733,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY treats ADRENALINE INDUCED ARRHYTHMIA,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3734,no_relation,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3735,no_relation,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3736,no_relation,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3737,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY treats ADRENALINE INDUCED ARRHYTHMIA,treats,0.668153104781061,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3738,AMYLOID DEPOSITION location AMYLOIDOSIS,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3739,AMYLOID DEPOSITION location AMYLOIDOSIS,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3740,AMYLOID DEPOSITION location AMYLOIDOSIS,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3741,no_relation,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3742,AMYLOIDOSIS location AMYLOID DEPOSITION,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3743,no_relation,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3744,no_relation,location,0.50709255283711,Our observations and descriptions in the literature indicate that the presence and degrees of AMYLOID DEPOSITION in the skeletal muscles would be related to the types of amyloid proteins in AMYLOIDOSIS,AMYLOID DEPOSITION,AMYLOIDOSIS
3745,no_relation,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3746,SMALL INTESTINE causes MALABSORPTION,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3747,no_relation,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3748,no_relation,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3749,no_relation,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3750,no_relation,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3751,SMALL INTESTINE causes MALABSORPTION,causes,0.311085508419128,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3752,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3753,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3754,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3755,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3756,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3757,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3758,SMALL INTESTINE location MALABSORPTION,location,0.933256525257383,"Gastrografin accelerated small bowel transit, leading to MALABSORPTION of the xylose in the SMALL INTESTINE and subsequent colonic metabolism of the xylose.",SMALL INTESTINE,MALABSORPTION
3759,no_relation,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3760,no_relation,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3761,BLADDER CANCER causes HEMATURIA,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3762,BLADDER CANCER causes HEMATURIA,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3763,no_relation,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3764,no_relation,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3765,BLADDER CANCER causes HEMATURIA,causes,0.643267520902677,"Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as HEMATURIA or a history of BLADDER CANCER.",HEMATURIA,BLADDER CANCER
3766,no_relation,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3767,no_relation,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3768,BLOOD PRESSURE ELEVATION treats HYPERTENSION,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3769,no_relation,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3770,BLOOD PRESSURE ELEVATION treats HYPERTENSION,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3771,HYPERTENSION treats BLOOD PRESSURE ELEVATION,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3772,no_relation,treats,0.437594974493684,Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga null mice with Cts prevents BLOOD PRESSURE ELEVATION indicating a direct role of Cts in preventing HYPERTENSION,BLOOD PRESSURE ELEVATION,HYPERTENSION
3773,FIRST LINE ANTITUBERCULOSIS DRUGS treats MYCOBACTERIUM TUBERCULOSIS,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3774,FIRST LINE ANTITUBERCULOSIS DRUGS treats MYCOBACTERIUM TUBERCULOSIS,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3775,no_relation,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3776,FIRST LINE ANTITUBERCULOSIS DRUGS treats MYCOBACTERIUM TUBERCULOSIS,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3777,FIRST LINE ANTITUBERCULOSIS DRUGS treats MYCOBACTERIUM TUBERCULOSIS,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3778,FIRST LINE ANTITUBERCULOSIS DRUGS treats MYCOBACTERIUM TUBERCULOSIS,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3779,FIRST LINE ANTITUBERCULOSIS DRUGS treats MYCOBACTERIUM TUBERCULOSIS,treats,0.9578262852211508,"Ruiz Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of   MYCOBACTERIUM TUBERCULOSIS  susceptible or resistant to FIRST LINE ANTITUBERCULOSIS DRUGS.",MYCOBACTERIUM TUBERCULOSIS,FIRST LINE ANTITUBERCULOSIS DRUGS
3780,ENDOMETRIAL CANCER diagnosis POSTMENOPAUSAL BLEEDING,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3781,no_relation,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3782,ENDOMETRIAL CANCER diagnosis POSTMENOPAUSAL BLEEDING,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3783,ENDOMETRIAL CANCER diagnosis POSTMENOPAUSAL BLEEDING,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3784,ENDOMETRIAL CANCER diagnosis POSTMENOPAUSAL BLEEDING,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3785,ENDOMETRIAL CANCER diagnosis POSTMENOPAUSAL BLEEDING,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3786,ENDOMETRIAL CANCER diagnosis POSTMENOPAUSAL BLEEDING,diagnosis,0.42426406871192895,? A prospective study was done to evaluate the role of three dimensional vs. two dimensional TVUS in diagnosing ENDOMETRIAL CANCER in patients with a history of POSTMENOPAUSAL BLEEDING,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
3787,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3788,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3789,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3790,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3791,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3792,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3793,LIDOCAINE treats PAIN,treats,0.9897433186107868,This study concluded that the addition of LIDOCAINE significantly reduced the PAIN felt in the circulatory tract selected for the injection of propofol.,PAIN,LIDOCAINE
3794,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3795,no_relation,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3796,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3797,no_relation,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3798,no_relation,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3799,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3800,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,causes,0.762000762001143,Because histologically prominent MICROVASCULAR PROLIFERATION is frequently present in GLIOBLASTOMA MULTIFORME it has been hypothesized that this neoplasm is particularly dependent on neovascularization for its continued growth and that antiangiogenic therapy might be especially useful.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
3801,ANAPLASTIC ASTROCYTOMAS treats ANAPLASIA,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3802,ANAPLASIA treats ANAPLASTIC ASTROCYTOMAS,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3803,no_relation,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3804,ANAPLASTIC ASTROCYTOMAS treats ANAPLASIA,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3805,ANAPLASTIC ASTROCYTOMAS treats ANAPLASIA,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3806,ANAPLASTIC ASTROCYTOMAS treats ANAPLASIA,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3807,ANAPLASTIC ASTROCYTOMAS treats ANAPLASIA,treats,0.37210420376762493,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
3808,SCHIZOPHRENIA causes HALLUCINATIONS,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3809,SCHIZOPHRENIA causes HALLUCINATIONS,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3810,SCHIZOPHRENIA causes HALLUCINATIONS,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3811,SCHIZOPHRENIA causes HALLUCINATIONS,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3812,HALLUCINATIONS causes SCHIZOPHRENIA,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3813,SCHIZOPHRENIA causes HALLUCINATIONS,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3814,SCHIZOPHRENIA causes HALLUCINATIONS,causes,0.979957887012223,"1   Simple SCHIZOPHRENIA denotes a milder psychosis (i.e., fewer HALLUCINATIONS and delusions and less disorganization), with cases typically featuring a schizoid lifestyle of reduced emotional experience and expression and reduced social drive and engagement.",HALLUCINATIONS,SCHIZOPHRENIA
3815,no_relation,causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3816,no_relation,causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3817,no_relation,causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3818,UPPER AIRWAY causes OBSTRUCTIVE SLEEP APNOEA (OSA),causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3819,no_relation,causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3820,OBSTRUCTIVE SLEEP APNOEA (OSA) causes UPPER AIRWAY,causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3821,UPPER AIRWAY causes OBSTRUCTIVE SLEEP APNOEA (OSA),causes,0.445435403187374,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
3822,VENOUS THROMBOSIS diagnosis THROMBOSED VEINS,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3823,no_relation,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3824,no_relation,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3825,THROMBOSED VEINS diagnosis VENOUS THROMBOSIS,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3826,VENOUS THROMBOSIS diagnosis THROMBOSED VEINS,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3827,VENOUS THROMBOSIS diagnosis THROMBOSED VEINS,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3828,VENOUS THROMBOSIS diagnosis THROMBOSED VEINS,diagnosis,0.43301270189221897,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
3829,DERMATOSES OF DIVERSE ETIOLOGIES causes SKIN DISEASES,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3830,DERMATOSES OF DIVERSE ETIOLOGIES causes SKIN DISEASES,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3831,DERMATOSES OF DIVERSE ETIOLOGIES causes SKIN DISEASES,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3832,no_relation,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3833,no_relation,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3834,DERMATOSES OF DIVERSE ETIOLOGIES causes SKIN DISEASES,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3835,no_relation,causes,0.304997140665209,The spectrum of SKIN DISEASES in such patients encompasses DERMATOSES OF DIVERSE ETIOLOGIES; a few are peculiar to patients with HIV while others are not.,SKIN DISEASES,DERMATOSES OF DIVERSE ETIOLOGIES
3836,LATE SYSTEMIC ALLERGIC REACTIONS causes NUMBER OF SYSTEMIC ALLERGIC,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3837,no_relation,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3838,NUMBER OF SYSTEMIC ALLERGIC causes LATE SYSTEMIC ALLERGIC REACTIONS,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3839,no_relation,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3840,LATE SYSTEMIC ALLERGIC REACTIONS causes NUMBER OF SYSTEMIC ALLERGIC,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3841,LATE SYSTEMIC ALLERGIC REACTIONS causes NUMBER OF SYSTEMIC ALLERGIC,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3842,NUMBER OF SYSTEMIC ALLERGIC causes LATE SYSTEMIC ALLERGIC REACTIONS,causes,0.4170288281141501,We conclude that LATE SYSTEMIC ALLERGIC REACTIONS account for a significant percent of the total NUMBER OF SYSTEMIC ALLERGIC reactions to inhalant allergen immunotherapy.,NUMBER OF SYSTEMIC ALLERGIC,LATE SYSTEMIC ALLERGIC REACTIONS
3843,MALIGNANT MELANOMA diagnosis MELANOMA PAN,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3844,MELANOMA PAN diagnosis MALIGNANT MELANOMA,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3845,MALIGNANT MELANOMA diagnosis MELANOMA PAN,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3846,MALIGNANT MELANOMA diagnosis MELANOMA PAN,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3847,MALIGNANT MELANOMA diagnosis MELANOMA PAN,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3848,no_relation,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3849,MELANOMA PAN diagnosis MALIGNANT MELANOMA,diagnosis,0.943456353049726,"Microscopic examination of the resected specimen revealed a MALIGNANT MELANOMA which was confirmed by immunohistochemical staining for HMB 45, S 100 protein, MELANOMA PAN and vimentin.",MELANOMA PAN,MALIGNANT MELANOMA
3850,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3851,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3852,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3853,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3854,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3855,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3856,BURKHOLDERIA PSEUDOMALLEI causes MELIOIDOSIS,causes,1.0,BURKHOLDERIA PSEUDOMALLEI is a gram negative bacillus that is the causative agent of MELIOIDOSIS,BURKHOLDERIA PSEUDOMALLEI,MELIOIDOSIS
3857,HYPERTENSION causes ACUTE HYPERTENSIVE ENCEPHALOPATHY,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3858,HYPERTENSION causes ACUTE HYPERTENSIVE ENCEPHALOPATHY,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3859,no_relation,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3860,HYPERTENSION causes ACUTE HYPERTENSIVE ENCEPHALOPATHY,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3861,HYPERTENSION causes ACUTE HYPERTENSIVE ENCEPHALOPATHY,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3862,HYPERTENSION causes ACUTE HYPERTENSIVE ENCEPHALOPATHY,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3863,ACUTE HYPERTENSIVE ENCEPHALOPATHY causes HYPERTENSION,causes,0.9931270663228408,Headache may occasionally be caused by severe HYPERTENSION which may also lead to the rare syndrome of ACUTE HYPERTENSIVE ENCEPHALOPATHY,HYPERTENSION,ACUTE HYPERTENSIVE ENCEPHALOPATHY
3864,ALLERGIC REACTIONS causes ALLERGIC DISORDERS,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3865,ALLERGIC REACTIONS causes ALLERGIC DISORDERS,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3866,ALLERGIC DISORDERS causes ALLERGIC REACTIONS,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3867,no_relation,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3868,no_relation,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3869,no_relation,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3870,ALLERGIC DISORDERS causes ALLERGIC REACTIONS,causes,0.9494253265550828,"Cutaneous sensitivity to histamine, responses to prick tests with allergens, and serum IgE concentrations were measured and hay fever assessed by questionnaire in an unselected population to determine whether increased sensitivity to histamine is an independent phenomenon contributing to ALLERGIC DISORDERS or may be caused by ALLERGIC REACTIONS",ALLERGIC DISORDERS,ALLERGIC REACTIONS
3871,no_relation,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3872,no_relation,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3873,SMZL causes INDOLENT CLINICAL COURSE,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3874,INDOLENT CLINICAL COURSE causes SMZL,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3875,INDOLENT CLINICAL COURSE causes SMZL,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3876,no_relation,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3877,INDOLENT CLINICAL COURSE causes SMZL,causes,0.971285862357264,SMZL is characterized by an INDOLENT CLINICAL COURSE and no previous report has described SMZL with bilateral renal invasion.,INDOLENT CLINICAL COURSE,SMZL
3878,no_relation,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3879,no_relation,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3880,no_relation,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3881,no_relation,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3882,COLD NODULES location MEDULLARY CARCINOMA,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3883,no_relation,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3884,no_relation,location,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
3885,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY causes ADRENALINE INDUCED ARRHYTHMIA,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3886,ADRENALINE INDUCED ARRHYTHMIA causes PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3887,no_relation,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3888,no_relation,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3889,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY causes ADRENALINE INDUCED ARRHYTHMIA,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3890,no_relation,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3891,ADRENALINE INDUCED ARRHYTHMIA causes PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY,causes,0.400891862868637,"Among the compounds tested, 1 (2 hydroxy 3 (4 phenylpiperidin 1 yl) propylpyrrolidin 2 one (5) was the most active in the PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY in ADRENALINE INDUCED ARRHYTHMIA in anesthetized rats.",ADRENALINE INDUCED ARRHYTHMIA,PROPHYLACTIC ANTIARRHYTHMIC ACTIVITY
3892,TREPONEMA PALLIDUM diagnosis SYPHILIS,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3893,SYPHILIS diagnosis TREPONEMA PALLIDUM,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3894,SYPHILIS diagnosis TREPONEMA PALLIDUM,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3895,SYPHILIS diagnosis TREPONEMA PALLIDUM,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3896,SYPHILIS diagnosis TREPONEMA PALLIDUM,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3897,TREPONEMA PALLIDUM diagnosis SYPHILIS,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3898,SYPHILIS diagnosis TREPONEMA PALLIDUM,diagnosis,0.9237604307034007,The CAPTIA Syphilis G enzyme immunoassay for the detection of antibodies to TREPONEMA PALLIDUM was evaluated as a screening test for SYPHILIS in comparison with the standard rapid plasma reagin (RPR) test.,TREPONEMA PALLIDUM,SYPHILIS
3899,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3900,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3901,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3902,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3903,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3904,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3905,LUNGS location LUNG CANCER,location,0.981980506061966,The distribution of ferruginous bodies in the LUNGS of ten LUNG CANCER patients with definite occupational history of asbestos exposure and the kind of core fibers in the center of the ferruginous bodies were evaluated.,LUNGS,LUNG CANCER
3906,SERTRALINE treats DEPRESSION,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3907,no_relation,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3908,SERTRALINE treats DEPRESSION,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3909,no_relation,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3910,SERTRALINE treats DEPRESSION,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3911,SERTRALINE treats DEPRESSION,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3912,SERTRALINE treats DEPRESSION,treats,0.929981109950554,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
3913,no_relation,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3914,MICROCALCIFICATION diagnosis DCIS,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3915,no_relation,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3916,MICROCALCIFICATION diagnosis DCIS,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3917,MICROCALCIFICATION diagnosis DCIS,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3918,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3919,MICROCALCIFICATION diagnosis DCIS,diagnosis,0.37210420376762493,"If only these 139 'true negative' screens are analysed, similar associations are seen between microcalcification on previous films and subsequent finding of DCIS (P=0.03) and between MICROCALCIFICATION on previous films and high grade invasive ductal carcinomas (P=0.015.",MICROCALCIFICATION,DCIS
3920,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3921,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3922,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3923,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3924,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3925,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3926,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
3927,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) causes DYSTONIA,causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3928,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) causes DYSTONIA,causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3929,DYSTONIA causes DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY),causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3930,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) causes DYSTONIA,causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3931,DYSTONIA causes DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY),causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3932,no_relation,causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3933,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) causes DYSTONIA,causes,0.936329177569044,"A case of Leigh's DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY) is reported with such noteworthy features as early onset, DYSTONIA paraparesis the presence of low attenuation areas in both basal ganglias on computerized tomography of the brain and the presence of a high signal intensity in both basal ganglias in T2 weighted image by MR. The electron microscopic findings of muscle biopsy are suggestive of pleoconial mitochondrial myopathy.",DYSTONIA,DISEASE (SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY)
3934,no_relation,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3935,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3936,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3937,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3938,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3939,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3940,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3941,no_relation,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3942,PSAMMOMA BODIES causes DUODENAL SOMATOSTATINOMAS,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3943,no_relation,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3944,DUODENAL SOMATOSTATINOMAS causes PSAMMOMA BODIES,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3945,DUODENAL SOMATOSTATINOMAS causes PSAMMOMA BODIES,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3946,no_relation,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3947,no_relation,causes,0.441726104299386,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
3948,no_relation,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3949,OXYGEN causes DECOMPRESSION SICKNESS,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3950,no_relation,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3951,OXYGEN causes DECOMPRESSION SICKNESS,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3952,OXYGEN causes DECOMPRESSION SICKNESS,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3953,OXYGEN causes DECOMPRESSION SICKNESS,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3954,OXYGEN causes DECOMPRESSION SICKNESS,causes,0.7453559924999301,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
3955,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3956,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3957,HYPERCHOLESTEROLEMIA treats LOVASTATIN,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3958,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3959,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3960,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3961,no_relation,treats,0.970494958830946,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3962,TENDONS location TENDON RUPTURE,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3963,TENDON RUPTURE location TENDONS,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3964,TENDONS location TENDON RUPTURE,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3965,TENDONS location TENDON RUPTURE,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3966,no_relation,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3967,TENDONS location TENDON RUPTURE,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3968,TENDON RUPTURE location TENDONS,location,0.762000762001143,Subsequent TENDON RUPTURE was minimal and even TENDONS found to be thinned out at the time of surgery remained intact.,TENDONS,TENDON RUPTURE
3969,no_relation,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3970,no_relation,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3971,no_relation,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3972,no_relation,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3973,no_relation,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3974,ENDEMIC GOITER location SELENIUM (SE) DEFICIENCY,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3975,SELENIUM (SE) DEFICIENCY location ENDEMIC GOITER,location,0.314485451016576,SELENIUM (SE) DEFICIENCY is said to contribute to the atrophy of the thyroid gland in certain ENDEMIC GOITER areas in Africa.,ENDEMIC GOITER,SELENIUM (SE) DEFICIENCY
3976,HISTOPLASMOSIS diagnosis HISTOPLASMIN,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3977,HISTOPLASMOSIS diagnosis HISTOPLASMIN,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3978,no_relation,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3979,HISTOPLASMOSIS diagnosis HISTOPLASMIN,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3980,HISTOPLASMOSIS diagnosis HISTOPLASMIN,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3981,HISTOPLASMOSIS diagnosis HISTOPLASMIN,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3982,no_relation,diagnosis,0.942809041582064,The second was composed of 15 cases of HISTOPLASMOSIS with strong HISTOPLASMIN skin tests.,HISTOPLASMOSIS,HISTOPLASMIN
3983,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3984,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3985,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3986,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3987,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3988,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3989,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.979957887012223,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
3990,HEADACHE causes POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3991,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3992,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3993,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3994,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3995,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3996,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,causes,0.99124070716193,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
3997,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
3998,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
3999,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
4000,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
4001,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
4002,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
4003,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,causes,0.997054485501582,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
4004,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4005,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4006,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4007,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4008,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4009,TUBERCULOSIS diagnosis TUBERCULIN TESTING,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4010,no_relation,diagnosis,0.9878291611472622,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
4011,DIABETIC NEUROPATHY causes DIABETES,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4012,DIABETES causes DIABETIC NEUROPATHY,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4013,DIABETES causes DIABETIC NEUROPATHY,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4014,no_relation,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4015,DIABETES causes DIABETIC NEUROPATHY,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4016,DIABETES causes DIABETIC NEUROPATHY,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4017,DIABETES causes DIABETIC NEUROPATHY,causes,0.9,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
4018,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4019,no_relation,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4020,PRIMARY HYPERPARATHYROIDISM causes MEN2A,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4021,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4022,no_relation,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4023,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4024,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.717137165600636,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4025,PPD treats TB,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4026,PPD treats TB,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4027,TB treats PPD,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4028,no_relation,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4029,no_relation,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4030,PPD treats TB,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4031,PPD treats TB,treats,0.36115755925730697,"If TB is a concern, a PPD is performed.",TB,PPD
4032,no_relation,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4033,no_relation,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4034,NEUROFIBROMATOSIS TYPE 2 location SPORADIC MENINGIOMA,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4035,no_relation,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4036,SPORADIC MENINGIOMA location NEUROFIBROMATOSIS TYPE 2,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4037,no_relation,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4038,NEUROFIBROMATOSIS TYPE 2 location SPORADIC MENINGIOMA,location,0.3396831102433789,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4039,SSPE BRAIN TISSUES location BRAIN,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4040,BRAIN location SSPE BRAIN TISSUES,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4041,BRAIN location SSPE BRAIN TISSUES,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4042,BRAIN location SSPE BRAIN TISSUES,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4043,BRAIN location SSPE BRAIN TISSUES,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4044,BRAIN location SSPE BRAIN TISSUES,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4045,no_relation,location,0.911684611677103,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
4046,BLEPHARITIS location EYELID,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4047,EYELID location BLEPHARITIS,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4048,no_relation,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4049,EYELID location BLEPHARITIS,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4050,EYELID location BLEPHARITIS,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4051,EYELID location BLEPHARITIS,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4052,EYELID location BLEPHARITIS,location,0.78086880944303,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4053,CHOLECYSTITIS causes GALLBLADDER METASTASIS,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4054,no_relation,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4055,CHOLECYSTITIS causes GALLBLADDER METASTASIS,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4056,GALLBLADDER METASTASIS causes CHOLECYSTITIS,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4057,CHOLECYSTITIS causes GALLBLADDER METASTASIS,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4058,CHOLECYSTITIS causes GALLBLADDER METASTASIS,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4059,CHOLECYSTITIS causes GALLBLADDER METASTASIS,causes,0.963086824686154,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
4060,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4061,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4062,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4063,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4064,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4065,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4066,BEPRIDIL treats ANGINA,treats,0.8834522085987719,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4067,SEGMENTAL BRONCHI location BRONCHIECTASIS,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4068,no_relation,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4069,SEGMENTAL BRONCHI location BRONCHIECTASIS,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4070,SEGMENTAL BRONCHI location BRONCHIECTASIS,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4071,SEGMENTAL BRONCHI location BRONCHIECTASIS,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4072,no_relation,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4073,BRONCHIECTASIS location SEGMENTAL BRONCHI,location,0.744208407535251,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
4074,DPA INDUCED CICATRICIAL PEMPHIGOID causes MUCOUS AND CUTANEOUS INVOLVEMENT,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4075,no_relation,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4076,no_relation,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4077,no_relation,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4078,no_relation,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4079,MUCOUS AND CUTANEOUS INVOLVEMENT causes DPA INDUCED CICATRICIAL PEMPHIGOID,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4080,no_relation,causes,0.768221279597376,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
4081,TESTICULAR GERM CELL CANCER location CONTRALATERAL TESTIS,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4082,CONTRALATERAL TESTIS location TESTICULAR GERM CELL CANCER,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4083,no_relation,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4084,CONTRALATERAL TESTIS location TESTICULAR GERM CELL CANCER,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4085,TESTICULAR GERM CELL CANCER location CONTRALATERAL TESTIS,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4086,CONTRALATERAL TESTIS location TESTICULAR GERM CELL CANCER,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4087,CONTRALATERAL TESTIS location TESTICULAR GERM CELL CANCER,location,0.8888888888888891,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4088,MEN2A diagnosis PRIMARY HYPERPARATHYROIDISM,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4089,MEN2A diagnosis PRIMARY HYPERPARATHYROIDISM,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4090,PRIMARY HYPERPARATHYROIDISM diagnosis MEN2A,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4091,no_relation,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4092,PRIMARY HYPERPARATHYROIDISM diagnosis MEN2A,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4093,no_relation,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4094,no_relation,diagnosis,0.358568582800318,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
4095,INTRACORPOREAL PAPAVERINE diagnosis ERECTILE DYSFUNCTION,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4096,ERECTILE DYSFUNCTION diagnosis INTRACORPOREAL PAPAVERINE,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4097,ERECTILE DYSFUNCTION diagnosis INTRACORPOREAL PAPAVERINE,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4098,INTRACORPOREAL PAPAVERINE diagnosis ERECTILE DYSFUNCTION,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4099,ERECTILE DYSFUNCTION diagnosis INTRACORPOREAL PAPAVERINE,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4100,ERECTILE DYSFUNCTION diagnosis INTRACORPOREAL PAPAVERINE,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4101,ERECTILE DYSFUNCTION diagnosis INTRACORPOREAL PAPAVERINE,diagnosis,0.997458699830735,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
4102,OHSS causes ASCITES,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4103,OHSS causes ASCITES,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4104,no_relation,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4105,OHSS causes ASCITES,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4106,no_relation,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4107,no_relation,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4108,OHSS causes ASCITES,causes,0.7977240352174659,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
4109,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4110,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4111,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4112,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4113,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4114,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4115,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4116,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4117,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4118,no_relation,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4119,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4120,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4121,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4122,no_relation,causes,0.968495996958186,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
4123,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4124,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4125,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4126,TUBERCULIN diagnosis TUBERCULOSIS,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4127,TUBERCULIN diagnosis TUBERCULOSIS,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4128,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4129,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.9760921603577252,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
4130,CANCER OF THE CERVIX causes UTERINE CERVIX,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4131,no_relation,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4132,no_relation,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4133,no_relation,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4134,UTERINE CERVIX causes CANCER OF THE CERVIX,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4135,no_relation,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4136,no_relation,causes,0.303045763365663,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4137,HASHIMOTO'S THYROIDITIS causes THYROID,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4138,no_relation,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4139,THYROID causes HASHIMOTO'S THYROIDITIS,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4140,no_relation,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4141,no_relation,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4142,no_relation,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4143,no_relation,causes,0.341743063086704,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
4144,BONE CELLS location OSTEOPOROSIS,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4145,BONE CELLS location OSTEOPOROSIS,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4146,no_relation,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4147,BONE CELLS location OSTEOPOROSIS,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4148,BONE CELLS location OSTEOPOROSIS,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4149,BONE CELLS location OSTEOPOROSIS,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4150,BONE CELLS location OSTEOPOROSIS,location,0.7947194142390258,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
4151,ANTIARRHYTHMIC causes ARRHYTHMIA,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4152,ANTIARRHYTHMIC causes ARRHYTHMIA,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4153,ARRHYTHMIA causes ANTIARRHYTHMIC,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4154,no_relation,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4155,no_relation,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4156,no_relation,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4157,no_relation,causes,0.496138938356834,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4158,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4159,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4160,no_relation,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4161,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4162,no_relation,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4163,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4164,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
4165,no_relation,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4166,no_relation,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4167,ANTIGENIC PROPERTIES OF SKIN diagnosis SKIN SPECIFIC PEMPHIGUS VULGARIS,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4168,SKIN SPECIFIC PEMPHIGUS VULGARIS diagnosis ANTIGENIC PROPERTIES OF SKIN,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4169,ANTIGENIC PROPERTIES OF SKIN diagnosis SKIN SPECIFIC PEMPHIGUS VULGARIS,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4170,SKIN SPECIFIC PEMPHIGUS VULGARIS diagnosis ANTIGENIC PROPERTIES OF SKIN,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4171,ANTIGENIC PROPERTIES OF SKIN diagnosis SKIN SPECIFIC PEMPHIGUS VULGARIS,diagnosis,0.6454972243679029,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
4172,CUSHING'S SYNDROME causes EXOGENOUS DEXAMETHASONE,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4173,CUSHING'S SYNDROME causes EXOGENOUS DEXAMETHASONE,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4174,no_relation,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4175,no_relation,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4176,no_relation,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4177,no_relation,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4178,no_relation,causes,0.7559289460184542,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
4179,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4180,INSULIN INDUCED HYPOGLYCEMIA treats GLUCAGON,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4181,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4182,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4183,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4184,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4185,no_relation,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4186,ACTINIC KERATOSIS treats SKIN CONDITIONS,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4187,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4188,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4189,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4190,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4191,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4192,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
4193,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4194,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4195,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4196,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4197,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4198,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4199,no_relation,causes,0.468521285665818,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
4200,ARRHYTHMIA treats ANTIARRHYTHMIC,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4201,no_relation,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4202,ANTIARRHYTHMIC treats ARRHYTHMIA,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4203,ANTIARRHYTHMIC treats ARRHYTHMIA,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4204,no_relation,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4205,ANTIARRHYTHMIC treats ARRHYTHMIA,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4206,ANTIARRHYTHMIC treats ARRHYTHMIA,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
4207,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4208,OSTEOGENESIS IMPERFECTA causes LOW BONE MASS,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4209,OSTEOGENESIS IMPERFECTA causes LOW BONE MASS,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4210,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4211,OSTEOGENESIS IMPERFECTA causes LOW BONE MASS,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4212,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4213,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,causes,0.997054485501582,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
4214,ELEVATED BP causes HYPERTENSION,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4215,ELEVATED BP causes HYPERTENSION,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4216,HYPERTENSION causes ELEVATED BP,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4217,ELEVATED BP causes HYPERTENSION,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4218,HYPERTENSION causes ELEVATED BP,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4219,ELEVATED BP causes HYPERTENSION,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4220,no_relation,causes,0.620173672946042,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
4221,PLASMODIUM FALCIPARUM INFECTION causes MALARIA,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4222,MALARIA causes PLASMODIUM FALCIPARUM INFECTION,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4223,no_relation,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4224,MALARIA causes PLASMODIUM FALCIPARUM INFECTION,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4225,PLASMODIUM FALCIPARUM INFECTION causes MALARIA,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4226,no_relation,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4227,no_relation,causes,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4228,no_relation,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4229,SPORADIC MENINGIOMA causes NEUROFIBROMATOSIS TYPE 2,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4230,no_relation,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4231,NEUROFIBROMATOSIS TYPE 2 causes SPORADIC MENINGIOMA,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4232,no_relation,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4233,NEUROFIBROMATOSIS TYPE 2 causes SPORADIC MENINGIOMA,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4234,no_relation,causes,0.905821627315676,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
4235,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4236,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4237,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4238,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4239,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4240,no_relation,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4241,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4242,LITHIUM treats BIPOLAR DISORDER,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4243,LITHIUM treats BIPOLAR DISORDER,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4244,LITHIUM treats BIPOLAR DISORDER,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4245,LITHIUM treats BIPOLAR DISORDER,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4246,LITHIUM treats BIPOLAR DISORDER,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4247,LITHIUM treats BIPOLAR DISORDER,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4248,no_relation,treats,1.0,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
4249,no_relation,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4250,POLIOVIRUS causes POLIOMYELITIS,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4251,POLIOVIRUS causes POLIOMYELITIS,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4252,no_relation,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4253,no_relation,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4254,POLIOVIRUS causes POLIOMYELITIS,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4255,POLIOVIRUS causes POLIOMYELITIS,causes,0.488677777425221,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
4256,no_relation,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4257,JAUNDICE causes HEPATIC CARCINOMA,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4258,no_relation,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4259,JAUNDICE causes HEPATIC CARCINOMA,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4260,no_relation,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4261,no_relation,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4262,no_relation,causes,0.4574957109978139,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
4263,MALIGNANT HYPERTHERMIA SYNDROME diagnosis HALOTHANE,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4264,HALOTHANE diagnosis MALIGNANT HYPERTHERMIA SYNDROME,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4265,MALIGNANT HYPERTHERMIA SYNDROME diagnosis HALOTHANE,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4266,MALIGNANT HYPERTHERMIA SYNDROME diagnosis HALOTHANE,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4267,MALIGNANT HYPERTHERMIA SYNDROME diagnosis HALOTHANE,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4268,MALIGNANT HYPERTHERMIA SYNDROME diagnosis HALOTHANE,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4269,MALIGNANT HYPERTHERMIA SYNDROME diagnosis HALOTHANE,diagnosis,0.997054485501582,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
4270,PLATELET SEQUESTRATION causes THROMBOCYTOPENIA,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4271,THROMBOCYTOPENIA causes PLATELET SEQUESTRATION,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4272,PLATELET SEQUESTRATION causes THROMBOCYTOPENIA,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4273,THROMBOCYTOPENIA causes PLATELET SEQUESTRATION,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4274,no_relation,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4275,THROMBOCYTOPENIA causes PLATELET SEQUESTRATION,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4276,no_relation,causes,0.857492925712544,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
4277,JOINTS location ARTHRITIS,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4278,JOINTS location ARTHRITIS,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4279,JOINTS location ARTHRITIS,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4280,no_relation,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4281,JOINTS location ARTHRITIS,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4282,JOINTS location ARTHRITIS,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4283,JOINTS location ARTHRITIS,location,0.940720868383597,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
4284,CANCER OF THE CERVIX location UTERINE CERVIX,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4285,UTERINE CERVIX location CANCER OF THE CERVIX,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4286,UTERINE CERVIX location CANCER OF THE CERVIX,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4287,UTERINE CERVIX location CANCER OF THE CERVIX,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4288,no_relation,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4289,UTERINE CERVIX location CANCER OF THE CERVIX,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4290,UTERINE CERVIX location CANCER OF THE CERVIX,location,0.505076272276105,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
4291,ANGINA causes BEPRIDIL,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4292,no_relation,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4293,ANGINA causes BEPRIDIL,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4294,BEPRIDIL causes ANGINA,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4295,no_relation,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4296,no_relation,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4297,no_relation,causes,0.441726104299386,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
4298,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4299,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4300,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4301,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4302,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4303,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4304,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
4305,GRANISETRON treats EMESIS,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4306,EMESIS treats GRANISETRON,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4307,EMESIS treats GRANISETRON,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4308,GRANISETRON treats EMESIS,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4309,no_relation,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4310,GRANISETRON treats EMESIS,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4311,no_relation,treats,0.9931270663228408,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
4312,EPILEPSY causes EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4313,EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES causes EPILEPSY,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4314,EPILEPSY causes EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4315,EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES causes EPILEPSY,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4316,EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES causes EPILEPSY,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4317,no_relation,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4318,EPILEPSY causes EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,causes,0.481543412343077,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
4319,no_relation,causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4320,HIV INFECTION causes HUMAN IMMUNODEFICIENCY VIRUS (HIV),causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4321,no_relation,causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4322,no_relation,causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4323,no_relation,causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4324,no_relation,causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4325,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes HIV INFECTION,causes,0.312771621085612,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
4326,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4327,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4328,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4329,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4330,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4331,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4332,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.997054485501582,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
4333,HAEMOPHILIA A causes VIII (FVIII) INHIBITORS,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4334,HAEMOPHILIA A causes VIII (FVIII) INHIBITORS,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4335,no_relation,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4336,VIII (FVIII) INHIBITORS causes HAEMOPHILIA A,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4337,no_relation,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4338,no_relation,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4339,HAEMOPHILIA A causes VIII (FVIII) INHIBITORS,causes,0.9578262852211508,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
4340,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4341,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4342,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4343,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4344,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4345,no_relation,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4346,UNEXPLAINED OPTIC ATROPHY causes WOLFRAM SYNDROME,causes,0.824163383692134,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
4347,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4348,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4349,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4350,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4351,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4352,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4353,CERVIX location CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),location,0.8846517369293829,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
4354,TESTICULAR GERM CELL CANCER causes CONTRALATERAL TESTIS,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4355,no_relation,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4356,no_relation,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4357,no_relation,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4358,no_relation,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4359,no_relation,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4360,no_relation,causes,0.33333333333333304,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
4361,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4362,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4363,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4364,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4365,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4366,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4367,INSULIN THERAPY treats TYPE 2 DIABETES,treats,0.986393923832143,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
4368,TB diagnosis PPD,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4369,no_relation,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4370,TB diagnosis PPD,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4371,TB diagnosis PPD,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4372,TB diagnosis PPD,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4373,no_relation,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4374,TB diagnosis PPD,diagnosis,0.8427009716003839,"If TB is a concern, a PPD is performed.",TB,PPD
4375,IBUPROFEN treats INFLAMMATION,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4376,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4377,IBUPROFEN treats INFLAMMATION,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4378,IBUPROFEN treats INFLAMMATION,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4379,IBUPROFEN treats INFLAMMATION,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4380,IBUPROFEN treats INFLAMMATION,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4381,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
4382,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4383,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4384,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4385,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4386,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4387,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4388,no_relation,treats,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
4389,no_relation,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4390,INSULIN INDUCED HYPOGLYCEMIA causes GLUCAGON,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4391,GLUCAGON causes INSULIN INDUCED HYPOGLYCEMIA,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4392,no_relation,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4393,no_relation,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4394,no_relation,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4395,INSULIN INDUCED HYPOGLYCEMIA causes GLUCAGON,causes,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
4396,DENTAL FLUOROSIS diagnosis FLUORIDE DEFICIENT AREAS,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4397,no_relation,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4398,FLUORIDE DEFICIENT AREAS diagnosis DENTAL FLUOROSIS,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4399,no_relation,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4400,no_relation,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4401,FLUORIDE DEFICIENT AREAS diagnosis DENTAL FLUOROSIS,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4402,FLUORIDE DEFICIENT AREAS diagnosis DENTAL FLUOROSIS,diagnosis,0.42857142857142894,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4403,no_relation,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4404,no_relation,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4405,no_relation,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4406,no_relation,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4407,no_relation,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4408,no_relation,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4409,HEMATURIA causes BLADDER CANCER,causes,0.40824829046386296,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
4410,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4411,ADVANCED RENAL CELL CARCINOMA treats INTERFERON THERAPY,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4412,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4413,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4414,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4415,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4416,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4417,FACIAL ASYMMETRY causes FACIAL HEMIHYPERTROPHY,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4418,FACIAL HEMIHYPERTROPHY causes FACIAL ASYMMETRY,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4419,no_relation,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4420,no_relation,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4421,no_relation,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4422,FACIAL ASYMMETRY causes FACIAL HEMIHYPERTROPHY,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4423,no_relation,causes,0.953462589245592,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
4424,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4425,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4426,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4427,no_relation,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4428,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4429,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4430,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
4431,NEUROENDOCRINE DIFFERENTIATION diagnosis LARGE CELL TYPE NEUROENDOCRINE TUMORS,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4432,no_relation,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4433,LARGE CELL TYPE NEUROENDOCRINE TUMORS diagnosis NEUROENDOCRINE DIFFERENTIATION,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4434,LARGE CELL TYPE NEUROENDOCRINE TUMORS diagnosis NEUROENDOCRINE DIFFERENTIATION,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4435,NEUROENDOCRINE DIFFERENTIATION diagnosis LARGE CELL TYPE NEUROENDOCRINE TUMORS,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4436,LARGE CELL TYPE NEUROENDOCRINE TUMORS diagnosis NEUROENDOCRINE DIFFERENTIATION,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4437,NEUROENDOCRINE DIFFERENTIATION diagnosis LARGE CELL TYPE NEUROENDOCRINE TUMORS,diagnosis,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4438,CRANIAL NERVES location NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4439,CRANIAL NERVES location NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4440,no_relation,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4441,CRANIAL NERVES location NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4442,CRANIAL NERVES location NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4443,no_relation,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4444,CRANIAL NERVES location NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,location,0.918558653543692,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
4445,NEUROENDOCRINE DIFFERENTIATION causes LARGE CELL TYPE NEUROENDOCRINE TUMORS,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4446,NEUROENDOCRINE DIFFERENTIATION causes LARGE CELL TYPE NEUROENDOCRINE TUMORS,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4447,no_relation,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4448,no_relation,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4449,no_relation,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4450,NEUROENDOCRINE DIFFERENTIATION causes LARGE CELL TYPE NEUROENDOCRINE TUMORS,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4451,no_relation,causes,0.356034497458156,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
4452,no_relation,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4453,CANDIDA causes CANDIDEMIA,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4454,CANDIDA causes CANDIDEMIA,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4455,no_relation,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4456,no_relation,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4457,CANDIDEMIA causes CANDIDA,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4458,CANDIDA causes CANDIDEMIA,causes,0.8192880303729141,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
4459,WOLFRAM SYNDROME causes DIABETES MELLITUS,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4460,WOLFRAM SYNDROME causes DIABETES MELLITUS,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4461,WOLFRAM SYNDROME causes DIABETES MELLITUS,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4462,WOLFRAM SYNDROME causes DIABETES MELLITUS,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4463,DIABETES MELLITUS causes WOLFRAM SYNDROME,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4464,WOLFRAM SYNDROME causes DIABETES MELLITUS,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4465,WOLFRAM SYNDROME causes DIABETES MELLITUS,causes,0.997785157856609,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
4466,no_relation,causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4467,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4468,ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) causes HUMAN IMMUNODEFICIENCY VIRUS (HIV),causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4469,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4470,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4471,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4472,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),causes,0.788263422531435,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
4473,no_relation,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4474,FLUORIDE DEFICIENT AREAS causes DENTAL FLUOROSIS,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4475,FLUORIDE DEFICIENT AREAS causes DENTAL FLUOROSIS,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4476,no_relation,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4477,FLUORIDE DEFICIENT AREAS causes DENTAL FLUOROSIS,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4478,DENTAL FLUOROSIS causes FLUORIDE DEFICIENT AREAS,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4479,no_relation,causes,0.7142857142857142,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
4480,no_relation,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4481,MECONIUM causes MECONIUM PERITONITIS,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4482,MECONIUM causes MECONIUM PERITONITIS,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4483,no_relation,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4484,MECONIUM PERITONITIS causes MECONIUM,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4485,no_relation,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4486,no_relation,causes,0.643267520902677,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
4487,PATELLO FEMORAL JOINT treats ARTHROSIS OF THE KNEE,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4488,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4489,PATELLO FEMORAL JOINT treats ARTHROSIS OF THE KNEE,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4490,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4491,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4492,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4493,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
4494,DRUG INDUCED DERMATITIS causes SKIN LESIONS,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4495,DRUG INDUCED DERMATITIS causes SKIN LESIONS,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4496,no_relation,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4497,DRUG INDUCED DERMATITIS causes SKIN LESIONS,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4498,no_relation,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4499,DRUG INDUCED DERMATITIS causes SKIN LESIONS,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4500,DRUG INDUCED DERMATITIS causes SKIN LESIONS,causes,0.5962847939999439,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
4501,SCIATICA causes PAIN,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4502,SCIATICA causes PAIN,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4503,no_relation,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4504,no_relation,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4505,SCIATICA causes PAIN,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4506,SCIATICA causes PAIN,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4507,PAIN causes SCIATICA,causes,0.5698028822981899,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
4508,PRE EXISTING EPILEPSY causes SEIZURES,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4509,PRE EXISTING EPILEPSY causes SEIZURES,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4510,PRE EXISTING EPILEPSY causes SEIZURES,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4511,PRE EXISTING EPILEPSY causes SEIZURES,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4512,PRE EXISTING EPILEPSY causes SEIZURES,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4513,no_relation,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4514,PRE EXISTING EPILEPSY causes SEIZURES,causes,0.9494253265550828,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
4515,GLUCOSE TESTING treats DIABETES,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4516,no_relation,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4517,no_relation,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4518,no_relation,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4519,no_relation,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4520,GLUCOSE TESTING treats DIABETES,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4521,GLUCOSE TESTING treats DIABETES,treats,0.369800130816819,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4522,no_relation,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4523,HAIR STEM CELLS causes ALOPECIA,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4524,no_relation,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4525,no_relation,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4526,no_relation,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4527,no_relation,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4528,no_relation,causes,0.948683298050514,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4529,no_relation,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4530,PROTEINASE K causes P CYCLOPIUM PROTEASE,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4531,no_relation,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4532,PROTEINASE K causes P CYCLOPIUM PROTEASE,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4533,PROTEINASE K causes P CYCLOPIUM PROTEASE,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4534,no_relation,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4535,P CYCLOPIUM PROTEASE causes PROTEINASE K,causes,0.33333333333333304,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
4536,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4537,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4538,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4539,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4540,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4541,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4542,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
4543,HAIR STEM CELLS location ALOPECIA,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4544,HAIR STEM CELLS location ALOPECIA,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4545,HAIR STEM CELLS location ALOPECIA,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4546,no_relation,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4547,HAIR STEM CELLS location ALOPECIA,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4548,HAIR STEM CELLS location ALOPECIA,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4549,no_relation,location,0.31622776601683805,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
4550,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4551,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4552,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4553,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4554,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4555,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4556,DIABETES diagnosis GLUCOSE TESTING,diagnosis,0.924500327042048,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
4557,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4558,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4559,no_relation,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4560,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4561,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4562,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4563,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.943456353049726,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
4564,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4565,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4566,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4567,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4568,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4569,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4570,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4571,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4572,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4573,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4574,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4575,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4576,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4577,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4578,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4579,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4580,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4581,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4582,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4583,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4584,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4585,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4586,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4587,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4588,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4589,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4590,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4591,EMESIS causes VOMITING,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4592,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4593,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4594,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4595,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4596,no_relation,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4597,VOMITING causes EMESIS,causes,0.6933752453,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
4598,THROMBOCYTOPENIA causes KASABACH-MERRITT SYNDROME,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4599,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4600,THROMBOCYTOPENIA causes KASABACH-MERRITT SYNDROME,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4601,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4602,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4603,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4604,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4605,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4606,THROMBOCYTOPENIA causes KASABACH-MERRITT SYNDROME,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4607,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4608,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4609,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4610,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4611,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4612,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4613,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4614,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4615,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4616,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4617,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4618,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4619,THROMBOCYTOPENIA causes KASABACH-MERRITT SYNDROME,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4620,THROMBOCYTOPENIA causes KASABACH-MERRITT SYNDROME,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4621,THROMBOCYTOPENIA causes KASABACH-MERRITT SYNDROME,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4622,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4623,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4624,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4625,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4626,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4627,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4628,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4629,KASABACH-MERRITT SYNDROME causes THROMBOCYTOPENIA,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4630,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4631,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4632,no_relation,causes,0.9647638212,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
4633,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4634,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4635,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4636,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4637,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4638,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4639,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4640,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4641,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4642,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4643,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4644,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4645,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4646,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4647,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4648,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4649,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4650,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4651,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4652,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4653,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4654,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4655,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4656,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4657,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4658,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4659,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4660,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4661,HEADACHE causes MIGRAINE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4662,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4663,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4664,MIGRAINE causes HEADACHE,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4665,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4666,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4667,no_relation,causes,0.700140042,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
4668,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4669,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4670,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4671,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4672,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4673,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4674,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4675,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4676,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4677,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4678,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4679,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4680,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4681,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4682,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4683,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4684,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4685,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4686,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4687,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4688,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4689,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4690,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4691,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4692,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4693,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4694,PSAMMOMA BODIES causes SOMATOSTATINOMA,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4695,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4696,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4697,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4698,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4699,SOMATOSTATINOMA causes PSAMMOMA BODIES,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4700,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4701,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4702,no_relation,causes,0.35856858280000004,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
4703,VOMITING causes HEMATEMESIS,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4704,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4705,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4706,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4707,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4708,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4709,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4710,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4711,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4712,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4713,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4714,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4715,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4716,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4717,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4718,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4719,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4720,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4721,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4722,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4723,VOMITING causes HEMATEMESIS,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4724,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4725,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4726,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4727,VOMITING causes HEMATEMESIS,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4728,VOMITING causes HEMATEMESIS,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4729,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4730,HEMATEMESIS causes VOMITING,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4731,VOMITING causes HEMATEMESIS,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4732,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4733,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4734,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4735,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4736,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4737,no_relation,causes,0.3939192986,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
4738,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4739,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4740,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4741,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4742,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4743,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4744,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4745,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4746,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4747,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4748,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4749,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4750,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4751,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4752,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4753,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4754,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4755,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4756,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4757,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4758,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4759,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4760,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4761,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4762,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4763,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4764,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4765,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4766,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4767,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4768,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4769,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4770,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4771,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4772,no_relation,causes,0.9091372901,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
4773,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4774,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4775,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4776,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4777,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4778,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4779,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4780,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4781,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4782,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4783,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4784,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4785,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4786,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4787,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4788,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4789,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4790,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4791,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4792,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4793,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4794,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4795,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4796,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4797,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4798,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4799,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4800,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4801,SECONDARY THROMBOCYTOSIS causes ELEVATED PLATELET COUNT,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4802,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4803,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4804,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4805,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4806,no_relation,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4807,ELEVATED PLATELET COUNT causes SECONDARY THROMBOCYTOSIS,causes,0.9534625892,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
4808,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4809,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4810,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4811,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4812,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4813,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4814,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4815,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4816,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4817,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4818,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4819,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4820,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4821,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4822,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4823,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4824,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4825,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4826,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4827,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4828,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4829,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4830,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4831,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4832,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4833,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4834,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4835,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4836,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4837,HEADACHES causes MIGRAINES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4838,MIGRAINES causes HEADACHES,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4839,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4840,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4841,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4842,no_relation,causes,0.4850712501,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
4843,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4844,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4845,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4846,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4847,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4848,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4849,CUTANEOUS PLAQUES causes WORINGER-KOLOPP DISEASE,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4850,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4851,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4852,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4853,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4854,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4855,CUTANEOUS PLAQUES causes WORINGER-KOLOPP DISEASE,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4856,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4857,CUTANEOUS PLAQUES causes WORINGER-KOLOPP DISEASE,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4858,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4859,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4860,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4861,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4862,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4863,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4864,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4865,CUTANEOUS PLAQUES causes WORINGER-KOLOPP DISEASE,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4866,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4867,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4868,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4869,CUTANEOUS PLAQUES causes WORINGER-KOLOPP DISEASE,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4870,WORINGER-KOLOPP DISEASE causes CUTANEOUS PLAQUES,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4871,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4872,CUTANEOUS PLAQUES causes WORINGER-KOLOPP DISEASE,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4873,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4874,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4875,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4876,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4877,no_relation,causes,0.4008918629,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
4878,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4879,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4880,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4881,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4882,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4883,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4884,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4885,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4886,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4887,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4888,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4889,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4890,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4891,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4892,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4893,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4894,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4895,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4896,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4897,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4898,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4899,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4900,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4901,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4902,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4903,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4904,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4905,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4906,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4907,HEAT EFFECT causes HEAT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4908,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4909,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4910,HEAT causes HEAT EFFECT,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4911,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4912,no_relation,causes,0.4200840252,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
4913,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4914,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4915,HEADACHE causes MIGRAINE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4916,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4917,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4918,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4919,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4920,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4921,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4922,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4923,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4924,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4925,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4926,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4927,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4928,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4929,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4930,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4931,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4932,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4933,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4934,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4935,HEADACHE causes MIGRAINE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4936,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4937,HEADACHE causes MIGRAINE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4938,HEADACHE causes MIGRAINE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4939,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4940,HEADACHE causes MIGRAINE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4941,HEADACHE causes MIGRAINE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4942,MIGRAINE causes HEADACHE,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4943,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4944,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4945,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4946,no_relation,causes,0.4529108137,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
4947,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4948,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4949,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4950,no_relation,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4951,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4952,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4953,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4954,no_relation,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4955,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4956,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4957,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4958,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4959,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4960,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4961,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4962,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4963,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4964,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4965,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4966,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4967,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4968,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4969,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4970,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4971,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4972,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4973,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4974,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4975,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4976,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4977,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4978,no_relation,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4979,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4980,no_relation,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4981,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.953998092,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
4982,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4983,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4984,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4985,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4986,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4987,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4988,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4989,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4990,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4991,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4992,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4993,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4994,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4995,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4996,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4997,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4998,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
4999,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5000,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5001,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5002,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5003,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5004,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5005,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5006,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5007,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5008,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5009,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5010,DIFFUSE LESIONS causes LYMPHANGIOMATOSIS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5011,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5012,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5013,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5014,LYMPHANGIOMATOSIS causes DIFFUSE LESIONS,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5015,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5016,no_relation,causes,0.4931969619,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
5017,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5018,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5019,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5020,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5021,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5022,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5023,ITCH causes PRURITUS,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5024,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5025,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5026,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5027,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5028,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5029,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5030,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5031,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5032,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5033,ITCH causes PRURITUS,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5034,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5035,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5036,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5037,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5038,ITCH causes PRURITUS,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5039,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5040,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5041,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5042,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5043,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5044,ITCH causes PRURITUS,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5045,ITCH causes PRURITUS,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5046,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5047,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5048,PRURITUS causes ITCH,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5049,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5050,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5051,no_relation,causes,0.91914503,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
5052,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5053,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5054,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5055,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5056,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5057,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5058,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5059,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5060,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5061,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5062,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5063,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5064,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5065,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5066,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5067,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5068,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5069,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5070,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5071,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5072,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5073,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5074,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5075,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5076,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5077,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5078,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5079,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5080,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5081,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5082,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5083,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5084,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5085,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5086,no_relation,causes,0.9534625892,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
5087,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5088,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5089,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5090,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5091,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5092,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5093,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5094,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5095,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5096,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5097,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5098,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5099,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5100,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5101,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5102,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5103,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5104,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5105,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5106,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5107,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5108,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5109,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5110,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5111,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5112,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5113,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5114,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5115,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5116,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5117,VACCINIA causes VACCINIA VIRUS,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5118,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5119,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5120,VACCINIA VIRUS causes VACCINIA,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5121,no_relation,causes,0.5570860145000001,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
5122,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5123,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5124,no_relation,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5125,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5126,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5127,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5128,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5129,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5130,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5131,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5132,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5133,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5134,no_relation,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5135,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5136,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5137,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5138,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5139,no_relation,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5140,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5141,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5142,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5143,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5144,no_relation,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5145,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5146,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5147,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5148,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5149,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5150,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5151,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5152,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5153,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5154,no_relation,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5155,BINGE EATING causes BINGE EATING DISORDER,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5156,BINGE EATING DISORDER causes BINGE EATING,causes,0.5298129428,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
5157,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5158,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5159,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5160,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5161,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5162,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5163,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5164,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5165,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5166,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5167,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5168,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5169,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5170,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5171,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5172,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5173,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5174,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5175,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5176,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5177,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5178,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5179,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5180,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5181,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5182,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5183,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5184,PAIN causes NEUROPATHIC PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5185,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5186,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5187,NEUROPATHIC PAIN causes PAIN,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5188,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5189,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5190,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5191,no_relation,causes,0.7624928517,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
5192,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5193,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5194,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5195,no_relation,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5196,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5197,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5198,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5199,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5200,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5201,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5202,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5203,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5204,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5205,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5206,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5207,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5208,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5209,no_relation,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5210,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5211,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5212,no_relation,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5213,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5214,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5215,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5216,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5217,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5218,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5219,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5220,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5221,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5222,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5223,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5224,no_relation,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5225,no_relation,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5226,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5227,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5228,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5229,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5230,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5231,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5232,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5233,DIABETES causes DIABETIC NEUROPATHY,causes,1.0,"The authors revealed that long-term compensation of diabetes, the duration of DIABETES and the biological age of the diabetics were statistically significant for the manifestation of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
5234,VENOUS STASIS causes VENOUS INSUFFICIENCY,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5235,VENOUS STASIS causes VENOUS INSUFFICIENCY,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5236,VENOUS STASIS causes VENOUS INSUFFICIENCY,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5237,VENOUS STASIS causes VENOUS INSUFFICIENCY,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5238,no_relation,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5239,no_relation,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5240,VENOUS STASIS causes VENOUS INSUFFICIENCY,causes,0.845154254728516,Use of a superficial femoral vein in competent profunda vein transposition is appropriate in selected cases of Klippel-Trenaunay syndrome; this allows for improvement of VENOUS INSUFFICIENCY and relief of symptoms secondary to VENOUS STASIS,VENOUS STASIS,VENOUS INSUFFICIENCY
5241,no_relation,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5242,ALLERGIC VASCULITIS causes HYPERSENSITIVITY REACTIONS,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5243,ALLERGIC VASCULITIS causes HYPERSENSITIVITY REACTIONS,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5244,HYPERSENSITIVITY REACTIONS causes ALLERGIC VASCULITIS,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5245,HYPERSENSITIVITY REACTIONS causes ALLERGIC VASCULITIS,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5246,HYPERSENSITIVITY REACTIONS causes ALLERGIC VASCULITIS,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5247,no_relation,causes,0.984731927834662,"HYPERSENSITIVITY REACTIONS to heparin consist of heparin-induced immune thrombocytopenia, ALLERGIC VASCULITIS, hypereosinophilia, immediate hypersensitivity as well as delayed-type skin reactions",ALLERGIC VASCULITIS,HYPERSENSITIVITY REACTIONS
5248,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5249,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5250,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5251,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5252,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5253,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5254,HAEMOPHILIA causes HAEMOPHILIC ARTHROPATHY,causes,0.948683298050514,"In fact, prophylaxis seems to be the only way to prevent the development of HAEMOPHILIC ARTHROPATHY in patients with HAEMOPHILIA",HAEMOPHILIC ARTHROPATHY,HAEMOPHILIA
5255,DIABETES MELLITUS causes DIABETIC AUTONOMIC NEUROPATHY,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5256,DIABETES MELLITUS causes DIABETIC AUTONOMIC NEUROPATHY,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5257,DIABETES MELLITUS causes DIABETIC AUTONOMIC NEUROPATHY,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5258,no_relation,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5259,DIABETES MELLITUS causes DIABETIC AUTONOMIC NEUROPATHY,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5260,DIABETIC AUTONOMIC NEUROPATHY causes DIABETES MELLITUS,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5261,DIABETES MELLITUS causes DIABETIC AUTONOMIC NEUROPATHY,causes,0.995893206467704,"In view of clinical reports implicating DIABETIC AUTONOMIC NEUROPATHY as the cause of gastrointestinal dysfunction in DIABETES MELLITUS, neurochemical and histochemical techniques were used to study changes in the innervation of the gut",DIABETIC AUTONOMIC NEUROPATHY,DIABETES MELLITUS
5262,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5263,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5264,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5265,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5266,no_relation,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5267,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5268,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9113223768657672,We describe DIABETIC KETOACIDOSIS and transient severe insulin resistance in a woman with DIABETES who was treated with subcutaneous terbutaline infusion,DIABETIC KETOACIDOSIS,DIABETES
5269,no_relation,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5270,MELENA causes GASTROINTESTINAL BLEEDING,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5271,no_relation,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5272,MELENA causes GASTROINTESTINAL BLEEDING,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5273,GASTROINTESTINAL BLEEDING causes MELENA,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5274,MELENA causes GASTROINTESTINAL BLEEDING,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5275,no_relation,causes,0.680413817439772,We report a rare cause of GASTROINTESTINAL BLEEDING in a 5-year-old boy with hematemesis and MELENA for a month,MELENA,GASTROINTESTINAL BLEEDING
5276,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5277,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5278,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5279,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5280,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5281,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5282,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5283,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5284,SPLENOMEGALY causes HAIRY CELL LEUKAEMIA,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5285,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5286,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5287,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5288,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5289,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
5290,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5291,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5292,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5293,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5294,no_relation,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5295,no_relation,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5296,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.979957887012223,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
5297,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5298,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5299,no_relation,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5300,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5301,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5302,no_relation,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5303,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5304,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5305,no_relation,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5306,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5307,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5308,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5309,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5310,no_relation,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5311,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5312,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5313,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5314,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5315,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5316,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5317,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
5318,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5319,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5320,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5321,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5322,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5323,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5324,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5325,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5326,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5327,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5328,WOLFRAM SYNDROME causes DIABETES INSIPIDUS,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5329,WOLFRAM SYNDROME causes DIABETES INSIPIDUS,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5330,no_relation,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5331,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
5332,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5333,no_relation,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5334,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5335,no_relation,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5336,no_relation,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5337,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5338,no_relation,causes,0.700140042014005,"Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for PRECOCIOUS PUBERTY in girls with the MCCUNE-ALBRIGHT SYNDROME",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5339,SIDS causes SUDDEN INFANT DEATH,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5340,SUDDEN INFANT DEATH causes SIDS,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5341,SIDS causes SUDDEN INFANT DEATH,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5342,no_relation,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5343,SIDS causes SUDDEN INFANT DEATH,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5344,no_relation,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5345,SIDS causes SUDDEN INFANT DEATH,causes,0.848528137423857,"The most common cause of SUDDEN INFANT DEATH is SIDS, defined as 'the sudden and unexpected death of an infant under 1 year of age, with onset of lethal episode apparently occurring during sleep, that remains unexplained after a thorough investigation including performance of a complete autopsy review of the circumstances of death and clinical history",SIDS,SUDDEN INFANT DEATH
5346,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5347,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5348,no_relation,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5349,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5350,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5351,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5352,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.577350269189626,"Likewise, the presence of maternal homocysteine concentrations have been associated both with increased habitual spontaneous abortion and PREGNANCY COMPLICATIONS (eg, placental abruption and PREECLAMPSIA), which increase the risk of poor pregnancy outcome and of decreased birth weight and gestation duration",PREGNANCY COMPLICATIONS,PREECLAMPSIA
5353,no_relation,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5354,no_relation,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5355,no_relation,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5356,no_relation,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5357,VERRUCAE causes HYPERKERATOSIS,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5358,no_relation,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5359,no_relation,causes,0.544331053951817,"Skin changes are common and include HYPERKERATOSIS, hyperpigmentation, VERRUCAE, papillomas, and fungal infections",HYPERKERATOSIS,VERRUCAE
5360,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5361,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5362,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5363,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5364,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5365,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5366,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.8164965809277259,"It is unknown why a patient with HYPERTENSION suddenly develops a HYPERTENSIVE CRISIS, but the renin-angiotension system seems to play an important role",HYPERTENSION,HYPERTENSIVE CRISIS
5367,SUFFOCATION causes ASPHYXIA,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5368,no_relation,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5369,SUFFOCATION causes ASPHYXIA,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5370,no_relation,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5371,SUFFOCATION causes ASPHYXIA,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5372,no_relation,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5373,SUFFOCATION causes ASPHYXIA,causes,0.635000635000953,"Although the examiners stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining the cause of death, the results of other studies have shown that the pink teeth phenomenon is a common finding related to cases of ASPHYXIA such as strangulation, drowning or SUFFOCATION",SUFFOCATION,ASPHYXIA
5374,no_relation,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5375,no_relation,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5376,no_relation,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5377,HYPERSENSITIVITY causes ALLERGIES,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5378,no_relation,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5379,no_relation,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5380,HYPERSENSITIVITY causes ALLERGIES,causes,0.4,"Infectious causes of conjunctivitis should always be investigated, but ALLERGIES and HYPERSENSITIVITY also should be considered if the history is appropriate",ALLERGIES,HYPERSENSITIVITY
5381,no_relation,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5382,LYMPH NODE METASTASIS causes METASTATIC LESION,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5383,no_relation,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5384,no_relation,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5385,LYMPH NODE METASTASIS causes METASTATIC LESION,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5386,METASTATIC LESION causes LYMPH NODE METASTASIS,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5387,no_relation,causes,0.824163383692134,"This indicates that OPN may contribute to LYMPH NODE METASTASIS and its advancement, and that the OPN level in METASTATIC LESION may be a prognostic indicator in uterine cervical cancers",METASTATIC LESION,LYMPH NODE METASTASIS
5388,MICROCEPHALY causes SMMCI,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5389,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5390,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5391,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5392,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5393,SMMCI causes MICROCEPHALY,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5394,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
5395,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5396,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5397,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5398,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5399,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5400,DEXAMETHASONE causes HYPERCORTISOLISM,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5401,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5402,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5403,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5404,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5405,no_relation,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5406,no_relation,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5407,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5408,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5409,no_relation,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5410,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5411,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5412,PATHOLOGIC FRACTURES causes BONE METASTASIS,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5413,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5414,PATHOLOGIC FRACTURES causes BONE METASTASIS,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5415,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5416,no_relation,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5417,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5418,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5419,no_relation,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5420,PATHOLOGIC FRACTURES causes BONE METASTASIS,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5421,PATHOLOGIC FRACTURES causes BONE METASTASIS,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5422,BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.848528137423857,"Bone metastases cause considerable skeletal morbidity, including bone pain, PATHOLOGIC FRACTURES, spinal cord compression and it is necessary to develop the effective treatment against BONE METASTASIS",PATHOLOGIC FRACTURES,BONE METASTASIS
5423,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5424,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5425,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5426,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5427,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5428,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5429,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5430,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5431,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5432,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5433,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5434,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5435,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5436,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5437,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5438,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5439,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5440,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5441,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5442,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5443,no_relation,causes,0.9113223768657672,"Renal infarction can be complicated by ARTERIAL HYPERTENSION, which is sometimes severe and may present as HYPERTENSIVE ENCEPHALOPATHY and epilepsy",ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
5444,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5445,LYMPHADENOPATHY causes MONONUCLEOSIS,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5446,LYMPHADENOPATHY causes MONONUCLEOSIS,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5447,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5448,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5449,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5450,MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5451,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5452,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5453,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5454,MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5455,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5456,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5457,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5458,MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5459,MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5460,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5461,MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5462,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5463,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5464,no_relation,causes,0.5962847939999439,"Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of MONONUCLEOSIS with LYMPHADENOPATHY, fatigue and fever",LYMPHADENOPATHY,MONONUCLEOSIS
5465,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5466,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5467,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5468,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CARCINOMA,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5469,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CARCINOMA,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5470,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5471,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CARCINOMA,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5472,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5473,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CARCINOMA,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5474,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5475,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5476,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5477,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5478,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5479,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5480,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5481,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5482,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5483,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5484,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5485,no_relation,causes,0.919145030018058,"So the combined use of hysteroscopical technique and directed biopsies is of great significance in finding out the causes of POSTMENOPAUSAL BLEEDING, making a definite diagnosis of ENDOMETRIAL CARCINOMA and precancerous lesion, and further preventing the occurrence of endometrial carcinoma",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
5486,RADIAL SCARS causes MICROCALCIFICATIONS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5487,MICROCALCIFICATIONS causes RADIAL SCARS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5488,RADIAL SCARS causes MICROCALCIFICATIONS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5489,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5490,RADIAL SCARS causes MICROCALCIFICATIONS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5491,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5492,MICROCALCIFICATIONS causes RADIAL SCARS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5493,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5494,MICROCALCIFICATIONS causes RADIAL SCARS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5495,RADIAL SCARS causes MICROCALCIFICATIONS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5496,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5497,MICROCALCIFICATIONS causes RADIAL SCARS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5498,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5499,MICROCALCIFICATIONS causes RADIAL SCARS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5500,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5501,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5502,RADIAL SCARS causes MICROCALCIFICATIONS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5503,MICROCALCIFICATIONS causes RADIAL SCARS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5504,RADIAL SCARS causes MICROCALCIFICATIONS,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5505,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5506,no_relation,causes,0.588348405414552,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5507,BRAIN location EPILEPSY,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5508,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5509,BRAIN location EPILEPSY,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5510,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5511,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5512,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5513,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5514,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5515,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5516,EPILEPSY location BRAIN,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5517,BRAIN location EPILEPSY,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5518,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5519,BRAIN location EPILEPSY,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5520,EPILEPSY location BRAIN,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5521,BRAIN location EPILEPSY,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5522,EPILEPSY location BRAIN,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5523,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5524,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5525,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5526,BRAIN location EPILEPSY,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5527,no_relation,location,0.676123403782813,Many similarities exist between cerebral ischemia and EPILEPSY regarding BRAIN-damaging and auto-protective mechanisms that are activated following the injurious insult,BRAIN,EPILEPSY
5528,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5529,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5530,no_relation,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5531,TREMOR causes PHEOCHROMOCYTOMA,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5532,no_relation,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5533,no_relation,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5534,no_relation,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5535,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5536,TREMOR causes PHEOCHROMOCYTOMA,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5537,TREMOR causes PHEOCHROMOCYTOMA,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5538,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5539,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5540,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5541,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5542,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5543,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5544,TREMOR causes PHEOCHROMOCYTOMA,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5545,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5546,no_relation,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5547,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5548,PHEOCHROMOCYTOMA causes TREMOR,causes,0.9931270663228408,"Patients with labile, significantly elevated BP and symptoms such as headache, palpitations, tachycardia, excessive perspiration, TREMOR, and pallor are screened for PHEOCHROMOCYTOMA (eg, by measuring plasma free metanephrines?see  Diagnosis",TREMOR,PHEOCHROMOCYTOMA
5549,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5550,no_relation,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5551,no_relation,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5552,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5553,no_relation,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5554,HYPERTENSIVE CRISIS causes HYPERTENSION,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5555,no_relation,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5556,no_relation,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5557,no_relation,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5558,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5559,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5560,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5561,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5562,HYPERTENSIVE CRISIS causes HYPERTENSION,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5563,HYPERTENSIVE CRISIS causes HYPERTENSION,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5564,HYPERTENSIVE CRISIS causes HYPERTENSION,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5565,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5566,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5567,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5568,HYPERTENSIVE CRISIS causes HYPERTENSION,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5569,HYPERTENSION causes HYPERTENSIVE CRISIS,causes,0.833333333333333,"Although such numbers represent only about 1% of the estimated 60 million Americans with HYPERTENSION, HYPERTENSIVE CRISIS often constitutes a major medical emergency, necessitating a focused, assertive, and reasoned therapeutic intervention",HYPERTENSION,HYPERTENSIVE CRISIS
5570,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5571,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5572,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5573,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5574,no_relation,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5575,no_relation,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5576,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5577,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5578,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5579,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5580,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5581,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5582,no_relation,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5583,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5584,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5585,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5586,MICROCALCIFICATIONS diagnosis RADIAL SCARS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5587,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5588,no_relation,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5589,RADIAL SCARS diagnosis MICROCALCIFICATIONS,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5590,no_relation,diagnosis,0.392232270276368,Only the presence of MICROCALCIFICATIONS in 11 of those patients helped the authors distinguish carcinoma from RADIAL SCARS,MICROCALCIFICATIONS,RADIAL SCARS
5591,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5592,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5593,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5594,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5595,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5596,no_relation,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5597,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5598,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5599,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5600,no_relation,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5601,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5602,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5603,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5604,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5605,no_relation,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5606,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5607,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5608,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5609,ALLERGIC FUNGAL SINUSITIS causes HYPERSENSITIVITY REACTION,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5610,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5611,HYPERSENSITIVITY REACTION causes ALLERGIC FUNGAL SINUSITIS,causes,0.635000635000953,ALLERGIC FUNGAL SINUSITIS is a benign noninvasive sinus disease related to a HYPERSENSITIVITY REACTION to fungal antigens,ALLERGIC FUNGAL SINUSITIS,HYPERSENSITIVITY REACTION
5612,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5613,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5614,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5615,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5616,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5617,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5618,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5619,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5620,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5621,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5622,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5623,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5624,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5625,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5626,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5627,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5628,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5629,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5630,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5631,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5632,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
5633,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5634,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5635,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5636,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5637,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5638,CHRONIC EOSINOPHILIC LEUKAEMIA location BONE MARROW,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5639,CHRONIC EOSINOPHILIC LEUKAEMIA location BONE MARROW,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5640,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5641,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5642,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5643,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5644,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5645,CHRONIC EOSINOPHILIC LEUKAEMIA location BONE MARROW,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5646,CHRONIC EOSINOPHILIC LEUKAEMIA location BONE MARROW,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5647,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5648,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5649,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5650,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5651,BONE MARROW location CHRONIC EOSINOPHILIC LEUKAEMIA,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5652,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5653,no_relation,location,0.7184212081071,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
5654,ROSAI-DORFMAN DISEASE causes EMPERIPOLESIS,causes,0.762000762001143,"Pathology showed inflammatory infiltrate in the absence of an infectious agent, EMPERIPOLESIS and a positive S100 stain was consistent with ROSAI-DORFMAN DISEASE",EMPERIPOLESIS,ROSAI-DORFMAN DISEASE
5655,EMPERIPOLESIS causes ROSAI-DORFMAN DISEASE,causes,0.762000762001143,"Pathology showed inflammatory infiltrate in the absence of an infectious agent, EMPERIPOLESIS and a positive S100 stain was consistent with ROSAI-DORFMAN DISEASE",EMPERIPOLESIS,ROSAI-DORFMAN DISEASE
5656,ROSAI-DORFMAN DISEASE causes EMPERIPOLESIS,causes,0.762000762001143,"Pathology showed inflammatory infiltrate in the absence of an infectious agent, EMPERIPOLESIS and a positive S100 stain was consistent with ROSAI-DORFMAN DISEASE",EMPERIPOLESIS,ROSAI-DORFMAN DISEASE
5657,ROSAI-DORFMAN DISEASE causes EMPERIPOLESIS,causes,0.762000762001143,"Pathology showed inflammatory infiltrate in the absence of an infectious agent, EMPERIPOLESIS and a positive S100 stain was consistent with ROSAI-DORFMAN DISEASE",EMPERIPOLESIS,ROSAI-DORFMAN DISEASE
5658,ROSAI-DORFMAN DISEASE causes EMPERIPOLESIS,causes,0.762000762001143,"Pathology showed inflammatory infiltrate in the absence of an infectious agent, EMPERIPOLESIS and a positive S100 stain was consistent with ROSAI-DORFMAN DISEASE",EMPERIPOLESIS,ROSAI-DORFMAN DISEASE
5659,no_relation,causes,0.762000762001143,"Pathology showed inflammatory infiltrate in the absence of an infectious agent, EMPERIPOLESIS and a positive S100 stain was consistent with ROSAI-DORFMAN DISEASE",EMPERIPOLESIS,ROSAI-DORFMAN DISEASE
5660,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5661,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5662,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
5663,SUPERFICIAL SPREADING MELANOMA causes RADIAL GROWTH PHASE,causes,0.384110639798688,The biologic behavior of the intraepidermal component of SUPERFICIAL SPREADING MELANOMA (the RADIAL GROWTH PHASE) has been demonstrated to have significantly different properties than those of the cells in the vertical growth phase,RADIAL GROWTH PHASE,SUPERFICIAL SPREADING MELANOMA
5664,SUPERFICIAL SPREADING MELANOMA causes RADIAL GROWTH PHASE,causes,0.384110639798688,The biologic behavior of the intraepidermal component of SUPERFICIAL SPREADING MELANOMA (the RADIAL GROWTH PHASE) has been demonstrated to have significantly different properties than those of the cells in the vertical growth phase,RADIAL GROWTH PHASE,SUPERFICIAL SPREADING MELANOMA
5665,no_relation,causes,0.384110639798688,The biologic behavior of the intraepidermal component of SUPERFICIAL SPREADING MELANOMA (the RADIAL GROWTH PHASE) has been demonstrated to have significantly different properties than those of the cells in the vertical growth phase,RADIAL GROWTH PHASE,SUPERFICIAL SPREADING MELANOMA
5666,ELEVATED PLATELET COUNT causes ESSENTIAL THROMBOCYTHEMIA,causes,0.308606699924184,"When accompanied by an ELEVATED PLATELET COUNT, these precursor stages may clinically mimick ESSENTIAL THROMBOCYTHEMIA because they are not recognized by the conventional criteria",ELEVATED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
5667,ESSENTIAL THROMBOCYTHEMIA causes ELEVATED PLATELET COUNT,causes,0.308606699924184,"When accompanied by an ELEVATED PLATELET COUNT, these precursor stages may clinically mimick ESSENTIAL THROMBOCYTHEMIA because they are not recognized by the conventional criteria",ELEVATED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
5668,no_relation,causes,0.308606699924184,"When accompanied by an ELEVATED PLATELET COUNT, these precursor stages may clinically mimick ESSENTIAL THROMBOCYTHEMIA because they are not recognized by the conventional criteria",ELEVATED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
5669,FEVER causes HEPATOCELLULAR CARCINOMA,causes,0.964901281354015,A 52-year-old man with HEPATOCELLULAR CARCINOMA (HCC) was admitted with cough and FEVER,FEVER,HEPATOCELLULAR CARCINOMA
5670,HEPATOCELLULAR CARCINOMA causes FEVER,causes,0.964901281354015,A 52-year-old man with HEPATOCELLULAR CARCINOMA (HCC) was admitted with cough and FEVER,FEVER,HEPATOCELLULAR CARCINOMA
5671,HEPATOCELLULAR CARCINOMA causes FEVER,causes,0.964901281354015,A 52-year-old man with HEPATOCELLULAR CARCINOMA (HCC) was admitted with cough and FEVER,FEVER,HEPATOCELLULAR CARCINOMA
5672,no_relation,causes,0.979957887012223,"CASE REPORT: Morgan, a 4-year-old boy with BLOOM SYNDROME, developed a WILMS TUMOR",WILMS TUMOR,BLOOM SYNDROME
5673,BLOOM SYNDROME causes WILMS TUMOR,causes,0.979957887012223,"CASE REPORT: Morgan, a 4-year-old boy with BLOOM SYNDROME, developed a WILMS TUMOR",WILMS TUMOR,BLOOM SYNDROME
5674,no_relation,causes,0.979957887012223,"CASE REPORT: Morgan, a 4-year-old boy with BLOOM SYNDROME, developed a WILMS TUMOR",WILMS TUMOR,BLOOM SYNDROME
5675,BLOOM SYNDROME causes WILMS TUMOR,causes,0.979957887012223,"CASE REPORT: Morgan, a 4-year-old boy with BLOOM SYNDROME, developed a WILMS TUMOR",WILMS TUMOR,BLOOM SYNDROME
5676,BLOOM SYNDROME causes WILMS TUMOR,causes,0.979957887012223,"CASE REPORT: Morgan, a 4-year-old boy with BLOOM SYNDROME, developed a WILMS TUMOR",WILMS TUMOR,BLOOM SYNDROME
5677,BLOOM SYNDROME causes WILMS TUMOR,causes,0.979957887012223,"CASE REPORT: Morgan, a 4-year-old boy with BLOOM SYNDROME, developed a WILMS TUMOR",WILMS TUMOR,BLOOM SYNDROME
5678,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.8616404368553291,We describe a case in which a diagnosis of SPLENIC RUPTURE occurring spontaneously on a background of INFECTIOUS MONONUCLEOSIS was made as a result of a high index of suspicion,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
5679,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.8616404368553291,We describe a case in which a diagnosis of SPLENIC RUPTURE occurring spontaneously on a background of INFECTIOUS MONONUCLEOSIS was made as a result of a high index of suspicion,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
5680,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.8616404368553291,We describe a case in which a diagnosis of SPLENIC RUPTURE occurring spontaneously on a background of INFECTIOUS MONONUCLEOSIS was made as a result of a high index of suspicion,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
5681,SPLENIC RUPTURE causes INFECTIOUS MONONUCLEOSIS,causes,0.8616404368553291,We describe a case in which a diagnosis of SPLENIC RUPTURE occurring spontaneously on a background of INFECTIOUS MONONUCLEOSIS was made as a result of a high index of suspicion,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
5682,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.8616404368553291,We describe a case in which a diagnosis of SPLENIC RUPTURE occurring spontaneously on a background of INFECTIOUS MONONUCLEOSIS was made as a result of a high index of suspicion,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
5683,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.8616404368553291,We describe a case in which a diagnosis of SPLENIC RUPTURE occurring spontaneously on a background of INFECTIOUS MONONUCLEOSIS was made as a result of a high index of suspicion,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
5684,GAMMA HEAVY CHAIN DISEASE diagnosis SPLENOMEGALY,diagnosis,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
5685,no_relation,diagnosis,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
5686,no_relation,diagnosis,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
5687,GAMMA HEAVY CHAIN DISEASE causes SPLENOMEGALY,causes,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
5688,GAMMA HEAVY CHAIN DISEASE causes SPLENOMEGALY,causes,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
5689,SPLENOMEGALY causes GAMMA HEAVY CHAIN DISEASE,causes,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
5690,MIGRAINE causes HEADACHE,causes,0.461880215351701,The effect was manifested in complete relief in six patients treated during an attack of MIGRAINE and in a relatively high number of other cases of HEADACHE with relief of pain,HEADACHE,MIGRAINE
5691,HEADACHE causes MIGRAINE,causes,0.461880215351701,The effect was manifested in complete relief in six patients treated during an attack of MIGRAINE and in a relatively high number of other cases of HEADACHE with relief of pain,HEADACHE,MIGRAINE
5692,MIGRAINE causes HEADACHE,causes,0.461880215351701,The effect was manifested in complete relief in six patients treated during an attack of MIGRAINE and in a relatively high number of other cases of HEADACHE with relief of pain,HEADACHE,MIGRAINE
5693,HEADACHE causes MIGRAINE,causes,0.461880215351701,The effect was manifested in complete relief in six patients treated during an attack of MIGRAINE and in a relatively high number of other cases of HEADACHE with relief of pain,HEADACHE,MIGRAINE
5694,MIGRAINE causes HEADACHE,causes,0.461880215351701,The effect was manifested in complete relief in six patients treated during an attack of MIGRAINE and in a relatively high number of other cases of HEADACHE with relief of pain,HEADACHE,MIGRAINE
5695,MIGRAINE causes HEADACHE,causes,0.461880215351701,The effect was manifested in complete relief in six patients treated during an attack of MIGRAINE and in a relatively high number of other cases of HEADACHE with relief of pain,HEADACHE,MIGRAINE
5696,EPILEPSY causes SEIZURES,causes,0.975900072948533,The treatment of EPILEPSY after the first epileptic seizure decreases effectively the number of SEIZURES within the first three years,SEIZURES,EPILEPSY
5697,EPILEPSY causes SEIZURES,causes,0.975900072948533,The treatment of EPILEPSY after the first epileptic seizure decreases effectively the number of SEIZURES within the first three years,SEIZURES,EPILEPSY
5698,EPILEPSY causes SEIZURES,causes,0.975900072948533,The treatment of EPILEPSY after the first epileptic seizure decreases effectively the number of SEIZURES within the first three years,SEIZURES,EPILEPSY
5699,no_relation,contraindicates,0.42426406871192895,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5700,no_relation,contraindicates,0.42426406871192895,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5701,no_relation,contraindicates,0.42426406871192895,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5702,EPILEPSY contraindicates SEIZURES,contraindicates,0.42426406871192895,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5703,no_relation,contraindicates,0.42426406871192895,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5704,no_relation,contraindicates,0.42426406871192895,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5705,EPILEPSY causes SEIZURES,causes,0.848528137423857,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5706,SEIZURES causes EPILEPSY,causes,0.848528137423857,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5707,SEIZURES causes EPILEPSY,causes,0.848528137423857,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5708,SEIZURES causes EPILEPSY,causes,0.848528137423857,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5709,no_relation,causes,0.848528137423857,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5710,EPILEPSY causes SEIZURES,causes,0.848528137423857,"Although LQTS can be potentially misdiagnosed as epilepsy when it presents with SEIZURES, it is important to differentiate LQTS from EPILEPSY because patients with LQTS are at risk of sudden death",SEIZURES,EPILEPSY
5711,no_relation,causes,0.676123403782813,"In the group of patients studied 50% suffered from HEADACHE, and 32.8% fulfilled the diagnostic criteria of MIGRAINE",HEADACHE,MIGRAINE
5712,MIGRAINE causes HEADACHE,causes,0.676123403782813,"In the group of patients studied 50% suffered from HEADACHE, and 32.8% fulfilled the diagnostic criteria of MIGRAINE",HEADACHE,MIGRAINE
5713,MIGRAINE causes HEADACHE,causes,0.676123403782813,"In the group of patients studied 50% suffered from HEADACHE, and 32.8% fulfilled the diagnostic criteria of MIGRAINE",HEADACHE,MIGRAINE
5714,MIGRAINE causes HEADACHE,causes,0.676123403782813,"In the group of patients studied 50% suffered from HEADACHE, and 32.8% fulfilled the diagnostic criteria of MIGRAINE",HEADACHE,MIGRAINE
5715,HEADACHE causes MIGRAINE,causes,0.676123403782813,"In the group of patients studied 50% suffered from HEADACHE, and 32.8% fulfilled the diagnostic criteria of MIGRAINE",HEADACHE,MIGRAINE
5716,no_relation,causes,0.676123403782813,"In the group of patients studied 50% suffered from HEADACHE, and 32.8% fulfilled the diagnostic criteria of MIGRAINE",HEADACHE,MIGRAINE
5717,TEMPORAL LOBE location TEMPORAL LOBE EPILEPSY,location,0.8846517369293829,"In TEMPORAL LOBE EPILEPSY, excitatory amino acid receptors in the hippocampus and TEMPORAL LOBE may contribute to both increased excitability and vulnerability to excitotoxic damage",TEMPORAL LOBE,TEMPORAL LOBE EPILEPSY
5718,TEMPORAL LOBE EPILEPSY location TEMPORAL LOBE,location,0.8846517369293829,"In TEMPORAL LOBE EPILEPSY, excitatory amino acid receptors in the hippocampus and TEMPORAL LOBE may contribute to both increased excitability and vulnerability to excitotoxic damage",TEMPORAL LOBE,TEMPORAL LOBE EPILEPSY
5719,TEMPORAL LOBE EPILEPSY location TEMPORAL LOBE,location,0.8846517369293829,"In TEMPORAL LOBE EPILEPSY, excitatory amino acid receptors in the hippocampus and TEMPORAL LOBE may contribute to both increased excitability and vulnerability to excitotoxic damage",TEMPORAL LOBE,TEMPORAL LOBE EPILEPSY
5720,TEMPORAL LOBE location TEMPORAL LOBE EPILEPSY,location,0.8846517369293829,"In TEMPORAL LOBE EPILEPSY, excitatory amino acid receptors in the hippocampus and TEMPORAL LOBE may contribute to both increased excitability and vulnerability to excitotoxic damage",TEMPORAL LOBE,TEMPORAL LOBE EPILEPSY
5721,TEMPORAL LOBE location TEMPORAL LOBE EPILEPSY,location,0.8846517369293829,"In TEMPORAL LOBE EPILEPSY, excitatory amino acid receptors in the hippocampus and TEMPORAL LOBE may contribute to both increased excitability and vulnerability to excitotoxic damage",TEMPORAL LOBE,TEMPORAL LOBE EPILEPSY
5722,no_relation,location,0.8846517369293829,"In TEMPORAL LOBE EPILEPSY, excitatory amino acid receptors in the hippocampus and TEMPORAL LOBE may contribute to both increased excitability and vulnerability to excitotoxic damage",TEMPORAL LOBE,TEMPORAL LOBE EPILEPSY
5723,LIVER location HEPATIC METASTASIS,location,0.956182887467515,A 45-year-old woman underwent a resection for a HEPATIC METASTASIS of the LIVER caused by a carcinoma of the colon,LIVER,HEPATIC METASTASIS
5724,LIVER location HEPATIC METASTASIS,location,0.956182887467515,A 45-year-old woman underwent a resection for a HEPATIC METASTASIS of the LIVER caused by a carcinoma of the colon,LIVER,HEPATIC METASTASIS
5725,HEPATIC METASTASIS location LIVER,location,0.956182887467515,A 45-year-old woman underwent a resection for a HEPATIC METASTASIS of the LIVER caused by a carcinoma of the colon,LIVER,HEPATIC METASTASIS
5726,no_relation,diagnosis,0.452267016866645,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
5727,SPINAL CORD diagnosis NEUROMYELITIS OPTICA,diagnosis,0.452267016866645,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
5728,SPINAL CORD diagnosis NEUROMYELITIS OPTICA,diagnosis,0.452267016866645,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
5729,SPINAL CORD location NEUROMYELITIS OPTICA,location,0.753778361444409,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
5730,SPINAL CORD location NEUROMYELITIS OPTICA,location,0.753778361444409,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
5731,SPINAL CORD location NEUROMYELITIS OPTICA,location,0.753778361444409,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
5732,SENILE DEMENTIA location BRAINS,location,0.919145030018058,Blood vessels with amyloid angiopathy and senile plaques in the cortices of the BRAINS with Alzheimer's disease and SENILE DEMENTIA were observed by means of a scanning electron microscope,BRAINS,SENILE DEMENTIA
5733,BRAINS location SENILE DEMENTIA,location,0.919145030018058,Blood vessels with amyloid angiopathy and senile plaques in the cortices of the BRAINS with Alzheimer's disease and SENILE DEMENTIA were observed by means of a scanning electron microscope,BRAINS,SENILE DEMENTIA
5734,BRAINS location SENILE DEMENTIA,location,0.919145030018058,Blood vessels with amyloid angiopathy and senile plaques in the cortices of the BRAINS with Alzheimer's disease and SENILE DEMENTIA were observed by means of a scanning electron microscope,BRAINS,SENILE DEMENTIA
5735,SENILE DEMENTIA location BRAINS,location,0.919145030018058,Blood vessels with amyloid angiopathy and senile plaques in the cortices of the BRAINS with Alzheimer's disease and SENILE DEMENTIA were observed by means of a scanning electron microscope,BRAINS,SENILE DEMENTIA
5736,BRAINS location SENILE DEMENTIA,location,0.919145030018058,Blood vessels with amyloid angiopathy and senile plaques in the cortices of the BRAINS with Alzheimer's disease and SENILE DEMENTIA were observed by means of a scanning electron microscope,BRAINS,SENILE DEMENTIA
5737,no_relation,location,0.919145030018058,Blood vessels with amyloid angiopathy and senile plaques in the cortices of the BRAINS with Alzheimer's disease and SENILE DEMENTIA were observed by means of a scanning electron microscope,BRAINS,SENILE DEMENTIA
5738,PANCREAS location PANCREATITIS,location,0.6488856845230501,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
5739,PANCREAS location PANCREATITIS,location,0.6488856845230501,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
5740,PANCREAS location PANCREATITIS,location,0.6488856845230501,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
5741,PANCREAS location PANCREATITIS,location,0.6488856845230501,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
5742,PANCREAS location PANCREATITIS,location,0.6488856845230501,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
5743,PANCREAS location PANCREATITIS,location,0.6488856845230501,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
5744,COLON causes COLITIS,causes,0.462910049886276,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
5745,COLON causes COLITIS,causes,0.462910049886276,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
5746,COLON causes COLITIS,causes,0.462910049886276,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
5747,BASAL GANGLIA STRUCTURES causes HUNTINGTON'S DISEASE,causes,0.676123403782813,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
5748,BASAL GANGLIA STRUCTURES causes HUNTINGTON'S DISEASE,causes,0.676123403782813,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
5749,no_relation,causes,0.676123403782813,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
5750,HUNTINGTON'S DISEASE location BASAL GANGLIA STRUCTURES,location,0.50709255283711,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
5751,BASAL GANGLIA STRUCTURES location HUNTINGTON'S DISEASE,location,0.50709255283711,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
5752,BASAL GANGLIA STRUCTURES location HUNTINGTON'S DISEASE,location,0.50709255283711,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
5753,SPINAL CORD INJURY treats SPINAL CORD,treats,0.617213399848368,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5754,no_relation,treats,0.617213399848368,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5755,SPINAL CORD treats SPINAL CORD INJURY,treats,0.617213399848368,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5756,SPINAL CORD location SPINAL CORD INJURY,location,0.7715167498104591,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5757,SPINAL CORD location SPINAL CORD INJURY,location,0.7715167498104591,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5758,SPINAL CORD location SPINAL CORD INJURY,location,0.7715167498104591,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5759,no_relation,location,0.7715167498104591,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5760,SPINAL CORD location SPINAL CORD INJURY,location,0.7715167498104591,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5761,no_relation,location,0.7715167498104591,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
5762,no_relation,treats,0.6575959492214289,"The effect of dehydroepiandrosterone (DEA), an adrenal androgen successfully used for preventing attacks in HEREDITARY ANGIONEUROTIC EDEMA (HANE) patients was studied on the activation of classical and alternative complement pathway",HEREDITARY ANGIONEUROTIC EDEMA,HANE
5763,HEREDITARY ANGIONEUROTIC EDEMA treats HANE,treats,0.6575959492214289,"The effect of dehydroepiandrosterone (DEA), an adrenal androgen successfully used for preventing attacks in HEREDITARY ANGIONEUROTIC EDEMA (HANE) patients was studied on the activation of classical and alternative complement pathway",HEREDITARY ANGIONEUROTIC EDEMA,HANE
5764,no_relation,treats,0.6575959492214289,"The effect of dehydroepiandrosterone (DEA), an adrenal androgen successfully used for preventing attacks in HEREDITARY ANGIONEUROTIC EDEMA (HANE) patients was studied on the activation of classical and alternative complement pathway",HEREDITARY ANGIONEUROTIC EDEMA,HANE
5765,HANE treats HEREDITARY ANGIONEUROTIC EDEMA,treats,0.6575959492214289,"The effect of dehydroepiandrosterone (DEA), an adrenal androgen successfully used for preventing attacks in HEREDITARY ANGIONEUROTIC EDEMA (HANE) patients was studied on the activation of classical and alternative complement pathway",HEREDITARY ANGIONEUROTIC EDEMA,HANE
5766,no_relation,treats,0.6575959492214289,"The effect of dehydroepiandrosterone (DEA), an adrenal androgen successfully used for preventing attacks in HEREDITARY ANGIONEUROTIC EDEMA (HANE) patients was studied on the activation of classical and alternative complement pathway",HEREDITARY ANGIONEUROTIC EDEMA,HANE
5767,no_relation,treats,0.6575959492214289,"The effect of dehydroepiandrosterone (DEA), an adrenal androgen successfully used for preventing attacks in HEREDITARY ANGIONEUROTIC EDEMA (HANE) patients was studied on the activation of classical and alternative complement pathway",HEREDITARY ANGIONEUROTIC EDEMA,HANE
5768,MICROANGIOPATHIC HEMOLYTIC ANEMIA causes FEVER,causes,0.387298334620742,"Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, MICROANGIOPATHIC HEMOLYTIC ANEMIA, FEVER, and renal and neurologic abnormalities",FEVER,MICROANGIOPATHIC HEMOLYTIC ANEMIA
5769,FEVER causes MICROANGIOPATHIC HEMOLYTIC ANEMIA,causes,0.387298334620742,"Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, MICROANGIOPATHIC HEMOLYTIC ANEMIA, FEVER, and renal and neurologic abnormalities",FEVER,MICROANGIOPATHIC HEMOLYTIC ANEMIA
5770,MICROANGIOPATHIC HEMOLYTIC ANEMIA causes FEVER,causes,0.387298334620742,"Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, MICROANGIOPATHIC HEMOLYTIC ANEMIA, FEVER, and renal and neurologic abnormalities",FEVER,MICROANGIOPATHIC HEMOLYTIC ANEMIA
5771,MICROANGIOPATHIC HEMOLYTIC ANEMIA causes FEVER,causes,0.387298334620742,"Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, MICROANGIOPATHIC HEMOLYTIC ANEMIA, FEVER, and renal and neurologic abnormalities",FEVER,MICROANGIOPATHIC HEMOLYTIC ANEMIA
5772,FEVER causes MICROANGIOPATHIC HEMOLYTIC ANEMIA,causes,0.387298334620742,"Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, MICROANGIOPATHIC HEMOLYTIC ANEMIA, FEVER, and renal and neurologic abnormalities",FEVER,MICROANGIOPATHIC HEMOLYTIC ANEMIA
5773,no_relation,causes,0.387298334620742,"Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, MICROANGIOPATHIC HEMOLYTIC ANEMIA, FEVER, and renal and neurologic abnormalities",FEVER,MICROANGIOPATHIC HEMOLYTIC ANEMIA
5774,no_relation,causes,0.514495755427526,DISEASE NAME AND SYNONYMS: Syndromic diarrhea - Phenotypic diarrhea - Tricho-hepato-enteric syndrome - Intractable diarrhea of infancy with facial dysmorphism - Trichorrhexis nodosa and CIRRHOSIS - NEONATAL HEMOCHROMATOSIS phenotype with intractable diarrhea and hair abnormalities - Intractable infant diarrhea associated with phenotypic abnormalities and immune deficiency,CIRRHOSIS,NEONATAL HEMOCHROMATOSIS
5775,NEONATAL HEMOCHROMATOSIS causes CIRRHOSIS,causes,0.514495755427526,DISEASE NAME AND SYNONYMS: Syndromic diarrhea - Phenotypic diarrhea - Tricho-hepato-enteric syndrome - Intractable diarrhea of infancy with facial dysmorphism - Trichorrhexis nodosa and CIRRHOSIS - NEONATAL HEMOCHROMATOSIS phenotype with intractable diarrhea and hair abnormalities - Intractable infant diarrhea associated with phenotypic abnormalities and immune deficiency,CIRRHOSIS,NEONATAL HEMOCHROMATOSIS
5776,no_relation,causes,0.514495755427526,DISEASE NAME AND SYNONYMS: Syndromic diarrhea - Phenotypic diarrhea - Tricho-hepato-enteric syndrome - Intractable diarrhea of infancy with facial dysmorphism - Trichorrhexis nodosa and CIRRHOSIS - NEONATAL HEMOCHROMATOSIS phenotype with intractable diarrhea and hair abnormalities - Intractable infant diarrhea associated with phenotypic abnormalities and immune deficiency,CIRRHOSIS,NEONATAL HEMOCHROMATOSIS
5777,ATOPIC DERMATITIS causes ASTHMA,causes,0.98058067569092,"Indeed, epicutaneous sensitization of mice to a protein antigen induces both a localized allergic dermatitis and hyperresponsiveness to methacholine, which suggests that epicutaneous exposure to antigen in ATOPIC DERMATITIS may enhance the development of ASTHMA",ASTHMA,ATOPIC DERMATITIS
5778,ATOPIC DERMATITIS causes ASTHMA,causes,0.98058067569092,"Indeed, epicutaneous sensitization of mice to a protein antigen induces both a localized allergic dermatitis and hyperresponsiveness to methacholine, which suggests that epicutaneous exposure to antigen in ATOPIC DERMATITIS may enhance the development of ASTHMA",ASTHMA,ATOPIC DERMATITIS
5779,ATOPIC DERMATITIS causes ASTHMA,causes,0.98058067569092,"Indeed, epicutaneous sensitization of mice to a protein antigen induces both a localized allergic dermatitis and hyperresponsiveness to methacholine, which suggests that epicutaneous exposure to antigen in ATOPIC DERMATITIS may enhance the development of ASTHMA",ASTHMA,ATOPIC DERMATITIS
5780,STURGE-WEBER SYNDROME causes GLAUCOMA,causes,0.629940788348712,"The results of our data can serve as a guide for estimating relative risk figures for seizures, GLAUCOMA, and mental retardation in children with STURGE-WEBER SYNDROME",GLAUCOMA,STURGE-WEBER SYNDROME
5781,STURGE-WEBER SYNDROME causes GLAUCOMA,causes,0.629940788348712,"The results of our data can serve as a guide for estimating relative risk figures for seizures, GLAUCOMA, and mental retardation in children with STURGE-WEBER SYNDROME",GLAUCOMA,STURGE-WEBER SYNDROME
5782,no_relation,causes,0.629940788348712,"The results of our data can serve as a guide for estimating relative risk figures for seizures, GLAUCOMA, and mental retardation in children with STURGE-WEBER SYNDROME",GLAUCOMA,STURGE-WEBER SYNDROME
5783,no_relation,causes,0.6488856845230501,"We review the role of platelets in inflammation, how they assist in the recruitment of leukocytes into lung tissue in ASTHMA, and evidence of their dysfunction in CYSTIC FIBROSIS (CF",ASTHMA,CYSTIC FIBROSIS
5784,ASTHMA causes CYSTIC FIBROSIS,causes,0.6488856845230501,"We review the role of platelets in inflammation, how they assist in the recruitment of leukocytes into lung tissue in ASTHMA, and evidence of their dysfunction in CYSTIC FIBROSIS (CF",ASTHMA,CYSTIC FIBROSIS
5785,no_relation,causes,0.6488856845230501,"We review the role of platelets in inflammation, how they assist in the recruitment of leukocytes into lung tissue in ASTHMA, and evidence of their dysfunction in CYSTIC FIBROSIS (CF",ASTHMA,CYSTIC FIBROSIS
5786,HAEMOLYTIC ANAEMIA causes LUPUS,causes,0.927172649945531,"The presence of HAEMOLYTIC ANAEMIA in LUPUS patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR = 2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015",HAEMOLYTIC ANAEMIA,LUPUS
5787,LUPUS causes HAEMOLYTIC ANAEMIA,causes,0.927172649945531,"The presence of HAEMOLYTIC ANAEMIA in LUPUS patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR = 2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015",HAEMOLYTIC ANAEMIA,LUPUS
5788,LUPUS causes HAEMOLYTIC ANAEMIA,causes,0.927172649945531,"The presence of HAEMOLYTIC ANAEMIA in LUPUS patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR = 2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015",HAEMOLYTIC ANAEMIA,LUPUS
5789,CYSTIC FIBROSIS causes ASTHMA,causes,0.493196961916072,"The cleavage of MUC5AC and the generation of the reactive new C-terminus could contribute to the adherent and viscous mucus found at chronic lung diseases such as ASTHMA and CYSTIC FIBROSIS, characterized by mucus hypersecretion and lowered pH of the airways",ASTHMA,CYSTIC FIBROSIS
5790,no_relation,causes,0.493196961916072,"The cleavage of MUC5AC and the generation of the reactive new C-terminus could contribute to the adherent and viscous mucus found at chronic lung diseases such as ASTHMA and CYSTIC FIBROSIS, characterized by mucus hypersecretion and lowered pH of the airways",ASTHMA,CYSTIC FIBROSIS
5791,no_relation,causes,0.493196961916072,"The cleavage of MUC5AC and the generation of the reactive new C-terminus could contribute to the adherent and viscous mucus found at chronic lung diseases such as ASTHMA and CYSTIC FIBROSIS, characterized by mucus hypersecretion and lowered pH of the airways",ASTHMA,CYSTIC FIBROSIS
5792,HUNTINGTON'S DISEASE causes DEMENTIA,causes,0.8888888888888891,"A controlled prospective study compared the performance of 14 patients with dementia of Alzheimer type (DAT) and 14 patients with HUNTINGTON'S DISEASE (HD), who were matched for overall level of DEMENTIA, on a battery of semantic and episodic memory tests",DEMENTIA,HUNTINGTON'S DISEASE
5793,HUNTINGTON'S DISEASE causes DEMENTIA,causes,0.8888888888888891,"A controlled prospective study compared the performance of 14 patients with dementia of Alzheimer type (DAT) and 14 patients with HUNTINGTON'S DISEASE (HD), who were matched for overall level of DEMENTIA, on a battery of semantic and episodic memory tests",DEMENTIA,HUNTINGTON'S DISEASE
5794,HUNTINGTON'S DISEASE causes DEMENTIA,causes,0.8888888888888891,"A controlled prospective study compared the performance of 14 patients with dementia of Alzheimer type (DAT) and 14 patients with HUNTINGTON'S DISEASE (HD), who were matched for overall level of DEMENTIA, on a battery of semantic and episodic memory tests",DEMENTIA,HUNTINGTON'S DISEASE
5795,MALIGNANT HYPERTHERMIA causes MUSCLE RIGIDITY,causes,0.3651483716701111,"We believe the presence of the myopathy warranted the use of a 'non-triggering' anaesthetic, as suxamethonium and volatile agents may be associated with significant complications such as MUSCLE RIGIDITY and rhabdomyolysis in myopathic patients, even in the absence of MALIGNANT HYPERTHERMIA",MUSCLE RIGIDITY,MALIGNANT HYPERTHERMIA
5796,MUSCLE RIGIDITY causes MALIGNANT HYPERTHERMIA,causes,0.3651483716701111,"We believe the presence of the myopathy warranted the use of a 'non-triggering' anaesthetic, as suxamethonium and volatile agents may be associated with significant complications such as MUSCLE RIGIDITY and rhabdomyolysis in myopathic patients, even in the absence of MALIGNANT HYPERTHERMIA",MUSCLE RIGIDITY,MALIGNANT HYPERTHERMIA
5797,MALIGNANT HYPERTHERMIA causes MUSCLE RIGIDITY,causes,0.3651483716701111,"We believe the presence of the myopathy warranted the use of a 'non-triggering' anaesthetic, as suxamethonium and volatile agents may be associated with significant complications such as MUSCLE RIGIDITY and rhabdomyolysis in myopathic patients, even in the absence of MALIGNANT HYPERTHERMIA",MUSCLE RIGIDITY,MALIGNANT HYPERTHERMIA
5798,MUSCLE RIGIDITY causes MALIGNANT HYPERTHERMIA,causes,0.3651483716701111,"We believe the presence of the myopathy warranted the use of a 'non-triggering' anaesthetic, as suxamethonium and volatile agents may be associated with significant complications such as MUSCLE RIGIDITY and rhabdomyolysis in myopathic patients, even in the absence of MALIGNANT HYPERTHERMIA",MUSCLE RIGIDITY,MALIGNANT HYPERTHERMIA
5799,MALIGNANT HYPERTHERMIA causes MUSCLE RIGIDITY,causes,0.3651483716701111,"We believe the presence of the myopathy warranted the use of a 'non-triggering' anaesthetic, as suxamethonium and volatile agents may be associated with significant complications such as MUSCLE RIGIDITY and rhabdomyolysis in myopathic patients, even in the absence of MALIGNANT HYPERTHERMIA",MUSCLE RIGIDITY,MALIGNANT HYPERTHERMIA
5800,no_relation,causes,0.3651483716701111,"We believe the presence of the myopathy warranted the use of a 'non-triggering' anaesthetic, as suxamethonium and volatile agents may be associated with significant complications such as MUSCLE RIGIDITY and rhabdomyolysis in myopathic patients, even in the absence of MALIGNANT HYPERTHERMIA",MUSCLE RIGIDITY,MALIGNANT HYPERTHERMIA
5801,no_relation,causes,0.7624928516630229,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
5802,TRICHOTILLOMANIA causes HAIR PULLING,causes,0.7624928516630229,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
5803,no_relation,causes,0.7624928516630229,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
5804,no_relation,causes,0.7624928516630229,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
5805,no_relation,causes,0.7624928516630229,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
5806,no_relation,causes,0.7624928516630229,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
5807,CHRISTMAS DISEASE causes HAEMOPHILIA B,causes,0.6575959492214289,A few cases of AIDS have occurred in HAEMOPHILIA B (CHRISTMAS DISEASE) patients,HAEMOPHILIA B,CHRISTMAS DISEASE
5808,no_relation,causes,0.6575959492214289,A few cases of AIDS have occurred in HAEMOPHILIA B (CHRISTMAS DISEASE) patients,HAEMOPHILIA B,CHRISTMAS DISEASE
5809,no_relation,causes,0.6575959492214289,A few cases of AIDS have occurred in HAEMOPHILIA B (CHRISTMAS DISEASE) patients,HAEMOPHILIA B,CHRISTMAS DISEASE
5810,no_relation,causes,0.6575959492214289,A few cases of AIDS have occurred in HAEMOPHILIA B (CHRISTMAS DISEASE) patients,HAEMOPHILIA B,CHRISTMAS DISEASE
5811,no_relation,causes,0.6575959492214289,A few cases of AIDS have occurred in HAEMOPHILIA B (CHRISTMAS DISEASE) patients,HAEMOPHILIA B,CHRISTMAS DISEASE
5812,HAEMOPHILIA B causes CHRISTMAS DISEASE,causes,0.6575959492214289,A few cases of AIDS have occurred in HAEMOPHILIA B (CHRISTMAS DISEASE) patients,HAEMOPHILIA B,CHRISTMAS DISEASE
5813,no_relation,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
5814,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
5815,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
5816,RUBELLA VACCINE treats RUBELLA,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
5817,RUBELLA VACCINE treats RUBELLA,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
5818,RUBELLA VACCINE treats RUBELLA,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
5819,PULMONARY EMBOLISM location TISSUE PLASMINOGEN ACTIVATOR,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5820,no_relation,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5821,no_relation,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5822,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5823,no_relation,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5824,no_relation,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5825,no_relation,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5826,MYELODYSPLASTIC SYNDROMES causes HYPERCELLULAR BONE MARROW,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5827,MYELODYSPLASTIC SYNDROMES causes HYPERCELLULAR BONE MARROW,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5828,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5829,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5830,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5831,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5832,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5833,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5834,FUROSEMIDE treats EDEMA,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5835,FUROSEMIDE treats EDEMA,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5836,FUROSEMIDE treats EDEMA,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5837,MALIGNANT PLEURAL MESOTHELIOMA causes CHEST PAIN,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
5838,MALIGNANT PLEURAL MESOTHELIOMA causes CHEST PAIN,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
5839,CHEST PAIN causes MALIGNANT PLEURAL MESOTHELIOMA,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
5840,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5841,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5842,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5843,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5844,WEIGHT LOSS causes PANCREATIC ADENOCARCINOMA,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5845,no_relation,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5846,no_relation,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
5847,no_relation,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
5848,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
5849,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5850,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5851,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5852,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5853,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5854,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5855,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
5856,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
5857,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
5858,CUSHING SYNDROME diagnosis DEXAMETHASONE,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5859,CUSHING SYNDROME diagnosis DEXAMETHASONE,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5860,no_relation,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5861,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5862,no_relation,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5863,HEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
5864,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5865,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5866,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5867,BUPIVACAINE causes PAIN,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
5868,no_relation,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
5869,PAIN causes BUPIVACAINE,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
5870,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
5871,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
5872,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
5873,IMIPRAMINE treats DEPRESSION,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
5874,IMIPRAMINE treats DEPRESSION,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
5875,IMIPRAMINE treats DEPRESSION,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
5876,PROMETHAZINE treats VOMITING,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
5877,no_relation,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
5878,PROMETHAZINE treats VOMITING,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
5879,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
5880,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
5881,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
5882,PULMONARY EMBOLISM treats TISSUE PLASMINOGEN ACTIVATOR,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5883,no_relation,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5884,TISSUE PLASMINOGEN ACTIVATOR treats PULMONARY EMBOLISM,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5885,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
5886,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
5887,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
5888,PRAVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
5889,PRAVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
5890,PRAVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
5891,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
5892,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
5893,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
5894,ERGOMETRINE treats VARIANT ANGINA,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
5895,ERGOMETRINE treats VARIANT ANGINA,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
5896,ERGOMETRINE treats VARIANT ANGINA,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
5897,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
5898,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
5899,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
5900,GABAPENTIN treats PAIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
5901,GABAPENTIN treats PAIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
5902,GABAPENTIN treats PAIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
5903,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
5904,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
5905,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
5906,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
5907,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
5908,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
5909,DEXAMETHASONE contraindicates HYPERCORTISOLISM,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5910,DEXAMETHASONE contraindicates HYPERCORTISOLISM,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5911,no_relation,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
5912,DIFLUNISAL treats RHEUMATOID ARTHRITIS,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
5913,DIFLUNISAL treats RHEUMATOID ARTHRITIS,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
5914,no_relation,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
5915,LANSOPRAZOLE treats GASTRIC ULCERS,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
5916,no_relation,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
5917,LANSOPRAZOLE treats GASTRIC ULCERS,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
5918,DEXAMETHASONE treats CUSHING SYNDROME,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5919,no_relation,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5920,DEXAMETHASONE treats CUSHING SYNDROME,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5921,CUSHING SYNDROME treats DEXAMETHASONE,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5922,no_relation,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
5923,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
5924,no_relation,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
5925,HYPERTENSION treats HYDROCHLOROTHIAZIDE,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
5926,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
5927,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
5928,WARFARIN treats PULMONARY EMBOLISM,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
5929,no_relation,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
5930,WARFARIN treats PULMONARY EMBOLISM,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
5931,no_relation,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
5932,WARFARIN treats PULMONARY EMBOLISM,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
5933,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
5934,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
5935,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
5936,no_relation,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
5937,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
5938,no_relation,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5939,TISSUE PLASMINOGEN ACTIVATOR location PULMONARY EMBOLISM,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5940,TISSUE PLASMINOGEN ACTIVATOR location PULMONARY EMBOLISM,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5941,no_relation,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5942,no_relation,location,0.557086014531156,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
5943,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
5944,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
5945,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
5946,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
5947,OBESITY treats ORLISTAT,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
5948,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5949,no_relation,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5950,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5951,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5952,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.956182887467515,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
5953,no_relation,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5954,no_relation,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5955,no_relation,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5956,HYPERCELLULAR BONE MARROW causes MYELODYSPLASTIC SYNDROMES,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5957,MYELODYSPLASTIC SYNDROMES causes HYPERCELLULAR BONE MARROW,causes,0.975900072948533,"MYELODYSPLASTIC SYNDROMES (MDS) are characterized by HYPERCELLULAR BONE MARROW, peripheral cytopenia and an increased rate of intramedullary apoptosis",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROMES
5958,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5959,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5960,no_relation,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5961,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5962,METHENAMINE treats URINARY INFECTIONS,treats,1.0,"The action of METHENAMINE, used in the treatment of URINARY INFECTIONS, is based on the release of formaldehyde in the body",URINARY INFECTIONS,METHENAMINE
5963,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5964,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5965,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5966,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5967,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.943456353049726,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
5968,DCIS causes MICROCALCIFICATION,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
5969,no_relation,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
5970,no_relation,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
5971,DCIS causes MICROCALCIFICATION,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
5972,MICROCALCIFICATION causes DCIS,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
5973,FUROSEMIDE treats EDEMA,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5974,FUROSEMIDE treats EDEMA,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5975,EDEMA treats FUROSEMIDE,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5976,FUROSEMIDE treats EDEMA,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5977,EDEMA treats FUROSEMIDE,treats,0.995893206467704,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
5978,no_relation,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5979,NEUTROPENIA diagnosis AMPHOTERICIN B,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5980,NEUTROPENIA diagnosis AMPHOTERICIN B,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5981,NEUTROPENIA diagnosis AMPHOTERICIN B,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5982,no_relation,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
5983,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5984,no_relation,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5985,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5986,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5987,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.995893206467704,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
5988,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5989,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5990,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5991,WEIGHT LOSS causes PANCREATIC ADENOCARCINOMA,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5992,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
5993,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5994,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5995,no_relation,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5996,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5997,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.98058067569092,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
5998,no_relation,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
5999,no_relation,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
6000,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
6001,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
6002,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
6003,no_relation,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
6004,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
6005,NEURAL TUBE DEFECTS treats FOLIC ACID,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
6006,no_relation,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
6007,no_relation,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
6008,no_relation,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
6009,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
6010,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
6011,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
6012,AMPHOTERICIN B treats NEUTROPENIA,treats,0.848528137423857,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
6013,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
6014,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
6015,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
6016,PATHOLOGIC FRACTURE causes BONE METASTASES,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
6017,BONE METASTASES causes PATHOLOGIC FRACTURE,causes,0.9045340337332908,"Bone is a preferred site of metastasis for many solid tumors, and the complications associated with BONE METASTASES can result in significant skeletal morbidity including severe bone pain, PATHOLOGIC FRACTURE, spinal cord compression, and hypercalcemia of malignancy (HCM",PATHOLOGIC FRACTURE,BONE METASTASES
6018,no_relation,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
6019,no_relation,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
6020,DEXAMETHASONE diagnosis CUSHING SYNDROME,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
6021,no_relation,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
6022,CUSHING SYNDROME diagnosis DEXAMETHASONE,diagnosis,0.609994281330419,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
6023,PANCYTOPENIA causes HEMOPHAGOCYTIC SYNDROME,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
6024,no_relation,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
6025,no_relation,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
6026,no_relation,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
6027,PANCYTOPENIA causes HEMOPHAGOCYTIC SYNDROME,causes,0.9918365981341758,HEMOPHAGOCYTIC SYNDROME (HPS) is a life-threatening disorder characterized by PANCYTOPENIA and activation of macrophages,PANCYTOPENIA,HEMOPHAGOCYTIC SYNDROME
6028,no_relation,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
6029,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
6030,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
6031,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
6032,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
6033,no_relation,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
6034,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
6035,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
6036,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
6037,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
6038,BUPIVACAINE causes PAIN,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
6039,no_relation,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
6040,no_relation,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
6041,BUPIVACAINE causes PAIN,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
6042,no_relation,causes,0.919145030018058,There was no difference in the rate of regression of sensory anesthesia or the development of PAIN among patients receiving BUPIVACAINE alone or bupivacaine with fentanyl,PAIN,BUPIVACAINE
6043,no_relation,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
6044,no_relation,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
6045,no_relation,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
6046,MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
6047,MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
6048,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
6049,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
6050,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
6051,SOLID PATTERN causes INVASIVE DUCTAL CARCINOMA,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
6052,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
6053,no_relation,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
6054,no_relation,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
6055,VOMITING treats PROMETHAZINE,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
6056,PROMETHAZINE treats VOMITING,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
6057,PROMETHAZINE treats VOMITING,treats,0.981980506061966,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
6058,VASOSPASTIC ANGINA diagnosis ERGONOVINE,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
6059,ERGONOVINE diagnosis VASOSPASTIC ANGINA,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
6060,VASOSPASTIC ANGINA diagnosis ERGONOVINE,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
6061,ERGONOVINE diagnosis VASOSPASTIC ANGINA,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
6062,VASOSPASTIC ANGINA diagnosis ERGONOVINE,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
6063,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
6064,no_relation,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
6065,no_relation,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
6066,no_relation,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
6067,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.929981109950554,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
6068,no_relation,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
6069,no_relation,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
6070,PULMONARY EMBOLISM treats TISSUE PLASMINOGEN ACTIVATOR,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
6071,TISSUE PLASMINOGEN ACTIVATOR treats PULMONARY EMBOLISM,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
6072,no_relation,treats,0.371390676354104,Urokinase versus TISSUE PLASMINOGEN ACTIVATOR in PULMONARY EMBOLISM,PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
6073,no_relation,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
6074,THYROXINE treats THYROID DEFICIENCY,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
6075,no_relation,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
6076,THYROXINE treats THYROID DEFICIENCY,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
6077,THYROXINE treats THYROID DEFICIENCY,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
6078,PRAVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
6079,no_relation,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
6080,HYPERCHOLESTEROLEMIA treats PRAVASTATIN,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
6081,PRAVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
6082,PRAVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.9918365981341758,"Comparison of the efficacy, safety and tolerability of simvastatin and PRAVASTATIN for HYPERCHOLESTEROLEMIA",HYPERCHOLESTEROLEMIA,PRAVASTATIN
6083,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
6084,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
6085,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
6086,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
6087,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
6088,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
6089,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
6090,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
6091,no_relation,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
6092,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
6093,no_relation,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
6094,GABAPENTIN treats PAIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
6095,GABAPENTIN treats PAIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
6096,GABAPENTIN treats PAIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
6097,PAIN treats GABAPENTIN,treats,0.995893206467704,"20 ,   21 ,   22 ,   23 ,   24 ,   25 ,   40 ,   41 ,   42 ,   43 ,   44 ,   45   40% of patients who receive GABAPENTIN for PAIN associated with diabetic neuropathy obtain good pain relief",PAIN,GABAPENTIN
6098,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
6099,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
6100,DYSRHYTHMIA treats ANTIARRHYTHMIC AGENTS,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
6101,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
6102,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,1.0,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
6103,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
6104,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
6105,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
6106,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
6107,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
6108,no_relation,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
6109,DIFLUNISAL treats RHEUMATOID ARTHRITIS,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
6110,DIFLUNISAL treats RHEUMATOID ARTHRITIS,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
6111,DIFLUNISAL treats RHEUMATOID ARTHRITIS,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
6112,DIFLUNISAL treats RHEUMATOID ARTHRITIS,treats,0.929981109950554,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
6113,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
6114,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
6115,SMMCI causes MICROCEPHALY,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
6116,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
6117,SMMCI causes MICROCEPHALY,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
6118,no_relation,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
6119,LANSOPRAZOLE treats GASTRIC ULCERS,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
6120,LANSOPRAZOLE treats GASTRIC ULCERS,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
6121,LANSOPRAZOLE treats GASTRIC ULCERS,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
6122,LANSOPRAZOLE treats GASTRIC ULCERS,treats,0.917662935482247,"cOmeprazole and lansoprazole are approved for GASTRIC ULCERS; omeprazole, LANSOPRAZOLE, and rabeprazole are approved for duodenal ulcers",GASTRIC ULCERS,LANSOPRAZOLE
6123,WT BONE causes RICKETS,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6124,WT BONE causes RICKETS,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6125,WT BONE causes RICKETS,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6126,no_relation,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6127,no_relation,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6128,WT BONE causes RICKETS,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6129,WT BONE causes RICKETS,causes,0.9950371902,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
6130,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6131,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6132,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6133,DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS causes SULFA ALLERGY,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6134,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6135,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6136,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,causes,0.9370425713,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
6137,no_relation,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6138,PATHOLOGICAL LUNG HALLMARK causes DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6139,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT causes PATHOLOGICAL LUNG HALLMARK,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6140,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT causes PATHOLOGICAL LUNG HALLMARK,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6141,no_relation,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6142,no_relation,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6143,no_relation,causes,0.8846517369,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
6144,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6145,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6146,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6147,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6148,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6149,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6150,BONE location OSTEOPOROSIS,location,0.7453559925,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
6151,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN diagnose_by_test_or_drug TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6152,no_relation,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6153,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY diagnose_by_test_or_drug CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6154,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY diagnose_by_test_or_drug CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6155,no_relation,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6156,no_relation,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6157,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY diagnose_by_test_or_drug CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,diagnosis,0.4866642634,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
6158,no_relation,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6159,EPILEPSIES causes SEIZURES,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6160,EPILEPSIES causes SEIZURES,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6161,EPILEPSIES causes SEIZURES,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6162,SEIZURES causes EPILEPSIES,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6163,SEIZURES causes EPILEPSIES,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6164,no_relation,causes,0.6666666667,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
6165,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6166,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6167,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6168,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6169,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6170,SEGMENTAL DEFECTS IN BONES causes CONGENITAL MALFORMATION OR NON UNION FRACTURES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6171,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,causes,0.9878783399,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
6172,LEGIONELLA INFECTION treats LEGIONELLA,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6173,no_relation,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6174,no_relation,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6175,no_relation,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6176,no_relation,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6177,LEGIONELLA INFECTION treats LEGIONELLA,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6178,LEGIONELLA treats LEGIONELLA INFECTION,treats,0.6708203932,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
6179,HAEMOPHILIA A causes VIII (FVIII) GENE,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6180,VIII (FVIII) GENE causes HAEMOPHILIA A,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6181,VIII (FVIII) GENE causes HAEMOPHILIA A,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6182,VIII (FVIII) GENE causes HAEMOPHILIA A,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6183,VIII (FVIII) GENE causes HAEMOPHILIA A,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6184,VIII (FVIII) GENE causes HAEMOPHILIA A,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6185,VIII (FVIII) GENE causes HAEMOPHILIA A,causes,0.9918365981,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
6186,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6187,DISTINCTIVE SKIN LESIONS causes EPIDERMAL NEVUS SYNDROME,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6188,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6189,DISTINCTIVE SKIN LESIONS causes EPIDERMAL NEVUS SYNDROME,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6190,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6191,no_relation,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6192,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,causes,0.9761870602,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
6193,TUBERCULOSIS diagnose_by_test_or_drug N PURIFIED PROTEIN DERIVATIV,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6194,TUBERCULOSIS diagnose_by_test_or_drug N PURIFIED PROTEIN DERIVATIV,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6195,TUBERCULOSIS diagnose_by_test_or_drug N PURIFIED PROTEIN DERIVATIV,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6196,N PURIFIED PROTEIN DERIVATIV diagnose_by_test_or_drug TUBERCULOSIS,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6197,no_relation,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6198,no_relation,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6199,N PURIFIED PROTEIN DERIVATIV diagnose_by_test_or_drug TUBERCULOSIS,diagnosis,0.9615239476,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
6200,MYASTHENIA GRAVIS treats (EDROPHONIUM CHLORIDE),treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6201,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6202,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6203,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6204,no_relation,treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6205,MYASTHENIA GRAVIS treats (EDROPHONIUM CHLORIDE),treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6206,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,treats,0.9761870602,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
6207,ALLERGIC REACTIONS causes ALLERGIES TO BEE AND,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6208,ALLERGIES TO BEE AND causes ALLERGIC REACTIONS,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6209,no_relation,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6210,no_relation,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6211,ALLERGIES TO BEE AND causes ALLERGIC REACTIONS,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6212,ALLERGIC REACTIONS causes ALLERGIES TO BEE AND,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6213,ALLERGIC REACTIONS causes ALLERGIES TO BEE AND,causes,0.4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
6214,MYELOFIBROSIS causes ACUTE MEGAKARYOCYTIC MYELOSIS,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6215,no_relation,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6216,no_relation,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6217,no_relation,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6218,MYELOFIBROSIS causes ACUTE MEGAKARYOCYTIC MYELOSIS,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6219,no_relation,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6220,MYELOFIBROSIS causes ACUTE MEGAKARYOCYTIC MYELOSIS,causes,0.3849001795000001,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
6221,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6222,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6223,DEXAMETHASONE diagnose_by_test_or_drug DEPRESSION,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6224,DEXAMETHASONE diagnose_by_test_or_drug DEPRESSION,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6225,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6226,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6227,DEXAMETHASONE diagnose_by_test_or_drug DEPRESSION,diagnosis,0.990147543,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
6228,no_relation,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6229,HEPATOMA causes HEPATOMEGALY,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6230,HEPATOMEGALY causes HEPATOMA,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6231,no_relation,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6232,no_relation,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6233,no_relation,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6234,no_relation,causes,0.914991422,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
6235,no_relation,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6236,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6237,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6238,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6239,no_relation,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6240,no_relation,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6241,no_relation,treats,0.4,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
6242,TESTES location SPERMATOGENIC ARREST,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6243,no_relation,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6244,TESTES location SPERMATOGENIC ARREST,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6245,no_relation,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6246,TESTES location SPERMATOGENIC ARREST,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6247,TESTES location SPERMATOGENIC ARREST,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6248,no_relation,location,0.7844645406,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
6249,INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION treats AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6250,no_relation,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6251,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6252,no_relation,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6253,no_relation,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6254,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6255,no_relation,treats,0.7302967432999999,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6256,no_relation,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6257,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN causes INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6258,no_relation,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6259,no_relation,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6260,no_relation,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6261,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN causes INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6262,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN causes INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,causes,0.5477225575,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
6263,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6264,no_relation,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6265,no_relation,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6266,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6267,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6268,DENTAL FLUOROSIS causes BLOOD FLUORIDE CONCENTRATION,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6269,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,causes,0.5570860145000001,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
6270,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6271,no_relation,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6272,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6273,no_relation,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6274,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6275,no_relation,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6276,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,causes,0.9630868247,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
6277,CROHN'S DISEASE causes DIARRHEA,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6278,no_relation,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6279,DIARRHEA causes CROHN'S DISEASE,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6280,CROHN'S DISEASE causes DIARRHEA,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6281,CROHN'S DISEASE causes DIARRHEA,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6282,no_relation,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6283,DIARRHEA causes CROHN'S DISEASE,causes,0.9263671131731708,"C]  5.1 Hospitalize patients with CROHN'S DISEASE with uncontrolled DIARRHEA uncontrolled pain, dehydration, or severe malnutrition.",DIARRHEA,CROHN'S DISEASE
6284,CHOLERA causes V CHOLERAE,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6285,no_relation,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6286,no_relation,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6287,CHOLERA causes V CHOLERAE,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6288,V CHOLERAE causes CHOLERA,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6289,V CHOLERAE causes CHOLERA,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6290,V CHOLERAE causes CHOLERA,causes,0.625,3.3 Obtain stool cultures for  V CHOLERAE  O1 or O139 to confirm the diagnosis of CHOLERA,CHOLERA,V CHOLERAE
6291,no_relation,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6292,no_relation,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6293,PCD causes SITUS INVERSUS,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6294,PCD causes SITUS INVERSUS,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6295,PCD causes SITUS INVERSUS,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6296,PCD causes SITUS INVERSUS,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6297,PCD causes SITUS INVERSUS,causes,0.7504787743864558,The number of PCD index patients who have SITUS INVERSUS (because of the randomization of left right symmetry) argues that the disease may be more common than previously suspected; this supposition could be verified if a sensitive and easily used screening test were available.,SITUS INVERSUS,PCD
6298,no_relation,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6299,NAUSEA causes MIGRAINE,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6300,no_relation,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6301,no_relation,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6302,no_relation,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6303,no_relation,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6304,no_relation,causes,0.628970902033151,"1 ,   9  Common Adverse Effects  IBS patients: headache, MIGRAINE dizziness, abdominal pain, diarrhea, NAUSEA flatulence, back pain, leg pain, accidental trauma, arthropathy.",NAUSEA,MIGRAINE
6305,SEVERE PAIN causes GLOSSOPHARYNGEAL NEURALGIA,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6306,GLOSSOPHARYNGEAL NEURALGIA causes SEVERE PAIN,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6307,GLOSSOPHARYNGEAL NEURALGIA causes SEVERE PAIN,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6308,GLOSSOPHARYNGEAL NEURALGIA causes SEVERE PAIN,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6309,GLOSSOPHARYNGEAL NEURALGIA causes SEVERE PAIN,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6310,GLOSSOPHARYNGEAL NEURALGIA causes SEVERE PAIN,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6311,no_relation,causes,0.8082903768654759,"GLOSSOPHARYNGEAL NEURALGIA  GLOSSOPHARYNGEAL NEURALGIA is recurrent attacks of SEVERE PAIN in the 9th cranial nerve distribution (posterior pharynx, tonsils, back of the tongue, middle ear.",SEVERE PAIN,GLOSSOPHARYNGEAL NEURALGIA
6312,no_relation,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6313,HPV INFECTION causes GENITAL WARTS,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6314,HPV INFECTION causes GENITAL WARTS,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6315,HPV INFECTION causes GENITAL WARTS,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6316,no_relation,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6317,HPV INFECTION causes GENITAL WARTS,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6318,no_relation,causes,0.5547001962252289,She is informed that HPV INFECTION is extremely common among sexually active adults and that GENITAL WARTS can occur in a monogamous relationship.,GENITAL WARTS,HPV INFECTION
6319,FACIAL TRICHILEMMOMAS causes COWDEN SYNDROME,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6320,COWDEN SYNDROME causes FACIAL TRICHILEMMOMAS,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6321,COWDEN SYNDROME causes FACIAL TRICHILEMMOMAS,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6322,FACIAL TRICHILEMMOMAS causes COWDEN SYNDROME,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6323,COWDEN SYNDROME causes FACIAL TRICHILEMMOMAS,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6324,no_relation,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6325,no_relation,causes,0.8660254037844392,"COWDEN SYNDROME  COWDEN SYNDROME is characterized by FACIAL TRICHILEMMOMAS and acral fibromas and is associated with an increased risk of cancer of the breast, thyroid, and gastrointestinal tract.",FACIAL TRICHILEMMOMAS,COWDEN SYNDROME
6326,no_relation,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6327,URINARY TRACT causes RENAL FAILURE,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6328,no_relation,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6329,RENAL FAILURE causes URINARY TRACT,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6330,no_relation,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6331,no_relation,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6332,no_relation,causes,0.830747160735697,"Common Adverse Effects  Patients treated for complicated skin and skin structure infections: GI effects (constipation, nausea, diarrhea, vomiting), injection site reactions, nervous system effects (headache, insomnia, dizziness), rash, pruritus, abnormal liver function test results, CK elevations, infections (fungal, URINARY TRACT hypotension, RENAL FAILURE anemia, dyspnea, fever.",URINARY TRACT,RENAL FAILURE
6333,no_relation,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6334,HELLP SYNDROME causes TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6335,HELLP SYNDROME causes TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6336,HELLP SYNDROME causes TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6337,HELLP SYNDROME causes TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6338,no_relation,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6339,HELLP SYNDROME causes TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,causes,0.8616404368553291,"HELLP SYNDROME is a clinical constellation of hemolysis, elevated liver TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS  Usually occurs in the third trimester.",TEST RESULTS AND THROMBOCYTOPENIA (LOW PLATELETS,HELLP SYNDROME
6340,no_relation,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6341,QUINIDINE GLUCONATE causes VENTRICULAR TACHYCARDIA,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6342,QUINIDINE GLUCONATE causes VENTRICULAR TACHYCARDIA,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6343,QUINIDINE GLUCONATE causes VENTRICULAR TACHYCARDIA,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6344,VENTRICULAR TACHYCARDIA causes QUINIDINE GLUCONATE,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6345,QUINIDINE GLUCONATE causes VENTRICULAR TACHYCARDIA,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6346,VENTRICULAR TACHYCARDIA causes QUINIDINE GLUCONATE,causes,0.9594032236002472,"b  While substantial cardiovascular toxicity generally has not occurred, ECG changes, including prolonged QT interval, widened QRS complex, and flattened T waves (without dysrhythmia), have occurred frequently and hypotension and VENTRICULAR TACHYCARDIA have occurred occasionally in patients receiving IV QUINIDINE GLUCONATE for the treatment of  Plasmodium falciparum  malaria.",VENTRICULAR TACHYCARDIA,QUINIDINE GLUCONATE
6347,no_relation,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6348,no_relation,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6349,no_relation,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6350,CENTRAL NERVOUS SYSTEM causes DISEASES,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6351,no_relation,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6352,no_relation,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6353,CENTRAL NERVOUS SYSTEM causes DISEASES,causes,0.5303300858899109,"Neuromuscular examination identifies patients with impaired mobility or DISEASES of the CENTRAL NERVOUS SYSTEM that predispose to urinary incontinence (e.g., stroke, Parkinson disease, or dementia.",CENTRAL NERVOUS SYSTEM,DISEASES
6354,no_relation,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6355,DIABETIC KETOACIDOSIS causes HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6356,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6357,DIABETIC KETOACIDOSIS causes HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6358,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6359,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6360,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9878291611472622,"1 ,   4 ,   17 ,   23 ,   73  Hyperglycemic Effects  HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,HYPERGLYCEMIA NEW ONSET DIABETES MELLITUS
6361,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6362,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6363,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6364,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6365,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6366,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6367,TRICHURIASIS causes TRICHURIS TRICHIURA,causes,1.0,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIASIS,TRICHURIS TRICHIURA
6368,no_relation,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6369,no_relation,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6370,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6371,PRIMARY HYPERPARATHYROIDISM causes MEN2A,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6372,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6373,MEN2A causes PRIMARY HYPERPARATHYROIDISM,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6374,no_relation,causes,0.573539334676404,PRIMARY HYPERPARATHYROIDISM is also seen in approximately 30% of patients with MEN2A ( 7.,PRIMARY HYPERPARATHYROIDISM,MEN2A
6375,no_relation,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6376,NEOMYCIN causes HYPERSENSITIVITY,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6377,NEOMYCIN causes HYPERSENSITIVITY,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6378,NEOMYCIN causes HYPERSENSITIVITY,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6379,NEOMYCIN causes HYPERSENSITIVITY,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6380,no_relation,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6381,no_relation,causes,0.881917103688197,"1 ,   2  Cautions  Contraindications  •  History of HYPERSENSITIVITY or serious toxic reactions to NEOMYCIN or other aminoglycosides.",HYPERSENSITIVITY,NEOMYCIN
6382,no_relation,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6383,no_relation,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6384,LISTERIOSIS causes LISTERIA MONOCYTOGENES,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6385,no_relation,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6386,no_relation,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6387,no_relation,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6388,no_relation,causes,0.492365963917331,"LISTERIOSIS  EPIDEMIOLOGY  LISTERIA MONOCYTOGENES  is found in soil, dust fertilizer, sewage, stream water, plants, processed foods, and the intestinal tract of many mammals.",LISTERIOSIS,LISTERIA MONOCYTOGENES
6389,no_relation,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6390,DRUG TOXICITY causes MEDICATION,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6391,DRUG TOXICITY causes MEDICATION,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6392,MEDICATION causes DRUG TOXICITY,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6393,no_relation,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6394,MEDICATION causes DRUG TOXICITY,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6395,no_relation,causes,0.953462589245592,"Evidence: • Treatment failure occurs in 9% of patients despite compliance with therapy, incomplete response occurs in 13% of treated patients, and DRUG TOXICITY that is sufficiently severe to cause premature discontinuation of MEDICATION occurs in 13% of patients ( 3 ;  152 ;  156.",DRUG TOXICITY,MEDICATION
6396,no_relation,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6397,ATAXIA causes WERNICKE KORSAKOFF SYNDROME,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6398,no_relation,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6399,no_relation,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6400,no_relation,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6401,WERNICKE KORSAKOFF SYNDROME causes ATAXIA,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6402,WERNICKE KORSAKOFF SYNDROME causes ATAXIA,causes,0.995893206467704,"Rationale: • Lack of thiamine, combined with a relative state of poor nutrition postoperatively, can lead to WERNICKE KORSAKOFF SYNDROME presenting acutely as altered mental status, ophthalmoplegia, ATAXIA and memory disorders.",ATAXIA,WERNICKE KORSAKOFF SYNDROME
6403,ANGLE CLOSURE GLAUCOMA causes ACUTE ANGLE CLOSURE,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6404,no_relation,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6405,no_relation,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6406,no_relation,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6407,no_relation,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6408,no_relation,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6409,ACUTE ANGLE CLOSURE causes ANGLE CLOSURE GLAUCOMA,causes,0.8955334711889901,ACUTE ANGLE CLOSURE  In patients with ANGLE CLOSURE GLAUCOMA dilation of the pupil may precipitate an acute attack.,ACUTE ANGLE CLOSURE,ANGLE CLOSURE GLAUCOMA
6410,no_relation,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6411,FMS causes WIDESPREAD PAIN,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6412,FMS causes WIDESPREAD PAIN,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6413,WIDESPREAD PAIN causes FMS,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6414,FMS causes WIDESPREAD PAIN,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6415,FMS causes WIDESPREAD PAIN,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6416,FMS causes WIDESPREAD PAIN,causes,0.9237604307034007,"• Count the number of tender points, diagnosing FMS by ACR criteria if a patient has WIDESPREAD PAIN  plus  at least 11 tender points.",WIDESPREAD PAIN,FMS
6417,BALANTIDIUM COLI causes BALANTIDIASIS,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6418,BALANTIDIUM COLI causes BALANTIDIASIS,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6419,BALANTIDIUM COLI causes BALANTIDIASIS,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6420,BALANTIDIUM COLI causes BALANTIDIASIS,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6421,BALANTIDIUM COLI causes BALANTIDIASIS,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6422,BALANTIDIUM COLI causes BALANTIDIASIS,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6423,BALANTIDIASIS causes BALANTIDIUM COLI,causes,0.971285862357264,"122 ,   123 ,   i  Balantidiasis  Treatment of BALANTIDIASIS   +    caused by  BALANTIDIUM COLI ; drug of choice.",BALANTIDIASIS,BALANTIDIUM COLI
6424,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6425,ACTINOMYCOSIS causes ACTINOMYCES ISRAELII,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6426,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6427,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6428,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6429,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6430,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,0.8944271909999159,a  Actinomycosis  Treatment of ACTINOMYCOSIS caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6431,LYMPHADENOPATHY causes SMALL LYMPHOCYTIC LYMPHOMA,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6432,LYMPHADENOPATHY causes SMALL LYMPHOCYTIC LYMPHOMA,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6433,LYMPHADENOPATHY causes SMALL LYMPHOCYTIC LYMPHOMA,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6434,SMALL LYMPHOCYTIC LYMPHOMA causes LYMPHADENOPATHY,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6435,SMALL LYMPHOCYTIC LYMPHOMA causes LYMPHADENOPATHY,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6436,no_relation,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6437,no_relation,causes,0.4200840252084029,Those with a B cell count less than 5×10 9 /L but who do have LYMPHADENOPATHY or hepatosplenomegaly should be considered to have the SMALL LYMPHOCYTIC LYMPHOMA (SLL) variant of CLL.,LYMPHADENOPATHY,SMALL LYMPHOCYTIC LYMPHOMA
6438,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6439,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6440,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6441,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6442,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6443,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6444,ANGINA DECUBITUS causes PAIN,causes,0.9761870601839532,"Unstable angina:  Symptoms are those of angina pectoris (see  Symptoms and Signs ), except that the PAIN or discomfort of unstable angina usually is more intense, lasts longer, is precipitated by less exertion, occurs spontaneously at rest (as ANGINA DECUBITUS is progressive (crescendo) in nature, or involves any combination of these features.",PAIN,ANGINA DECUBITUS
6445,PERTUSSIS (WHOOPING COUGH) causes BORDETELLA PERTUSSIS,causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6446,BORDETELLA PERTUSSIS causes PERTUSSIS (WHOOPING COUGH),causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6447,BORDETELLA PERTUSSIS causes PERTUSSIS (WHOOPING COUGH),causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6448,BORDETELLA PERTUSSIS causes PERTUSSIS (WHOOPING COUGH),causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6449,BORDETELLA PERTUSSIS causes PERTUSSIS (WHOOPING COUGH),causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6450,BORDETELLA PERTUSSIS causes PERTUSSIS (WHOOPING COUGH),causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6451,BORDETELLA PERTUSSIS causes PERTUSSIS (WHOOPING COUGH),causes,1.0,"198 ,   199  PERTUSSIS (WHOOPING COUGH) is an acute respiratory tract infection caused by  BORDETELLA PERTUSSIS",PERTUSSIS (WHOOPING COUGH),BORDETELLA PERTUSSIS
6452,ESTROGEN causes PREGNANCY,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6453,PREGNANCY causes ESTROGEN,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6454,PREGNANCY causes ESTROGEN,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6455,PREGNANCY causes ESTROGEN,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6456,PREGNANCY causes ESTROGEN,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6457,no_relation,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6458,PREGNANCY causes ESTROGEN,causes,0.555555555555556,During PREGNANCY the placenta is an endocrine gland that secretes ESTROGEN and progesterone to maintain pregnancy.,PREGNANCY,ESTROGEN
6459,LOFFLER'S SYNDROME causes PERIPHERAL BLOOD EOSINOPHILIA,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6460,LOFFLER'S SYNDROME causes PERIPHERAL BLOOD EOSINOPHILIA,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6461,no_relation,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6462,LOFFLER'S SYNDROME causes PERIPHERAL BLOOD EOSINOPHILIA,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6463,LOFFLER'S SYNDROME causes PERIPHERAL BLOOD EOSINOPHILIA,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6464,no_relation,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6465,no_relation,causes,0.964763821237732,"LOFFLER'S SYNDROME  LOFFLER'S SYNDROME is characterized by absent or mild respiratory symptoms, fleeting migratory pulmonary opacities, and PERIPHERAL BLOOD EOSINOPHILIA",PERIPHERAL BLOOD EOSINOPHILIA,LOFFLER'S SYNDROME
6466,INFLAMMATORY BREAST CANCER causes ERYTHEMA,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6467,ERYTHEMA causes INFLAMMATORY BREAST CANCER,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6468,no_relation,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6469,no_relation,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6470,no_relation,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6471,no_relation,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6472,INFLAMMATORY BREAST CANCER causes ERYTHEMA,causes,0.987878339907213,"The cumulative risk by age 50 is 2% and the median age of women with a new diagnosis is 64 Physical exam  ERYTHEMA scaliness, or peau d'orange signs  INFLAMMATORY BREAST CANCER can sometimes be misdiagnosed as mastitis Physical exam  New lump or nipple discharge, nipple retraction, and skin dimpling Physical exam  Axillary adenopathy  May indicate  2 disease.",ERYTHEMA,INFLAMMATORY BREAST CANCER
6473,no_relation,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6474,no_relation,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6475,no_relation,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6476,no_relation,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6477,ATYPICAL ANGINA causes NONANGINAL CHEST PAIN,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6478,no_relation,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6479,no_relation,causes,0.7293249574894731,"• How would you characterize these symptoms (typical angina, ATYPICAL ANGINA NONANGINAL CHEST PAIN",NONANGINAL CHEST PAIN,ATYPICAL ANGINA
6480,INFLAMMATORY PSEUDOTUMOR causes FEVER,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6481,no_relation,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6482,INFLAMMATORY PSEUDOTUMOR causes FEVER,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6483,no_relation,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6484,FEVER causes INFLAMMATORY PSEUDOTUMOR,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6485,no_relation,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6486,INFLAMMATORY PSEUDOTUMOR causes FEVER,causes,1.0,"Fisher RG, Wright PF, Johnson JE: INFLAMMATORY PSEUDOTUMOR presenting as FEVER of unknown origin.",FEVER,INFLAMMATORY PSEUDOTUMOR
6487,SYSTEMIC MASTOCYTOSIS causes SKIN,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6488,no_relation,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6489,no_relation,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6490,no_relation,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6491,no_relation,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6492,no_relation,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6493,no_relation,causes,0.875189948987367,"SYSTEMIC MASTOCYTOSIS  In this rare condition, the SKIN (99% of cases), bones (9%), liver (12%), spleen (11%), lymph nodes, and GI tract are involved with proliferating mast cells.",SKIN,SYSTEMIC MASTOCYTOSIS
6494,HEREDITARY SPHEROCYTOSIS causes HEMOLYSIS,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6495,HEREDITARY SPHEROCYTOSIS causes HEMOLYSIS,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6496,HEREDITARY SPHEROCYTOSIS causes HEMOLYSIS,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6497,HEREDITARY SPHEROCYTOSIS causes HEMOLYSIS,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6498,HEREDITARY SPHEROCYTOSIS causes HEMOLYSIS,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6499,no_relation,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6500,no_relation,causes,0.629940788348712,Evidence: • Splenectomy virtually eliminates HEMOLYSIS in common forms of HEREDITARY SPHEROCYTOSIS and it should be performed in all but the mildest cases ( 31 ;  32 ;  33.,HEMOLYSIS,HEREDITARY SPHEROCYTOSIS
6501,no_relation,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6502,no_relation,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6503,no_relation,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6504,no_relation,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6505,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6506,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6507,no_relation,causes,0.889000889001333,"difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cephalexin, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
6508,no_relation,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6509,no_relation,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6510,no_relation,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6511,CEREBRAL PALSY causes DEGENERATIVE OR METABOLIC CNS DISORDERS,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6512,no_relation,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6513,no_relation,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6514,DEGENERATIVE OR METABOLIC CNS DISORDERS causes CEREBRAL PALSY,causes,0.441726104299386,"Dystonia may be primary (idiopathic) or secondary to DEGENERATIVE OR METABOLIC CNS DISORDERS (eg, Wilson's disease, Hallervorden Spatz disease, various lipidoses, CEREBRAL PALSY stroke) or drugs (most often phenothiazines, thioxanthenes, butyrophenones, and antiemetics.",DEGENERATIVE OR METABOLIC CNS DISORDERS,CEREBRAL PALSY
6515,no_relation,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6516,RICKETTSIA TYPHI causes DISEASE,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6517,RICKETTSIA TYPHI causes DISEASE,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6518,DISEASE causes RICKETTSIA TYPHI,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6519,RICKETTSIA TYPHI causes DISEASE,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6520,no_relation,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6521,RICKETTSIA TYPHI causes DISEASE,causes,0.9878291611472622,A DISEASE caused by  RICKETTSIA TYPHI  and occurring in nature as a mild infection of rats and transmitted from rat to rat by the rat louse or flea.,DISEASE,RICKETTSIA TYPHI
6522,PV causes AQUAGENIC PRURITUS AND SPLENOMEGALY,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6523,no_relation,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6524,PV causes AQUAGENIC PRURITUS AND SPLENOMEGALY,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6525,no_relation,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6526,no_relation,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6527,no_relation,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6528,PV causes AQUAGENIC PRURITUS AND SPLENOMEGALY,causes,0.9,"Rationale: • PV is characterized by thrombohemorrhagic complications, vasomotor symptoms, AQUAGENIC PRURITUS AND SPLENOMEGALY",AQUAGENIC PRURITUS AND SPLENOMEGALY,PV
6529,GLUCOSE causes HYPOGLYCEMIA,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6530,no_relation,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6531,no_relation,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6532,no_relation,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6533,no_relation,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6534,no_relation,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6535,no_relation,causes,0.737209780774486,"Intervention to reduce perioperative risk: Non drug intervention: Educate Mr. DM on his perioperative risk, symptoms of HYPOGLYCEMIA and cardiac ischemia and urge more frequent monitoring of GLUCOSE at home (fasting and pre meal) and smoking cessation.",HYPOGLYCEMIA,GLUCOSE
6536,no_relation,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6537,FEBRILE RESPIRATORY ILLNESS causes INFLUENZA,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6538,FEBRILE RESPIRATORY ILLNESS causes INFLUENZA,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6539,FEBRILE RESPIRATORY ILLNESS causes INFLUENZA,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6540,FEBRILE RESPIRATORY ILLNESS causes INFLUENZA,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6541,no_relation,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6542,FEBRILE RESPIRATORY ILLNESS causes INFLUENZA,causes,0.781133465884943,"INFLUENZA activity in the community is marked by increased medical contacts for FEBRILE RESPIRATORY ILLNESS increased absenteeism from school and the workplace, subsequent increased hospitalizations for pneumonia and other cardiopulmonary disorders, and increased mortality.",INFLUENZA,FEBRILE RESPIRATORY ILLNESS
6543,no_relation,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6544,no_relation,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6545,INTERLEUKIN 2 PLUS INTERFERON ALPHA causes RENAL CELL CARCINOMA,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6546,RENAL CELL CARCINOMA causes INTERLEUKIN 2 PLUS INTERFERON ALPHA,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6547,RENAL CELL CARCINOMA causes INTERLEUKIN 2 PLUS INTERFERON ALPHA,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6548,no_relation,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6549,no_relation,causes,0.522232967867094,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
6550,INFECTIOUS MONONUCLEOSIS causes SPONTANEOUS SPLENIC RUPTURE,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6551,no_relation,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6552,INFECTIOUS MONONUCLEOSIS causes SPONTANEOUS SPLENIC RUPTURE,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6553,no_relation,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6554,no_relation,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6555,no_relation,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6556,INFECTIOUS MONONUCLEOSIS causes SPONTANEOUS SPLENIC RUPTURE,causes,0.9931270663228408,INFECTIOUS MONONUCLEOSIS presenting as SPONTANEOUS SPLENIC RUPTURE without other symptoms.,SPONTANEOUS SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
6557,no_relation,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6558,no_relation,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6559,no_relation,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6560,no_relation,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6561,no_relation,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6562,no_relation,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6563,BENAZEPRIL causes PREGNANCY,causes,0.6575959492214289,"1 ,   11 ,   12  Fetal/Neonatal Morbidity and Mortality  Possible fetal and neonatal morbidity and mortality when BENAZEPRIL is used during PREGNANCY",PREGNANCY,BENAZEPRIL
6564,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6565,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6566,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6567,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6568,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6569,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6570,FLUORINE causes FLUOROSIS,causes,1.0,"Fluoridation of water that contains  Toxicity:  Excess FLUORINE can accumulate in teeth and bones, causing FLUOROSIS",FLUOROSIS,FLUORINE
6571,CONGENITAL CHLORIDORRHEA causes DIARRHEA,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6572,no_relation,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6573,CONGENITAL CHLORIDORRHEA causes DIARRHEA,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6574,CONGENITAL CHLORIDORRHEA causes DIARRHEA,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6575,CONGENITAL CHLORIDORRHEA causes DIARRHEA,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6576,no_relation,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6577,CONGENITAL CHLORIDORRHEA causes DIARRHEA,causes,0.90913729009699,"Among these causes are receipt of thiazide diuretics, loss of gastric secretions (even in patients with achlorhydria), sweat losses in patients with cystic fibrosis, and DIARRHEA in some patients with villous adenomas or CONGENITAL CHLORIDORRHEA",DIARRHEA,CONGENITAL CHLORIDORRHEA
6578,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6579,ACTINOMYCOSIS causes ACTINOMYCES ISRAELII,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6580,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6581,ACTINOMYCOSIS causes ACTINOMYCES ISRAELII,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6582,ACTINOMYCOSIS causes ACTINOMYCES ISRAELII,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6583,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6584,ACTINOMYCES ISRAELII causes ACTINOMYCOSIS,causes,1.0,Human ACTINOMYCOSIS is primarily caused by  ACTINOMYCES ISRAELII.,ACTINOMYCOSIS,ACTINOMYCES ISRAELII
6585,FIRST TRIMESTER OF PREGNANCY causes MEPROBAMATE,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6586,no_relation,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6587,no_relation,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6588,no_relation,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6589,no_relation,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6590,no_relation,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6591,no_relation,causes,0.8944271909999159,"b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,MEPROBAMATE
6592,INTERFERON ALFA THERAPY causes AUTOIMMUNE DISEASE,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6593,INTERFERON ALFA THERAPY causes AUTOIMMUNE DISEASE,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6594,no_relation,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6595,INTERFERON ALFA THERAPY causes AUTOIMMUNE DISEASE,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6596,no_relation,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6597,INTERFERON ALFA THERAPY causes AUTOIMMUNE DISEASE,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6598,no_relation,causes,0.881917103688197,"b  Closely monitor, or discontinue INTERFERON ALFA THERAPY in patients who develop an AUTOIMMUNE DISEASE while receiving the drug.",AUTOIMMUNE DISEASE,INTERFERON ALFA THERAPY
6599,LOCALIZATION RELATED EPILEPSIES causes SEIZURES,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6600,LOCALIZATION RELATED EPILEPSIES causes SEIZURES,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6601,no_relation,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6602,LOCALIZATION RELATED EPILEPSIES causes SEIZURES,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6603,SEIZURES causes LOCALIZATION RELATED EPILEPSIES,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6604,no_relation,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6605,no_relation,causes,0.8616404368553291,LOCALIZATION RELATED EPILEPSIES are those in which SEIZURES originate from a specific focus.,SEIZURES,LOCALIZATION RELATED EPILEPSIES
6606,CROHN'S DISEASE causes APHTHOUS ULCERS,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6607,no_relation,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6608,CROHN'S DISEASE causes APHTHOUS ULCERS,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6609,APHTHOUS ULCERS causes CROHN'S DISEASE,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6610,no_relation,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6611,no_relation,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6612,CROHN'S DISEASE causes APHTHOUS ULCERS,causes,0.802955068546966,"SYN:   aphthous stomatitis ;  canker sore  ETIOLOGY: APHTHOUS ULCERS are found in stomatitis, Beh et's syndrome, CROHN'S DISEASE acquired immunodeficiency syndrome (AIDS), and some cancers.",APHTHOUS ULCERS,CROHN'S DISEASE
6613,DYSMENORRHEA causes PAIN,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6614,DYSMENORRHEA causes PAIN,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6615,DYSMENORRHEA causes PAIN,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6616,DYSMENORRHEA causes PAIN,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6617,no_relation,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6618,PAIN causes DYSMENORRHEA,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6619,PAIN causes DYSMENORRHEA,causes,0.987878339907213,A]  Specific recommendation: • Consider oral contraceptives dosed continuously with active pills to avoid menstruation if DYSMENORRHEA is a predominate feature of PAIN or if symptoms are exacerbated by menses.,PAIN,DYSMENORRHEA
6620,no_relation,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6621,no_relation,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6622,no_relation,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6623,no_relation,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6624,URTICARIA causes CUTANEOUS INVOLVEMENT,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6625,no_relation,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6626,no_relation,causes,0.33333333333333304,"Physical Examination  CUTANEOUS INVOLVEMENT   Flushing, URTICARIA and angioedema have been reported in 88% to 100% of patients experiencing anaphylaxis.",CUTANEOUS INVOLVEMENT,URTICARIA
6627,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6628,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6629,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6630,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6631,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6632,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6633,no_relation,causes,0.768349819927832,"The SKIN affected by the RASH which occurs most often on the vulva, is often thin, shiny, and scarred.",SKIN,RASH
6634,ACETAZOLAMIDE causes AMS,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6635,no_relation,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6636,no_relation,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6637,no_relation,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6638,no_relation,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6639,no_relation,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6640,no_relation,causes,0.75,• Unlike ACETAZOLAMIDE dexamethasone does not increase the rate of acclimatization but masks the symptoms of AMS resulting in 'rebound' when it is withdrawn,AMS,ACETAZOLAMIDE
6641,PHTHIRUS PUBIS causes PEDICULOSIS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6642,PHTHIRUS PUBIS causes PEDICULOSIS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6643,PEDICULOSIS PUBIS causes PHTHIRUS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6644,PHTHIRUS PUBIS causes PEDICULOSIS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6645,PHTHIRUS PUBIS causes PEDICULOSIS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6646,PHTHIRUS PUBIS causes PEDICULOSIS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6647,PEDICULOSIS PUBIS causes PHTHIRUS PUBIS,causes,0.9878291611472622,"PEDICULOSIS PUBIS which is caused by infestation with  PHTHIRUS PUBIS  [ see Figure 6 ], tends to be limited to the pubic area but occasionally affects the axillae, eyelashes, or other hairy parts of the body.",PEDICULOSIS PUBIS,PHTHIRUS PUBIS
6648,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6649,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6650,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6651,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6652,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6653,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6654,RESPIRATORY SYNCYTIAL VIRUSES causes COLDS,causes,1.0,"ETIOLOGY: Most COLDS are caused by rhinoviruses, adenoviruses, coronaviruses, coxsackieviruses, influenza viruses, parainfluenza viruses, or RESPIRATORY SYNCYTIAL VIRUSES",COLDS,RESPIRATORY SYNCYTIAL VIRUSES
6655,no_relation,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6656,no_relation,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6657,TROPICAL PULMONARY EOSINOPHILIA causes EOSINOPHILIA,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6658,TROPICAL PULMONARY EOSINOPHILIA causes EOSINOPHILIA,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6659,TROPICAL PULMONARY EOSINOPHILIA causes EOSINOPHILIA,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6660,TROPICAL PULMONARY EOSINOPHILIA causes EOSINOPHILIA,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6661,TROPICAL PULMONARY EOSINOPHILIA causes EOSINOPHILIA,causes,1.0,"TROPICAL PULMONARY EOSINOPHILIA (TPE)  is an uncommon manifestation with recurrent bronchospasm, transitory lung infiltrates, low grade fever, and marked EOSINOPHILIA",EOSINOPHILIA,TROPICAL PULMONARY EOSINOPHILIA
6662,BK VIRUS ASSOCIATED NEPHROPATHY causes LATENT VIRAL INFECTIONS,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6663,no_relation,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6664,LATENT VIRAL INFECTIONS causes BK VIRUS ASSOCIATED NEPHROPATHY,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6665,LATENT VIRAL INFECTIONS causes BK VIRUS ASSOCIATED NEPHROPATHY,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6666,LATENT VIRAL INFECTIONS causes BK VIRUS ASSOCIATED NEPHROPATHY,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6667,no_relation,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6668,no_relation,causes,0.583459965991578,"476 ,   477 ,   478  Latent Viral Infections  Increased risk of reactivation of LATENT VIRAL INFECTIONS including BK VIRUS ASSOCIATED NEPHROPATHY (BKVN.",LATENT VIRAL INFECTIONS,BK VIRUS ASSOCIATED NEPHROPATHY
6669,no_relation,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6670,no_relation,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6671,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6672,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6673,PELVIC PAIN causes ENDOMETRIOSIS,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6674,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6675,no_relation,causes,0.919145030018058,ENDOMETRIOSIS and mechanisms of PELVIC PAIN,PELVIC PAIN,ENDOMETRIOSIS
6676,no_relation,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6677,TN causes MASTICATORY PAIN,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6678,no_relation,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6679,no_relation,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6680,no_relation,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6681,no_relation,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6682,TN causes MASTICATORY PAIN,causes,0.4200840252084029,"The dentist must ensure a correct diagnosis does not mistake TN as a temporomandibular disorder.[17] Since triggering may be caused by movements of the tongue or facial muscles, TN must be differentiated from MASTICATORY PAIN that has the clinical characteristics of deep somatic rather than neuropathic pain.",MASTICATORY PAIN,TN
6683,HAEMOPHILUS DUCREYI causes CHANCROID,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6684,HAEMOPHILUS DUCREYI causes CHANCROID,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6685,HAEMOPHILUS DUCREYI causes CHANCROID,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6686,HAEMOPHILUS DUCREYI causes CHANCROID,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6687,CHANCROID causes HAEMOPHILUS DUCREYI,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6688,HAEMOPHILUS DUCREYI causes CHANCROID,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6689,HAEMOPHILUS DUCREYI causes CHANCROID,causes,0.99654575824488,137  Chancroid  Treatment of CHANCROID caused by  HAEMOPHILUS DUCREYI.,CHANCROID,HAEMOPHILUS DUCREYI
6690,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6691,MALIGNANT HYPERTHERMIA causes ANESTHETIC AGENTS,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6692,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6693,no_relation,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6694,no_relation,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6695,no_relation,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6696,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
6697,MITRAL VALVE PROLAPSE causes MARFAN SYNDROME,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6698,MITRAL VALVE PROLAPSE causes MARFAN SYNDROME,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6699,no_relation,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6700,MITRAL VALVE PROLAPSE causes MARFAN SYNDROME,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6701,no_relation,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6702,MITRAL VALVE PROLAPSE causes MARFAN SYNDROME,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6703,MITRAL VALVE PROLAPSE causes MARFAN SYNDROME,causes,0.445435403187374,MITRAL VALVE PROLAPSE is usually an isolated abnormality but may cause some degree of mitral regurgitation or be accompanied by MARFAN SYNDROME or an atrial septal defect.,MITRAL VALVE PROLAPSE,MARFAN SYNDROME
6704,HUS causes MICROANGIOPATHIC HEMOLYSIS,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6705,HUS causes MICROANGIOPATHIC HEMOLYSIS,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6706,no_relation,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6707,MICROANGIOPATHIC HEMOLYSIS causes HUS,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6708,HUS causes MICROANGIOPATHIC HEMOLYSIS,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6709,HUS causes MICROANGIOPATHIC HEMOLYSIS,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6710,HUS causes MICROANGIOPATHIC HEMOLYSIS,causes,0.787838597158335,"MICROANGIOPATHIC HEMOLYSIS neutrophilic leukocytosis, and a negative direct Coombs test (direct antiglobulin test) strongly suggest TTP or HUS",MICROANGIOPATHIC HEMOLYSIS,HUS
6711,PV causes HEMORRHAGE,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6712,no_relation,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6713,PV causes HEMORRHAGE,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6714,PV causes HEMORRHAGE,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6715,PV causes HEMORRHAGE,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6716,PV causes HEMORRHAGE,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6717,HEMORRHAGE causes PV,causes,0.828517156108491,Evidence: • Several studies documented the increased blood viscosity associated with high hematocrit levels in PV and the subsequent increased risk of thrombosis and HEMORRHAGE ( 29 ;  30 ;  31.,HEMORRHAGE,PV
6718,PROGRESSIVE SUPRANUCLEAR PALSY causes PROGRESSIVE AXIAL DYSTONIA,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6719,PROGRESSIVE SUPRANUCLEAR PALSY causes PROGRESSIVE AXIAL DYSTONIA,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6720,PROGRESSIVE AXIAL DYSTONIA causes PROGRESSIVE SUPRANUCLEAR PALSY,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6721,PROGRESSIVE SUPRANUCLEAR PALSY causes PROGRESSIVE AXIAL DYSTONIA,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6722,PROGRESSIVE SUPRANUCLEAR PALSY causes PROGRESSIVE AXIAL DYSTONIA,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6723,PROGRESSIVE SUPRANUCLEAR PALSY causes PROGRESSIVE AXIAL DYSTONIA,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6724,PROGRESSIVE SUPRANUCLEAR PALSY causes PROGRESSIVE AXIAL DYSTONIA,causes,0.9878291611472622,"PROGRESSIVE SUPRANUCLEAR PALSY  (Steele Richardson Olszewski Syndrome)  PROGRESSIVE SUPRANUCLEAR PALSY is a rare, degenerative CNS disorder causing loss of voluntary eye movements, bradykinesia, muscular rigidity with PROGRESSIVE AXIAL DYSTONIA pseudobulbar palsy, and dementia.",PROGRESSIVE AXIAL DYSTONIA,PROGRESSIVE SUPRANUCLEAR PALSY
6725,no_relation,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6726,INAPPROPRIATE SINUS TACHYCARDIA causes POSTURAL SINUS TACHYCARDIA,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6727,no_relation,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6728,POSTURAL SINUS TACHYCARDIA causes INAPPROPRIATE SINUS TACHYCARDIA,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6729,INAPPROPRIATE SINUS TACHYCARDIA causes POSTURAL SINUS TACHYCARDIA,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6730,no_relation,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6731,no_relation,causes,0.917662935482247,"Main article: INAPPROPRIATE SINUS TACHYCARDIA [edit] Postural orthostatic tachycardia syndrome (POTS)  Usually in women with no heart problems, this syndrome is characterized by normal resting heart rate but exaggerated POSTURAL SINUS TACHYCARDIA with or without orthostatic hypotension.",POSTURAL SINUS TACHYCARDIA,INAPPROPRIATE SINUS TACHYCARDIA
6732,YELLOW FEVER VIRUS causes FULMINANT YELLOW FEVER,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6733,YELLOW FEVER VIRUS causes FULMINANT YELLOW FEVER,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6734,YELLOW FEVER VIRUS causes FULMINANT YELLOW FEVER,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6735,YELLOW FEVER VIRUS causes FULMINANT YELLOW FEVER,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6736,FULMINANT YELLOW FEVER causes YELLOW FEVER VIRUS,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6737,no_relation,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6738,YELLOW FEVER VIRUS causes FULMINANT YELLOW FEVER,causes,0.99654575824488,101  Vaccine associated viscerotropic disease resembles FULMINANT YELLOW FEVER caused by wild type YELLOW FEVER VIRUS,FULMINANT YELLOW FEVER,YELLOW FEVER VIRUS
6739,NPS causes SCOLIOSIS,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6740,no_relation,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6741,no_relation,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6742,no_relation,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6743,NPS causes SCOLIOSIS,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6744,no_relation,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6745,NPS causes SCOLIOSIS,causes,0.792593923901217,"Also, some research shows people with NPS are more prone to glaucoma and SCOLIOSIS due to poorly developed spines.",SCOLIOSIS,NPS
6746,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6747,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6748,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6749,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6750,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6751,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6752,BORRELIA RECURRENTIS causes RELAPSING FEVER,causes,0.99654575824488,"d ,   e  Relapsing Fever  Treatment of RELAPSING FEVER caused by  BORRELIA RECURRENTIS.",RELAPSING FEVER,BORRELIA RECURRENTIS
6753,TOXOPLASMA GONDII causes CONGENITAL TOXOPLASMOSIS,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6754,TOXOPLASMA GONDII causes CONGENITAL TOXOPLASMOSIS,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6755,CONGENITAL TOXOPLASMOSIS causes TOXOPLASMA GONDII,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6756,TOXOPLASMA GONDII causes CONGENITAL TOXOPLASMOSIS,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6757,CONGENITAL TOXOPLASMOSIS causes TOXOPLASMA GONDII,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6758,TOXOPLASMA GONDII causes CONGENITAL TOXOPLASMOSIS,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6759,TOXOPLASMA GONDII causes CONGENITAL TOXOPLASMOSIS,causes,1.0,CONGENITAL TOXOPLASMOSIS is caused by transplacental acquisition of  TOXOPLASMA GONDII,CONGENITAL TOXOPLASMOSIS,TOXOPLASMA GONDII
6760,no_relation,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6761,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6762,no_relation,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6763,no_relation,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6764,no_relation,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6765,no_relation,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6766,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,causes,0.5656854249492379,"Severe THROMBOCYTOPENIA may occur, however; IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) may be an initial presentation of SLE.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
6767,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6768,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6769,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6770,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6771,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6772,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6773,ENDOMETRIOSIS causes PAIN,causes,1.0,"In three large studies of women with chronic pelvic pain, ENDOMETRIOSIS was found to be the cause of the PAIN in 70 to 80% of cases.",PAIN,ENDOMETRIOSIS
6774,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6775,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6776,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6777,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6778,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6779,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6780,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,b  Diazoxide is ineffective in the management of HYPERTENSION caused by PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
6781,ANTHRAX causes B ANTHRACIS,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6782,B ANTHRACIS causes ANTHRAX,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6783,B ANTHRACIS causes ANTHRAX,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6784,B ANTHRACIS causes ANTHRAX,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6785,B ANTHRACIS causes ANTHRAX,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6786,B ANTHRACIS causes ANTHRAX,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6787,B ANTHRACIS causes ANTHRAX,causes,0.99654575824488,ANTHRAX caused by B ANTHRACIS has gained new importance as a potential bioterrorism weapon after the 2001 attacks.,ANTHRAX,B ANTHRACIS
6788,no_relation,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6789,ASYMPTOMATIC GONORRHEA causes N GONORRHOEAE,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6790,N GONORRHOEAE causes ASYMPTOMATIC GONORRHEA,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6791,no_relation,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6792,no_relation,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6793,N GONORRHOEAE causes ASYMPTOMATIC GONORRHEA,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6794,N GONORRHOEAE causes ASYMPTOMATIC GONORRHEA,causes,0.7559289460184542,"ASYMPTOMATIC GONORRHEA occurs in 5 to 10% of pregnancies, so  N GONORRHOEAE  may be a pathogen.",ASYMPTOMATIC GONORRHEA,N GONORRHOEAE
6795,no_relation,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6796,no_relation,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6797,no_relation,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6798,no_relation,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6799,no_relation,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6800,SLE causes RHEUMATOID ARTHRITIS,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6801,no_relation,causes,0.393919298579168,"BC]  Specific recommendation: • Consider underlying SLE mixed connective tissue disease, RHEUMATOID ARTHRITIS and other collagen vascular diseases as possible causes of pleuritic chest pain.",RHEUMATOID ARTHRITIS,SLE
6802,no_relation,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6803,no_relation,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6804,no_relation,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6805,VASCULITIS causes CUTANEOUS VESSELS,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6806,no_relation,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6807,VASCULITIS causes CUTANEOUS VESSELS,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6808,no_relation,causes,0.824163383692134,PREDOMINANTLY CUTANEOUS VASCULITIS  (Leukocytoclastic Vasculitis; Hypersensitivity Vasculitis)  Primarily cutaneous vasculitis is VASCULITIS that affects mainly small CUTANEOUS VESSELS causing skin lesions.,CUTANEOUS VESSELS,VASCULITIS
6809,CLUSTER HEADACHES causes PERIORBITAL OR TEMPORAL PAIN,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6810,CLUSTER HEADACHES causes PERIORBITAL OR TEMPORAL PAIN,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6811,CLUSTER HEADACHES causes PERIORBITAL OR TEMPORAL PAIN,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6812,CLUSTER HEADACHES causes PERIORBITAL OR TEMPORAL PAIN,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6813,CLUSTER HEADACHES causes PERIORBITAL OR TEMPORAL PAIN,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6814,PERIORBITAL OR TEMPORAL PAIN causes CLUSTER HEADACHES,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6815,CLUSTER HEADACHES causes PERIORBITAL OR TEMPORAL PAIN,causes,1.0,"CLUSTER HEADACHE  CLUSTER HEADACHES cause excruciating, unilateral PERIORBITAL OR TEMPORAL PAIN with ipsilateral autonomic symptoms (ptosis, lacrimation, rhinorrhea, nasal congestion.",PERIORBITAL OR TEMPORAL PAIN,CLUSTER HEADACHES
6816,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6817,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6818,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6819,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6820,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6821,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6822,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.9931270663228408,BONE METASTASES cause severe pain and PATHOLOGIC FRACTURES,PATHOLOGIC FRACTURES,BONE METASTASES
6823,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6824,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6825,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6826,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6827,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6828,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6829,GALACTOSEMIA causes CATARACTS,causes,0.9950371902099888,"2.3 Recognize that certain metabolic diseases, such as GALACTOSEMIA diabetes, and genetic aberrations, can cause CATARACTS in the neonatal period and early childhood.",CATARACTS,GALACTOSEMIA
6830,no_relation,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6831,TACHYCARDIAS causes JUNCTIONAL TACHYCARDIA,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6832,no_relation,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6833,no_relation,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6834,JUNCTIONAL TACHYCARDIA causes TACHYCARDIAS,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6835,no_relation,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6836,no_relation,causes,0.474712663277541,These patients tend to have persistent TACHYCARDIAS that have been referred to as the permanent form of JUNCTIONAL TACHYCARDIA (PJRT.,TACHYCARDIAS,JUNCTIONAL TACHYCARDIA
6837,no_relation,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6838,no_relation,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6839,no_relation,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6840,no_relation,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6841,no_relation,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6842,COLON causes (GRANULOMATOUS COLITIS,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6843,no_relation,causes,0.7293249574894731,"About 35% of Crohn's disease cases involve the ileum alone (ileitis); about 45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about 20% involve the COLON alone (GRANULOMATOUS COLITIS most of which, unlike ulcerative colitis (UC), spare the rectum.",COLON,(GRANULOMATOUS COLITIS
6844,BURKHOLDERIA MALLEI causes GLANDERS,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6845,BURKHOLDERIA MALLEI causes GLANDERS,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6846,BURKHOLDERIA MALLEI causes GLANDERS,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6847,BURKHOLDERIA MALLEI causes GLANDERS,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6848,BURKHOLDERIA MALLEI causes GLANDERS,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6849,GLANDERS causes BURKHOLDERIA MALLEI,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6850,BURKHOLDERIA MALLEI causes GLANDERS,causes,0.9838699100999068,114  Burkholderia Infections  Treatment of GLANDERS   +    caused by  BURKHOLDERIA MALLEI,GLANDERS,BURKHOLDERIA MALLEI
6851,no_relation,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6852,INTERRUPTED URINARY STREAM BLADDER CARCINOMA causes INTERMITTENT PAINLESS HEMATURIA,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6853,no_relation,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6854,INTERRUPTED URINARY STREAM BLADDER CARCINOMA causes INTERMITTENT PAINLESS HEMATURIA,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6855,INTERRUPTED URINARY STREAM BLADDER CARCINOMA causes INTERMITTENT PAINLESS HEMATURIA,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6856,INTERMITTENT PAINLESS HEMATURIA causes INTERRUPTED URINARY STREAM BLADDER CARCINOMA,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6857,INTERRUPTED URINARY STREAM BLADDER CARCINOMA causes INTERMITTENT PAINLESS HEMATURIA,causes,0.986393923832143,Patients may have dysuria and suprapubic pain that radiates to the tip of the penis and an INTERRUPTED URINARY STREAM BLADDER CARCINOMA  Usually presents as INTERMITTENT PAINLESS HEMATURIA,INTERMITTENT PAINLESS HEMATURIA,INTERRUPTED URINARY STREAM BLADDER CARCINOMA
6858,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6859,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6860,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6861,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6862,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6863,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6864,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.913811548620257,Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
6865,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6866,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6867,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6868,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6869,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6870,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6871,FUNGI causes TINEA UNGUIUM,causes,0.985527456652574,"Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, TINEA UNGUIUM caused by susceptible FUNGI",TINEA UNGUIUM,FUNGI
6872,FABRY DISEASE causes NEPHRITIC RENAL FAILURE,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6873,no_relation,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6874,FABRY DISEASE causes NEPHRITIC RENAL FAILURE,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6875,FABRY DISEASE causes NEPHRITIC RENAL FAILURE,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6876,FABRY DISEASE causes NEPHRITIC RENAL FAILURE,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6877,FABRY DISEASE causes NEPHRITIC RENAL FAILURE,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6878,FABRY DISEASE causes NEPHRITIC RENAL FAILURE,causes,0.9090909090909092,"41   In men (homozygotes), FABRY DISEASE often progresses to NEPHRITIC RENAL FAILURE stroke, and cardiomyopathy.",NEPHRITIC RENAL FAILURE,FABRY DISEASE
6879,TRICHOSPORON BEIGELII causes WHITE PIEDRA,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6880,WHITE PIEDRA causes TRICHOSPORON BEIGELII,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6881,TRICHOSPORON BEIGELII causes WHITE PIEDRA,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6882,TRICHOSPORON BEIGELII causes WHITE PIEDRA,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6883,TRICHOSPORON BEIGELII causes WHITE PIEDRA,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6884,TRICHOSPORON BEIGELII causes WHITE PIEDRA,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6885,TRICHOSPORON BEIGELII causes WHITE PIEDRA,causes,1.0,"piedra    (            audio )  [Sp., stone] Sheathlike nodular masses in the hair of the beard and mustache from growth of either  Piedraia hortai,  which causes black piedra, or  TRICHOSPORON BEIGELII  which causes WHITE PIEDRA",WHITE PIEDRA,TRICHOSPORON BEIGELII
6886,SEPTO OPTIC DYSPLASIA causes OPTIC DISK AND SEPTUM PELLUCIDUM,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6887,no_relation,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6888,no_relation,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6889,no_relation,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6890,no_relation,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6891,SEPTO OPTIC DYSPLASIA causes OPTIC DISK AND SEPTUM PELLUCIDUM,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6892,no_relation,causes,0.905821627315676,"SEPTO OPTIC DYSPLASIA    A rare developmental disorder of the brain and eye in which the OPTIC DISK AND SEPTUM PELLUCIDUM do not develop normally, resulting in blindness, hormonal deficiencies, learning disabilities, decreased muscular tone, and, occasionally, seizures.",OPTIC DISK AND SEPTUM PELLUCIDUM,SEPTO OPTIC DYSPLASIA
6893,no_relation,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6894,LIPOSOMAL AMPHOTERICIN B causes VISCERAL LEISHMANIASIS,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6895,no_relation,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6896,no_relation,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6897,LIPOSOMAL AMPHOTERICIN B causes VISCERAL LEISHMANIASIS,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6898,VISCERAL LEISHMANIASIS causes LIPOSOMAL AMPHOTERICIN B,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6899,LIPOSOMAL AMPHOTERICIN B causes VISCERAL LEISHMANIASIS,causes,0.441726104299386,"di Martino L, Davidson RN, Giacchinno R et al. Treatment of VISCERAL LEISHMANIASIS in children with LIPOSOMAL AMPHOTERICIN B.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
6900,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6901,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6902,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6903,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6904,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6905,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6906,PENICILLAMINE causes MEMBRANOUS NEPHROPATHY,causes,1.0,"Gold, PENICILLAMINE NSAIDs, and mercury have been shown to cause MEMBRANOUS NEPHROPATHY",MEMBRANOUS NEPHROPATHY,PENICILLAMINE
6907,EPIDERMAL NEVUS SYNDROME causes SEIZURES,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6908,SEIZURES causes EPIDERMAL NEVUS SYNDROME,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6909,SEIZURES causes EPIDERMAL NEVUS SYNDROME,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6910,no_relation,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6911,EPIDERMAL NEVUS SYNDROME causes SEIZURES,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6912,no_relation,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6913,EPIDERMAL NEVUS SYNDROME causes SEIZURES,causes,0.979957887012223,"EPIDERMAL NEVUS SYNDROME  The EPIDERMAL NEVUS SYNDROME is characterized by systemic manifestations, such as SEIZURES mental retardation, blindness, and skeletal abnormalities in association with large epidermal nevi.",SEIZURES,EPIDERMAL NEVUS SYNDROME
6914,FM causes PAIN,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6915,no_relation,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6916,no_relation,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6917,FM causes PAIN,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6918,FM causes PAIN,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6919,FM causes PAIN,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6920,FM causes PAIN,causes,0.981980506061966,"PATHOPHYSIOLOGY  Enormous progress in our understanding of the pathophysiologic underpinnings of PAIN fatigue, and other symptoms in FM has been made in the last few years.",PAIN,FM
6921,no_relation,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6922,no_relation,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6923,no_relation,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6924,no_relation,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6925,no_relation,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6926,HERPES ZOSTER causes VARICELLA,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6927,no_relation,causes,0.679366220486757,"41   However, those who develop varicella or HERPES ZOSTER  after  transplantation should be considered immune to VARICELLA",VARICELLA,HERPES ZOSTER
6928,no_relation,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6929,SYSTEMIC MASTOCYTOSIS causes SKIN LYMPH NODES LIVER,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6930,no_relation,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6931,SYSTEMIC MASTOCYTOSIS causes SKIN LYMPH NODES LIVER,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6932,SYSTEMIC MASTOCYTOSIS causes SKIN LYMPH NODES LIVER,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6933,no_relation,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6934,no_relation,causes,0.5714285714285711,"SYSTEMIC MASTOCYTOSIS most commonly occurs in adults and is characterized by multifocal bone marrow lesions; it often involves other organs, most commonly SKIN LYMPH NODES LIVER spleen, or GI tract.",SKIN LYMPH NODES LIVER,SYSTEMIC MASTOCYTOSIS
6935,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6936,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6937,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6938,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6939,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6940,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6941,TREPONEMA PERTENUE causes YAWS,causes,0.9284766908852592,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
6942,no_relation,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6943,PREGNANCY causes THALIDOMIDE,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6944,PREGNANCY causes THALIDOMIDE,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6945,no_relation,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6946,no_relation,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6947,PREGNANCY causes THALIDOMIDE,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6948,no_relation,causes,0.384110639798688,"Because thalidomide is a known human teratogen and can cause severe, life threatening birth defects if administered during PREGNANCY commercially available THALIDOMIDE must be obtained through a restricted distribution program, the System for Thalidomide Education and Prescribing Safety (STEPS), designed to help ensure that fetal exposure to the drug does not occur.",PREGNANCY,THALIDOMIDE
6949,no_relation,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6950,• WILSON'S DISEASE causes ACUTE HEPATIC FAILURE,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6951,no_relation,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6952,• WILSON'S DISEASE causes ACUTE HEPATIC FAILURE,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6953,• WILSON'S DISEASE causes ACUTE HEPATIC FAILURE,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6954,• WILSON'S DISEASE causes ACUTE HEPATIC FAILURE,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6955,• WILSON'S DISEASE causes ACUTE HEPATIC FAILURE,causes,0.98058067569092,• WILSON'S DISEASE may present as acute hepatic injury or ACUTE HEPATIC FAILURE,ACUTE HEPATIC FAILURE,• WILSON'S DISEASE
6956,no_relation,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6957,no_relation,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6958,no_relation,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6959,no_relation,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6960,no_relation,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6961,no_relation,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6962,PERILYMPHATIC FISTULA causes MIDDLE AND INNER EAR,causes,0.635000635000953,"Large ambient pressure changes or strenuous activities, such as weight lifting, can induce a PERILYMPHATIC FISTULA between the MIDDLE AND INNER EAR",MIDDLE AND INNER EAR,PERILYMPHATIC FISTULA
6963,NEISSERIA GONORRHOEAE causes GONORRHEA,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6964,NEISSERIA GONORRHOEAE causes GONORRHEA,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6965,GONORRHEA causes NEISSERIA GONORRHOEAE,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6966,NEISSERIA GONORRHOEAE causes GONORRHEA,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6967,no_relation,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6968,NEISSERIA GONORRHOEAE causes GONORRHEA,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6969,NEISSERIA GONORRHOEAE causes GONORRHEA,causes,0.98058067569092,"c ,   116  Gonorrhea and Associated Infections  Alternative for treatment of uncomplicated GONORRHEA (including urethritis) caused by susceptible  NEISSERIA GONORRHOEAE",GONORRHEA,NEISSERIA GONORRHOEAE
6970,no_relation,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6971,OLIGODENDROGLIOMAS causes HEMORRHAGE,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6972,OLIGODENDROGLIOMAS causes HEMORRHAGE,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6973,HEMORRHAGE causes OLIGODENDROGLIOMAS,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6974,HEMORRHAGE causes OLIGODENDROGLIOMAS,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6975,OLIGODENDROGLIOMAS causes HEMORRHAGE,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6976,OLIGODENDROGLIOMAS causes HEMORRHAGE,causes,0.552344770738994,HEMORRHAGE is more likely to occur with OLIGODENDROGLIOMAS than with astrocytomas.,HEMORRHAGE,OLIGODENDROGLIOMAS
6977,no_relation,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6978,RESPIRATORY SYNCYTIAL VIRUS causes PNEUMONIA,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6979,PNEUMONIA causes RESPIRATORY SYNCYTIAL VIRUS,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6980,RESPIRATORY SYNCYTIAL VIRUS causes PNEUMONIA,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6981,no_relation,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6982,PNEUMONIA causes RESPIRATORY SYNCYTIAL VIRUS,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6983,no_relation,causes,0.9901475429766742,Economic impact of PNEUMONIA due to RESPIRATORY SYNCYTIAL VIRUS (RSV) infection.,PNEUMONIA,RESPIRATORY SYNCYTIAL VIRUS
6984,no_relation,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6985,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6986,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6987,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6988,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6989,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6990,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.768221279597376,"121  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +   , including  N. asteroides, N. brasiliensis , and  N. caviae.",NOCARDIA INFECTIONS,NOCARDIA
6991,BRADYCARDIA causes BRADYCARDIA TACHYCARDIA SYNDROME,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6992,no_relation,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6993,BRADYCARDIA TACHYCARDIA SYNDROME causes BRADYCARDIA,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6994,no_relation,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6995,BRADYCARDIA TACHYCARDIA SYNDROME causes BRADYCARDIA,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6996,no_relation,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6997,BRADYCARDIA TACHYCARDIA SYNDROME causes BRADYCARDIA,causes,0.917662935482247,The BRADYCARDIA TACHYCARDIA SYNDROME is characterized by atrial tachyarrhythmias (usually atrial fibrillation) alternating with periods of BRADYCARDIA or sinus pauses.,BRADYCARDIA,BRADYCARDIA TACHYCARDIA SYNDROME
6998,no_relation,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
6999,no_relation,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
7000,RESPIRATORY VIRAL INFECTIONS causes INFLUENZA,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
7001,RESPIRATORY VIRAL INFECTIONS causes INFLUENZA,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
7002,no_relation,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
7003,RESPIRATORY VIRAL INFECTIONS causes INFLUENZA,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
7004,no_relation,causes,0.321633760451338,"RESPIRATORY VIRAL INFECTIONS are a leading cause of morbidity, hospitalization, and mortality throughout the world; INFLUENZA and pneumonia were the most prevalent infectious causes of death during the 20th century in the United States.",INFLUENZA,RESPIRATORY VIRAL INFECTIONS
7005,no_relation,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7006,LISTERIA MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7007,LISTERIA MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7008,LISTERIA INFECTIONS causes LISTERIA MONOCYTOGENES,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7009,LISTERIA MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7010,LISTERIA MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7011,LISTERIA MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.8834522085987719,11  LISTERIA INFECTIONS  Treatment of infections caused by  LISTERIA MONOCYTOGENES ; used alone or in conjunction with an aminoglycoside.,LISTERIA INFECTIONS,LISTERIA MONOCYTOGENES
7012,no_relation,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7013,no_relation,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7014,no_relation,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7015,DIARRHEA causes DYSENTERY,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7016,no_relation,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7017,no_relation,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7018,no_relation,causes,0.329292779969071,"However, zinc in combination with vitamin A reduced the prevalence of persistent diarrhea (DIARRHEA lasting ≥ 14 d) (rate ratio 0.79, CI 0.66 to 0.94) and DYSENTERY (blood and mucus in stools) (rate ratio 0.80, CI 0.67 to 0.95.",DIARRHEA,DYSENTERY
7019,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS causes MILD DIARRHEA TO FATAL COLITIS,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7020,no_relation,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7021,no_relation,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7022,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS causes MILD DIARRHEA TO FATAL COLITIS,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7023,no_relation,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7024,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS causes MILD DIARRHEA TO FATAL COLITIS,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7025,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS causes MILD DIARRHEA TO FATAL COLITIS,causes,0.8660254037844392,"100 ,   101 ,   102 ,   103 ,   104 ,   105    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS or pseudomembranous colitis) has been reported with nearly all anti infectives, including lincomycin, and may range in severity from MILD DIARRHEA TO FATAL COLITIS.",MILD DIARRHEA TO FATAL COLITIS,ANTIBIOTIC ASSOCIATED DIARRHEA AND COLITIS
7026,no_relation,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7027,FIBROMYALGIA causes GENERALIZED PAIN AND TENDERNESS,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7028,FIBROMYALGIA causes GENERALIZED PAIN AND TENDERNESS,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7029,FIBROMYALGIA causes GENERALIZED PAIN AND TENDERNESS,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7030,FIBROMYALGIA causes GENERALIZED PAIN AND TENDERNESS,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7031,FIBROMYALGIA causes GENERALIZED PAIN AND TENDERNESS,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7032,no_relation,causes,0.979957887012223,FIBROMYALGIA is suspected in patients with GENERALIZED PAIN AND TENDERNESS especially disproportionate to the physical findings; with negative laboratory results despite widespread symptoms; or when fatigue is the predominant symptom.,GENERALIZED PAIN AND TENDERNESS,FIBROMYALGIA
7033,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7034,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7035,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7036,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7037,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7038,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7039,VULVODYNIA causes PAIN,causes,0.744208407535251,"The applied mass per area (kg/cm 2 ) that will elicit a complaint of pain in subjects with PAINful conditions, e.g., fibromyalgia, temperomandibular joint dysfunction, or VULVODYNIA",PAIN,VULVODYNIA
7040,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7041,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7042,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7043,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7044,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7045,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7046,C PSITTACI causes PSITTACOSIS,causes,0.975900072948533,Treatment of PSITTACOSIS (ornithosis) caused by  C PSITTACI,PSITTACOSIS,C PSITTACI
7047,no_relation,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7048,no_relation,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7049,UNSTABLE ANGINA causes PAIN,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7050,UNSTABLE ANGINA causes PAIN,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7051,UNSTABLE ANGINA causes PAIN,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7052,UNSTABLE ANGINA causes PAIN,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7053,no_relation,causes,0.843274042711568,"Symptoms of UNSTABLE ANGINA or infarction, ischemic stroke, or rest PAIN in the limbs may develop when unstable plaques rupture and acutely occlude a major artery, with superimposition of thrombosis or embolism.",PAIN,UNSTABLE ANGINA
7054,EPILEPSY causes SEIZURE,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7055,SEIZURE causes EPILEPSY,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7056,SEIZURE causes EPILEPSY,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7057,EPILEPSY causes SEIZURE,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7058,no_relation,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7059,no_relation,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7060,no_relation,causes,0.7559289460184542,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
7061,PODOPHYLLUM RESIN causes WARTS,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7062,no_relation,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7063,PODOPHYLLUM RESIN causes WARTS,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7064,no_relation,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7065,no_relation,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7066,no_relation,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7067,no_relation,causes,0.5252257314388901,100 •  Advise patients that PODOPHYLLUM RESIN is not a cure for HPV; new HPV WARTS may develop during or after therapy with the drug.,WARTS,PODOPHYLLUM RESIN
7068,HEPATITIS C INFECTION causes HEPATITIS C,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7069,HEPATITIS C INFECTION causes HEPATITIS C,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7070,HEPATITIS C INFECTION causes HEPATITIS C,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7071,no_relation,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7072,HEPATITIS C causes HEPATITIS C INFECTION,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7073,no_relation,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7074,HEPATITIS C INFECTION causes HEPATITIS C,causes,0.4472135954999579,"Because concurrent HEPATITIS C INFECTION is common and may be asymptomatic, serum markers for HEPATITIS C (see    ) should be obtained.",HEPATITIS C INFECTION,HEPATITIS C
7075,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7076,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7077,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7078,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7079,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7080,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7081,EPSTEIN BARR VIRUS  EBV causes MONONUCLEOSIS,causes,1.0,41  EPSTEIN BARR VIRUS  EBV causes infectious MONONUCLEOSIS and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,MONONUCLEOSIS,EPSTEIN BARR VIRUS  EBV
7082,HEMOCHROMATOSIS causes ARRHYTHMIAS,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7083,ARRHYTHMIAS causes HEMOCHROMATOSIS,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7084,ARRHYTHMIAS causes HEMOCHROMATOSIS,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7085,ARRHYTHMIAS causes HEMOCHROMATOSIS,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7086,HEMOCHROMATOSIS causes ARRHYTHMIAS,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7087,no_relation,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7088,HEMOCHROMATOSIS causes ARRHYTHMIAS,causes,1.0,"Rationale: • HEMOCHROMATOSIS may lead to dilated or restrictive cardiomyopathy, cardiac arrhythmias, or both, and the most common arrhythmias are atrial tachyARRHYTHMIAS, followed by ventricular premature beats and, rarely, ventricular tachycardia.",ARRHYTHMIAS,HEMOCHROMATOSIS
7089,DOXYCYCLINE causes PLASMODIUM FALCIPARUM MALARIA,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7090,no_relation,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7091,DOXYCYCLINE causes PLASMODIUM FALCIPARUM MALARIA,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7092,DOXYCYCLINE causes PLASMODIUM FALCIPARUM MALARIA,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7093,no_relation,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7094,no_relation,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7095,no_relation,causes,0.304603849540086,"A randomized, double blind, placebo controlled trial  Failure of DOXYCYCLINE as a causal prophylactic agent against PLASMODIUM FALCIPARUM MALARIA in healthy nonimmune volunteers  Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity.",PLASMODIUM FALCIPARUM MALARIA,DOXYCYCLINE
7096,GALACTOSEMIA causes EARLY CATARACT FORMATION,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7097,no_relation,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7098,GALACTOSEMIA causes EARLY CATARACT FORMATION,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7099,no_relation,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7100,no_relation,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7101,GALACTOSEMIA causes EARLY CATARACT FORMATION,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7102,GALACTOSEMIA causes EARLY CATARACT FORMATION,causes,0.875189948987367,• EARLY CATARACT FORMATION in GALACTOSEMIA can be reversed by early diagnosis and dietary intervention.,EARLY CATARACT FORMATION,GALACTOSEMIA
7103,no_relation,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7104,no_relation,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7105,NODE REENTRY (AVNRT REENTRY) causes TACHYCARDIA,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7106,no_relation,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7107,no_relation,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7108,no_relation,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7109,NODE REENTRY (AVNRT REENTRY) causes TACHYCARDIA,causes,0.666666666666667,"For almost all patients with PSVT, the underlying mechanism of the tachycardia is atrioventricular NODE REENTRY (AVNRT REENTRY) involving an accessory pathway (AVRT), or atrial TACHYCARDIA.",TACHYCARDIA,NODE REENTRY (AVNRT REENTRY)
7110,no_relation,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7111,no_relation,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7112,no_relation,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7113,no_relation,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7114,no_relation,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7115,SLE causes PERICARDITIS,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7116,no_relation,causes,0.845154254728516,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
7117,COXIELLA BURNETII causes Q FEVER,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7118,Q FEVER causes COXIELLA BURNETII,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7119,COXIELLA BURNETII causes Q FEVER,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7120,COXIELLA BURNETII causes Q FEVER,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7121,COXIELLA BURNETII causes Q FEVER,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7122,COXIELLA BURNETII causes Q FEVER,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7123,COXIELLA BURNETII causes Q FEVER,causes,0.961074462327142,Q Fever  Treatment of Q FEVER endocarditis   +    caused by  COXIELLA BURNETII ; used in conjunction with doxycycline.,Q FEVER,COXIELLA BURNETII
7124,BENIGN JUVENILE MELANOMA causes PAPULE,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7125,BENIGN JUVENILE MELANOMA causes PAPULE,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7126,BENIGN JUVENILE MELANOMA causes PAPULE,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7127,no_relation,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7128,no_relation,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7129,BENIGN JUVENILE MELANOMA causes PAPULE,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7130,BENIGN JUVENILE MELANOMA causes PAPULE,causes,0.9901475429766742,"Formerly called BENIGN JUVENILE MELANOMA spindle cell nevus usually arises in childhood as a pink or reddish brown, smooth or slightly scaly, firm PAPULE with a predilection for the face, especially the cheeks [ see  Figure 13.",PAPULE,BENIGN JUVENILE MELANOMA
7131,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7132,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7133,no_relation,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7134,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7135,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7136,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7137,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.9594032236002472,• Note that the differential diagnosis and work up may be slightly different for a patient with suspected endometriosis and primarily PELVIC PAIN than for a patient with suspected ENDOMETRIOSIS and primarily fertility concerns.,PELVIC PAIN,ENDOMETRIOSIS
7138,no_relation,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7139,no_relation,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7140,KLIPPEL TRENAUNAY WEBER SYNDROME causes CONGENITAL ARTERIOVENOUS FISTULAS,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7141,KLIPPEL TRENAUNAY WEBER SYNDROME causes CONGENITAL ARTERIOVENOUS FISTULAS,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7142,KLIPPEL TRENAUNAY WEBER SYNDROME causes CONGENITAL ARTERIOVENOUS FISTULAS,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7143,KLIPPEL TRENAUNAY WEBER SYNDROME causes CONGENITAL ARTERIOVENOUS FISTULAS,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7144,no_relation,causes,0.5625439504630121,"Rarely, varicose veins are part of KLIPPEL TRENAUNAY WEBER SYNDROME which includes CONGENITAL ARTERIOVENOUS FISTULAS and diffuse cutaneous capillary angiomas.",CONGENITAL ARTERIOVENOUS FISTULAS,KLIPPEL TRENAUNAY WEBER SYNDROME
7145,MYOCARDIAL INFARCTION causes CARVEDILOL REDUCED MORTALITY,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7146,no_relation,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7147,MYOCARDIAL INFARCTION causes CARVEDILOL REDUCED MORTALITY,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7148,MYOCARDIAL INFARCTION causes CARVEDILOL REDUCED MORTALITY,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7149,no_relation,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7150,MYOCARDIAL INFARCTION causes CARVEDILOL REDUCED MORTALITY,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7151,no_relation,causes,0.9830783046228492,CARVEDILOL REDUCED MORTALITY and morbidity caused by myocardial infarction in patients with left ventricular dysfunction  Keywords: MYOCARDIAL INFARCTION Left ventricular function Adrenergic beta agonists  ACP Journal Club.,MYOCARDIAL INFARCTION,CARVEDILOL REDUCED MORTALITY
7152,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION causes PURE 'SMALL FIBER' POLYNEUROPATHIES,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7153,no_relation,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7154,no_relation,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7155,PURE 'SMALL FIBER' POLYNEUROPATHIES causes AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7156,PURE 'SMALL FIBER' POLYNEUROPATHIES causes AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7157,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION causes PURE 'SMALL FIBER' POLYNEUROPATHIES,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7158,PURE 'SMALL FIBER' POLYNEUROPATHIES causes AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,causes,0.9615239476408228,Tendon reflexes are depressed more frequently in demyelinating or large fiber polyneuropathies and are not depressed in PURE 'SMALL FIBER' POLYNEUROPATHIES Physical exam  Autonomic dysfunction         Signs of AUTONOMIC NERVOUS SYSTEM DYSFUNCTION may be seen in polyneuropathy if autonomic fibers are involved,AUTONOMIC NERVOUS SYSTEM DYSFUNCTION,PURE 'SMALL FIBER' POLYNEUROPATHIES
7159,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7160,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7161,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7162,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7163,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7164,TULAREMIA causes FRANCISELLA TULARENSIS,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7165,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.9931270663228408,"SYN:   Treacher Collins syndrome    FRANCISELLA TULARENSIS    (                                audio )  [Edward Francis, Tulare County, California] A gram negative, aerobic, non spore forming bacillus that causes TULAREMIA in humans and animals.",TULAREMIA,FRANCISELLA TULARENSIS
7166,no_relation,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7167,SEPSIS causes SIRS,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7168,no_relation,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7169,no_relation,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7170,no_relation,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7171,SEPSIS causes SIRS,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7172,no_relation,causes,0.9113223768657672,Specific recommendation: • Distinguish SEPSIS from other causes of SIRS,SIRS,SEPSIS
7173,no_relation,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7174,no_relation,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7175,CPPD DISEASE causes SWOLLEN JOINT,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7176,CPPD DISEASE causes SWOLLEN JOINT,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7177,no_relation,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7178,CPPD DISEASE causes SWOLLEN JOINT,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7179,CPPD DISEASE causes SWOLLEN JOINT,causes,0.768221279597376,"• Consider aspirating a SWOLLEN JOINT to document the presence of CPPD crystals or document an arthritic process other than CPPD DISEASE e.g., septic arthritis or gout.",SWOLLEN JOINT,CPPD DISEASE
7180,no_relation,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7181,no_relation,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7182,no_relation,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7183,no_relation,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7184,no_relation,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7185,MIGRAINE causes HEADACHE,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7186,no_relation,causes,0.7330166661378309,"Early treatment, when the HEADACHE is mild, is much more effective than later treatment, when the MIGRAINE is moderate or severe in intensity.",HEADACHE,MIGRAINE
7187,MYCOBACTERIUM TUBERCULOSIS causes NONCAVITY PULMONARY TB,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7188,NONCAVITY PULMONARY TB causes MYCOBACTERIUM TUBERCULOSIS,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7189,MYCOBACTERIUM TUBERCULOSIS causes NONCAVITY PULMONARY TB,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7190,MYCOBACTERIUM TUBERCULOSIS causes NONCAVITY PULMONARY TB,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7191,MYCOBACTERIUM TUBERCULOSIS causes NONCAVITY PULMONARY TB,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7192,MYCOBACTERIUM TUBERCULOSIS causes NONCAVITY PULMONARY TB,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7193,MYCOBACTERIUM TUBERCULOSIS causes NONCAVITY PULMONARY TB,causes,0.997054485501582,"14  ATS, CDC, and IDSA state that rifapentine can be used in conjunction with isoniazid in the continuation phase in HIV seronegative patients with NONCAVITY PULMONARY TB caused by susceptible  MYCOBACTERIUM TUBERCULOSIS ; rifapentine is an alternative to rifampin for use in conjunction with isoniazid in the continuation phase.",NONCAVITY PULMONARY TB,MYCOBACTERIUM TUBERCULOSIS
7194,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7195,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7196,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7197,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7198,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7199,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7200,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,causes,0.997054485501582,"Included are infections caused by the pathogenic organism  RICKETTSIA RICKETTSII , which causes ROCKY MOUNTAIN SPOTTED FEVER",ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII
7201,EBV INFECTION causes EBV LYMPHOPROLIFERATIVE SYNDROMES,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7202,no_relation,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7203,no_relation,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7204,no_relation,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7205,EBV LYMPHOPROLIFERATIVE SYNDROMES causes EBV INFECTION,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7206,EBV LYMPHOPROLIFERATIVE SYNDROMES causes EBV INFECTION,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7207,no_relation,causes,0.896258159530272,69  EBV INFECTION in the Immunocompromised Host  Immunocompromised hosts are susceptible to overwhelming EBV LYMPHOPROLIFERATIVE SYNDROMES.,EBV INFECTION,EBV LYMPHOPROLIFERATIVE SYNDROMES
7208,KALLMANN SYNDROME causes ANOSMIA,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7209,KALLMANN SYNDROME causes ANOSMIA,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7210,no_relation,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7211,no_relation,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7212,no_relation,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7213,no_relation,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7214,no_relation,causes,0.625,This disorder is termed KALLMANN SYNDROME when it is accompanied by ANOSMIA and has also been termed idiopathic hypogonadotropic hypogonadism (IHH.,ANOSMIA,KALLMANN SYNDROME
7215,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7216,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7217,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7218,no_relation,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7219,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7220,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7221,no_relation,causes,0.997054485501582,"INFECTIOUS MONONUCLEOSIS  Clinical features   Patients usually present with fever, pharyngitis, and LYMPHADENOPATHY",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
7222,PHEOCHROMOCYTOMAS causes HYPERTENSION,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7223,HYPERTENSION causes PHEOCHROMOCYTOMAS,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7224,no_relation,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7225,no_relation,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7226,no_relation,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7227,no_relation,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7228,PHEOCHROMOCYTOMAS causes HYPERTENSION,causes,0.953462589245592,"• Clinical spells and HYPERTENSION from circulating catecholamines are insufficiently sensitive to be used as primary indicators of PHEOCHROMOCYTOMAS but, when present, may herald life threatening crises.",HYPERTENSION,PHEOCHROMOCYTOMAS
7229,ACUTE ARTERITIS WITH EOSINOPHILIA causes HYPEREOSINOPHILIC SYNDROME,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7230,ACUTE ARTERITIS WITH EOSINOPHILIA causes HYPEREOSINOPHILIC SYNDROME,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7231,HYPEREOSINOPHILIC SYNDROME causes ACUTE ARTERITIS WITH EOSINOPHILIA,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7232,ACUTE ARTERITIS WITH EOSINOPHILIA causes HYPEREOSINOPHILIC SYNDROME,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7233,ACUTE ARTERITIS WITH EOSINOPHILIA causes HYPEREOSINOPHILIC SYNDROME,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7234,HYPEREOSINOPHILIC SYNDROME causes ACUTE ARTERITIS WITH EOSINOPHILIA,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7235,HYPEREOSINOPHILIC SYNDROME causes ACUTE ARTERITIS WITH EOSINOPHILIA,causes,0.9237604307034007,"Loffler's syndrome (a subcategory of HYPEREOSINOPHILIC SYNDROME with primary cardiac involvement), which occurs in the tropics, begins as an ACUTE ARTERITIS WITH EOSINOPHILIA followed by thrombus formation on the endocardium, chordae, and atrioventricular (AV) valves, progressing to fibrosis.",ACUTE ARTERITIS WITH EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME
7236,CHRONIC PAIN FROM BRACHIAL PLEXUS causes RSD,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7237,CHRONIC PAIN FROM BRACHIAL PLEXUS causes RSD,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7238,no_relation,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7239,CHRONIC PAIN FROM BRACHIAL PLEXUS causes RSD,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7240,no_relation,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7241,CHRONIC PAIN FROM BRACHIAL PLEXUS causes RSD,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7242,RSD causes CHRONIC PAIN FROM BRACHIAL PLEXUS,causes,0.9237604307034007,"CHRONIC PAIN FROM BRACHIAL PLEXUS injury becomes RSD once additional, RSD defining symptoms develop.",CHRONIC PAIN FROM BRACHIAL PLEXUS,RSD
7243,ECLAMPSIA causes COMPLICATION,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7244,COMPLICATION causes ECLAMPSIA,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7245,no_relation,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7246,ECLAMPSIA causes COMPLICATION,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7247,ECLAMPSIA causes COMPLICATION,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7248,ECLAMPSIA causes COMPLICATION,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7249,no_relation,causes,0.5,ECLAMPSIA is the most serious COMPLICATION of pregnancy induced hypertension (PIH.,COMPLICATION,ECLAMPSIA
7250,ELEVATED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7251,ELEVATED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7252,ELEVATED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7253,ELEVATED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7254,PAPILLEDEMA causes ELEVATED INTRACRANIAL PRESSURE,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7255,ELEVATED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7256,ELEVATED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.970142500145332,PAPILLEDEMA is a sign of ELEVATED INTRACRANIAL PRESSURE and is almost always bilateral.,PAPILLEDEMA,ELEVATED INTRACRANIAL PRESSURE
7257,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7258,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7259,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7260,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7261,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7262,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7263,no_relation,causes,0.6575959492214289,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
7264,LEPTOSPIRA INTERROGANS causes LEPTOSPIROSIS,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7265,LEPTOSPIRA INTERROGANS causes LEPTOSPIROSIS,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7266,LEPTOSPIROSIS causes LEPTOSPIRA INTERROGANS,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7267,LEPTOSPIRA INTERROGANS causes LEPTOSPIROSIS,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7268,LEPTOSPIROSIS causes LEPTOSPIRA INTERROGANS,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7269,no_relation,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7270,LEPTOSPIRA INTERROGANS causes LEPTOSPIROSIS,causes,0.9901475429766742,"physician, 1848 1916] LEPTOSPIROSIS caused by any one of several serotypes of  LEPTOSPIRA INTERROGANS  such as  L. icterohemorrhagica  in rats,  L. pomona  in swine, or  L. canicola  in dogs.",LEPTOSPIROSIS,LEPTOSPIRA INTERROGANS
7271,no_relation,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7272,no_relation,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7273,no_relation,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7274,LOW BACK PAIN causes FIBROMYALGIA,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7275,no_relation,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7276,no_relation,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7277,FIBROMYALGIA causes LOW BACK PAIN,causes,0.5669467095138411,"• Systematic reviews of treatment modalities for osteoarthritis ( 28 ;  29 ), rheumatoid arthritis ( 30 ;  31 ;  32 ;  33 ), FIBROMYALGIA ( 34 ), and LOW BACK PAIN ( 35 ;  36 ;  37 ) confirm that each of these specific pain syndromes responds to specific treatment modalities and that accurate diagnosis is important to guide optimal pain management.",LOW BACK PAIN,FIBROMYALGIA
7278,RSD causes CENTRAL POSTSTROKE PAIN,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7279,RSD causes CENTRAL POSTSTROKE PAIN,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7280,no_relation,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7281,no_relation,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7282,no_relation,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7283,RSD causes CENTRAL POSTSTROKE PAIN,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7284,RSD causes CENTRAL POSTSTROKE PAIN,causes,0.577350269189626,"• The complex symptoms of RSD and their significant overlap with neurologic and rheumatologic conditions justify a neurologic and possibly rheumatologic evaluation in most cases to help distinguish RSD from neuropathy, radiculopathy, plexopathy, or CENTRAL POSTSTROKE PAIN and from rheumatic or collagen vascular disease.",CENTRAL POSTSTROKE PAIN,RSD
7285,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7286,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7287,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7288,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7289,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7290,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7291,BABESIA MICROTI causes BABESIOSIS,causes,0.997054485501582,Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
7292,DRAVET SYNDROME causes SEIZURE,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7293,DRAVET SYNDROME causes SEIZURE,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7294,DRAVET SYNDROME causes SEIZURE,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7295,no_relation,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7296,DRAVET SYNDROME causes SEIZURE,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7297,DRAVET SYNDROME causes SEIZURE,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7298,SEIZURE causes DRAVET SYNDROME,causes,0.994134846772434,Treatment/Management  Children and Adults with DRAVET SYNDROME experience multiple SEIZURE types that are resistant to most anti epileptic medications.,SEIZURE,DRAVET SYNDROME
7299,no_relation,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7300,no_relation,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7301,no_relation,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7302,AMPHOTERICIN B LIPID COMPLEX causes FUNGAL INFECTIONS,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7303,FUNGAL INFECTIONS causes AMPHOTERICIN B LIPID COMPLEX,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7304,AMPHOTERICIN B LIPID COMPLEX causes FUNGAL INFECTIONS,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7305,AMPHOTERICIN B LIPID COMPLEX causes FUNGAL INFECTIONS,causes,0.5656854249492379,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
7306,no_relation,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7307,YELLOW NAIL SYNDROME causes YELLOW NAILS,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7308,YELLOW NAILS causes YELLOW NAIL SYNDROME,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7309,no_relation,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7310,YELLOW NAIL SYNDROME causes YELLOW NAILS,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7311,YELLOW NAILS causes YELLOW NAIL SYNDROME,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7312,YELLOW NAIL SYNDROME causes YELLOW NAILS,causes,0.7947194142390258,"all patients with ovarian mass, ascites, and pleural effusion are inoperable; diagnosis requires disappearance of ascites and effusion postoperatively YELLOW NAIL SYNDROME Triad of pleural effusion, lymphedema, and YELLOW NAILS; elements may appear decades apart; pleural fluid has relatively high protein but low LDH; effusion tends to recur, and there is no pleuritic chest pain   Table 60 3.",YELLOW NAIL SYNDROME,YELLOW NAILS
7313,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7314,no_relation,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7315,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7316,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7317,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7318,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7319,LEPROSY causes MYCOBACTERIUM LEPRAE,causes,1.0,"Hansen's bacillus    (            audio )  [Gerhard H. A. Hansen, Norwegian physician, 1841 1912]  MYCOBACTERIUM LEPRAE  the cause of LEPROSY which Hansen discovered in 1871.",LEPROSY,MYCOBACTERIUM LEPRAE
7320,no_relation,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7321,no_relation,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7322,DEXAMETHASONE SUPPRESSION causes CUSHING'S SYNDROME,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7323,CUSHING'S SYNDROME causes DEXAMETHASONE SUPPRESSION,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7324,no_relation,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7325,no_relation,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7326,no_relation,causes,0.8090398349558909,• CUSHING'S SYNDROME patients with normal UFC levels or DEXAMETHASONE SUPPRESSION may have elevated midnight plasma cortisol ( 49 ;  50.,CUSHING'S SYNDROME,DEXAMETHASONE SUPPRESSION
7327,SAW PALMETTO causes BENIGN PROSTATIC HYPERPLASIA,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7328,no_relation,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7329,no_relation,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7330,no_relation,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7331,no_relation,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7332,no_relation,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7333,no_relation,causes,0.38490017945975,SAW PALMETTO did not differ from placebo for BENIGN PROSTATIC HYPERPLASIA in men  General Internal Medicine/Family Practitioner/General Practitioner Nephrology  About Star Ratings  Keywords: Androgen antagonists Plant extracts Prostatic hyperplasia  ACP Journal Club.,BENIGN PROSTATIC HYPERPLASIA,SAW PALMETTO
7334,ERYSIPELOTHRIX RHUSIOPATHIAE causes ERYSIPELOID,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7335,no_relation,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7336,ERYSIPELOID causes ERYSIPELOTHRIX RHUSIOPATHIAE,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7337,ERYSIPELOTHRIX RHUSIOPATHIAE causes ERYSIPELOID,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7338,ERYSIPELOTHRIX RHUSIOPATHIAE causes ERYSIPELOID,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7339,ERYSIPELOTHRIX RHUSIOPATHIAE causes ERYSIPELOID,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7340,ERYSIPELOTHRIX RHUSIOPATHIAE causes ERYSIPELOID,causes,0.99654575824488,"1  >     Uncomplicated Infections (e.g., ERYSIPELOID Caused by ERYSIPELOTHRIX RHUSIOPATHIAE  IM:  Penicillin G procaine: 600,000 to 1 million units daily.",ERYSIPELOID,ERYSIPELOTHRIX RHUSIOPATHIAE
7341,DISEASE (HD causes DEMENTIA,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7342,DISEASE (HD causes DEMENTIA,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7343,DISEASE (HD causes DEMENTIA,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7344,no_relation,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7345,no_relation,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7346,no_relation,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7347,DISEASE (HD causes DEMENTIA,causes,0.8867963503478641,Hyperkinetic Movement Disorders  HUNTINGTON DISEASE  Huntington DISEASE (HD is an autosomal dominant neurodegenerative condition characterized by an adult onset choreiform disorder and DEMENTIA,DEMENTIA,DISEASE (HD
7348,CNS causes MENINGITIS,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7349,CNS causes MENINGITIS,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7350,CNS causes MENINGITIS,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7351,no_relation,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7352,CNS causes MENINGITIS,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7353,no_relation,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7354,CNS causes MENINGITIS,causes,0.9878291611472622,"Evidence: • Although enterovirus affecting the CNS primarily causes MENINGITIS cases of enterovirus presenting as chronic, recurring encephalitis have been reported in patients with deficiencies in humoral immunity ( 22.",CNS,MENINGITIS
7355,no_relation,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7356,no_relation,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7357,A OR B VIRUS IN ADULTS causes AND B VIRUS INFECTIONS,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7358,A OR B VIRUS IN ADULTS causes AND B VIRUS INFECTIONS,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7359,A OR B VIRUS IN ADULTS causes AND B VIRUS INFECTIONS,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7360,A OR B VIRUS IN ADULTS causes AND B VIRUS INFECTIONS,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7361,AND B VIRUS INFECTIONS causes A OR B VIRUS IN ADULTS,causes,0.7293249574894731,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
7362,no_relation,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7363,MYELODYSPLASTIC SYNDROME causes HYPERCELLULAR BONE MARROW,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7364,MYELODYSPLASTIC SYNDROME causes HYPERCELLULAR BONE MARROW,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7365,HYPERCELLULAR BONE MARROW causes MYELODYSPLASTIC SYNDROME,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7366,no_relation,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7367,MYELODYSPLASTIC SYNDROME causes HYPERCELLULAR BONE MARROW,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7368,HYPERCELLULAR BONE MARROW causes MYELODYSPLASTIC SYNDROME,causes,0.625,"MYELODYSPLASTIC SYNDROME involves a group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a HYPERCELLULAR BONE MARROW and a high risk of conversion to AML.",HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
7369,no_relation,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7370,no_relation,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7371,no_relation,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7372,no_relation,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7373,HYPERTENSION IN MEN IIA causes PHEOCHROMOCYTOMA,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7374,PHEOCHROMOCYTOMA causes HYPERTENSION IN MEN IIA,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7375,PHEOCHROMOCYTOMA causes HYPERTENSION IN MEN IIA,causes,0.8082903768654759,"HYPERTENSION IN MEN IIA patients with PHEOCHROMOCYTOMA is more often paroxysmal than sustained, in contrast to the usual sporadic case.",HYPERTENSION IN MEN IIA,PHEOCHROMOCYTOMA
7376,METASTASES causes METASTATIC LESION,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7377,no_relation,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7378,METASTASES causes METASTATIC LESION,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7379,no_relation,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7380,METASTATIC LESION causes METASTASES,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7381,METASTASES causes METASTATIC LESION,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7382,METASTASES causes METASTATIC LESION,causes,0.534522483824849,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
7383,ENTAMOEBA HISTOLYTICA causes AMEBIASIS,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7384,ENTAMOEBA HISTOLYTICA causes AMEBIASIS,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7385,ENTAMOEBA HISTOLYTICA causes AMEBIASIS,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7386,AMEBIASIS causes ENTAMOEBA HISTOLYTICA,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7387,ENTAMOEBA HISTOLYTICA causes AMEBIASIS,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7388,ENTAMOEBA HISTOLYTICA causes AMEBIASIS,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7389,AMEBIASIS causes ENTAMOEBA HISTOLYTICA,causes,0.99654575824488,Uses  Amebiasis  Treatment of AMEBIASIS caused by  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
7390,ECHINOCOCCUS GRANULOSUS causes HYDATID DISEASE,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7391,no_relation,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7392,ECHINOCOCCUS GRANULOSUS causes HYDATID DISEASE,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7393,ECHINOCOCCUS GRANULOSUS causes HYDATID DISEASE,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7394,ECHINOCOCCUS GRANULOSUS causes HYDATID DISEASE,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7395,ECHINOCOCCUS GRANULOSUS causes HYDATID DISEASE,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7396,ECHINOCOCCUS GRANULOSUS causes HYDATID DISEASE,causes,0.997054485501582,"In humans,  T. solium  causes cysticercosis, and  ECHINOCOCCUS GRANULOSUS  and  E. multilocularis cause  HYDATID DISEASE",HYDATID DISEASE,ECHINOCOCCUS GRANULOSUS
7397,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7398,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7399,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7400,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7401,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7402,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7403,CYCLOSPORINE causes HYPERTENSION,causes,0.9897433186107868,"CYCLOSPORINE can cause HYPERTENSION renal toxicity, hypomagnesemia, hypophosphatemia, vitiligo, tremors, hypertrichosis, susceptibility to  Pneumocystis carinii  pneumonia (PCP), and gingival hyperplasia.",HYPERTENSION,CYCLOSPORINE
7404,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7405,no_relation,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7406,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7407,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7408,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7409,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7410,no_relation,causes,0.878114079917523,"HTLV 1 causes adult T cell leukemia/lymphoma (ATL), T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
7411,no_relation,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7412,PSYCHOTROPIC DRUGS causes OVERDOSE,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7413,PSYCHOTROPIC DRUGS causes OVERDOSE,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7414,PSYCHOTROPIC DRUGS causes OVERDOSE,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7415,PSYCHOTROPIC DRUGS causes OVERDOSE,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7416,PSYCHOTROPIC DRUGS causes OVERDOSE,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7417,no_relation,causes,0.911684611677103,Cutaneous reactions to PSYCHOTROPIC DRUGS; atrial fibrillation and anabolic steroids; accidental olanzapine OVERDOSE in a child.,OVERDOSE,PSYCHOTROPIC DRUGS
7418,DIARRHEA causes ANTIBIOTIC ASSOCIATED DIARRHEA,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7419,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7420,no_relation,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7421,no_relation,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7422,no_relation,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7423,no_relation,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7424,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.738548945875996,"100 ,   120 ,   121    Clostridium difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefadroxil, and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7425,CAUSES AND NEURALGIA TH causes EAR PAIN HAS,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7426,CAUSES AND NEURALGIA TH causes EAR PAIN HAS,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7427,EAR PAIN HAS causes CAUSES AND NEURALGIA TH,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7428,EAR PAIN HAS causes CAUSES AND NEURALGIA TH,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7429,EAR PAIN HAS causes CAUSES AND NEURALGIA TH,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7430,no_relation,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7431,no_relation,causes,0.98058067569092,C]  Specific recommendation:  Consult an ENT specialist if the patient has: ; Pain in the ear or throat ; Constant facial pain with sinus tenderness ; Foul nasal discharge ; Facial swelling  Rationale:  EAR PAIN HAS many common otologic CAUSES AND NEURALGIA THat involves the ear is rare.,EAR PAIN HAS,CAUSES AND NEURALGIA TH
7432,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7433,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7434,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7435,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7436,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7437,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7438,no_relation,causes,0.480384461415261,"relapse ; Identifying and treating suboptimal responses (i.e., treatment failure, incomplete response, and DRUG TOXICITY ; Managing MEDICATION SIDE EFFECTS especially myelosuppression and vertebral compression.",MEDICATION SIDE EFFECTS,DRUG TOXICITY
7439,VIRUS INDUCED DEMYELINATION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7440,VIRUS INDUCED DEMYELINATION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7441,no_relation,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7442,VIRUS INDUCED DEMYELINATION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7443,no_relation,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7444,no_relation,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7445,VIRUS INDUCED DEMYELINATION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.956182887467515,VIRUS INDUCED DEMYELINATION includes progressive multifocal leukoencephalopathy and SUBACUTE SCLEROSING PANENCEPHALITIS,SUBACUTE SCLEROSING PANENCEPHALITIS,VIRUS INDUCED DEMYELINATION
7446,no_relation,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7447,FIBROSITIS causes PAIN,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7448,FIBROSITIS causes PAIN,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7449,FIBROSITIS causes PAIN,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7450,FIBROSITIS causes PAIN,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7451,no_relation,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7452,FIBROSITIS causes PAIN,causes,0.994936676326182,"SYN:   fibromyositis ;  FIBROSITIS   SEE:   table  PATIENT CARE: Fibromyalgia is a condition in which objective findings are limited, but subjective fatigue, PAIN and distress are often significant.",PAIN,FIBROSITIS
7453,no_relation,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7454,no_relation,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7455,no_relation,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7456,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA causes LIVER ENLARGEMENT,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7457,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA causes LIVER ENLARGEMENT,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7458,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA causes LIVER ENLARGEMENT,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7459,LIVER ENLARGEMENT causes 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA,causes,0.979957887012223,"Symptoms  Galactose 1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA is characterized by poor growth in children, mental retardation, speech abnormality, vision impairment (due to formation of cataract) and LIVER ENLARGEMENT (which may be fatal.",LIVER ENLARGEMENT,1 PHOSPHATE URIDYLYLTRANSFERASE GALACTOSEMIA
7460,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7461,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7462,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7463,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7464,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7465,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7466,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.976546150525391,Endometriosis lesions grow when serum estradiol concentration is in the premenopausal range (30 to 300 pg/mL) and regress when estradiol levels are in the menopausal range (  40  Progestins  High dose synthetic progestins have been demonstrated in multiple clinical trials to be effective in the treatment of PELVIC PAIN caused by ENDOMETRIOSIS [ see  Table 5.,PELVIC PAIN,ENDOMETRIOSIS
7467,no_relation,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7468,ETFORMIN C causes ENAL FAILURE,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7469,no_relation,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7470,no_relation,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7471,no_relation,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7472,ETFORMIN C causes ENAL FAILURE,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7473,ENAL FAILURE causes ETFORMIN C,causes,0.950255268139496," METFORMIN Can accumulate in patients who develop rENAL FAILURE and metformin accumulation can lead to lactic acidosis, which can be fatal.",ENAL FAILURE,ETFORMIN C
7474,no_relation,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7475,CARBAMAZEPINE causes TRIGEMINAL NEURALGIA,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7476,no_relation,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7477,CARBAMAZEPINE causes TRIGEMINAL NEURALGIA,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7478,no_relation,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7479,CARBAMAZEPINE causes TRIGEMINAL NEURALGIA,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7480,CARBAMAZEPINE causes TRIGEMINAL NEURALGIA,causes,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
7481,DRUG INDUCED NEUTROPENIA causes NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7482,DRUG INDUCED NEUTROPENIA causes NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7483,DRUG INDUCED NEUTROPENIA causes NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7484,NEUTROPENIA causes DRUG INDUCED NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7485,DRUG INDUCED NEUTROPENIA causes NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7486,DRUG INDUCED NEUTROPENIA causes NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7487,DRUG INDUCED NEUTROPENIA causes NEUTROPENIA,causes,1.0,DRUG INDUCED NEUTROPENIA is one of the most common causes of NEUTROPENIA,NEUTROPENIA,DRUG INDUCED NEUTROPENIA
7488,no_relation,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7489,no_relation,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7490,no_relation,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7491,CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA causes KSS,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7492,no_relation,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7493,no_relation,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7494,no_relation,causes,0.520755643923296,"In persons older than 20 years in whom ophthalmoplegia is the predominant phenotype, KSS is classified as CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (CPEO.",CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KSS
7495,CHRONIC PAIN FOLLOWING HERPES causes POSTHERPETIC NEURALGIA,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7496,no_relation,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7497,CHRONIC PAIN FOLLOWING HERPES causes POSTHERPETIC NEURALGIA,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7498,no_relation,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7499,no_relation,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7500,CHRONIC PAIN FOLLOWING HERPES causes POSTHERPETIC NEURALGIA,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7501,no_relation,causes,0.929981109950554,Involvement of the tip of the nose in the zoster rash is a strong predictor of herpes ophthalmicus.[46]  POSTHERPETIC NEURALGIA   a condition of CHRONIC PAIN FOLLOWING HERPES zoster.,CHRONIC PAIN FOLLOWING HERPES,POSTHERPETIC NEURALGIA
7502,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7503,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7504,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7505,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7506,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7507,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7508,no_relation,causes,0.6154574548966639,Physical findings in the FEET of patients with BILATERAL FOOT PAIN from small fiber polyneuropathy.,FEET,BILATERAL FOOT PAIN
7509,EWING SARCOMA causes FEVER,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7510,no_relation,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7511,EWING SARCOMA causes FEVER,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7512,EWING SARCOMA causes FEVER,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7513,EWING SARCOMA causes FEVER,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7514,no_relation,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7515,EWING SARCOMA causes FEVER,causes,0.979957887012223,"Diagnosis  Patients with Ewing sarcoma present with fever, weight loss, malaise, poorly localized bone pain, and a rapidly enlarging mass. With leukocytosis, FEVER and an elevated erythrocyte sedimentation rate, EWING SARCOMA mimics osteomyelitis.",FEVER,EWING SARCOMA
7516,M TUBERCULOSIS causes DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7517,M TUBERCULOSIS causes DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7518,no_relation,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7519,M TUBERCULOSIS causes DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7520,M TUBERCULOSIS causes DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7521,M TUBERCULOSIS causes DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7522,M TUBERCULOSIS causes DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,causes,0.9760921603577252,"Longer courses of therapy are required for DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT disease (i.e., disease caused by  M TUBERCULOSIS  that is resistant to at least isoniazid and rifampin).Treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase.",DRUG RESISTANT TUBERCULOSIS ESPECIALLY MULTIDRUG RESISTANT,M TUBERCULOSIS
7523,COXIELLA BURNETII causes Q FEVER ENDOCARDITIS,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7524,COXIELLA BURNETII causes Q FEVER ENDOCARDITIS,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7525,COXIELLA BURNETII causes Q FEVER ENDOCARDITIS,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7526,no_relation,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7527,COXIELLA BURNETII causes Q FEVER ENDOCARDITIS,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7528,COXIELLA BURNETII causes Q FEVER ENDOCARDITIS,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7529,COXIELLA BURNETII causes Q FEVER ENDOCARDITIS,causes,0.9918365981341758,"568 ,   625   Has been effective for Q FEVER ENDOCARDITIS caused by  COXIELLA BURNETII    +     625   and Mediterranean spotted fever caused by  Rickettsia conorii    +.",Q FEVER ENDOCARDITIS,COXIELLA BURNETII
7530,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7531,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7532,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7533,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7534,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7535,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7536,FUNGI causes FUNGAL INFECTION,causes,1.0,"bronchomycosis    (                      audio )  [&dblprime; +  mykes , fungus, +  osis , condition] Any FUNGAL INFECTION of the bronchi or bronchial tubes, usually caused by FUNGI of the genus  Candida.",FUNGAL INFECTION,FUNGI
7537,HUMAN EWINGII EHRLICHIOSIS causes EHRLICHIA CHAFFEENSIS,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7538,no_relation,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7539,HUMAN EWINGII EHRLICHIOSIS causes EHRLICHIA CHAFFEENSIS,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7540,no_relation,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7541,HUMAN EWINGII EHRLICHIOSIS causes EHRLICHIA CHAFFEENSIS,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7542,EHRLICHIA CHAFFEENSIS causes HUMAN EWINGII EHRLICHIOSIS,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7543,HUMAN EWINGII EHRLICHIOSIS causes EHRLICHIA CHAFFEENSIS,causes,0.964901281354015,"Six species are now implicated in human diseases [ see  Table 1  ]:  EHRLICHIA CHAFFEENSIS , which causes human monocytic ehrlichiosis;  Anaplasma phagocytophilum , which causes human anaplasmosis;  Ehrlichia ewingii , which causes HUMAN EWINGII EHRLICHIOSIS;  Ehrlichia canis ;  Ehrlichia ruminantium ; and  Neorickettsia sennetsu.",HUMAN EWINGII EHRLICHIOSIS,EHRLICHIA CHAFFEENSIS
7544,RICKETTSIA TSUTSUGAMUSHI causes MITE BORNE DISEASE,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7545,RICKETTSIA TSUTSUGAMUSHI causes MITE BORNE DISEASE,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7546,MITE BORNE DISEASE causes RICKETTSIA TSUTSUGAMUSHI,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7547,RICKETTSIA TSUTSUGAMUSHI causes MITE BORNE DISEASE,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7548,RICKETTSIA TSUTSUGAMUSHI causes MITE BORNE DISEASE,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7549,MITE BORNE DISEASE causes RICKETTSIA TSUTSUGAMUSHI,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7550,RICKETTSIA TSUTSUGAMUSHI causes MITE BORNE DISEASE,causes,0.9931270663228408,SCRUB TYPHUS  (Tsutsugamushi Disease; Mite Borne Typhus; Tropical Typhus)  Scrub typhus is a MITE BORNE DISEASE caused by  RICKETTSIA TSUTSUGAMUSHI.,MITE BORNE DISEASE,RICKETTSIA TSUTSUGAMUSHI
7551,no_relation,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7552,no_relation,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7553,no_relation,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7554,DIGITALIS causes HEART FAILURE,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7555,no_relation,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7556,no_relation,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7557,DIGITALIS causes HEART FAILURE,causes,0.583459965991578,"Exclusion criteria were coronary disease, HEART FAILURE left ventricular systolic dysfunction, cardiomyopathy, valvular or congenital heart disease, past renal or cardiac transplantation, atrial fibrillation, DIGITALIS use, pacemaker or defibrillator placement, or end stage renal disease.",HEART FAILURE,DIGITALIS
7558,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7559,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7560,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7561,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7562,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7563,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7564,no_relation,causes,0.707106781186547,"1   If the tachycardia is regular and comparison with a baseline electrocardiogram shows that the QRS complex is identical to that during sinus rhythm, the patient may have supraventricular TACHYCARDIA (SVT) with bundle branch block (BBB) or antidromic ATRIOVENTRICULAR REENTRANT TACHYCARDIA (AVRT.",TACHYCARDIA,ATRIOVENTRICULAR REENTRANT TACHYCARDIA
7565,BLADDER CANCER causes HEMATURIA,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7566,BLADDER CANCER causes HEMATURIA,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7567,BLADDER CANCER causes HEMATURIA,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7568,HEMATURIA causes BLADDER CANCER,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7569,no_relation,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7570,HEMATURIA causes BLADDER CANCER,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7571,no_relation,causes,0.8082903768654759,"• HEMATURIA can precede the diagnosis of BLADDER CANCER by several years according to a retrospective review of 20,571 men and women enrolled in a large prepaid health plan in California ( 53.",HEMATURIA,BLADDER CANCER
7572,PROMYELOCYTIC LEUKEMIA (APL) causes DISSEMINATED INTRAVASCULAR COAGULATION,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7573,no_relation,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7574,PROMYELOCYTIC LEUKEMIA (APL) causes DISSEMINATED INTRAVASCULAR COAGULATION,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7575,no_relation,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7576,no_relation,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7577,no_relation,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7578,no_relation,causes,0.784464540552736,"In acute PROMYELOCYTIC LEUKEMIA (APL) and some other cases of AML, DISSEMINATED INTRAVASCULAR COAGULATION (DIC) may be present on diagnosis and may worsen as leukemic cell lysis releases procoagulant.",DISSEMINATED INTRAVASCULAR COAGULATION,PROMYELOCYTIC LEUKEMIA (APL)
7579,CHEMICAL ASPIRATION PNEUMONIAS causes RESPIRATORY TRACT,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7580,no_relation,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7581,no_relation,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7582,CHEMICAL ASPIRATION PNEUMONIAS causes RESPIRATORY TRACT,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7583,RESPIRATORY TRACT causes CHEMICAL ASPIRATION PNEUMONIAS,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7584,no_relation,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7585,no_relation,causes,0.6837634587578281,"CHEMICAL ASPIRATION PNEUMONIAS often occur because of silent reflux regurgitation, resulting in acidic stomach contents and gram negative organisms entering the RESPIRATORY TRACT",RESPIRATORY TRACT,CHEMICAL ASPIRATION PNEUMONIAS
7586,HEPARIN causes DIC,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7587,HEPARIN causes DIC,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7588,HEPARIN causes DIC,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7589,DIC causes HEPARIN,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7590,HEPARIN causes DIC,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7591,no_relation,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7592,HEPARIN causes DIC,causes,0.938314863256836,DIC occurred in 9 of 16 (56%) patients who received heparin compared to 1 of 16 (6%) patients who did not receive HEPARIN.,DIC,HEPARIN
7593,no_relation,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7594,no_relation,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7595,INFECTION causes MEASLES MUMPS RUBELLA,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7596,no_relation,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7597,no_relation,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7598,MEASLES MUMPS RUBELLA causes INFECTION,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7599,no_relation,causes,0.917662935482247,"Naturally occurring measles can cause severe, often fatal, INFECTION in AIDS patients, and MEASLES MUMPS RUBELLA rarely causes serious complications.",MEASLES MUMPS RUBELLA,INFECTION
7600,UNSTABLE ANGINA causes CHEST PAIN,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7601,no_relation,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7602,no_relation,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7603,UNSTABLE ANGINA causes CHEST PAIN,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7604,UNSTABLE ANGINA causes CHEST PAIN,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7605,UNSTABLE ANGINA causes CHEST PAIN,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7606,CHEST PAIN causes UNSTABLE ANGINA,causes,0.986393923832143,"CONCLUSION  Among patients who were diagnosed for the first time with UNSTABLE ANGINA after presenting to the emergency department with CHEST PAIN women received fewer cardiac procedures than did men within 90 days; after adjustment for baseline characteristics, men experienced worse outcomes during follow up.",CHEST PAIN,UNSTABLE ANGINA
7607,MENTAL RETARDATION causes KINKY HAIR DISEASE,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7608,KINKY HAIR DISEASE causes MENTAL RETARDATION,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7609,KINKY HAIR DISEASE causes MENTAL RETARDATION,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7610,MENTAL RETARDATION causes KINKY HAIR DISEASE,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7611,KINKY HAIR DISEASE causes MENTAL RETARDATION,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7612,no_relation,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7613,KINKY HAIR DISEASE causes MENTAL RETARDATION,causes,0.986393923832143,"KINKY HAIR DISEASE    A congenital syndrome caused by an autosomal recessive gene, consisting of short, sparse, often poorly pigmented, kinky hair and physical and MENTAL RETARDATION",MENTAL RETARDATION,KINKY HAIR DISEASE
7614,HEMOTHERAPY INDUCED NEUTROPENIA causes EUTROPENIA I,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7615,HEMOTHERAPY INDUCED NEUTROPENIA causes EUTROPENIA I,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7616,no_relation,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7617,no_relation,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7618,no_relation,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7619,no_relation,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7620,no_relation,causes,0.5962847939999439,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
7621,CLASSICAL NODULAR SCLEROSIS causes MEDIASTINAL LYMPHADENOPATHY,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7622,CLASSICAL NODULAR SCLEROSIS causes MEDIASTINAL LYMPHADENOPATHY,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7623,no_relation,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7624,no_relation,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7625,no_relation,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7626,CLASSICAL NODULAR SCLEROSIS causes MEDIASTINAL LYMPHADENOPATHY,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7627,CLASSICAL NODULAR SCLEROSIS causes MEDIASTINAL LYMPHADENOPATHY,causes,0.9578262852211508,"MEDIASTINAL LYMPHADENOPATHY is common at presentation, especially in patients 15 to 35 years of age with CLASSICAL NODULAR SCLEROSIS",MEDIASTINAL LYMPHADENOPATHY,CLASSICAL NODULAR SCLEROSIS
7628,YERSINIA PESTIS causes PLAGUE,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7629,YERSINIA PESTIS causes PLAGUE,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7630,YERSINIA PESTIS causes PLAGUE,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7631,no_relation,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7632,PLAGUE causes YERSINIA PESTIS,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7633,PLAGUE causes YERSINIA PESTIS,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7634,YERSINIA PESTIS causes PLAGUE,causes,0.936382183834624,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
7635,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7636,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7637,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7638,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7639,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7640,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7641,no_relation,causes,0.707106781186547,"b ,   c ,   144  A positive reaction may indicate latent infection, prior infection, and/or  M TUBERCULOSIS  disease and may not indicate ACTIVE TB;  c ,   d   individuals with a positive reaction should be considered positive by current public health guidelines and referred for further medical evaluation.",ACTIVE TB,M TUBERCULOSIS
7642,no_relation,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7643,no_relation,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7644,WEIGHT LOSS causes CELIACS,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7645,no_relation,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7646,no_relation,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7647,CELIACS causes WEIGHT LOSS,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7648,no_relation,causes,0.975900072948533,15   Many patients today are identified as CELIACS who do not manifest the classic symptoms of steatorrhea and WEIGHT LOSS,WEIGHT LOSS,CELIACS
7649,LISTERIOSIS causes LISTERIA MONOCYTOGENES,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7650,LISTERIOSIS causes LISTERIA MONOCYTOGENES,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7651,LISTERIA MONOCYTOGENES causes LISTERIOSIS,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7652,LISTERIA MONOCYTOGENES causes LISTERIOSIS,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7653,LISTERIA MONOCYTOGENES causes LISTERIOSIS,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7654,LISTERIA MONOCYTOGENES causes LISTERIOSIS,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7655,LISTERIA MONOCYTOGENES causes LISTERIOSIS,causes,0.988371697650617,l  Listeria Infections  Alternative for treatment of LISTERIOSIS caused by  LISTERIA MONOCYTOGENES,LISTERIOSIS,LISTERIA MONOCYTOGENES
7656,PREECLAMPSIA causes PROTEINURIA,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7657,no_relation,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7658,no_relation,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7659,no_relation,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7660,PREECLAMPSIA causes PROTEINURIA,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7661,PROTEINURIA causes PREECLAMPSIA,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7662,PREECLAMPSIA causes PROTEINURIA,causes,0.707106781186547,PREECLAMPSIA AND ECLAMPSIA  PREECLAMPSIA is pregnancy induced hypertension plus PROTEINURIA,PROTEINURIA,PREECLAMPSIA
7663,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7664,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7665,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7666,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7667,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7668,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7669,CELL MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC CONTACT DERMATITIS,causes,1.0,"ALLERGIC CONTACT DERMATITIS is caused by a T CELL MEDIATED HYPERSENSITIVITY REACTION to environmental allergens, either natural or synthetic.",ALLERGIC CONTACT DERMATITIS,CELL MEDIATED HYPERSENSITIVITY REACTION
7670,no_relation,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7671,no_relation,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7672,no_relation,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7673,no_relation,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7674,no_relation,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7675,no_relation,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7676,INHALATIONAL ANTHRAX causes ANTHRAX,causes,0.589767824619588,• All 11 INHALATIONAL ANTHRAX patients in the 2001 ANTHRAX outbreak initially presented with nonspecific flu like illnesses ( 28 ;  37.,INHALATIONAL ANTHRAX,ANTHRAX
7677,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7678,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7679,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7680,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7681,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7682,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7683,KLEBSIELLA GRANULOMATIS causes DONOVANOSIS,causes,1.0,Alternative for treatment of granuloma inguinale   +    (DONOVANOSIS caused by  KLEBSIELLA GRANULOMATIS  (formerly  Calymmatobacterium granulomatis.,DONOVANOSIS,KLEBSIELLA GRANULOMATIS
7684,UVEITIS causes SARCOIDOSIS,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7685,no_relation,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7686,no_relation,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7687,SARCOIDOSIS causes UVEITIS,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7688,no_relation,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7689,no_relation,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7690,no_relation,causes,0.9760921603577252,"SARCOIDOSIS is suggested by the presence of UVEITIS and erythema nodosum, the presence of hilar adenopathy without parenchymal infiltrates, or improvement after short term steroid treatment.",UVEITIS,SARCOIDOSIS
7691,PARKINSONIAN causes MULTIPLE SYSTEM ATROPHY,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7692,no_relation,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7693,no_relation,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7694,PARKINSONIAN causes MULTIPLE SYSTEM ATROPHY,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7695,MULTIPLE SYSTEM ATROPHY causes PARKINSONIAN,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7696,no_relation,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7697,no_relation,causes,0.919145030018058,"Differential Diagnosis of Parkinson's Disease  Normal;           Differential Diagnosis of Parkinson's Disease Disease  Characteristics  Notes MULTIPLE SYSTEM ATROPHY  May occur with PARKINSONIAN (MSA P), autonomic (MSA A), or cerebellar features (MSA C), or with any combination of the three.",PARKINSONIAN,MULTIPLE SYSTEM ATROPHY
7698,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7699,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7700,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7701,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7702,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7703,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7704,no_relation,causes,0.7559289460184542,"A positive DAT result, defining AUTOIMMUNE HEMOLYSIS is often present in APLA syndrome  As with SLE, some reports suggest that APLA syndrome may overlap with TTP (tvml 77tvml ; tvml 78tvml.",AUTOIMMUNE HEMOLYSIS,TTP
7705,no_relation,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7706,no_relation,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7707,RESPIRATORY TRACT causes UPPER RESPIRATORY TRACT INFECTION,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7708,no_relation,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7709,no_relation,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7710,RESPIRATORY TRACT causes UPPER RESPIRATORY TRACT INFECTION,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7711,no_relation,causes,0.412081691846067,"A viral UPPER RESPIRATORY TRACT INFECTION may predispose to meningitis by allowing bacteria that are colonizing the RESPIRATORY TRACT especially  N. meningitidis , to enter the bloodstream and invade the meninges.",RESPIRATORY TRACT,UPPER RESPIRATORY TRACT INFECTION
7712,no_relation,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7713,no_relation,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7714,no_relation,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7715,no_relation,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7716,SECRETORY DIARRHEA causes VOLUME OR WATERY DIARRHEA,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7717,no_relation,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7718,no_relation,causes,0.4200840252084029,• Twenty four hour stool collection for quantification of volume may be helpful in large VOLUME OR WATERY DIARRHEA to confirm severity and indicate SECRETORY DIARRHEA if volume over 1 liter.,VOLUME OR WATERY DIARRHEA,SECRETORY DIARRHEA
7719,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7720,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7721,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7722,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7723,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7724,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7725,ORF VIRUS causes CONTAGIOUS PUSTULAR DERMATITIS,causes,0.997054485501582,"SYN:   hypocretins ;  hypocretin    orf    (       audio )  A CONTAGIOUS PUSTULAR DERMATITIS caused by the ORF VIRUS a DNA virus of the Parapoxvirus genus, which is related to the vaccinia variola subgroup of poxviruses.",CONTAGIOUS PUSTULAR DERMATITIS,ORF VIRUS
7726,COLD TEMPERATURES causes HYPOTHERMIA,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7727,COLD TEMPERATURES causes HYPOTHERMIA,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7728,HYPOTHERMIA causes COLD TEMPERATURES,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7729,COLD TEMPERATURES causes HYPOTHERMIA,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7730,COLD TEMPERATURES causes HYPOTHERMIA,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7731,COLD TEMPERATURES causes HYPOTHERMIA,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7732,COLD TEMPERATURES causes HYPOTHERMIA,causes,0.953462589245592,COLD TEMPERATURES are a particular hazard because HYPOTHERMIA can develop rapidly and affect judgment and dexterity or induce fatal cardiac arrhythmias in susceptible people.,HYPOTHERMIA,COLD TEMPERATURES
7733,TREMOR causes WILSON DISEASE,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7734,WILSON DISEASE causes TREMOR,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7735,WILSON DISEASE causes TREMOR,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7736,WILSON DISEASE causes TREMOR,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7737,WILSON DISEASE causes TREMOR,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7738,no_relation,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7739,no_relation,causes,0.911684611677103,WILSON DISEASE should be considered when TREMOR or another movement disorder develops in a person younger than 50 years.,TREMOR,WILSON DISEASE
7740,no_relation,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7741,no_relation,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7742,no_relation,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7743,no_relation,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7744,PAIN causes CAUSALGIA,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7745,no_relation,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7746,no_relation,causes,0.7302967433402209,"Most benign and malignant tumors present as a painless mass. However, malignant tumors may invade nerves, causing localized or regional PAIN numbness, paresthesia, CAUSALGIA or a loss of motor function.",PAIN,CAUSALGIA
7747,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7748,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7749,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7750,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7751,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7752,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7753,no_relation,causes,0.426401432711221,"100  Hematologic Effects  LEUKOPENIA   100   neutropenia,  100   eosinophilia,  a   AGRANULOCYTOSIS  100   and thrombocytopenic purpura  100   reported.",LEUKOPENIA,AGRANULOCYTOSIS
7754,no_relation,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7755,no_relation,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7756,no_relation,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7757,no_relation,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7758,ACUTE DIARRHEA causes CHRONIC DIARRHEA,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7759,no_relation,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7760,no_relation,causes,0.514495755427526,"Chronic Diarrhea  In contrast to ACUTE DIARRHEA in which infection is the overwhelmingly likely cause of illness, CHRONIC DIARRHEA has an extensive and daunting list of possible causes [ see  Table 3.",CHRONIC DIARRHEA,ACUTE DIARRHEA
7761,UNCOMPLICATED VARICELLA causes NOSOCOMIAL TRANSMISSION OF VZV,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7762,UNCOMPLICATED VARICELLA causes NOSOCOMIAL TRANSMISSION OF VZV,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7763,NOSOCOMIAL TRANSMISSION OF VZV causes UNCOMPLICATED VARICELLA,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7764,no_relation,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7765,UNCOMPLICATED VARICELLA causes NOSOCOMIAL TRANSMISSION OF VZV,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7766,UNCOMPLICATED VARICELLA causes NOSOCOMIAL TRANSMISSION OF VZV,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7767,no_relation,causes,0.75,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
7768,ETANERCEPT causes SEPSIS,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7769,no_relation,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7770,no_relation,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7771,no_relation,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7772,no_relation,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7773,no_relation,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7774,ETANERCEPT causes SEPSIS,causes,0.98058067569092,"129 ,   131   Discontinue ETANERCEPT if serious infection or SEPSIS develops.",SEPSIS,ETANERCEPT
7775,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7776,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7777,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7778,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7779,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7780,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7781,no_relation,causes,0.8401680504168059,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
7782,MIGRAINE causes NAUSEA,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7783,no_relation,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7784,MIGRAINE causes NAUSEA,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7785,no_relation,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7786,MIGRAINE causes NAUSEA,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7787,no_relation,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7788,no_relation,causes,0.961074462327142,Common MIGRAINE has a similar onset with or without NAUSEA,NAUSEA,MIGRAINE
7789,FIBROMYALGIA causes PAIN,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7790,FIBROMYALGIA causes PAIN,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7791,no_relation,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7792,FIBROMYALGIA causes PAIN,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7793,FIBROMYALGIA causes PAIN,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7794,FIBROMYALGIA causes PAIN,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7795,FIBROMYALGIA causes PAIN,causes,0.924500327042048,The patient complained of long standing aching PAIN in both lower legs which was diagnosed and managed as FIBROMYALGIA,PAIN,FIBROMYALGIA
7796,GONOCOCCI causes OPHTHALMIA NEONATORUM,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7797,GONOCOCCI causes OPHTHALMIA NEONATORUM,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7798,GONOCOCCI causes OPHTHALMIA NEONATORUM,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7799,GONOCOCCI causes OPHTHALMIA NEONATORUM,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7800,no_relation,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7801,no_relation,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7802,GONOCOCCI causes OPHTHALMIA NEONATORUM,causes,1.0,In newborns this type of conjunctivitis is encountered more frequently than OPHTHALMIA NEONATORUM caused by GONOCOCCI,OPHTHALMIA NEONATORUM,GONOCOCCI
7803,MIGRAINE HEADACHES causes MIGRAINE VARIANT,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7804,MIGRAINE VARIANT causes MIGRAINE HEADACHES,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7805,MIGRAINE HEADACHES causes MIGRAINE VARIANT,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7806,no_relation,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7807,no_relation,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7808,no_relation,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7809,no_relation,causes,0.317999364001908,The condition may be associated with MIGRAINE HEADACHES possibly representing a MIGRAINE VARIANT,MIGRAINE HEADACHES,MIGRAINE VARIANT
7810,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7811,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7812,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7813,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7814,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7815,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7816,no_relation,causes,0.5698028822981899,"The diagnosis of LEPROSY is made by nerve or skin biopsy, using the Fite method to stain and identify  M LEPRAE",LEPROSY,M LEPRAE
7817,ESSENTIAL THROMBOCYTHEMIA causes INCREASED PLATELET COUNT,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7818,ESSENTIAL THROMBOCYTHEMIA causes INCREASED PLATELET COUNT,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7819,no_relation,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7820,ESSENTIAL THROMBOCYTHEMIA causes INCREASED PLATELET COUNT,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7821,no_relation,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7822,ESSENTIAL THROMBOCYTHEMIA causes INCREASED PLATELET COUNT,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7823,ESSENTIAL THROMBOCYTHEMIA causes INCREASED PLATELET COUNT,causes,0.970142500145332,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary Thrombocythemia)  ESSENTIAL THROMBOCYTHEMIA is characterized by an INCREASED PLATELET COUNT megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",INCREASED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
7824,DRUGS causes LICHENOID DRUG ERUPTION,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7825,DRUGS causes LICHENOID DRUG ERUPTION,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7826,no_relation,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7827,DRUGS causes LICHENOID DRUG ERUPTION,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7828,no_relation,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7829,DRUGS causes LICHENOID DRUG ERUPTION,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7830,DRUGS causes LICHENOID DRUG ERUPTION,causes,0.962250448649376,"DRUGS (especially β blockers, NSAIDs, ACE inhibitors, sulfonylureas, gold, antimalarial agents, penicillamine, and thiazides) can cause LP; drug induced LP (sometimes called LICHENOID DRUG ERUPTION may be indistinguishable from non drug induced LP or may have a pattern that is more eczematous.",LICHENOID DRUG ERUPTION,DRUGS
7831,MALIGNANT HYPERTHERMIA causes SUCCINYLCHOLINE,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7832,SUCCINYLCHOLINE causes MALIGNANT HYPERTHERMIA,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7833,SUCCINYLCHOLINE causes MALIGNANT HYPERTHERMIA,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7834,SUCCINYLCHOLINE causes MALIGNANT HYPERTHERMIA,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7835,MALIGNANT HYPERTHERMIA causes SUCCINYLCHOLINE,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7836,SUCCINYLCHOLINE causes MALIGNANT HYPERTHERMIA,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7837,SUCCINYLCHOLINE causes MALIGNANT HYPERTHERMIA,causes,0.970494958830946,"Rationale: • MALIGNANT HYPERTHERMIA is a rare disorder (highest rate estimated at 1:15,000 procedures) that can be provoked by the anesthetic agents halothane and SUCCINYLCHOLINE",MALIGNANT HYPERTHERMIA,SUCCINYLCHOLINE
7838,no_relation,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7839,no_relation,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7840,no_relation,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7841,no_relation,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7842,no_relation,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7843,METHICILLIN RESISTANT STAPH causes STAPHYLOCOCCI,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7844,no_relation,causes,0.923380516876639,SEE:   boil  ETIOLOGY: STAPHYLOCOCCI including METHICILLIN RESISTANT STAPH are the usual cause.,METHICILLIN RESISTANT STAPH,STAPHYLOCOCCI
7845,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7846,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7847,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7848,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7849,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7850,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7851,VULVODYNIA causes SUPERFICIAL PAIN,causes,0.8944271909999159,"61   SUPERFICIAL PAIN is associated with light touch around the clitoris, labia, and vestibule and tends to be caused by anatomic abnormalities, dermatitis, dermatosis, infection, and VULVODYNIA or vestibulitis.",SUPERFICIAL PAIN,VULVODYNIA
7852,no_relation,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7853,no_relation,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7854,NEPHRITIS causes SLE WITH PROTEINURIA,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7855,no_relation,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7856,SLE WITH PROTEINURIA causes NEPHRITIS,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7857,no_relation,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7858,SLE WITH PROTEINURIA causes NEPHRITIS,causes,0.848874687627165,"SLE WITH PROTEINURIA warrants a biopsy to determine the type of NEPHRITIS extent of activity, and presence of fibrosis.",NEPHRITIS,SLE WITH PROTEINURIA
7859,CHRONIC PELVIC PAIN causes ENDOMETRIOSIS,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7860,ENDOMETRIOSIS causes CHRONIC PELVIC PAIN,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7861,ENDOMETRIOSIS causes CHRONIC PELVIC PAIN,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7862,ENDOMETRIOSIS causes CHRONIC PELVIC PAIN,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7863,no_relation,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7864,CHRONIC PELVIC PAIN causes ENDOMETRIOSIS,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7865,ENDOMETRIOSIS causes CHRONIC PELVIC PAIN,causes,1.0,Comments: • Note that adhesions and some cases of ENDOMETRIOSIS both of which are causes of CHRONIC PELVIC PAIN may not have ultrasound manifestations.,CHRONIC PELVIC PAIN,ENDOMETRIOSIS
7866,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7867,no_relation,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7868,no_relation,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7869,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7870,no_relation,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7871,no_relation,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7872,no_relation,causes,0.9918365981341758,Marked HYPERTENSION and regular tachycardia suggest PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
7873,PREGNANCY causes RIBAVIRIN THERAPY,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7874,no_relation,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7875,no_relation,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7876,no_relation,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7877,RIBAVIRIN THERAPY causes PREGNANCY,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7878,no_relation,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7879,no_relation,causes,0.381000381000572,"349 ,   377 ,   a ,   b ,   c   Extreme care must be taken to avoid PREGNANCY during and for 6 months following RIBAVIRIN THERAPY in female patients and in female partners of male patients receiving ribavirin.",PREGNANCY,RIBAVIRIN THERAPY
7880,PAIN causes VULVODYNIA LICHEN SCLEROSUS,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7881,VULVODYNIA LICHEN SCLEROSUS causes PAIN,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7882,VULVODYNIA LICHEN SCLEROSUS causes PAIN,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7883,VULVODYNIA LICHEN SCLEROSUS causes PAIN,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7884,VULVODYNIA LICHEN SCLEROSUS causes PAIN,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7885,VULVODYNIA LICHEN SCLEROSUS causes PAIN,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7886,VULVODYNIA LICHEN SCLEROSUS causes PAIN,causes,0.948683298050514,"Usually does not cause a vulvitis or VULVODYNIA LICHEN SCLEROSUS  Patients complain primarily of pruritus and burning PAIN of the vulva, perineal body, and perianus.",PAIN,VULVODYNIA LICHEN SCLEROSUS
7887,T PLL causes LYMPHADENOPATHY,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7888,no_relation,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7889,LYMPHADENOPATHY causes T PLL,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7890,T PLL causes LYMPHADENOPATHY,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7891,LYMPHADENOPATHY causes T PLL,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7892,no_relation,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7893,no_relation,causes,0.9901475429766742,"68   T PLL typically presents with LYMPHADENOPATHY hepatosplenomegaly (65%), cytopenias (50%), skin involvement (20%), and marked peripheral blood lymphocytosis (often > 100×10 9 /L.",LYMPHADENOPATHY,T PLL
7894,SUSCEPTIBLE GRAM NEGATIVE BACTERIA causes GRAM NEGATIVE BACILLARY BACTEREMIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7895,SUSCEPTIBLE GRAM NEGATIVE BACTERIA causes GRAM NEGATIVE BACILLARY BACTEREMIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7896,SUSCEPTIBLE GRAM NEGATIVE BACTERIA causes GRAM NEGATIVE BACILLARY BACTEREMIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7897,SUSCEPTIBLE GRAM NEGATIVE BACTERIA causes GRAM NEGATIVE BACILLARY BACTEREMIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7898,SUSCEPTIBLE GRAM NEGATIVE BACTERIA causes GRAM NEGATIVE BACILLARY BACTEREMIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7899,SUSCEPTIBLE GRAM NEGATIVE BACTERIA causes GRAM NEGATIVE BACILLARY BACTEREMIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7900,GRAM NEGATIVE BACILLARY BACTEREMIA causes SUSCEPTIBLE GRAM NEGATIVE BACTERIA,causes,1.0,1  Treatment of GRAM NEGATIVE BACILLARY BACTEREMIA caused by SUSCEPTIBLE GRAM NEGATIVE BACTERIA; used in conjunction with another suitable anti infective.,GRAM NEGATIVE BACILLARY BACTEREMIA,SUSCEPTIBLE GRAM NEGATIVE BACTERIA
7901,ERGOT causes ERGOT POISONING,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7902,no_relation,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7903,no_relation,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7904,ERGOT causes ERGOT POISONING,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7905,ERGOT POISONING causes ERGOT,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7906,ERGOT causes ERGOT POISONING,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7907,ERGOT causes ERGOT POISONING,causes,0.486664263392288,ERGOT POISONING    SEE: under   poisoning    ergotrate    (              audio )  An active principle isolated from ERGOT,ERGOT POISONING,ERGOT
7908,SLE causes ARTHRITIS,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7909,no_relation,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7910,ARTHRITIS causes SLE,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7911,no_relation,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7912,ARTHRITIS causes SLE,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7913,no_relation,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7914,no_relation,causes,0.5669467095138411,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a feature of both SLE and WG Physical exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,SLE
7915,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7916,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7917,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7918,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7919,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7920,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7921,VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.995893206467704,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by Hanta virus or related VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUSES
7922,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7923,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7924,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7925,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7926,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7927,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7928,THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,0.9918365981341758,Antigens are commonly categorized by type and occupation (see  Table 55 4 ); FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,THERMOPHILIC ACTINOMYCETES
7929,no_relation,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7930,no_relation,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7931,no_relation,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7932,no_relation,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7933,no_relation,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7934,no_relation,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7935,KERATOUVEITIS causes CORNEA,causes,0.781133465884943,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
7936,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7937,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7938,no_relation,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7939,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7940,no_relation,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7941,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7942,ANTIBIOTIC ASSOCIATED DIARRHEA causes DIARRHEA,causes,0.7947194142390258,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in severity from mild DIARRHEA to fatal colitis.",DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
7943,no_relation,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7944,no_relation,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7945,HEMATURIA causes RCC,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7946,no_relation,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7947,no_relation,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7948,RCC causes HEMATURIA,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7949,no_relation,causes,0.9901475429766742,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
7950,no_relation,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7951,LATE STAGE ROSACEA causes RHINOPHYMA,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7952,LATE STAGE ROSACEA causes RHINOPHYMA,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7953,LATE STAGE ROSACEA causes RHINOPHYMA,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7954,no_relation,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7955,RHINOPHYMA causes LATE STAGE ROSACEA,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7956,no_relation,causes,0.8660254037844392,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
7957,no_relation,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7958,no_relation,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7959,no_relation,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7960,no_relation,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7961,no_relation,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7962,THROMBOEMBOLIC DISEASE causes ESTROGEN DEPENDENT BREAST CANCER,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7963,no_relation,causes,0.696310623822791,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
7964,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7965,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7966,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7967,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7968,no_relation,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7969,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7970,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.99654575824488,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
7971,BLOCK PC causes FEVER,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7972,no_relation,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7973,no_relation,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7974,no_relation,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7975,no_relation,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7976,no_relation,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7977,FEVER causes BLOCK PC,causes,0.468521285665818,"1]  Livelli FD Jr, Johnson RA, McEnany MT, Sherman E, Newell J, BLOCK PC et al. Unexplained in hospital FEVER following cardiac surgery.",FEVER,BLOCK PC
7978,RAGGED RED FIBERS causes MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7979,MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES) causes RAGGED RED FIBERS,causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7980,MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES) causes RAGGED RED FIBERS,causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7981,MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES) causes RAGGED RED FIBERS,causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7982,no_relation,causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7983,MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES) causes RAGGED RED FIBERS,causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7984,no_relation,causes,0.977355554850442,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES), dementia, ataxia and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MUSCLE CONTRACTIONS (MYOCLONIC SEIZURES),RAGGED RED FIBERS
7985,no_relation,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7986,no_relation,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7987,no_relation,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7988,no_relation,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7989,no_relation,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7990,no_relation,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7991,POSTINFLAMMATORY HYPERPIGMENTATION causes HEMOCHROMATOSIS,causes,0.50709255283711,"POSTINFLAMMATORY HYPERPIGMENTATION pityriasis rosea, lichen planus, fixed drug eruption, Addison disease, pinta, syphilis, macular amyloidosis, HEMOCHROMATOSIS and argyria must be distinguished from EDP.",POSTINFLAMMATORY HYPERPIGMENTATION,HEMOCHROMATOSIS
7992,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7993,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7994,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7995,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7996,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7997,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7998,PHN causes DERMATOMAL PAIN,causes,1.0,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
7999,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8000,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8001,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8002,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8003,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8004,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8005,no_relation,causes,0.7624928516630229,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8006,no_relation,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8007,no_relation,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8008,no_relation,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8009,no_relation,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8010,no_relation,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8011,no_relation,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8012,HEPATOMEGALY causes GSD TYPE II,causes,0.8082903768654759,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the organ cells (eg, HEPATOMEGALY in hepatic forms of GSD and many lysosomal storage diseases, cardiomegaly in GSD TYPE II",HEPATOMEGALY,GSD TYPE II
8013,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8014,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8015,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8016,GRANULOMA INGUINALE causes CALYMMATOBACTERIUM GRANULOMATIS,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8017,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8018,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8019,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.9128709291752768,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
8020,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8021,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8022,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8023,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8024,HEREDITARY FRUCTOSE INTOLERANCE causes DEFICIENCY,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8025,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8026,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.99654575824488,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8027,no_relation,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8028,ALOSETRON causes ISCHEMIC COLITIS,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8029,no_relation,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8030,ALOSETRON causes ISCHEMIC COLITIS,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8031,no_relation,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8032,no_relation,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8033,no_relation,causes,0.824957911384306,1 •  Do not resume ALOSETRON in patients who develop ISCHEMIC COLITIS,ISCHEMIC COLITIS,ALOSETRON
8034,FIBROMYALGIA causes PAIN,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8035,FIBROMYALGIA causes PAIN,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8036,no_relation,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8037,FIBROMYALGIA causes PAIN,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8038,FIBROMYALGIA causes PAIN,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8039,PAIN causes FIBROMYALGIA,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8040,FIBROMYALGIA causes PAIN,causes,0.9878291611472622,"• FIBROMYALGIA characterized by widespread PAIN and multiple tender points, occurs mostly among women (90% of the cases) and is most commonly seen in the 40 to 60 age group.",PAIN,FIBROMYALGIA
8041,BABESIA MICROTI causes BABESIOSIS,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8042,BABESIA MICROTI causes BABESIOSIS,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8043,BABESIA MICROTI causes BABESIOSIS,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8044,BABESIOSIS causes BABESIA MICROTI,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8045,no_relation,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8046,BABESIA MICROTI causes BABESIOSIS,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8047,BABESIA MICROTI causes BABESIOSIS,causes,0.9838699100999068,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8048,no_relation,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8049,no_relation,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8050,COMPLEX REGIONAL PAIN SYNDROME causes PAIN,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8051,no_relation,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8052,COMPLEX REGIONAL PAIN SYNDROME causes PAIN,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8053,COMPLEX REGIONAL PAIN SYNDROME causes PAIN,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8054,COMPLEX REGIONAL PAIN SYNDROME causes PAIN,causes,0.923380516876639,COMPLEX REGIONAL PAIN SYNDROME sometimes involves sympathetically maintained PAIN,PAIN,COMPLEX REGIONAL PAIN SYNDROME
8055,no_relation,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8056,no_relation,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8057,no_relation,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8058,no_relation,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8059,no_relation,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8060,NON IRON DEFICIENCY ANEMIAS causes IRON DEFICIENCY ANEMIA,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8061,no_relation,causes,0.486664263392288,"• In determining etiology, first separate hemolytic anemias from nonhemolytic anemias, and then separate IRON DEFICIENCY ANEMIA from NON IRON DEFICIENCY ANEMIAS",NON IRON DEFICIENCY ANEMIAS,IRON DEFICIENCY ANEMIA
8062,no_relation,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8063,no_relation,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8064,GIARDIA causes METRONIDAZOLE,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8065,no_relation,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8066,no_relation,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8067,no_relation,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8068,GIARDIA causes METRONIDAZOLE,causes,0.707106781186548,"It also interferes with glucose uptake of the organism.[28]  [edit] Special circumstances in management therapy [edit] Drug use during pregnancy and lactation  Pregnant patients who are infected but asymptomatic are advised not to receive treatment for GIARDIA because there are underlying risks in current therapies.[28] For instance, METRONIDAZOLE is rapidly absorbed and easily enters fetal circulation.",GIARDIA,METRONIDAZOLE
8069,no_relation,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8070,no_relation,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8071,no_relation,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8072,PREGNANCY causes WARFARIN,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8073,no_relation,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8074,no_relation,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8075,WARFARIN causes PREGNANCY,causes,0.42426406871192895,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8076,no_relation,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8077,no_relation,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8078,HEMOLYSIS causes HAPTEN MEDIATED AIHA,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8079,HAPTEN MEDIATED AIHA causes HEMOLYSIS,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8080,no_relation,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8081,no_relation,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8082,HAPTEN MEDIATED AIHA causes HEMOLYSIS,causes,0.338061701891407,"With α methyldopa type AIHA, hemolysis usually ceases within 3 wk; however, a positive Coombs' test may persist for > 1 yr. With HAPTEN MEDIATED AIHA HEMOLYSIS ceases when the drug is cleared from the plasma.",HEMOLYSIS,HAPTEN MEDIATED AIHA
8083,no_relation,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8084,no_relation,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8085,no_relation,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8086,no_relation,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8087,FFI causes ATAXIA,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8088,no_relation,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8089,no_relation,causes,0.781133465884943,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
8090,no_relation,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8091,no_relation,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8092,no_relation,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8093,no_relation,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8094,no_relation,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8095,no_relation,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8096,PPD causes TB,causes,0.312771621085612,Patients should be screened for TB with a chest x ray or PPD,TB,PPD
8097,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8098,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8099,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8100,ORNITHOSIS causes CHLAMYDIA PSITTACI,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8101,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8102,no_relation,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8103,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.9761870601839532,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8104,no_relation,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8105,no_relation,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8106,FEATURE OF BOTH SLE AND WG PHYSICAL causes ARTHRITIS,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8107,ARTHRITIS causes FEATURE OF BOTH SLE AND WG PHYSICAL,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8108,ARTHRITIS causes FEATURE OF BOTH SLE AND WG PHYSICAL,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8109,no_relation,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8110,FEATURE OF BOTH SLE AND WG PHYSICAL causes ARTHRITIS,causes,0.3779644730092271,"Abdominal pain related to serositis, vasculitis, or panniculitis may occur with SLE Physical exam  Musculoskeletal exam  ARTHRITIS is a FEATURE OF BOTH SLE AND WG PHYSICAL exam  Peripheral vascular exam  Asymmetry of pulses or the presence of vascular bruits may suggest vasculitis or large vessel arterial disease.",ARTHRITIS,FEATURE OF BOTH SLE AND WG PHYSICAL
8111,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8112,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8113,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8114,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8115,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8116,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8117,no_relation,causes,0.5,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
8118,VIRUS OR RELATED VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8119,VIRUS OR RELATED VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8120,VIRUS OR RELATED VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8121,ARTHROPOD BORNE VIRAL DISEASE causes VIRUS OR RELATED VIRUSES,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8122,ARTHROPOD BORNE VIRAL DISEASE causes VIRUS OR RELATED VIRUSES,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8123,VIRUS OR RELATED VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8124,VIRUS OR RELATED VIRUSES causes ARTHROPOD BORNE VIRAL DISEASE,causes,0.9950371902099888,fever with renal syndrome     An ARTHROPOD BORNE VIRAL DISEASE caused by hanta VIRUS OR RELATED VIRUSES,ARTHROPOD BORNE VIRAL DISEASE,VIRUS OR RELATED VIRUSES
8125,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8126,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8127,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8128,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8129,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8130,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8131,PRODUCTION OF BOTULINUM TOXIN IN THE COLON causes BOTULISM,causes,1.0,BOTULISM caused BY PRODUCTION OF BOTULINUM TOXIN IN THE COLON following ingestion of spores of  Clostridium botulinum.,BOTULISM,PRODUCTION OF BOTULINUM TOXIN IN THE COLON
8132,no_relation,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8133,DUST CONTAINING THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8134,DUST CONTAINING THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8135,DUST CONTAINING THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8136,FARMER'S LUNG causes DUST CONTAINING THERMOPHILIC ACTINOMYCETES,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8137,DUST CONTAINING THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8138,DUST CONTAINING THERMOPHILIC ACTINOMYCETES causes FARMER'S LUNG,causes,1.0,Antigens are commonly categorized by type and occupation (see  Table 55 4  FARMER'S LUNG caused by inhalation of hay dust containing THERMOPHILIC ACTINOMYCETES is the prototype.,FARMER'S LUNG,DUST CONTAINING THERMOPHILIC ACTINOMYCETES
8139,no_relation,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8140,ANTIBIOTIC ASSOCIATED DIARRHEA causes SEVERITY FROM MILD DIARRHEA,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8141,no_relation,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8142,ANTIBIOTIC ASSOCIATED DIARRHEA causes SEVERITY FROM MILD DIARRHEA,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8143,ANTIBIOTIC ASSOCIATED DIARRHEA causes SEVERITY FROM MILD DIARRHEA,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8144,ANTIBIOTIC ASSOCIATED DIARRHEA causes SEVERITY FROM MILD DIARRHEA,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8145,no_relation,causes,0.8620436566990359,"1 ,   19 ,   20 ,   21 ,   22 ,   23    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives and may range in SEVERITY FROM MILD DIARRHEA to fatal colitis.",SEVERITY FROM MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
8146,no_relation,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8147,RCC causes HEMATURIA,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8148,no_relation,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8149,RCC causes HEMATURIA,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8150,HEMATURIA causes RCC,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8151,no_relation,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8152,no_relation,causes,0.857142857142857,"• Ask about: ◊ Abdominal or flank pain ◊ Episodes of HEMATURIA ◊ Symptoms suggesting possible metastatic disease, including: — Cough — Fever or night sweats — Weight loss — Bone pain — Fatigue ◊ A close family history of RCC may suggest a genetic predilection • See table  History and Physical Examination Elements for RCC",HEMATURIA,RCC
8153,no_relation,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8154,LATE STAGE ROSACEA causes RHINOPHYMA,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8155,LATE STAGE ROSACEA causes RHINOPHYMA,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8156,no_relation,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8157,no_relation,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8158,no_relation,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8159,no_relation,causes,0.938314863256836,"Some patients go on to develop LATE STAGE ROSACEA characterized by coarse tissue hyperplasia of the cheeks and nose (RHINOPHYMA caused by tissue inflammation, collagen deposition, and sebaceous gland hyperplasia.",RHINOPHYMA,LATE STAGE ROSACEA
8160,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8161,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8162,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8163,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8164,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8165,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8166,no_relation,causes,0.4574957109978139,"• About 80% of stones contain calcium, and about 80% OF CALCIUM STONES are composed mostly of calcium oxalate; the rest are CALCIUM PHOSPHATE",80% OF CALCIUM STONES,CALCIUM PHOSPHATE
8167,RABIES VIRUS causes ENCEPHALITIC OR PARALYTIC RABIES,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8168,no_relation,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8169,ENCEPHALITIC OR PARALYTIC RABIES causes RABIES VIRUS,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8170,no_relation,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8171,no_relation,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8172,RABIES VIRUS causes ENCEPHALITIC OR PARALYTIC RABIES,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8173,RABIES VIRUS causes ENCEPHALITIC OR PARALYTIC RABIES,causes,0.905821627315676,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting ENCEPHALITIC OR PARALYTIC RABIES",ENCEPHALITIC OR PARALYTIC RABIES,RABIES VIRUS
8174,no_relation,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8175,PROPRANOLOL causes SUPRAVENTRICULAR TACHYCARDIA,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8176,no_relation,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8177,no_relation,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8178,no_relation,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8179,no_relation,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8180,no_relation,causes,0.36115755925730697,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
8181,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8182,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8183,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8184,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8185,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8186,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8187,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,1.0,26  Brucellosis  Treatment of BRUCELLOSIS caused by  BRUCELLA MELITENSIS.,BRUCELLOSIS,BRUCELLA MELITENSIS
8188,no_relation,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8189,RAGGED RED FIBERS causes MYOCLONIC SEIZURES,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8190,MYOCLONIC SEIZURES causes RAGGED RED FIBERS,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8191,MYOCLONIC SEIZURES causes RAGGED RED FIBERS,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8192,MYOCLONIC SEIZURES causes RAGGED RED FIBERS,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8193,no_relation,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8194,RAGGED RED FIBERS causes MYOCLONIC SEIZURES,causes,0.966736489045664,"Myoclonic epilepsy with ragged red fibers (MERRF):  This is a progressive disease characterized by uncontrolled muscle contractions (MYOCLONIC SEIZURES) dementia, ataxia, and myopathy, which shows RAGGED RED FIBERS (indicating mitochondrial proliferation) with specialized stains when biopsied.",MYOCLONIC SEIZURES,RAGGED RED FIBERS
8195,PHN causes DERMATOMAL PAIN,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8196,no_relation,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8197,PHN causes DERMATOMAL PAIN,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8198,PHN causes DERMATOMAL PAIN,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8199,PHN causes DERMATOMAL PAIN,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8200,PHN causes DERMATOMAL PAIN,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8201,PHN causes DERMATOMAL PAIN,causes,0.9931270663228408,"Patients with PHN experience a continuous burning DERMATOMAL PAIN on which brief, lancinating pains may be superimposed.",DERMATOMAL PAIN,PHN
8202,no_relation,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8203,no_relation,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8204,no_relation,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8205,FEBRILE SEIZURE causes EPILEPSY,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8206,FEBRILE SEIZURE causes EPILEPSY,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8207,no_relation,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8208,no_relation,causes,0.583459965991578,"Again, it is easier to inform and instruct parents once they have been reassured that their child's FEBRILE SEIZURE does not mean that he or she has EPILEPSY",FEBRILE SEIZURE,EPILEPSY
8209,no_relation,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8210,CARDIOMEGALY IN GSD TYPE II causes ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8211,no_relation,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8212,ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS causes CARDIOMEGALY IN GSD TYPE II,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8213,ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS causes CARDIOMEGALY IN GSD TYPE II,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8214,no_relation,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8215,CARDIOMEGALY IN GSD TYPE II causes ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,causes,0.50709255283711,"Organomegaly may reflect a failure in substrate degradation resulting in substrate accumulation within the ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS of GSD and many lysosomal storage diseases, CARDIOMEGALY IN GSD TYPE II",ORGAN CELLS (EG) HEPATOMEGALY IN HEPATIC FORMS,CARDIOMEGALY IN GSD TYPE II
8216,DRUG CONCENTRATIONS causes DRUG TOXICITY,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8217,DRUG CONCENTRATIONS causes DRUG TOXICITY,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8218,no_relation,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8219,DRUG CONCENTRATIONS causes DRUG TOXICITY,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8220,DRUG CONCENTRATIONS causes DRUG TOXICITY,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8221,DRUG CONCENTRATIONS causes DRUG TOXICITY,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8222,no_relation,causes,0.963086824686154,• Rewarming may unintentionally increase DRUG CONCENTRATIONS producing DRUG TOXICITY,DRUG TOXICITY,DRUG CONCENTRATIONS
8223,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8224,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8225,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8226,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8227,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8228,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8229,DEFICIENCY causes HEREDITARY FRUCTOSE INTOLERANCE,causes,0.997054485501582,Fructose 1 phosphate aldolase (aldolase B) deficiency:  This DEFICIENCY causes the clinical syndrome of HEREDITARY FRUCTOSE INTOLERANCE,DEFICIENCY,HEREDITARY FRUCTOSE INTOLERANCE
8230,BABESIA MICROTI causes BABESIOSIS,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8231,BABESIA MICROTI causes BABESIOSIS,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8232,BABESIA MICROTI causes BABESIOSIS,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8233,BABESIA MICROTI causes BABESIOSIS,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8234,no_relation,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8235,BABESIA MICROTI causes BABESIOSIS,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8236,BABESIOSIS causes BABESIA MICROTI,causes,0.8741572761215379,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
8237,no_relation,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8238,COMPLEX REGIONAL PAIN SYNDROME causes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8239,INVOLVES SYMPATHETICALLY MAINTAINED PAIN causes COMPLEX REGIONAL PAIN SYNDROME,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8240,no_relation,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8241,no_relation,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8242,no_relation,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8243,no_relation,causes,0.8366600265340759,COMPLEX REGIONAL PAIN SYNDROME sometimes INVOLVES SYMPATHETICALLY MAINTAINED PAIN,INVOLVES SYMPATHETICALLY MAINTAINED PAIN,COMPLEX REGIONAL PAIN SYNDROME
8244,no_relation,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8245,no_relation,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8246,no_relation,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8247,TTP causes THROMBOCYTOPENIA,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8248,no_relation,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8249,THROMBOCYTOPENIA causes TTP,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8250,no_relation,causes,0.9282791216329142,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
8251,no_relation,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8252,no_relation,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8253,no_relation,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8254,PREGNANCY causes WARFARIN,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8255,PREGNANCY causes WARFARIN,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8256,no_relation,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8257,no_relation,causes,0.5656854249492379,"Exclusion criteria were IgM anticardiolipin antibodies only; clinically significant bleeding diathesis; intracranial hemorrhage, stroke, or gastrointestinal bleeding in the previous 3 months; contraindication to warfarin; objectively confirmed recurrent thrombosis while receiving WARFARIN (target international normalized ratio [INR] ≥ 2.0); pregnancy or planning PREGNANCY; or geographic location that would prevent follow up.",PREGNANCY,WARFARIN
8258,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8259,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8260,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8261,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8262,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8263,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8264,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.99654575824488,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
8265,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8266,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8267,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8268,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8269,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8270,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8271,no_relation,causes,0.609994281330419,"• Avoid using PODOPHYLLIN podophyllotoxin, and imiquimod during PREGNANCY",PREGNANCY,PODOPHYLLIN
8272,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8273,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8274,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8275,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8276,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8277,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8278,OVARIAN HYPERSTIMULATION SYNDROME causes POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,causes,0.980196058819607,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA.",POTENTIALLY LIFE THREATENING ASCITES AND HYPOVOLEMIA,OVARIAN HYPERSTIMULATION SYNDROME
8279,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8280,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8281,ORNITHOSIS causes CHLAMYDIA PSITTACI,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8282,ORNITHOSIS causes CHLAMYDIA PSITTACI,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8283,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8284,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8285,CHLAMYDIA PSITTACI causes ORNITHOSIS,causes,0.964763821237732,Chlamydial Infections  Treatment of psittacosis   +    (ORNITHOSIS caused by  CHLAMYDIA PSITTACI,ORNITHOSIS,CHLAMYDIA PSITTACI
8286,PLASMODIUM FALCIPARUM causes UNCOMPLICATED MALARIA,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8287,PLASMODIUM FALCIPARUM causes UNCOMPLICATED MALARIA,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8288,PLASMODIUM FALCIPARUM causes UNCOMPLICATED MALARIA,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8289,PLASMODIUM FALCIPARUM causes UNCOMPLICATED MALARIA,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8290,PLASMODIUM FALCIPARUM causes UNCOMPLICATED MALARIA,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8291,no_relation,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8292,PLASMODIUM FALCIPARUM causes UNCOMPLICATED MALARIA,causes,0.970142500145332,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
8293,no_relation,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8294,no_relation,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8295,CYTOMEGALOVIRUS causes CYTOMEGALIC INCLUSION DISEASE,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8296,no_relation,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8297,no_relation,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8298,CYTOMEGALOVIRUS causes CYTOMEGALIC INCLUSION DISEASE,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8299,no_relation,causes,0.848874687627165,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
8300,ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8301,ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8302,ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8303,ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8304,ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8305,ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8306,no_relation,causes,0.9784921095801627,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
8307,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8308,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8309,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8310,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8311,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8312,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8313,LONG TERM LEAD EXPOSURE causes SATURNINE GOUT,causes,0.8908708063747479,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
8314,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8315,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8316,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8317,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8318,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8319,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8320,no_relation,causes,0.351123441588392,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
8321,no_relation,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8322,MIGRAINE causes HEADACHE,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8323,HEADACHE causes MIGRAINE,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8324,no_relation,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8325,no_relation,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8326,no_relation,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8327,MIGRAINE causes HEADACHE,causes,0.528270543795374,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
8328,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8329,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8330,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8331,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8332,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8333,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8334,no_relation,causes,0.620173672946042,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
8335,no_relation,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8336,MEDROXYPROGESTERONE CONTRACEPTION causes PREGNANCY,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8337,no_relation,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8338,no_relation,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8339,no_relation,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8340,no_relation,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8341,PREGNANCY causes MEDROXYPROGESTERONE CONTRACEPTION,causes,0.956182887467515,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
8342,no_relation,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8343,MORPHINE causes DYSPNEA,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8344,no_relation,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8345,no_relation,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8346,MORPHINE causes DYSPNEA,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8347,no_relation,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8348,no_relation,causes,0.35218036253025004,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
8349,ADRENAL CARCINOMA causes RAPID ONSET VIRILIZATION,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8350,no_relation,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8351,ADRENAL CARCINOMA causes RAPID ONSET VIRILIZATION,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8352,RAPID ONSET VIRILIZATION causes ADRENAL CARCINOMA,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8353,no_relation,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8354,ADRENAL CARCINOMA causes RAPID ONSET VIRILIZATION,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8355,ADRENAL CARCINOMA causes RAPID ONSET VIRILIZATION,causes,0.866921446863011,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
8356,no_relation,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8357,NASAL MUCOUS MEMBRANE causes MUCOUS MEMBRANE,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8358,no_relation,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8359,no_relation,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8360,no_relation,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8361,no_relation,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8362,no_relation,causes,0.7337993857053431,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
8363,INFLUENZA A OR B causes INFECTION,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8364,INFLUENZA A OR B causes INFECTION,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8365,INFLUENZA A OR B causes INFECTION,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8366,no_relation,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8367,INFECTION causes INFLUENZA A OR B,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8368,INFECTION causes INFLUENZA A OR B,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8369,no_relation,causes,0.455842305838552,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
8370,no_relation,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8371,no_relation,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8372,ECLAMPSIA causes SEIZURES,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8373,no_relation,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8374,no_relation,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8375,no_relation,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8376,no_relation,causes,0.9491579957524988,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
8377,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8378,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8379,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8380,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8381,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8382,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8383,VIRUSES causes COLDS,causes,0.997054485501582,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
8384,CROHN'S DISEASE causes DIARRHEA,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8385,no_relation,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8386,no_relation,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8387,CROHN'S DISEASE causes DIARRHEA,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8388,CROHN'S DISEASE causes DIARRHEA,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8389,no_relation,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8390,CROHN'S DISEASE causes DIARRHEA,causes,0.964236519799838,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
8391,CAMPYLOBACTER causes CAMPYLOBACTER INFECTIONS,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8392,CAMPYLOBACTER causes CAMPYLOBACTER INFECTIONS,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8393,CAMPYLOBACTER causes CAMPYLOBACTER INFECTIONS,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8394,CAMPYLOBACTER causes CAMPYLOBACTER INFECTIONS,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8395,no_relation,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8396,CAMPYLOBACTER causes CAMPYLOBACTER INFECTIONS,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8397,CAMPYLOBACTER causes CAMPYLOBACTER INFECTIONS,causes,0.813788458771159,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
8398,no_relation,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8399,no_relation,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8400,AVIAN AND ANIMAL SCHISTOSOMES causes SCHISTOSOME DERMATITIS,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8401,AVIAN AND ANIMAL SCHISTOSOMES causes SCHISTOSOME DERMATITIS,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8402,AVIAN AND ANIMAL SCHISTOSOMES causes SCHISTOSOME DERMATITIS,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8403,no_relation,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8404,no_relation,causes,0.929669680201368,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
8405,ANAPLASTIC ASTROCYTOMAS causes NUCLEAR ATYPIA,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8406,ANAPLASTIC ASTROCYTOMAS causes NUCLEAR ATYPIA,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8407,ANAPLASTIC ASTROCYTOMAS causes NUCLEAR ATYPIA,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8408,no_relation,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8409,ANAPLASTIC ASTROCYTOMAS causes NUCLEAR ATYPIA,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8410,no_relation,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8411,no_relation,causes,0.9931270663228408,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
8412,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8413,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8414,no_relation,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8415,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8416,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8417,no_relation,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8418,no_relation,causes,0.615587011251092,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
8419,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8420,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8421,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8422,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CARCINOMA,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8423,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8424,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8425,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.9918365981341758,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
8426,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8427,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8428,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8429,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8430,no_relation,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8431,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8432,NOCARDIA causes NOCARDIA INFECTIONS,causes,0.7416198487095659,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
8433,no_relation,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8434,SARCOIDOSIS causes COUGH,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8435,no_relation,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8436,no_relation,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8437,no_relation,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8438,no_relation,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8439,no_relation,causes,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
8440,CLOSTRIDIUM PERFRINGENS causes CLOSTRIDIUM INFECTIONS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8441,CLOSTRIDIUM PERFRINGENS causes CLOSTRIDIUM INFECTIONS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8442,CLOSTRIDIUM PERFRINGENS causes CLOSTRIDIUM INFECTIONS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8443,CLOSTRIDIUM PERFRINGENS causes CLOSTRIDIUM INFECTIONS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8444,CLOSTRIDIUM PERFRINGENS causes CLOSTRIDIUM INFECTIONS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8445,CLOSTRIDIUM PERFRINGENS causes CLOSTRIDIUM INFECTIONS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8446,CLOSTRIDIUM INFECTIONS causes CLOSTRIDIUM PERFRINGENS,causes,0.8628403050799641,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
8447,no_relation,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8448,no_relation,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8449,no_relation,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8450,SEIZURES causes STATUS EPILEPTICUS,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8451,STATUS EPILEPTICUS causes SEIZURES,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8452,no_relation,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8453,no_relation,causes,0.8427009716003839,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
8454,no_relation,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8455,PTSD causes ANXIETY,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8456,PTSD causes ANXIETY,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8457,PTSD causes ANXIETY,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8458,PTSD causes ANXIETY,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8459,PTSD causes ANXIETY,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8460,no_relation,causes,0.8888888888888891,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
8461,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8462,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8463,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8464,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8465,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8466,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8467,PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,causes,1.0,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
8468,no_relation,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8469,BONE causes FRACTURE,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8470,no_relation,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8471,no_relation,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8472,no_relation,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8473,no_relation,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8474,no_relation,causes,0.4780914437337581,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
8475,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8476,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8477,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8478,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8479,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8480,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8481,no_relation,causes,0.301511344577764,"3 , 202 ]   Droperidol Concomitant administration has produced satisfactory analgesia (during and after surgery [ 60 ] and also in a terminally ill patient with severe, CHRONIC PAIN that was previously unresponsive to buprenorphine alone [ 37 ])    FENTANYL",CHRONIC PAIN,FENTANYL
8482,HERPES ZOSTER causes REFLECT VZV REACTIVATION FROM GANGLIA,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8483,no_relation,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8484,HERPES ZOSTER causes REFLECT VZV REACTIVATION FROM GANGLIA,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8485,no_relation,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8486,HERPES ZOSTER causes REFLECT VZV REACTIVATION FROM GANGLIA,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8487,no_relation,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8488,no_relation,causes,0.918558653543692,Most HERPES ZOSTER cases REFLECT VZV REACTIVATION FROM GANGLIA.,HERPES ZOSTER,REFLECT VZV REACTIVATION FROM GANGLIA
8489,no_relation,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8490,no_relation,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8491,no_relation,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8492,MCCUNE ALBRIGHT SYNDROME causes CAFÉ AU LAIT SPOTS,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8493,no_relation,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8494,CAFÉ AU LAIT SPOTS causes MCCUNE ALBRIGHT SYNDROME,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8495,CAFÉ AU LAIT SPOTS causes MCCUNE ALBRIGHT SYNDROME,causes,0.5,"Associated conditions     Neurofibromatosis type I café au lait spot    While CAFÉ AU LAIT SPOTS do not cause any ailment themselves, having multiple spots has been linked with neurofibromatosis and the rare MCCUNE ALBRIGHT SYNDROME",CAFÉ AU LAIT SPOTS,MCCUNE ALBRIGHT SYNDROME
8496,no_relation,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8497,no_relation,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8498,no_relation,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8499,no_relation,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8500,no_relation,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8501,no_relation,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8502,WARFARIN causes STROKE,causes,0.480384461415261,"744 ,   773 ,   776 ,   826  Intermediate risk for STROKE: 325 mg daily or WARFARIN",STROKE,WARFARIN
8503,TRIGEMINAL NEURALGIA causes PAIN,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8504,no_relation,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8505,no_relation,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8506,TRIGEMINAL NEURALGIA causes PAIN,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8507,TRIGEMINAL NEURALGIA causes PAIN,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8508,TRIGEMINAL NEURALGIA causes PAIN,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8509,TRIGEMINAL NEURALGIA causes PAIN,causes,0.700140042014005,"Because gamma knife radiosurgery works as well as the other procedures, but has the fewest risks, it can be recommended for almost anyone with TRIGEMINAL NEURALGIA who is bothered either by the pain or medicines used to treat the PAIN.",PAIN,TRIGEMINAL NEURALGIA
8510,CHRONIC PROGRESSIVE OPTIC NEUROPATHY causes OPTIC NERVE DAMAGE,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8511,no_relation,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8512,no_relation,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8513,OPTIC NERVE DAMAGE causes CHRONIC PROGRESSIVE OPTIC NEUROPATHY,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8514,CHRONIC PROGRESSIVE OPTIC NEUROPATHY causes OPTIC NERVE DAMAGE,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8515,no_relation,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8516,CHRONIC PROGRESSIVE OPTIC NEUROPATHY causes OPTIC NERVE DAMAGE,causes,0.6030226891555269,"Glaucoma  Glaucoma, characteristic OPTIC NERVE DAMAGE and visual field loss, is a CHRONIC PROGRESSIVE OPTIC NEUROPATHY   characterized by excavation of the optic nerve head and visual field loss in the midperiphery.",OPTIC NERVE DAMAGE,CHRONIC PROGRESSIVE OPTIC NEUROPATHY
8517,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8518,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8519,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8520,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8521,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8522,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8523,CROHN'S DISEASE causes DIARRHEA,causes,0.970494958830946,"C]  Specific recommendation: • Consider endoscopy to investigate associated illnesses such as CROHN'S DISEASE only in patients with atypical fissure or other symptoms such as fever, DIARRHEA weight loss, or significant rectal bleeding.",DIARRHEA,CROHN'S DISEASE
8524,MYCOBACTERIAL INFECTIONS causes MYCOBACTERIUM ABSCESSUS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8525,MYCOBACTERIUM ABSCESSUS causes MYCOBACTERIAL INFECTIONS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8526,MYCOBACTERIUM ABSCESSUS causes MYCOBACTERIAL INFECTIONS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8527,MYCOBACTERIUM ABSCESSUS causes MYCOBACTERIAL INFECTIONS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8528,MYCOBACTERIUM ABSCESSUS causes MYCOBACTERIAL INFECTIONS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8529,MYCOBACTERIUM ABSCESSUS causes MYCOBACTERIAL INFECTIONS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8530,MYCOBACTERIUM ABSCESSUS causes MYCOBACTERIAL INFECTIONS,causes,0.8908708063747479,100  MYCOBACTERIAL INFECTIONS  Treatment of infections caused by  MYCOBACTERIUM ABSCESSUS    +     157   or  M. fortuitum    +   ;  157   used in conjunction with other antimycobacterial anti infectives.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM ABSCESSUS
8531,no_relation,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8532,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8533,no_relation,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8534,no_relation,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8535,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8536,INFECTIOUS MONONUCLEOSIS causes ADENOPATHY,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8537,ADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.964901281354015,"Exudative pharyngitis, anterior cervical lymphadenopathy, and fever may be clinically indistinguishable from those caused by group A β hemolytic streptococci; however, posterior cervical or generalized ADENOPATHY or hepatosplenomegaly suggest INFECTIOUS MONONUCLEOSIS",ADENOPATHY,INFECTIOUS MONONUCLEOSIS
8538,no_relation,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8539,no_relation,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8540,no_relation,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8541,no_relation,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8542,BECLOMETHASONE causes CHRONIC ASTHMA,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8543,no_relation,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8544,no_relation,causes,0.398014876083996,CONCLUSIONS  In patients with CHRONIC ASTHMA who are symptomatic while receiving moderate to high doses of inhaled BECLOMETHASONE the addition of 2 to 4 times the licensed dose of antileukotriene (AL) agents reduces the rate of exacerbations that require systemic corticosteroids.,CHRONIC ASTHMA,BECLOMETHASONE
8545,POXVIRUSES OF ANIMALS causes ZOONOTIC POXVIRUS INFECTIONS,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8546,no_relation,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8547,POXVIRUSES OF ANIMALS causes ZOONOTIC POXVIRUS INFECTIONS,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8548,POXVIRUSES OF ANIMALS causes ZOONOTIC POXVIRUS INFECTIONS,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8549,POXVIRUSES OF ANIMALS causes ZOONOTIC POXVIRUS INFECTIONS,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8550,POXVIRUSES OF ANIMALS causes ZOONOTIC POXVIRUS INFECTIONS,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8551,POXVIRUSES OF ANIMALS causes ZOONOTIC POXVIRUS INFECTIONS,causes,0.936329177569044,"71,72  ZOONOTIC POXVIRUS INFECTIONS IN HUMANS  Several POXVIRUSES OF ANIMALS can infect humans, including paravaccinia, orf, monkeypox, and tanapox; human infections result from direct contact with natural animal reservoirs of these agents or arthropod vectors, and humans are only incidental hosts.",ZOONOTIC POXVIRUS INFECTIONS,POXVIRUSES OF ANIMALS
8552,no_relation,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8553,FACIAL NERVE causes FACIAL PARALYSIS,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8554,no_relation,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8555,no_relation,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8556,no_relation,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8557,FACIAL PARALYSIS causes FACIAL NERVE,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8558,FACIAL NERVE causes FACIAL PARALYSIS,causes,0.99124070716193,"edit] Complications  As the skull base is progressively involved, the adjacent exiting cranial nerves and their branches, especially the FACIAL NERVE and the vagus nerve, may be affected, resulting in FACIAL PARALYSIS and hoarseness, respectively.",FACIAL NERVE,FACIAL PARALYSIS
8559,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8560,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8561,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8562,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8563,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8564,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8565,PLASMODIUM VIVAX causes MALARIA,causes,0.995893206467704,MALARIA caused by  PLASMODIUM VIVAX.,MALARIA,PLASMODIUM VIVAX
8566,no_relation,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8567,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8568,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8569,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8570,no_relation,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8571,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8572,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.971285862357264,"INFECTIVE ENDOCARDITIS  INFECTIVE ENDOCARDITIS is infection of the endocardium, usually with BACTERIA (commonly, streptococci and staphylococci) or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
8573,HERMANSKY PUDLAK SYNDROME causes ALBINISM,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8574,no_relation,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8575,HERMANSKY PUDLAK SYNDROME causes ALBINISM,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8576,no_relation,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8577,ALBINISM causes HERMANSKY PUDLAK SYNDROME,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8578,no_relation,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8579,ALBINISM causes HERMANSKY PUDLAK SYNDROME,causes,0.8137334712067349,"The secondary varieties of ALBINISM in which the primary defect is not specific for the melanin synthetic pathway, include HERMANSKY PUDLAK SYNDROME  87   Chediak Higashi syndrome, Cross McKusick Breen syndrome, Prader Willi syndrome, and Angelman syndrome.",ALBINISM,HERMANSKY PUDLAK SYNDROME
8580,no_relation,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8581,MITES causes MANGE,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8582,MITES causes MANGE,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8583,MITES causes MANGE,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8584,MITES causes MANGE,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8585,MITES causes MANGE,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8586,MITES causes MANGE,causes,1.0,"Some MITES are parasitic and cause conditions such as asthma, MANGE and scabies; others are vectors of disease organisms and are intermediate hosts for certain Cestodes.",MANGE,MITES
8587,PHEOCHROMOCYTOMA CRISIS causes HYPERTHERMIA,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8588,PHEOCHROMOCYTOMA CRISIS causes HYPERTHERMIA,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8589,PHEOCHROMOCYTOMA CRISIS causes HYPERTHERMIA,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8590,no_relation,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8591,PHEOCHROMOCYTOMA CRISIS causes HYPERTHERMIA,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8592,HYPERTHERMIA causes PHEOCHROMOCYTOMA CRISIS,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8593,PHEOCHROMOCYTOMA CRISIS causes HYPERTHERMIA,causes,0.485642931178632,"The HYPERTHERMIA that may accompany thyroid storm and PHEOCHROMOCYTOMA CRISIS also results from increased heat production, triggered in these cases by the calorigenic properties of thyroid hormones  11   and catecholamines.",HYPERTHERMIA,PHEOCHROMOCYTOMA CRISIS
8594,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8595,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8596,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8597,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8598,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8599,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8600,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,causes,0.970494958830946,"Diagnosis  ENDOMETRIAL CANCER is suspected in women with POSTMENOPAUSAL BLEEDING in premenopausal women with abnormal bleeding, in postmenopausal women with a routine Pap test showing endometrial cells, and in any women with a routine Pap test showing atypical endometrial cells.",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER
8601,no_relation,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8602,ULTRAVIOLET RADIATION causes SUNBURN,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8603,ULTRAVIOLET RADIATION causes SUNBURN,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8604,SUNBURN causes ULTRAVIOLET RADIATION,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8605,ULTRAVIOLET RADIATION causes SUNBURN,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8606,no_relation,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8607,no_relation,causes,0.811107105653813,"a ,   b ,   c  Lesions of psoriasis may be aggravated by concomitant exposure to ULTRAVIOLET RADIATION; possible 'recall' radiation dermatitis and SUNBURN with methotrexate use",SUNBURN,ULTRAVIOLET RADIATION
8608,no_relation,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8609,no_relation,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8610,no_relation,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8611,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8612,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8613,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8614,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.676123403782813,"66   Since albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
8615,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8616,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8617,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8618,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8619,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8620,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8621,no_relation,causes,0.6030226891555269,"In a patient who has not eaten in the past 6 hours, a splashing sound over the STOMACH when the body is shaken (succussion) suggests GASTRIC OUTLET OBSTRUCTION or delayed gastric emptying caused by ileus.",STOMACH,GASTRIC OUTLET OBSTRUCTION
8622,POLYCYSTIC KIDNEY DISEASE causes INTRACRANIAL ANEURYSMS,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8623,POLYCYSTIC KIDNEY DISEASE causes INTRACRANIAL ANEURYSMS,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8624,no_relation,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8625,no_relation,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8626,POLYCYSTIC KIDNEY DISEASE causes INTRACRANIAL ANEURYSMS,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8627,no_relation,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8628,POLYCYSTIC KIDNEY DISEASE causes INTRACRANIAL ANEURYSMS,causes,0.787838597158335,Follow up of INTRACRANIAL ANEURYSMS in autosomal dominant POLYCYSTIC KIDNEY DISEASE by magnetic resonance angiography.,INTRACRANIAL ANEURYSMS,POLYCYSTIC KIDNEY DISEASE
8629,no_relation,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8630,no_relation,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8631,NEOMYCIN causes ALLERGY,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8632,no_relation,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8633,NEOMYCIN causes ALLERGY,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8634,NEOMYCIN causes ALLERGY,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8635,ALLERGY causes NEOMYCIN,causes,0.824957911384306,77  ALLERGY to Neomycin or Other Anti infectives  DTaP IPV/Hib (Pentacel ® ): Contains trace amounts of NEOMYCIN sulfate (≤4 pg) and polymyxin B (≤4 pg.,ALLERGY,NEOMYCIN
8636,no_relation,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8637,PREECLAMPSIA causes PROTEINURIA,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8638,PREECLAMPSIA causes PROTEINURIA,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8639,PREECLAMPSIA causes PROTEINURIA,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8640,PROTEINURIA causes PREECLAMPSIA,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8641,PREECLAMPSIA causes PROTEINURIA,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8642,no_relation,causes,0.9760921603577252,"PREECLAMPSIA is not primarily a hypertensive disease, despite being defined by its most common clinical manifestations: hypertension and PROTEINURIA",PROTEINURIA,PREECLAMPSIA
8643,ECLAMPSIA causes SEIZURES,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8644,no_relation,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8645,no_relation,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8646,ECLAMPSIA causes SEIZURES,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8647,ECLAMPSIA causes SEIZURES,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8648,no_relation,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8649,ECLAMPSIA causes SEIZURES,causes,0.8006407690254359,ECLAMPSIA always requires delivery after SEIZURES and severe hypertension have been controlled.,SEIZURES,ECLAMPSIA
8650,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8651,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8652,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8653,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8654,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8655,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8656,KLEBSIELLA RHINOSCLEROMATIS causes RHINOSCLEROMA,causes,0.99654575824488,"Although rare in the United States, RHINOSCLEROMA believed to be caused by  KLEBSIELLA RHINOSCLEROMATIS , can occur in immigrants from developing countries or in HIV infected persons.",RHINOSCLEROMA,KLEBSIELLA RHINOSCLEROMATIS
8657,no_relation,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8658,EXTRAOCULAR MUSCLE WEAKNESS causes MULTIPLE SCLEROSIS,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8659,MULTIPLE SCLEROSIS causes EXTRAOCULAR MUSCLE WEAKNESS,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8660,MULTIPLE SCLEROSIS causes EXTRAOCULAR MUSCLE WEAKNESS,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8661,MULTIPLE SCLEROSIS causes EXTRAOCULAR MUSCLE WEAKNESS,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8662,no_relation,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8663,no_relation,causes,0.7715167498104591,EXTRAOCULAR MUSCLE WEAKNESS is not fatigable  Due to inflammation in extraocular muscles and orbital connective tissues; most often associated with Graves hyperthyroidism ACh = acetylcholine; AChR = acetylcholine receptor; ALS = amyotrophic lateral sclerosis; EMG = ELECTROMYOGRAPHY MS = MULTIPLE SCLEROSIS; TIA = transient ischemic attack.,EXTRAOCULAR MUSCLE WEAKNESS,MULTIPLE SCLEROSIS
8664,PRIMARY G CSF PROPHYLAXIS causes NEUTROPENIA,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8665,no_relation,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8666,PRIMARY G CSF PROPHYLAXIS causes NEUTROPENIA,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8667,no_relation,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8668,no_relation,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8669,no_relation,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8670,no_relation,causes,0.387298334620742,Study selection and assessment:  Randomized controlled trials (RCTs) that compared PRIMARY G CSF PROPHYLAXIS (given during the first chemotherapy cycle and before NEUTROPENIA onset) with placebo or no treatment in adult patients with cancer receiving conventional dose chemotherapy for a solid tumor or malignant lymphoma.,NEUTROPENIA,PRIMARY G CSF PROPHYLAXIS
8671,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8672,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8673,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8674,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8675,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8676,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8677,PHEOCHROMOCYTOMAS causes HEADACHES,causes,0.9615239476408228,"Patients with PHEOCHROMOCYTOMAS may have paroxysmal palpitations, anxiety, HEADACHES or sweating; many are asymptomatic.",HEADACHES,PHEOCHROMOCYTOMAS
8678,SEIZURES causes PETIT MAL GRAND MAL OR,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8679,no_relation,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8680,PETIT MAL GRAND MAL OR causes SEIZURES,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8681,PETIT MAL GRAND MAL OR causes SEIZURES,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8682,no_relation,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8683,no_relation,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8684,no_relation,causes,0.938314863256836,SEIZURES may be the sole presenting symptom and may be PETIT MAL OR GRAND MAL focal ( 6 ;  7.,SEIZURES,PETIT MAL GRAND MAL OR
8685,HYPEREMESIS GRAVIDARUM causes PREGNANCY INDUCED VOMITING,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8686,no_relation,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8687,no_relation,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8688,HYPEREMESIS GRAVIDARUM causes PREGNANCY INDUCED VOMITING,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8689,PREGNANCY INDUCED VOMITING causes HYPEREMESIS GRAVIDARUM,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8690,HYPEREMESIS GRAVIDARUM causes PREGNANCY INDUCED VOMITING,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8691,no_relation,causes,0.404061017820884,"Hyperemesis gravidarum (see  HYPEREMESIS GRAVIDARUM ) is persistent PREGNANCY INDUCED VOMITING that causes significant dehydration, often with electrolyte abnormalities or ketosis.",PREGNANCY INDUCED VOMITING,HYPEREMESIS GRAVIDARUM
8692,no_relation,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8693,FIBROMYALGIA SYNDROME causes PAIN,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8694,FIBROMYALGIA SYNDROME causes PAIN,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8695,FIBROMYALGIA SYNDROME causes PAIN,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8696,FIBROMYALGIA SYNDROME causes PAIN,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8697,FIBROMYALGIA SYNDROME causes PAIN,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8698,no_relation,causes,0.8846517369293829,Duloxetine (Cymbalta    60 mg/d  Approximately 20% 30% better than placebo  Elevated blood pressure  Only indicated for diabetic neuropathy (and possibly FIBROMYALGIA SYNDROME in the future) PAIN,PAIN,FIBROMYALGIA SYNDROME
8699,no_relation,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8700,BC causes DYSPNEA,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8701,DYSPNEA causes BC,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8702,no_relation,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8703,no_relation,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8704,no_relation,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8705,no_relation,causes,0.43301270189221897,"BC]  History and Physical Examination  3.1 Obtain a careful history focusing on recent systemic illnesses, fever, chest pain, and DYSPNEA",DYSPNEA,BC
8706,CMV causes CMV INFECTION,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8707,no_relation,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8708,CMV causes CMV INFECTION,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8709,CMV INFECTION causes CMV,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8710,CMV INFECTION causes CMV,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8711,CMV INFECTION causes CMV,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8712,CMV INFECTION causes CMV,causes,0.914991421995628,"More frequently, CMV INFECTION develops in patients who have received multiple blood transfusions or who have undergone organ transplantation; CMV is the cause of 50% of all febrile episodes in renal transplant recipients.",CMV INFECTION,CMV
8713,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8714,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8715,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8716,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8717,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8718,DRUG RESISTANT TB causes MYCOBACTERIUM TUBERCULOSIS,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8719,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.997054485501582,"106 ,   107 ,   127  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to ethionamide when isoniazid and/or rifampin cannot be used because of resistance and/or intolerance.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
8720,HERPES ZOSTER causes CHICKENPOX,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8721,no_relation,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8722,no_relation,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8723,HERPES ZOSTER causes CHICKENPOX,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8724,HERPES ZOSTER causes CHICKENPOX,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8725,HERPES ZOSTER causes CHICKENPOX,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8726,no_relation,causes,0.8082903768654759,"Chickenpox is caused by the varicella zoster virus (human herpesvirus type 3), CHICKENPOX being the acute invasive phase of the virus and herpes zoster (shingles) representing reactivation of the latent phase (see  HERPES ZOSTER.",CHICKENPOX,HERPES ZOSTER
8727,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8728,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8729,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8730,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8731,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8732,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8733,no_relation,causes,0.7184212081071,C]  History and Physical Examination  3.1 Evaluate symptoms to distinguish CLUSTER HEADACHE from migraine and other TRIGEMINAL AUTONOMIC HEADACHES,TRIGEMINAL AUTONOMIC HEADACHES,CLUSTER HEADACHE
8734,INFECTIONS causes INFLUENZA,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8735,no_relation,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8736,INFLUENZA causes INFECTIONS,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8737,no_relation,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8738,INFLUENZA causes INFECTIONS,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8739,INFLUENZA causes INFECTIONS,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8740,INFLUENZA causes INFECTIONS,causes,0.938314863256836,"Other community acquired respiratory viruses (e.g., influenza, paraINFLUENZA respiratory syncytial virus, metapneumo virus, and rhinovirus) have caused significant infections; a suspicion of these respiratory viruses should inform the clinical evaluation of all upper and lower respiratory tract INFECTIONS.",INFLUENZA,INFECTIONS
8741,no_relation,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8742,SEIZURES causes ECLAMPSIA,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8743,ECLAMPSIA causes SEIZURES,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8744,ECLAMPSIA causes SEIZURES,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8745,ECLAMPSIA causes SEIZURES,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8746,ECLAMPSIA causes SEIZURES,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8747,ECLAMPSIA causes SEIZURES,causes,0.8728715609439692,"Biophysical profile    A nonstress test combined with an obstetric ultrasound using a total of five components to gauge fetal well being (nonstress test result, amniotic fluid volume, fetal breathing movements, fetal gross body movements, and fetal tone)  Eclampsia    PreECLAMPSIA with the presence of SEIZURES",SEIZURES,ECLAMPSIA
8748,no_relation,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8749,INFLUENZA VIRUS causes COLDS,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8750,COLDS causes INFLUENZA VIRUS,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8751,INFLUENZA VIRUS causes COLDS,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8752,INFLUENZA VIRUS causes COLDS,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8753,INFLUENZA VIRUS causes COLDS,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8754,INFLUENZA VIRUS causes COLDS,causes,1.0,"RSV, PIV, INFLUENZA VIRUS adenovirus, and some enteroviruses also cause COLDS",COLDS,INFLUENZA VIRUS
8755,FATAL DYSENTERY causes MILD DIARRHEA,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8756,no_relation,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8757,no_relation,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8758,no_relation,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8759,no_relation,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8760,no_relation,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8761,no_relation,causes,0.7624928516630229,It contains a number of species that cause digestive disturbance ranging from MILD DIARRHEA to a severe and often FATAL DYSENTERY,MILD DIARRHEA,FATAL DYSENTERY
8762,no_relation,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8763,no_relation,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8764,PREGNANCY causes ISOTRETINOIN,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8765,no_relation,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8766,no_relation,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8767,no_relation,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8768,no_relation,causes,0.7302967433402209,"Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving ISOTRETINOIN in any amount even for short periods of time; teratogenicity generally characterized by malformations involving craniofacial, cardiovascular, thymus and parathyroid gland, and CNS structures.",PREGNANCY,ISOTRETINOIN
8769,no_relation,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8770,DEMENTIA WITH LEWY BODIES causes PARKINSONISM,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8771,no_relation,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8772,DEMENTIA WITH LEWY BODIES causes PARKINSONISM,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8773,PARKINSONISM causes DEMENTIA WITH LEWY BODIES,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8774,PARKINSONISM causes DEMENTIA WITH LEWY BODIES,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8775,PARKINSONISM causes DEMENTIA WITH LEWY BODIES,causes,0.8366600265340759,"Ferman TJ, Boeve BF, Smith GE, et alDEMENTIA WITH LEWY BODIES may present as dementia and REM sleep behavior disorder without PARKINSONISM or hallucinations.",PARKINSONISM,DEMENTIA WITH LEWY BODIES
8776,no_relation,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8777,no_relation,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8778,HERPES SIMPLEX VIRUS causes VIRAL INFECTIONS,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8779,no_relation,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8780,no_relation,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8781,no_relation,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8782,no_relation,causes,0.3651483716701111,"Other VIRAL INFECTIONS (eg, cytomegalovirus, HERPES SIMPLEX VIRUS may cause liver inflammation along with their other manifestations.",VIRAL INFECTIONS,HERPES SIMPLEX VIRUS
8783,MOTION causes SEASICKNESS,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8784,no_relation,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8785,MOTION causes SEASICKNESS,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8786,MOTION causes SEASICKNESS,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8787,no_relation,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8788,no_relation,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8789,MOTION causes SEASICKNESS,causes,0.9950371902099888,SEASICKNESS has such a remarkable effect because both the sense of sight and touch are disturbed by the MOTION of a craft on water.,SEASICKNESS,MOTION
8790,no_relation,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8791,no_relation,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8792,no_relation,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8793,FANCONI SYNDROME causes HEPATOMEGALY,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8794,no_relation,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8795,HEPATOMEGALY causes FANCONI SYNDROME,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8796,FANCONI SYNDROME causes HEPATOMEGALY,causes,0.919145030018058,"Vomiting, HEPATOMEGALY poor growth, lethargy, diarrhea, and septicemia (usually  Escherichia coli ) develop, as does renal dysfunction (eg, proteinuria, aminoaciduria, FANCONI SYNDROME leading to metabolic acidosis and edema.",HEPATOMEGALY,FANCONI SYNDROME
8797,ENDOMETRIOSIS causes PAIN,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8798,ENDOMETRIOSIS causes PAIN,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8799,ENDOMETRIOSIS causes PAIN,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8800,ENDOMETRIOSIS causes PAIN,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8801,PAIN causes ENDOMETRIOSIS,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8802,no_relation,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8803,ENDOMETRIOSIS causes PAIN,causes,0.857142857142857,"• In women with a normal pelvic exam, failure to improve with a GnRH agonist typically excludes a diagnosis of ENDOMETRIOSIS as a cause of PAIN",PAIN,ENDOMETRIOSIS
8804,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8805,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8806,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8807,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8808,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8809,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8810,MALIGNANT HYPERTHERMIA causes SEVERE HYPERTHERMIA,causes,0.9931270663228408,"The most important causes of SEVERE HYPERTHERMIA are heatstroke, neuroleptic syndrome, and MALIGNANT HYPERTHERMIA of anesthesia.",SEVERE HYPERTHERMIA,MALIGNANT HYPERTHERMIA
8811,PV causes BUDD CHIARI SYNDROME,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8812,no_relation,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8813,BUDD CHIARI SYNDROME causes PV,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8814,BUDD CHIARI SYNDROME causes PV,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8815,no_relation,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8816,no_relation,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8817,BUDD CHIARI SYNDROME causes PV,causes,0.929981109950554,"Diagnosis  PV must be considered in patients with suggestive symptoms, particularly BUDD CHIARI SYNDROME but is often first suspected because of an abnormal CBC (eg, Hct > 54% in men or > 49% in women.",BUDD CHIARI SYNDROME,PV
8818,SUSTAINED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8819,SUSTAINED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8820,SUSTAINED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8821,SUSTAINED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8822,no_relation,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8823,SUSTAINED HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8824,no_relation,causes,0.994936676326182,Features of acclimatization include SUSTAINED HYPERVENTILATION which increases tissue oxygenation but also causes RESPIRATORY ALKALOSIS,RESPIRATORY ALKALOSIS,SUSTAINED HYPERVENTILATION
8825,IMIQUIMOD THERAPY causes PENILE CONDYLOMA WITH EROSION,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8826,IMIQUIMOD THERAPY causes PENILE CONDYLOMA WITH EROSION,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8827,no_relation,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8828,no_relation,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8829,IMIQUIMOD THERAPY causes PENILE CONDYLOMA WITH EROSION,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8830,IMIQUIMOD THERAPY causes PENILE CONDYLOMA WITH EROSION,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8831,no_relation,causes,0.8192880303729141,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
8832,PRIMARY PULMONARY HYPERTENSION causes DYSPNEA,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8833,PRIMARY PULMONARY HYPERTENSION causes DYSPNEA,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8834,PRIMARY PULMONARY HYPERTENSION causes DYSPNEA,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8835,PRIMARY PULMONARY HYPERTENSION causes DYSPNEA,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8836,PRIMARY PULMONARY HYPERTENSION causes DYSPNEA,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8837,PRIMARY PULMONARY HYPERTENSION causes DYSPNEA,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8838,no_relation,causes,0.97439119569462,May be associated with antiphospholipid syndrome PRIMARY PULMONARY HYPERTENSION  May present with DYSPNEA and physical findings of pulmonary hypertension as seen in chronic thromboembolic disease Pericarditis  May present with pleuritic chest pain similar to pulmonary embolism.,DYSPNEA,PRIMARY PULMONARY HYPERTENSION
8839,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8840,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8841,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8842,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8843,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8844,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8845,no_relation,causes,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
8846,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8847,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8848,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8849,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8850,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8851,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8852,no_relation,causes,0.437594974493684,"Osborne JP, Cocksedge S. Children with ASTHMA: will nebulised SALBUTAMOL reduce hospital admissions.",ASTHMA,SALBUTAMOL
8853,PROTEINURIA causes PREECLAMPSIA,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8854,no_relation,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8855,PROTEINURIA causes PREECLAMPSIA,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8856,PREECLAMPSIA causes PROTEINURIA,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8857,no_relation,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8858,no_relation,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8859,PREECLAMPSIA causes PROTEINURIA,causes,0.618852747755276,"Comments: • If a patient presents beyond 20 weeks with PROTEINURIA and hypertension, the most common diagnosis would be PREECLAMPSIA",PROTEINURIA,PREECLAMPSIA
8860,ENDOMETRIOSIS causes PAIN ASSOCIATED WITH DYSMENORRHEA,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8861,no_relation,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8862,ENDOMETRIOSIS causes PAIN ASSOCIATED WITH DYSMENORRHEA,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8863,ENDOMETRIOSIS causes PAIN ASSOCIATED WITH DYSMENORRHEA,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8864,ENDOMETRIOSIS causes PAIN ASSOCIATED WITH DYSMENORRHEA,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8865,PAIN ASSOCIATED WITH DYSMENORRHEA causes ENDOMETRIOSIS,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8866,ENDOMETRIOSIS causes PAIN ASSOCIATED WITH DYSMENORRHEA,causes,0.924500327042048,"More chronic, cyclic pain, particularly PAIN ASSOCIATED WITH DYSMENORRHEA dyspareunia, and menorrhagia, suggests ENDOMETRIOSIS or adenomyosis.",PAIN ASSOCIATED WITH DYSMENORRHEA,ENDOMETRIOSIS
8867,no_relation,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8868,no_relation,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8869,no_relation,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8870,FAMILIAL HEMIPLEGIC MIGRAINE causes HEMIPLEGIA,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8871,no_relation,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8872,no_relation,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8873,no_relation,causes,0.963086824686154,FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare variant of migraine with aura accompanied by HEMIPLEGIA or hemiparesis and other manifestations.,HEMIPLEGIA,FAMILIAL HEMIPLEGIC MIGRAINE
8874,no_relation,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8875,no_relation,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8876,no_relation,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8877,VIRUSES causes VIRAL HEPATITIS,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8878,no_relation,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8879,VIRUSES causes VIRAL HEPATITIS,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8880,VIRUSES causes VIRAL HEPATITIS,causes,0.8867963503478641,"125  Since albumin is prepared from pooled human plasma, it is a potential vehicle for transmission of human VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,VIRUSES
8881,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8882,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8883,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8884,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8885,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8886,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8887,FIBROMYALGIA causes ACHY PAIN,causes,0.9931270663228408,"FIBROMYALGIA is a common nonarticular disorder of unknown cause characterized by ACHY PAIN tenderness, and stiffness of muscles, areas of tendon insertions, and adjacent soft tissues.",ACHY PAIN,FIBROMYALGIA
8888,DERMATOPHYTES causes TINEA CAPITIS,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8889,TINEA CAPITIS causes DERMATOPHYTES,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8890,DERMATOPHYTES causes TINEA CAPITIS,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8891,DERMATOPHYTES causes TINEA CAPITIS,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8892,DERMATOPHYTES causes TINEA CAPITIS,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8893,DERMATOPHYTES causes TINEA CAPITIS,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8894,DERMATOPHYTES causes TINEA CAPITIS,causes,0.988371697650617,"Tinea Capitis  Treatment of TINEA CAPITIS (scalp ringworm) caused by susceptible DERMATOPHYTES (e.g.,  Trichophyton ,  Microsporum.",TINEA CAPITIS,DERMATOPHYTES
8895,MONOSYMPTOMATIC CELIAC DISEASE causes SHORT STATURE,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8896,no_relation,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8897,MONOSYMPTOMATIC CELIAC DISEASE causes SHORT STATURE,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8898,MONOSYMPTOMATIC CELIAC DISEASE causes SHORT STATURE,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8899,MONOSYMPTOMATIC CELIAC DISEASE causes SHORT STATURE,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8900,MONOSYMPTOMATIC CELIAC DISEASE causes SHORT STATURE,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8901,MONOSYMPTOMATIC CELIAC DISEASE causes SHORT STATURE,causes,0.994134846772434,"2]  Bonamico M, Scire G, Mariani P, Pasquino AM, Triglione P, Scaccia S, et al. SHORT STATURE as the primary manifestation of MONOSYMPTOMATIC CELIAC DISEASE",SHORT STATURE,MONOSYMPTOMATIC CELIAC DISEASE
8902,INTESTINAL BOTULISM causes BOTULINUM TOXIN POISONING,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8903,no_relation,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8904,BOTULINUM TOXIN POISONING causes INTESTINAL BOTULISM,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8905,no_relation,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8906,no_relation,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8907,no_relation,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8908,INTESTINAL BOTULISM causes BOTULINUM TOXIN POISONING,causes,0.5962847939999439,• INTESTINAL BOTULISM in infants is the most common form of BOTULINUM TOXIN POISONING with approximately 100 cases in the U.S. annually.,INTESTINAL BOTULISM,BOTULINUM TOXIN POISONING
8909,AEROBIC AND ANAEROBIC BACTERIA causes BACTERIAL VAGINOSIS,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8910,BACTERIAL VAGINOSIS causes AEROBIC AND ANAEROBIC BACTERIA,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8911,no_relation,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8912,AEROBIC AND ANAEROBIC BACTERIA causes BACTERIAL VAGINOSIS,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8913,no_relation,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8914,no_relation,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8915,no_relation,causes,0.609994281330419,PID usually also involves other AEROBIC AND ANAEROBIC BACTERIA including pathogens involved in bacterial vaginosis (see  BACTERIAL VAGINOSIS.,BACTERIAL VAGINOSIS,AEROBIC AND ANAEROBIC BACTERIA
8916,no_relation,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8917,RUBBER GLOVES causes LATEX SENSITIVITY,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8918,RUBBER GLOVES causes LATEX SENSITIVITY,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8919,RUBBER GLOVES causes LATEX SENSITIVITY,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8920,no_relation,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8921,RUBBER GLOVES causes LATEX SENSITIVITY,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8922,RUBBER GLOVES causes LATEX SENSITIVITY,causes,0.858116330321033,"Latex Sensitivity  LATEX SENSITIVITY is an exaggerated immune response to water soluble proteins in latex products (eg, RUBBER GLOVES dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs), causing urticaria, angioedema, a nd anaphylaxis.",LATEX SENSITIVITY,RUBBER GLOVES
8923,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8924,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8925,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8926,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8927,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8928,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8929,no_relation,causes,0.488677777425221,"ACELLULAR (A) PERTUSSIS VACCINES containing semipurified or purified components of  B PERTUSSIS  (eg, pertussis toxin; filamentous hemagglutinin; fimbriae; and pertactin, a protein) and D and T (DTaP) are usually preferred because they less often cause fever and local reactions.",ACELLULAR (A) PERTUSSIS VACCINES,B PERTUSSIS
8930,no_relation,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8931,no_relation,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8932,no_relation,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8933,no_relation,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8934,P AERUGINOSA causes ECTHYMA GANGRENOSUM,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8935,no_relation,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8936,no_relation,causes,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
8937,no_relation,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8938,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8939,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8940,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8941,TULAREMIA causes FRANCISELLA TULARENSIS,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8942,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8943,FRANCISELLA TULARENSIS causes TULAREMIA,causes,0.997458699830735,101  Tularemia  Treatment of TULAREMIA caused by  FRANCISELLA TULARENSIS,TULAREMIA,FRANCISELLA TULARENSIS
8944,MERALGIA PARESTHETICA causes PAIN,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8945,MERALGIA PARESTHETICA causes PAIN,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8946,no_relation,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8947,MERALGIA PARESTHETICA causes PAIN,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8948,no_relation,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8949,MERALGIA PARESTHETICA causes PAIN,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8950,no_relation,causes,1.0,"No trauma history in MERALGIA PARESTHETICA Multiple sclerosis  Generally optic neuritis, intranuclear ophthalmoplegia, sensorimotor or cerebellar symptoms before pain, but PAIN can be the presenting symptom.",PAIN,MERALGIA PARESTHETICA
8951,no_relation,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8952,PROGRESSIVE SUPRANUCLEAR PALSY causes APATHY,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8953,no_relation,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8954,no_relation,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8955,no_relation,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8956,APATHY causes PROGRESSIVE SUPRANUCLEAR PALSY,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8957,no_relation,causes,0.971285862357264,"Aphasia, apraxia, and agnosia are rare  Usually found in advanced HIV disease PROGRESSIVE SUPRANUCLEAR PALSY  Prominent slowness of thought, APATHY and depression.",APATHY,PROGRESSIVE SUPRANUCLEAR PALSY
8958,RICKETTSIA causes EASTERN TICK BORNE RICKETTSIOSES,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8959,RICKETTSIA causes EASTERN TICK BORNE RICKETTSIOSES,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8960,RICKETTSIA causes EASTERN TICK BORNE RICKETTSIOSES,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8961,RICKETTSIA causes EASTERN TICK BORNE RICKETTSIOSES,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8962,RICKETTSIA causes EASTERN TICK BORNE RICKETTSIOSES,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8963,EASTERN TICK BORNE RICKETTSIOSES causes RICKETTSIA,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8964,RICKETTSIA causes EASTERN TICK BORNE RICKETTSIOSES,causes,0.997458699830735,EASTERN TICK BORNE RICKETTSIOSES  EASTERN TICK BORNE RICKETTSIOSES are caused by various RICKETTSIA transmitted by ixodid ticks.,EASTERN TICK BORNE RICKETTSIOSES,RICKETTSIA
8965,BACTERIA causes SEPTIC ARTHRITIS,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8966,BACTERIA causes SEPTIC ARTHRITIS,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8967,BACTERIA causes SEPTIC ARTHRITIS,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8968,BACTERIA causes SEPTIC ARTHRITIS,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8969,BACTERIA causes SEPTIC ARTHRITIS,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8970,no_relation,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8971,no_relation,causes,0.927172649945531,CSF and joint fluid Gram stains reveal BACTERIA in 70 to 80% of cases of meningitis and SEPTIC ARTHRITIS respectively.,SEPTIC ARTHRITIS,BACTERIA
8972,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8973,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8974,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8975,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8976,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8977,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8978,FUNCTIONAL CAP causes PAIN,causes,0.9797958971132712,FUNCTIONAL CAP may result in PAIN similar to that of physiologic origin.,PAIN,FUNCTIONAL CAP
8979,no_relation,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8980,no_relation,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8981,no_relation,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8982,no_relation,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8983,BLOODY DIARRHEA causes SEVERE DIARRHEA,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8984,no_relation,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8985,no_relation,causes,0.6868028197434449,"Stool cultures or examinations for ova and parasites are rarely indicated without a supporting travel history or supporting symptoms (eg, fever, BLOODY DIARRHEA, acute onset of SEVERE DIARRHEA)",SEVERE DIARRHEA,BLOODY DIARRHEA
8986,no_relation,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8987,WARFARIN THERAPY causes ATRIAL FIBRILLATION,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8988,no_relation,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8989,no_relation,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8990,no_relation,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8991,no_relation,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8992,no_relation,causes,0.40824829046386296,"CONCLUSION  In older patients with ATRIAL FIBRILLATION who were receiving WARFARIN THERAPY at hospital discharge, a bleeding risk model predicted major bleeding.",ATRIAL FIBRILLATION,WARFARIN THERAPY
8993,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
8994,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
8995,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
8996,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
8997,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
8998,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
8999,PIRIFORMIS SYNDROME causes PAIN,causes,0.9899494936611658,"PIRIFORMIS SYNDROME  PIRIFORMIS SYNDROME is compression of the sciatic nerve by the piriformis muscle, causing PAIN",PAIN,PIRIFORMIS SYNDROME
9000,no_relation,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9001,no_relation,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9002,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME causes EOSINOPHILIA,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9003,no_relation,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9004,no_relation,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9005,no_relation,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9006,no_relation,causes,0.847998304005088,"IDIOPATHIC HYPEREOSINOPHILIC SYNDROME  (Disseminated Eosinophilic Collagen Disease); Eosinophilic Leukemia; Loffler's Fibroplastic Endocarditis with EOSINOPHILIA  IDIOPATHIC HYPEREOSINOPHILIC SYNDROME is a condition defined by peripheral blood eosinophilia > 1500/μL persisting ≥ 6 mo with manifestations of organ system involvement or dysfunction directly related to eosinophilia in the absence of parasitic, allergic, or other causes of eosinophilia.",EOSINOPHILIA,IDIOPATHIC HYPEREOSINOPHILIC SYNDROME
9007,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9008,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9009,no_relation,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9010,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9011,no_relation,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9012,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9013,no_relation,causes,0.9284766908852592,"167  Fixed combination Vaccine Containing DTaP, HepB, and IPV (DTaP HepB IPV; Pediarix ® )  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., yeast, NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, hepatitis B, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
9014,ERYTHROMELALGIA causes PAIN,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9015,no_relation,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9016,PAIN causes ERYTHROMELALGIA,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9017,ERYTHROMELALGIA causes PAIN,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9018,ERYTHROMELALGIA causes PAIN,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9019,ERYTHROMELALGIA causes PAIN,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9020,ERYTHROMELALGIA causes PAIN,causes,0.7826237921249258,There is much urgency within pharmaceutical companies to provide a solution to those who suffer with PAIN such as that with ERYTHROMELALGIA,PAIN,ERYTHROMELALGIA
9021,GLOSSOPHARYNGEAL NEURALGIA causes PAIN,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9022,GLOSSOPHARYNGEAL NEURALGIA causes PAIN,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9023,GLOSSOPHARYNGEAL NEURALGIA causes PAIN,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9024,GLOSSOPHARYNGEAL NEURALGIA causes PAIN,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9025,GLOSSOPHARYNGEAL NEURALGIA causes PAIN,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9026,PAIN causes GLOSSOPHARYNGEAL NEURALGIA,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9027,GLOSSOPHARYNGEAL NEURALGIA causes PAIN,causes,1.0,"GLOSSOPHARYNGEAL NEURALGIA from cranial nerve IX, causes PAIN in the back of the throat or behind the angle of the jaw.",PAIN,GLOSSOPHARYNGEAL NEURALGIA
9028,no_relation,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9029,no_relation,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9030,no_relation,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9031,JOINT causes OSTEOARTHRITIS,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9032,JOINT causes OSTEOARTHRITIS,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9033,no_relation,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9034,OSTEOARTHRITIS causes JOINT,causes,0.8955334711889901,"X ray films show subchondral erosive changes causing a 'gull wing' appearance  May be a severe form of nodal generalized osteoarthritis, although there does not seem to be a familial tendency Osteoarthritis due to trauma or mechanical factors  An injury to a JOINT may predispose it to develop OSTEOARTHRITIS",JOINT,OSTEOARTHRITIS
9035,NEISSERIA MENINGITIDIS causes MENINGOCOCCAL DISEASE,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9036,no_relation,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9037,no_relation,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9038,no_relation,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9039,no_relation,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9040,MENINGOCOCCAL DISEASE causes NEISSERIA MENINGITIDIS,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9041,no_relation,causes,0.5656854249492379,191  NEISSERIA MENINGITIDIS Infections  Prophylaxis to prevent meningococcal disease in household or other close contacts of individuals with invasive MENINGOCOCCAL DISEASE   +    when the risk of infection is high.,MENINGOCOCCAL DISEASE,NEISSERIA MENINGITIDIS
9042,SOMATOSTATINOMAS causes SECRETORY DIARRHEA,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9043,SOMATOSTATINOMAS causes SECRETORY DIARRHEA,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9044,no_relation,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9045,SOMATOSTATINOMAS causes SECRETORY DIARRHEA,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9046,SECRETORY DIARRHEA causes SOMATOSTATINOMAS,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9047,no_relation,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9048,SOMATOSTATINOMAS causes SECRETORY DIARRHEA,causes,0.975900072948533,"33  Endocrine causes of SECRETORY DIARRHEA include hyperthyroidism, Addison disease, and a group of rare tumors of the endocrine cells of the gut, including gastrinomas, carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), SOMATOSTATINOMAS and medullary carcinoma of the thyroid.",SECRETORY DIARRHEA,SOMATOSTATINOMAS
9049,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9050,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9051,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9052,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9053,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9054,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9055,VZV causes CHICKENPOX,causes,0.9931270663228408,"1 ,   4 ,   8 ,   9 ,   65 ,   67 •    VZV causes varicella (CHICKENPOX) and herpes zoster (shingles, zoster).",CHICKENPOX,VZV
9056,H DUCREYI causes CHANCROID,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9057,H DUCREYI causes CHANCROID,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9058,no_relation,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9059,no_relation,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9060,H DUCREYI causes CHANCROID,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9061,H DUCREYI causes CHANCROID,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9062,H DUCREYI causes CHANCROID,causes,0.973067265599682,"b ,   c  Chancroid  Has been used for treatment of CHANCROID caused by  H DUCREYI",CHANCROID,H DUCREYI
9063,TYPICAL TRIGEMINAL NEURALGIA causes SHARP ELECTRIC LIKE PAINS,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9064,TYPICAL TRIGEMINAL NEURALGIA causes SHARP ELECTRIC LIKE PAINS,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9065,TYPICAL TRIGEMINAL NEURALGIA causes SHARP ELECTRIC LIKE PAINS,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9066,TYPICAL TRIGEMINAL NEURALGIA causes SHARP ELECTRIC LIKE PAINS,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9067,no_relation,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9068,no_relation,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9069,no_relation,causes,0.8164965809277259,"Treatments for typical trigeminal neuralgia, as discussed in the rest of this paper, are likely to relieve the SHARP ELECTRIC LIKE PAINS that are triggered by light touch even in patients with aTYPICAL TRIGEMINAL NEURALGIA but are less likely to relieve the constant, untriggered pains.",SHARP ELECTRIC LIKE PAINS,TYPICAL TRIGEMINAL NEURALGIA
9070,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9071,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9072,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9073,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9074,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9075,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9076,no_relation,causes,0.3973597071195129,"120   Because few patients mount an effective immune response—as manifested by seroconversion from HBV SURFACE ANTIGEN (HBSAG) to surface antibody (HBVsAb)—and most anti HBV therapy suppresses rather than cures the infection, treatment is usually prolonged; indeed, to maintain HBV suppression, anti HBV therapy may need to be continued indefinitely.",HBV SURFACE ANTIGEN,HBSAG
9077,no_relation,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9078,no_relation,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9079,OPTIC NERVE causes NEURITIS,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9080,no_relation,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9081,no_relation,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9082,no_relation,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9083,no_relation,causes,0.938314863256836,"NEURITIS of the retinal fibers of the OPTIC NERVE causing disturbed vision, contracted field, enlarged blind spot, and fundus findings such as exudates, hemorrhages, and abnormal condition of the blood vessels.",OPTIC NERVE,NEURITIS
9084,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9085,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9086,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9087,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9088,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9089,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9090,YERSINIA PESTIS causes PLAGUE,causes,0.9838699100999068,101  Plague  Treatment of PLAGUE caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
9091,DERMATOPHYTES causes TINEA CRURIS (JOCK ITCH),causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9092,DERMATOPHYTES causes TINEA CRURIS (JOCK ITCH),causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9093,TINEA CRURIS (JOCK ITCH) causes DERMATOPHYTES,causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9094,no_relation,causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9095,no_relation,causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9096,DERMATOPHYTES causes TINEA CRURIS (JOCK ITCH),causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9097,TINEA CRURIS (JOCK ITCH) causes DERMATOPHYTES,causes,0.9933992677987828,"Other findings: tinea pedis (athlete's foot) and TINEA CRURIS (JOCK ITCH) are common  Broad category of fungal nail disease; may be caused by DERMATOPHYTES yeasts, or molds Tinea unguium  Major subtype of onychomycosis.",TINEA CRURIS (JOCK ITCH),DERMATOPHYTES
9098,no_relation,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9099,no_relation,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9100,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS causes SEIZURES,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9101,no_relation,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9102,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS causes SEIZURES,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9103,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS causes SEIZURES,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9104,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS causes SEIZURES,causes,0.843274042711568,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
9105,no_relation,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9106,no_relation,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9107,no_relation,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9108,no_relation,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9109,HYPERTENSION causes ACEBUTOLOL TO DIURETICS IN,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9110,no_relation,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9111,no_relation,causes,0.33541019662496896,"Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of ACEBUTOLOL TO DIURETICS IN HYPERTENSION",HYPERTENSION,ACEBUTOLOL TO DIURETICS IN
9112,no_relation,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9113,EBV SERONEGATIVE causes EBV INFECTION,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9114,EBV INFECTION causes EBV SERONEGATIVE,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9115,EBV SERONEGATIVE causes EBV INFECTION,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9116,EBV SERONEGATIVE causes EBV INFECTION,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9117,EBV SERONEGATIVE causes EBV INFECTION,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9118,EBV SERONEGATIVE causes EBV INFECTION,causes,0.847998304005088,Only 5% to 10% of persons over age 40 are EBV SERONEGATIVE and hence susceptible to primary EBV INFECTION ( 4.,EBV INFECTION,EBV SERONEGATIVE
9119,no_relation,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9120,no_relation,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9121,no_relation,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9122,no_relation,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9123,no_relation,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9124,LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B causes VARICELLA ZOSTER VIRUS,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9125,no_relation,causes,0.468521285665818,"Rituximab is generally well tolerated, although one should be aware of the potential of reactivation of LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B, cytomegalovirus, and VARICELLA ZOSTER VIRUS",LATENT VIRAL INFECTIONS INCLUDING HEPATITIS B,VARICELLA ZOSTER VIRUS
9126,VIRAL INFECTIONS causes HUMAN T LYMPHOTROPIC VIRUSES,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9127,no_relation,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9128,no_relation,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9129,VIRAL INFECTIONS causes HUMAN T LYMPHOTROPIC VIRUSES,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9130,no_relation,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9131,no_relation,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9132,no_relation,causes,0.617213399848368,"VIRAL INFECTIONS in short term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and HUMAN T LYMPHOTROPIC VIRUSES",VIRAL INFECTIONS,HUMAN T LYMPHOTROPIC VIRUSES
9133,PMR causes PROXIMAL MUSCLE PAIN,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9134,no_relation,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9135,no_relation,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9136,PMR causes PROXIMAL MUSCLE PAIN,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9137,no_relation,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9138,no_relation,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9139,no_relation,causes,0.975900072948533,PMR is characterized by PROXIMAL MUSCLE PAIN with nocturnal and early morning worsening.,PROXIMAL MUSCLE PAIN,PMR
9140,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9141,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9142,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9143,no_relation,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9144,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9145,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9146,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.986393923832143,441  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9147,no_relation,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9148,no_relation,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9149,PROXIMAL INTERPHALANGEAL JOINTS causes CHRONIC TOPHACEOUS GOUT,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9150,no_relation,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9151,CHRONIC TOPHACEOUS GOUT causes PROXIMAL INTERPHALANGEAL JOINTS,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9152,no_relation,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9153,no_relation,causes,0.7302967433402209,"If gout is suspected, fluid from the involved joint(s) should be examined for crystals  CHRONIC TOPHACEOUS GOUT may involve the distal interphalangeal and PROXIMAL INTERPHALANGEAL JOINTS and first metatarsophalangeal joint causing angulation deformities and bony enlargement akin to osteoarthritis.",PROXIMAL INTERPHALANGEAL JOINTS,CHRONIC TOPHACEOUS GOUT
9154,ARTHRITIS causes CHARCOT'S JOINT,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9155,CHARCOT'S JOINT causes ARTHRITIS,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9156,no_relation,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9157,CHARCOT'S JOINT causes ARTHRITIS,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9158,no_relation,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9159,no_relation,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9160,CHARCOT'S JOINT causes ARTHRITIS,causes,0.393919298579168,"ETIOLOGY: Arthritis may result from infections (e.g., rheumatic fever, staphylococcal infections, gonorrhea, tuberculosis), metabolic disturbances (e.g., gout, calcium pyrophosphate crystal disease), multisystem autoimmune diseases (e.g., psoriasis, rheumatoid ARTHRITIS, systemic lupus erythematosus), neuropathies (e.g., CHARCOT'S JOINT joint trauma, endocrine diseases (e.g., acromegaly), and other illnesses.",CHARCOT'S JOINT,ARTHRITIS
9161,no_relation,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9162,no_relation,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9163,no_relation,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9164,no_relation,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9165,CELIAC DISEASE causes IRON DEFICIENCY,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9166,IRON DEFICIENCY causes CELIAC DISEASE,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9167,CELIAC DISEASE causes IRON DEFICIENCY,causes,0.995893206467704,• IRON DEFICIENCY is a common sign of CELIAC DISEASE and is often seen in newly diagnosed patients.,IRON DEFICIENCY,CELIAC DISEASE
9168,MS causes SPASTICITY,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9169,no_relation,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9170,MS causes SPASTICITY,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9171,MS causes SPASTICITY,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9172,MS causes SPASTICITY,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9173,MS causes SPASTICITY,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9174,MS causes SPASTICITY,causes,0.8888888888888891,The weakness associated with MS is of the upper motor neuron type and is accompanied by SPASTICITY and increased reflexes.,SPASTICITY,MS
9175,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS causes IGE MEDIATED HYPERSENSITIVITY REACTION,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9176,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS causes IGE MEDIATED HYPERSENSITIVITY REACTION,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9177,IGE MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9178,IGE MEDIATED HYPERSENSITIVITY REACTION causes ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9179,no_relation,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9180,no_relation,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9181,no_relation,causes,0.3779644730092271,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS  ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is an IGE MEDIATED HYPERSENSITIVITY REACTION to colonization of the airways by  Aspergillus  species.,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,IGE MEDIATED HYPERSENSITIVITY REACTION
9182,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9183,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9184,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9185,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9186,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9187,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9188,PHN causes PAIN,causes,0.9282791216329142,"PHN involves three types of pain: a constant burning or deep aching; an intermittent spontaneous PAIN with a jabbing or lancinating quality; and a superficial, sharp, or radiating pain or itching provoked by light touch (allodynia), which is present in 90% of persons with PHN and often interferes with sleep.",PAIN,PHN
9189,FUNGUS causes MYCOSIS,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9190,no_relation,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9191,MYCOSIS causes FUNGUS,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9192,FUNGUS causes MYCOSIS,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9193,FUNGUS causes MYCOSIS,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9194,FUNGUS causes MYCOSIS,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9195,no_relation,causes,0.964901281354015,mycotic    (             audio )  Caused by or infected with FUNGUS; concerning MYCOSIS,MYCOSIS,FUNGUS
9196,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9197,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9198,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9199,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9200,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9201,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9202,no_relation,causes,0.5303300858899109,"Reindollar RH, Novak M, Tho SP, McDonough PG ADULT ONSET AMENORRHEA: a study of 262 patients.",ADULT ONSET AMENORRHEA,PG
9203,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9204,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9205,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9206,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9207,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9208,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9209,TREPONEMA PERTENUE causes YAWS,causes,0.857492925712544,"c ,   116 ,   i  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.",YAWS,TREPONEMA PERTENUE
9210,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS causes SALMONELLA TYPHI,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9211,SALMONELLA TYPHI causes TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9212,SALMONELLA TYPHI causes TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9213,SALMONELLA TYPHI causes TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9214,SALMONELLA TYPHI causes TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9215,SALMONELLA TYPHI causes TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9216,SALMONELLA TYPHI causes TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,causes,0.917662935482247,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9217,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9218,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9219,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9220,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9221,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9222,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9223,no_relation,causes,0.7921180343813391,Progressive HYDROCEPHALUS occurs rarely with PORENCEPHALY,HYDROCEPHALUS,PORENCEPHALY
9224,TOURETTE SYNDROME causes VOCAL AND MOTOR TICS,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9225,TOURETTE SYNDROME causes VOCAL AND MOTOR TICS,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9226,VOCAL AND MOTOR TICS causes TOURETTE SYNDROME,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9227,TOURETTE SYNDROME causes VOCAL AND MOTOR TICS,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9228,no_relation,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9229,TOURETTE SYNDROME causes VOCAL AND MOTOR TICS,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9230,TOURETTE SYNDROME causes VOCAL AND MOTOR TICS,causes,0.9878291611472622,VOCAL AND MOTOR TICS that begin early in life and then wax and wane are prominent features of TOURETTE SYNDROME (TS.,VOCAL AND MOTOR TICS,TOURETTE SYNDROME
9231,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9232,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9233,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9234,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9235,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9236,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9237,no_relation,causes,0.314485451016576,LACTULOSE reduced symptoms of HEPATIC ENCEPHALOPATHY in an RCT (tvml 110tvml ) Labetalol  Noncardioselective b blocker with a 1 blocking properties.,HEPATIC ENCEPHALOPATHY,LACTULOSE
9238,ACUTE DIARRHEA causes CHRONIC DIARRHEA,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9239,CHRONIC DIARRHEA causes ACUTE DIARRHEA,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9240,no_relation,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9241,no_relation,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9242,no_relation,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9243,no_relation,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9244,ACUTE DIARRHEA causes CHRONIC DIARRHEA,causes,0.917662935482247,"Finally, ACUTE DIARRHEA may represent the initial stages of CHRONIC DIARRHEA",CHRONIC DIARRHEA,ACUTE DIARRHEA
9245,ENDOMETRIOMAS causes PAIN,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9246,ENDOMETRIOMAS causes PAIN,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9247,no_relation,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9248,ENDOMETRIOMAS causes PAIN,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9249,ENDOMETRIOMAS causes PAIN,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9250,ENDOMETRIOMAS causes PAIN,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9251,ENDOMETRIOMAS causes PAIN,causes,0.9578262852211508,SURGICAL EXCISION OF OVARIAN MASSES  Ovarian Endometriosis Cysts (Endometriomas)  ENDOMETRIOMAS require surgical excision if they cause PAIN or become enlarged.,PAIN,ENDOMETRIOMAS
9252,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9253,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9254,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9255,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9256,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9257,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9258,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELER'S DIARRHEA,causes,0.997054485501582,"Over 75% of cases of TRAVELER'S DIARRHEA are caused by bacteria, with ENTEROTOXIGENIC  ESCHERICHIA COLI  being the most frequent cause.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
9259,ORAL CLONIDINE causes WITHDRAWAL SYNDROME,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9260,ORAL CLONIDINE causes WITHDRAWAL SYNDROME,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9261,ORAL CLONIDINE causes WITHDRAWAL SYNDROME,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9262,no_relation,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9263,ORAL CLONIDINE causes WITHDRAWAL SYNDROME,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9264,ORAL CLONIDINE causes WITHDRAWAL SYNDROME,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9265,no_relation,causes,0.640512615220348,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
9266,VZV causes VARICELLA,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9267,VZV causes VARICELLA,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9268,VARICELLA causes VZV,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9269,VZV causes VARICELLA,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9270,VZV causes VARICELLA,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9271,VZV causes VARICELLA,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9272,VARICELLA causes VZV,causes,0.9878291611472622,'Breakthrough' VARICELLA that occurs in an immunized person after exposure to VZV is almost always mild with low grade fever and few cutaneous lesions,VARICELLA,VZV
9273,DRUG causes DRUG HYPERSENSITIVITY,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9274,DRUG causes DRUG HYPERSENSITIVITY,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9275,no_relation,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9276,no_relation,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9277,DRUG causes DRUG HYPERSENSITIVITY,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9278,DRUG causes DRUG HYPERSENSITIVITY,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9279,DRUG causes DRUG HYPERSENSITIVITY,causes,0.9722718241315028,DRUG HYPERSENSITIVITY  DRUG HYPERSENSITIVITY is an immune mediated reaction to a DRUG,DRUG HYPERSENSITIVITY,DRUG
9280,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9281,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9282,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9283,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9284,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9285,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9286,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA causes BLISTERING,causes,1.0,"33  Epidermolysis Bullosa  RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA is a congenital bullous disease with recurrent BLISTERING and scarring, particularly on the hands and feet [ see 2:IX Vesiculobullous Diseases.",BLISTERING,RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
9287,no_relation,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9288,THROMBOCYTOPENIA causes THROMBOTIC THROMBOCYTOPENIC PURPURA,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9289,THROMBOCYTOPENIA causes THROMBOTIC THROMBOCYTOPENIC PURPURA,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9290,no_relation,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9291,no_relation,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9292,no_relation,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9293,no_relation,causes,0.985329278164293,"THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS)  THROMBOTIC THROMBOCYTOPENIC PURPURA and hemolytic uremic syndrome are acute, fulminant disorders characterized by THROMBOCYTOPENIA and microangiopathic hemolytic anemia.",THROMBOCYTOPENIA,THROMBOTIC THROMBOCYTOPENIC PURPURA
9294,no_relation,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9295,no_relation,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9296,no_relation,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9297,no_relation,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9298,CLL causes PROGRESSIVE LYMPHADENOPATHY,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9299,CLL causes PROGRESSIVE LYMPHADENOPATHY,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9300,CLL causes PROGRESSIVE LYMPHADENOPATHY,causes,0.9494253265550828,"CLL patients with Richter's transformation (approximately 10%) have sudden onset of B symptoms, PROGRESSIVE LYMPHADENOPATHY extra nodal involvement, an M spike, increased LDH, and/or hypercalcemia.",PROGRESSIVE LYMPHADENOPATHY,CLL
9301,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9302,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9303,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9304,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9305,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9306,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9307,STREPTOCOCCI causes STREPTOCOCCAL INFECTIONS,causes,0.9901475429766742,"5 ,   30 ,   57  Other STREPTOCOCCAL INFECTIONS  Treatment of mild to moderately severe infections (without bacteremia) caused by susceptible STREPTOCOCCI including upper respiratory tract infections and scarlet fever.",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
9308,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME causes HYPOPARATHYROIDISM,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9309,no_relation,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9310,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME causes HYPOPARATHYROIDISM,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9311,no_relation,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9312,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME causes HYPOPARATHYROIDISM,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9313,HYPOPARATHYROIDISM causes TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9314,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME causes HYPOPARATHYROIDISM,causes,0.792593923901217,"a TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME consists mainly of adrenal insufficiency, HYPOPARATHYROIDISM and mucocutaneous candidiasis.",HYPOPARATHYROIDISM,TYPE I AUTOIMMUNE POLYGLANDULAR SYNDROME
9315,BACTERIA causes SEPTIC ARTHRITIS,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9316,BACTERIA causes SEPTIC ARTHRITIS,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9317,BACTERIA causes SEPTIC ARTHRITIS,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9318,no_relation,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9319,BACTERIA causes SEPTIC ARTHRITIS,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9320,no_relation,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9321,BACTERIA causes SEPTIC ARTHRITIS,causes,0.997054485501582,BC]  Specific recommendation: • Know the local sensitivity data of BACTERIA in addition to the most frequent cause of SEPTIC ARTHRITIS in your local community to aid the selection of antimicrobial agents before culture and sensitivity results.,SEPTIC ARTHRITIS,BACTERIA
9322,PERSISTENT MEASLES VIRUS INFECTION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9323,SUBACUTE SCLEROSING PANENCEPHALITIS causes PERSISTENT MEASLES VIRUS INFECTION,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9324,PERSISTENT MEASLES VIRUS INFECTION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9325,PERSISTENT MEASLES VIRUS INFECTION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9326,PERSISTENT MEASLES VIRUS INFECTION causes SUBACUTE SCLEROSING PANENCEPHALITIS,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9327,no_relation,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9328,no_relation,causes,0.7559289460184542,SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) is probably a PERSISTENT MEASLES VIRUS INFECTION (see  Measles.,SUBACUTE SCLEROSING PANENCEPHALITIS,PERSISTENT MEASLES VIRUS INFECTION
9329,no_relation,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9330,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9331,DIABETIC KETOACIDOSIS causes DIABETES,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9332,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9333,no_relation,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9334,no_relation,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9335,DIABETES causes DIABETIC KETOACIDOSIS,causes,0.9901475429766742,DIABETIC KETOACIDOSIS may be the presenting feature of previously unrecognized DIABETES,DIABETIC KETOACIDOSIS,DIABETES
9336,no_relation,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9337,ANAL CROHN'S DISEASE causes DIARRHEA,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9338,ANAL CROHN'S DISEASE causes DIARRHEA,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9339,DIARRHEA causes ANAL CROHN'S DISEASE,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9340,no_relation,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9341,no_relation,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9342,no_relation,causes,0.981980506061966,"Other symptoms of colitis may be present, including DIARRHEA and bleeding or weight loss  ANAL CROHN'S DISEASE is the most significant secondary diagnosis to consider in patients with atypical fissures.",DIARRHEA,ANAL CROHN'S DISEASE
9343,PV causes THROMBOCYTHEMIA,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9344,THROMBOCYTHEMIA causes PV,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9345,no_relation,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9346,no_relation,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9347,PV causes THROMBOCYTHEMIA,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9348,no_relation,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9349,THROMBOCYTHEMIA causes PV,causes,0.7559289460184542,• A review on the natural history of PV addresses the vascular complications in patients with PV in regard to microvascular circulatory disturbances typical of THROMBOCYTHEMIA and points out that the risk of major vascular ischemic episodes in poorly controlled PV with a hematocrit between 45% to 50% is high ( 2.,THROMBOCYTHEMIA,PV
9350,no_relation,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9351,no_relation,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9352,no_relation,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9353,no_relation,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9354,C PSITTACI causes PSITTACOSIS,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9355,C PSITTACI causes PSITTACOSIS,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9356,no_relation,causes,0.458831467741123,"The diagnosis of PSITTACOSIS is best confirmed by serologic studies, because  C PSITTACI  is difficult to isolate from blood or infected secretions.",PSITTACOSIS,C PSITTACI
9357,no_relation,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9358,no_relation,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9359,HEMIHYPERTROPHY causes BWS,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9360,no_relation,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9361,no_relation,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9362,BWS causes HEMIHYPERTROPHY,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9363,no_relation,causes,0.320256307610174,Individuals who do not have BWS can also have HEMIHYPERTROPHY,HEMIHYPERTROPHY,BWS
9364,MERALGIA PARESTHETICA causes PAIN,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9365,MERALGIA PARESTHETICA causes PAIN,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9366,PAIN causes MERALGIA PARESTHETICA,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9367,MERALGIA PARESTHETICA causes PAIN,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9368,MERALGIA PARESTHETICA causes PAIN,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9369,PAIN causes MERALGIA PARESTHETICA,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9370,MERALGIA PARESTHETICA causes PAIN,causes,0.78086880944303,Occasionally followed by shoulder girdle muscle atrophy  Entrapment MERALGIA PARESTHETICA  Lateral femoral cutaneous  Thigh  Yes  No  Stinging PAIN in the anterolateral thigh.,PAIN,MERALGIA PARESTHETICA
9371,DEXTROCARDIA causes PCD,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9372,no_relation,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9373,DEXTROCARDIA causes PCD,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9374,DEXTROCARDIA causes PCD,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9375,PCD causes DEXTROCARDIA,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9376,PCD causes DEXTROCARDIA,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9377,no_relation,causes,0.948683298050514,"PATHOGENESIS  The underlying cause of all three manifestations of PCD (i.e., bronchiectasis, DEXTROCARDIA and male infertility) is the loss of adequate ciliary beating; this defect results in an inability (1) to escalate respiratory secretions from small airways; (2) to drive the flow of extraembryonic fluid that establishes left right symmetry in the embryo; and (3) to propel spermatzoa forward.",DEXTROCARDIA,PCD
9378,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) causes PHOTOSENSITIVITY,causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9379,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) causes PHOTOSENSITIVITY,causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9380,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) causes PHOTOSENSITIVITY,causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9381,PHOTOSENSITIVITY causes SYSTEMIC LUPUS ERYTHEMATOSUS (SLE),causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9382,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) causes PHOTOSENSITIVITY,causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9383,PHOTOSENSITIVITY causes SYSTEMIC LUPUS ERYTHEMATOSUS (SLE),causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9384,no_relation,causes,0.8006407690254359,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
9385,no_relation,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9386,no_relation,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9387,ANEMIA causes RENAL DYSFUNCTION,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9388,no_relation,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9389,ANEMIA causes RENAL DYSFUNCTION,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9390,no_relation,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9391,no_relation,causes,0.304997140665209,"Diagnosis   Classically, TTP is defined by a pentad of clinical findings: fever, thrombocytopenia, microangiopathic hemolytic ANEMIA neurologic abnormalities, and RENAL DYSFUNCTION",RENAL DYSFUNCTION,ANEMIA
9392,FMS causes PAIN,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9393,FMS causes PAIN,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9394,FMS causes PAIN,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9395,FMS causes PAIN,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9396,no_relation,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9397,FMS causes PAIN,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9398,FMS causes PAIN,causes,0.929981109950554,• Emphasize that FMS does not 'kill or cripple' but the PAIN is real and not imaginary,PAIN,FMS
9399,ESSENTIAL TREMOR causes PROPRANOLOL,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9400,no_relation,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9401,ESSENTIAL TREMOR causes PROPRANOLOL,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9402,PROPRANOLOL causes ESSENTIAL TREMOR,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9403,no_relation,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9404,no_relation,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9405,no_relation,causes,0.629940788348712,"Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and PROPRANOLOL in ESSENTIAL TREMOR: a double blind controlled clinical trial.",ESSENTIAL TREMOR,PROPRANOLOL
9406,no_relation,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9407,no_relation,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9408,CONFUSION causes RECURRENT TTP,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9409,no_relation,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9410,RECURRENT TTP causes CONFUSION,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9411,no_relation,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9412,RECURRENT TTP causes CONFUSION,causes,0.971285862357264,C]  Specific recommendation: • Inform patients that many different systemic symptoms may herald the onset of RECURRENT TTP such as: ◊ Weakness ◊ CONFUSION ◊ Severe headaches ◊ Gastrointestinal symptoms ◊ Chest pain ◊ Dyspnea ◊ Bruising or excessive bleeding.,CONFUSION,RECURRENT TTP
9413,no_relation,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9414,no_relation,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9415,COAGULASE NEGATIVE STAPHYLOCOCCI causes STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9416,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME causes COAGULASE NEGATIVE STAPHYLOCOCCI,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9417,no_relation,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9418,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME causes COAGULASE NEGATIVE STAPHYLOCOCCI,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9419,no_relation,causes,0.8090398349558909,Clinical Manifestations of STAPHYLOCOCCAL TOXIC SHOCK SYNDROME]  COAGULASE NEGATIVE STAPHYLOCOCCI  S. epidermidis  and other coagulase negative staphylococcal species are organisms of low pathogenic potential that are universally present as part of the normal skin flora.,STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,COAGULASE NEGATIVE STAPHYLOCOCCI
9420,PRIMARY HEADACHE causes TENSION TYPE HEADACHE,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9421,no_relation,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9422,PRIMARY HEADACHE causes TENSION TYPE HEADACHE,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9423,PRIMARY HEADACHE causes TENSION TYPE HEADACHE,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9424,no_relation,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9425,TENSION TYPE HEADACHE causes PRIMARY HEADACHE,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9426,no_relation,causes,0.301511344577764,Comments: • A significant number of patients with PRIMARY HEADACHE may have coexistent migraine and TENSION TYPE HEADACHE,PRIMARY HEADACHE,TENSION TYPE HEADACHE
9427,no_relation,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9428,MYCOBACTERIUM TUBERCULOSIS causes TB,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9429,MYCOBACTERIUM TUBERCULOSIS causes TB,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9430,MYCOBACTERIUM TUBERCULOSIS causes TB,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9431,MYCOBACTERIUM TUBERCULOSIS causes TB,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9432,MYCOBACTERIUM TUBERCULOSIS causes TB,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9433,MYCOBACTERIUM TUBERCULOSIS causes TB,causes,0.913811548620257,"100 ,   124 ,   126 ,   d ,   e  First line agent for treatment of all forms of TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to the drug.",TB,MYCOBACTERIUM TUBERCULOSIS
9434,CML causes SPLENOMEGALY,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9435,CML causes SPLENOMEGALY,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9436,SPLENOMEGALY causes CML,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9437,CML causes SPLENOMEGALY,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9438,CML causes SPLENOMEGALY,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9439,SPLENOMEGALY causes CML,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9440,no_relation,causes,0.99654575824488,"• Systemic or constitutional symptoms in CML reflect cell hyperproliferation, extramedullary hematopoiesis, SPLENOMEGALY and cytokine release or bone marrow failure due to the expansion of the neoplastic clone.",SPLENOMEGALY,CML
9441,BONE causes SEVERE OSTEOMALACIA,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9442,BONE causes SEVERE OSTEOMALACIA,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9443,BONE causes SEVERE OSTEOMALACIA,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9444,no_relation,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9445,no_relation,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9446,no_relation,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9447,no_relation,causes,0.790569415042095,"Aluminum containing compounds should be avoided in renal failure, especially in patients receiving long term dialysis, to prevent accumulation in BONE resulting in SEVERE OSTEOMALACIA",BONE,SEVERE OSTEOMALACIA
9448,no_relation,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9449,MIGRAINE causes HEADACHE,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9450,HEADACHE causes MIGRAINE,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9451,MIGRAINE causes HEADACHE,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9452,MIGRAINE causes HEADACHE,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9453,no_relation,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9454,MIGRAINE causes HEADACHE,causes,0.830747160735697,"66   This MIGRAINE occurs in adolescents and young adults; typically presents as visual loss or aura, vertigo, ataxia, dysarthria, and dysesthesia lasting up to 45 minutes; and is always followed by a throbbing HEADACHE frequently with vomiting.",HEADACHE,MIGRAINE
9455,PTSD causes ANXIETY,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9456,PTSD causes ANXIETY,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9457,ANXIETY causes PTSD,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9458,no_relation,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9459,no_relation,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9460,PTSD causes ANXIETY,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9461,PTSD causes ANXIETY,causes,0.801783725737273,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
9462,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9463,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9464,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9465,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9466,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9467,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9468,no_relation,causes,0.481543412343077,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
9469,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9470,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9471,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9472,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9473,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9474,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9475,KRABBE'S DISEASE causes BLINDNESS,causes,0.995893206467704,"KRABBE'S DISEASE  KRABBE'S DISEASE is a sphingolipidosis that causes retardation, paralysis, BLINDNESS deafness, and pseudobulbar palsy, progressing to death.",BLINDNESS,KRABBE'S DISEASE
9476,no_relation,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9477,no_relation,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9478,SPINE causes SPINAL DEFORMITY,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9479,no_relation,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9480,no_relation,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9481,SPINAL DEFORMITY causes SPINE,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9482,no_relation,causes,0.573539334676404,"hydromyelomeningocele    (                                 audio )  [&dblprime; +  myelos , marrow, +  meninx , membrane, +  kele , tumor, swelling] SPINAL DEFORMITY in which a fluid filled sac containing spinal cord and surrounding membranes protrudes through the SPINE",SPINE,SPINAL DEFORMITY
9483,CELIAC DISEASE causes INFERTILITY,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9484,CELIAC DISEASE causes INFERTILITY,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9485,no_relation,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9486,CELIAC DISEASE causes INFERTILITY,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9487,CELIAC DISEASE causes INFERTILITY,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9488,CELIAC DISEASE causes INFERTILITY,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9489,no_relation,causes,0.737209780774486,B]  Specific recommendation: • Screen for CELIAC DISEASE in men and women with unexplained INFERTILITY,INFERTILITY,CELIAC DISEASE
9490,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9491,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9492,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9493,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9494,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9495,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9496,GABHS causes STREPTOCOCCAL PHARYNGITIS,causes,1.0,STREPTOCOCCAL PHARYNGITIS is usually caused by GABHS,STREPTOCOCCAL PHARYNGITIS,GABHS
9497,no_relation,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9498,PERICARDITIS causes NEURAL LUPUS,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9499,no_relation,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9500,no_relation,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9501,no_relation,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9502,PERICARDITIS causes NEURAL LUPUS,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9503,no_relation,causes,0.8660254037844392,"Other signs include pleuritis, PERICARDITIS myocarditis, neurological changes including behavioral changes and seizure activity (NEURAL LUPUS), gastrointestinal ulcerations, Raynaud's phenomenon (present in about 20% of patients), and other problems caused by inflammatory changes of the blood vessels or connective tissue.",PERICARDITIS,NEURAL LUPUS
9504,no_relation,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9505,TEMPOROMANDIBULAR JOINT MOVEMENT causes JOINT DYSFUNCTION,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9506,TEMPOROMANDIBULAR JOINT MOVEMENT causes JOINT DYSFUNCTION,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9507,TEMPOROMANDIBULAR JOINT MOVEMENT causes JOINT DYSFUNCTION,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9508,no_relation,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9509,TEMPOROMANDIBULAR JOINT MOVEMENT causes JOINT DYSFUNCTION,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9510,no_relation,causes,0.61394061351492,"In dentistry, a noise associated with TEMPOROMANDIBULAR JOINT MOVEMENT sometimes accompanied by pain or JOINT DYSFUNCTION",TEMPOROMANDIBULAR JOINT MOVEMENT,JOINT DYSFUNCTION
9511,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9512,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9513,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9514,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9515,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9516,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9517,BLASTOMYCES DERMATITIDIS causes PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,causes,0.988371697650617,423  Blastomycosis  Treatment of PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS caused by  BLASTOMYCES DERMATITIDIS,PULMONARY AND EXTRAPULMONARY BLASTOMYCOSIS,BLASTOMYCES DERMATITIDIS
9518,no_relation,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9519,no_relation,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9520,UVEITIS causes DRY EYES,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9521,no_relation,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9522,no_relation,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9523,no_relation,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9524,no_relation,causes,0.762000762001143,"Itching suggests an allergic cause; nasal pain suggests dacryocystitis; constant foreign body sensation suggests a corneal foreign body, corneal abrasion, corneal ulcer, or trichiasis; intermittent foreign body sensation suggests DRY EYES; other symptoms (eg, photophobia) suggest UVEITIS or keratitis.",DRY EYES,UVEITIS
9525,no_relation,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9526,no_relation,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9527,HD causes CHOREA,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9528,HD causes CHOREA,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9529,no_relation,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9530,HD causes CHOREA,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9531,HD causes CHOREA,causes,0.905821627315676,"In some HD patients, the CHOREA becomes severe and impairs function; in those instances, treatment is appropriate.",CHOREA,HD
9532,no_relation,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9533,no_relation,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9534,no_relation,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9535,no_relation,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9536,no_relation,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9537,no_relation,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9538,MIGRAINE causes HEADACHE,causes,0.8090398349558909,3.2 Evaluate symptoms to distinguish MIGRAINE from tension type or other types of HEADACHE in patients with a normal neurologic exam.,HEADACHE,MIGRAINE
9539,NMS causes ANTIPSYCHOTIC AGENTS,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9540,no_relation,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9541,NMS causes ANTIPSYCHOTIC AGENTS,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9542,no_relation,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9543,NMS causes ANTIPSYCHOTIC AGENTS,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9544,no_relation,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9545,NMS causes ANTIPSYCHOTIC AGENTS,causes,0.7947194142390258,"a ,   b  Possible increased risk of NMS and increased sensitivity to ANTIPSYCHOTIC AGENTS in patients with parkinsonian syndrome or dementia with Lewy bodies; manifestations of sensitivity may include confusion, obtundation, postural instability with more frequent falling, or extrapyramidal adverse effects  104 ,   a ,   b  Patients with recent history of MI or unstable heart disease generally were excluded from premarketing clinical studies.",NMS,ANTIPSYCHOTIC AGENTS
9546,VANCOMYCIN causes NEUTROPENIA,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9547,no_relation,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9548,VANCOMYCIN causes NEUTROPENIA,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9549,VANCOMYCIN causes NEUTROPENIA,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9550,no_relation,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9551,VANCOMYCIN causes NEUTROPENIA,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9552,VANCOMYCIN causes NEUTROPENIA,causes,0.346410161513775,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
9553,CROHN DISEASE causes ANAL FISTULAS,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9554,CROHN DISEASE causes ANAL FISTULAS,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9555,CROHN DISEASE causes ANAL FISTULAS,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9556,CROHN DISEASE causes ANAL FISTULAS,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9557,no_relation,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9558,CROHN DISEASE causes ANAL FISTULAS,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9559,CROHN DISEASE causes ANAL FISTULAS,causes,0.99654575824488,Other manifestations of CROHN DISEASE include inguinal abscesses and sinuses and ANAL FISTULAS,ANAL FISTULAS,CROHN DISEASE
9560,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9561,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9562,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9563,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9564,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9565,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9566,no_relation,causes,0.8682431421244592,"C]  History and Physical Examination  3.1 Use history to elicit symptoms and signs indicative of ENDOMETRIOSIS particularly PELVIC PAIN a complex adnexal mass, or infertility.",PELVIC PAIN,ENDOMETRIOSIS
9567,no_relation,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9568,no_relation,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9569,no_relation,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9570,no_relation,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9571,no_relation,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9572,TYPHOID VACCINE causes ACUTE TYPHOID INFECTION,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9573,TYPHOID VACCINE causes ACUTE TYPHOID INFECTION,causes,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
9574,no_relation,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9575,no_relation,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9576,LIPOSOMAL AMPHOTERICIN B GROUP causes FUNGAL INFECTIONS,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9577,LIPOSOMAL AMPHOTERICIN B GROUP causes FUNGAL INFECTIONS,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9578,no_relation,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9579,no_relation,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9580,LIPOSOMAL AMPHOTERICIN B GROUP causes FUNGAL INFECTIONS,causes,0.493196961916072,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
9581,PALLIDUM causes SECONDARY SYPHILIS,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9582,no_relation,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9583,no_relation,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9584,PALLIDUM causes SECONDARY SYPHILIS,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9585,PALLIDUM causes SECONDARY SYPHILIS,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9586,no_relation,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9587,no_relation,causes,0.520755643923296,"Rationale: •   TPALLIDUM  in patients with early latent syphilis is presumed to replicate at rates approximating primary and SECONDARY SYPHILIS and therefore, like those early stages of syphilis, requires a relatively short course of therapy.",SECONDARY SYPHILIS,PALLIDUM
9588,HPV causes WARTS (CONDYLOMATA ACUMINATA),causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9589,HPV causes WARTS (CONDYLOMATA ACUMINATA),causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9590,HPV causes WARTS (CONDYLOMATA ACUMINATA),causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9591,HPV causes WARTS (CONDYLOMATA ACUMINATA),causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9592,WARTS (CONDYLOMATA ACUMINATA) causes HPV,causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9593,HPV causes WARTS (CONDYLOMATA ACUMINATA),causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9594,HPV causes WARTS (CONDYLOMATA ACUMINATA),causes,0.9950371902099888,Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA) caused by HPV,WARTS (CONDYLOMATA ACUMINATA),HPV
9595,DIABETES MELLITUS causes DKA,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9596,DIABETES MELLITUS causes DKA,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9597,no_relation,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9598,DIABETES MELLITUS causes DKA,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9599,DKA causes DIABETES MELLITUS,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9600,DIABETES MELLITUS causes DKA,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9601,DIABETES MELLITUS causes DKA,causes,0.9918365981341758,DKA may be the initial presentation of DIABETES MELLITUS,DKA,DIABETES MELLITUS
9602,REFRACTORY TRIGEMINAL NEURALGIA causes PAIN,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9603,REFRACTORY TRIGEMINAL NEURALGIA causes PAIN,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9604,REFRACTORY TRIGEMINAL NEURALGIA causes PAIN,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9605,REFRACTORY TRIGEMINAL NEURALGIA causes PAIN,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9606,no_relation,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9607,REFRACTORY TRIGEMINAL NEURALGIA causes PAIN,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9608,REFRACTORY TRIGEMINAL NEURALGIA causes PAIN,causes,0.848874687627165,Evidence: • Gabapentin relieved PAIN completely in six of seven patients with MS and REFRACTORY TRIGEMINAL NEURALGIA and significantly in the seventh patient ( 87.,PAIN,REFRACTORY TRIGEMINAL NEURALGIA
9609,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9610,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9611,no_relation,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9612,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9613,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9614,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9615,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,1.0,Headache and PAPILLEDEMA may result from INCREASED INTRACRANIAL PRESSURE caused by meningeal infiltration and obstruction of the outflow of cerebrospinal fluid (CSF.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
9616,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9617,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9618,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9619,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9620,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9621,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9622,WARFARIN causes INTRACEREBRAL HEMORRHAGE,causes,0.970494958830946,"COMMENTARY  In patients taking WARFARIN the risk for major bleeding, including INTRACEREBRAL HEMORRHAGE increases significantly with INRs ≥ 4.5  (1).",INTRACEREBRAL HEMORRHAGE,WARFARIN
9623,no_relation,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9624,GENITAL HPV INFECTION causes EXTERNAL GENITAL WARTS,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9625,no_relation,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9626,no_relation,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9627,no_relation,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9628,no_relation,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9629,GENITAL HPV INFECTION causes EXTERNAL GENITAL WARTS,causes,0.320256307610174,"1]  Manhart LE, Koutsky LA. Do condoms prevent GENITAL HPV INFECTION EXTERNAL GENITAL WARTS or cervical neoplasia.",EXTERNAL GENITAL WARTS,GENITAL HPV INFECTION
9630,HCL causes SPLENOMEGALY,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9631,HCL causes SPLENOMEGALY,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9632,HCL causes SPLENOMEGALY,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9633,HCL causes SPLENOMEGALY,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9634,no_relation,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9635,HCL causes SPLENOMEGALY,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9636,HCL causes SPLENOMEGALY,causes,0.9284766908852592,"68   Clinically, HCL typically presents as pancytopenia, SPLENOMEGALY and opportunistic infection.",SPLENOMEGALY,HCL
9637,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9638,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9639,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9640,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9641,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9642,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9643,ENDOMETRIOMA causes ACUTE ABDOMINAL PAIN,causes,0.9901475429766742,"Occasionally, an ENDOMETRIOMA ruptures or leaks, causing ACUTE ABDOMINAL PAIN and peritoneal symptoms.",ACUTE ABDOMINAL PAIN,ENDOMETRIOMA
9644,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9645,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9646,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9647,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9648,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9649,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9650,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.99654575824488,GRANULOMA INGUINALE  (Donovanosis)  GRANULOMA INGUINALE is a progressive infection of genital skin caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
9651,no_relation,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9652,no_relation,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9653,BACTERIA causes BACTEREMIA,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9654,BACTERIA causes BACTEREMIA,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9655,no_relation,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9656,no_relation,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9657,BACTERIA causes BACTEREMIA,causes,0.943456353049726,BACTEREMIA is the presence of BACTERIA in the bloodstream.,BACTEREMIA,BACTERIA
9658,no_relation,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9659,no_relation,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9660,CONJUNCTIVITIS causes DRY EYE,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9661,CONJUNCTIVITIS causes DRY EYE,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9662,no_relation,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9663,no_relation,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9664,CONJUNCTIVITIS causes DRY EYE,causes,0.787838597158335,"c  Common Adverse Effects  0.5% solution: Discomfort, hyperemia, pruritus, tearing, lid edema, dry mouth, foreign body sensation, blanching, blurred vision, CONJUNCTIVITIS discharge, DRY EYE",DRY EYE,CONJUNCTIVITIS
9665,GITELMAN SYNDROME causes HYPOCALCIURIA,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9666,no_relation,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9667,GITELMAN SYNDROME causes HYPOCALCIURIA,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9668,GITELMAN SYNDROME causes HYPOCALCIURIA,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9669,no_relation,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9670,GITELMAN SYNDROME causes HYPOCALCIURIA,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9671,no_relation,causes,0.8660254037844392,"In contrast to patients with Bartter syndrome, who have a defect in urinary concentrating ability (normal function of the loop of Henle is needed to generate a high interstitial osmotic gradient), patients with GITELMAN SYNDROME can demonstrate normal urinary concentrating ability and have HYPOCALCIURIA",HYPOCALCIURIA,GITELMAN SYNDROME
9672,SEBORRHEIC KERATOSIS (SEBORRHEIC WART) causes PAPULE,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9673,no_relation,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9674,no_relation,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9675,no_relation,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9676,no_relation,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9677,no_relation,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9678,no_relation,causes,0.6741998624632421,"Diagnosis  SEBORRHEIC KERATOSIS (SEBORRHEIC WART) consists of a sharply circumscribed, rough or smooth PAPULE or plaque that is 1 mm to several centimeters in size and dirty yellow or light to dark brown in color.",PAPULE,SEBORRHEIC KERATOSIS (SEBORRHEIC WART)
9679,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9680,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9681,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9682,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9683,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9684,PATELLO FEMORAL JOINT treats ARTHROSIS OF THE KNEE,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9685,no_relation,treats,0.337526370277807,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
9686,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9687,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9688,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9689,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9690,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9691,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9692,ETHOSUXIMIDE treats CHILDHOOD ABSENCE EPILEPSY,treats,1.0,In a study published in the March 2010 Pakistan Journal of Medicine it was found that ETHOSUXIMIDE was the most effective treatment for CHILDHOOD ABSENCE EPILEPSY,CHILDHOOD ABSENCE EPILEPSY,ETHOSUXIMIDE
9693,no_relation,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9694,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9695,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9696,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9697,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9698,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9699,no_relation,treats,0.78086880944303,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順�GLIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順�����渇���申in tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
9700,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9701,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9702,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9703,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9704,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9705,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9706,INTRAVENOUS VERAPAMIL THERAPY treats IMMINENT MYOCARDIAL INFARCTION,treats,0.9760921603577252,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
9707,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS treats TOXIC SHOCK SYNDROME,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9708,no_relation,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9709,TOXIC SHOCK SYNDROME treats TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9710,TOXIC SHOCK SYNDROME treats TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9711,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS treats TOXIC SHOCK SYNDROME,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9712,no_relation,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9713,no_relation,treats,0.342997170285018,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
9714,no_relation,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9715,no_relation,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9716,NOCARDIOSIS treats NOCARDIA,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9717,NOCARDIOSIS treats NOCARDIA,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9718,no_relation,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9719,no_relation,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9720,NOCARDIA treats NOCARDIOSIS,treats,0.31622776601683805,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
9721,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES treats CMV INFECTION,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9722,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES treats CMV INFECTION,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9723,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES treats CMV INFECTION,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9724,CMV INFECTION treats CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9725,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES treats CMV INFECTION,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9726,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES treats CMV INFECTION,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9727,CMV INFECTION treats CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES,treats,0.9970544855015808,intravenous     An immune globulin preparation containing CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES used to treat or prevent CMV INFECTION after organ or tissue transplantation.,CMV INFECTION,CYTOMEGALOVIRUS (CMV SPECIFIC ANTIBODIES
9728,LEVODOPA treats PARKINSON'S DISEASE,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9729,LEVODOPA treats PARKINSON'S DISEASE,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9730,LEVODOPA treats PARKINSON'S DISEASE,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9731,LEVODOPA treats PARKINSON'S DISEASE,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9732,LEVODOPA treats PARKINSON'S DISEASE,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9733,PARKINSON'S DISEASE treats LEVODOPA,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9734,LEVODOPA treats PARKINSON'S DISEASE,treats,0.9970544855015808,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
9735,[DABIGATRAN 110 MG] treats [MAJOR BLEEDING],treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9736,no_relation,treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9737,no_relation,treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9738,[DABIGATRAN 110 MG] treats [MAJOR BLEEDING],treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9739,no_relation,treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9740,[DABIGATRAN 110 MG] treats [MAJOR BLEEDING],treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9741,no_relation,treats,0.676123403782813,[MAJOR BLEEDING] occurred significantly less often with [DABIGATRAN 110 MG] than warfarin; dabigatran 150 mg had similar bleeding to warfarin.,[MAJOR BLEEDING],[DABIGATRAN 110 MG]
9742,DIAZEPAM treats BARBITURATE,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9743,BARBITURATE treats DIAZEPAM,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9744,no_relation,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9745,DIAZEPAM treats BARBITURATE,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9746,no_relation,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9747,DIAZEPAM treats BARBITURATE,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9748,DIAZEPAM treats BARBITURATE,treats,0.34815531191139604,In addition [DIAZEPAM] has been shown to be able to substitute for the behavioural effects of [BARBITURATE]s in a primate study.,BARBITURATE,DIAZEPAM
9749,SERTRALINE treats POSTTRAUMATIC STRESS DISORDER,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9750,SERTRALINE treats POSTTRAUMATIC STRESS DISORDER,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9751,SERTRALINE treats POSTTRAUMATIC STRESS DISORDER,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9752,SERTRALINE treats POSTTRAUMATIC STRESS DISORDER,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9753,POSTTRAUMATIC STRESS DISORDER treats SERTRALINE,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9754,SERTRALINE treats POSTTRAUMATIC STRESS DISORDER,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9755,POSTTRAUMATIC STRESS DISORDER treats SERTRALINE,treats,1.0,"Efficacy of SERTRALINE in preventing relapse of POSTTRAUMATIC STRESS DISORDER: results of a 28 week double blind, placebo controlled study.",POSTTRAUMATIC STRESS DISORDER,SERTRALINE
9756,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9757,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9758,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9759,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9760,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9761,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9762,INSULIN SECRETAGOGUES treats TYPE 2 DIABETES,treats,0.997458699830735,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
9763,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9764,no_relation,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9765,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9766,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9767,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9768,no_relation,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9769,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.962250448649376,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
9770,no_relation,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9771,RANS RETINOIC ACID I treats PL I,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9772,RANS RETINOIC ACID I treats PL I,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9773,RANS RETINOIC ACID I treats PL I,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9774,RANS RETINOIC ACID I treats PL I,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9775,RANS RETINOIC ACID I treats PL I,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9776,no_relation,treats,0.970494958830946, Include all tRANS RETINOIC ACID In the therapy for APL In induction combined with multiple courses of post remission chemotherapy ('4+2' or arsenic trioxide) to eradicate minimal residual disease,PL I,RANS RETINOIC ACID I
9777,SALMONELLA TYPHI treats TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9778,no_relation,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9779,no_relation,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9780,SALMONELLA TYPHI treats TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9781,no_relation,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9782,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS treats SALMONELLA TYPHI,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9783,no_relation,treats,0.34412360080584303,280  TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS  Alternative for treatment of typhoid fever   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER AND OTHER SALMONELLA INFECTIONS,SALMONELLA TYPHI
9784,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9785,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9786,no_relation,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9787,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9788,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9789,no_relation,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9790,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.832050294337844,Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
9791,no_relation,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9792,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9793,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9794,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9795,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9796,GRAFT VERSUS HOST DISEASE treats CYCLOSPORINE,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9797,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE,treats,0.940720868383597,"Nash RA, Pepe MS, Storb R, et al: Acute GRAFT VERSUS HOST DISEASE: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with CYCLOSPORINE and methotrexate.",GRAFT VERSUS HOST DISEASE,CYCLOSPORINE
9798,ALPRAZOLAM treats PANIC DISORDER,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9799,ALPRAZOLAM treats PANIC DISORDER,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9800,ALPRAZOLAM treats PANIC DISORDER,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9801,PANIC DISORDER treats ALPRAZOLAM,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9802,ALPRAZOLAM treats PANIC DISORDER,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9803,ALPRAZOLAM treats PANIC DISORDER,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9804,ALPRAZOLAM treats PANIC DISORDER,treats,0.997458699830735,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
9805,no_relation,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9806,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9807,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9808,no_relation,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9809,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9810,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9811,no_relation,treats,0.923380516876639,"The most appropriate role of warfarin for secondary prevention after a MYOCARDIAL INFARCTION in patients on ASPIRIN remains unclear, especially since the widespread use of dual antiplatelet therapy, and particularly given the availability of new, more potent P2Y12 inhibitors that are on the horizon.",MYOCARDIAL INFARCTION,ASPIRIN
9812,NICOTINE treats NICOTINE ADDICTION,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9813,no_relation,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9814,no_relation,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9815,NICOTINE ADDICTION treats NICOTINE,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9816,no_relation,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9817,no_relation,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9818,no_relation,treats,0.577350269189626,Vaccination against NICOTINE represents a promising novel concept for treating NICOTINE ADDICTION,NICOTINE ADDICTION,NICOTINE
9819,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9820,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9821,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9822,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9823,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9824,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9825,NICARDIPINE treats HYPERTENSION,treats,0.99124070716193,"1]  Jannet D, Carbonne B, Sebban E, Milliez JNICARDIPINE versus metoprolol in the treatment of HYPERTENSION during pregnancy: a randomized comparative trial.",HYPERTENSION,NICARDIPINE
9826,OSTEOARTHRITIS treats PIROXICAM,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9827,PIROXICAM treats OSTEOARTHRITIS,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9828,no_relation,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9829,PIROXICAM treats OSTEOARTHRITIS,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9830,PIROXICAM treats OSTEOARTHRITIS,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9831,PIROXICAM treats OSTEOARTHRITIS,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9832,PIROXICAM treats OSTEOARTHRITIS,treats,0.997458699830735,Double blind study comparing PIROXICAM and aspirin in the treatment of OSTEOARTHRITIS,OSTEOARTHRITIS,PIROXICAM
9833,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9834,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9835,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9836,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9837,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9838,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9839,WARFARIN treats VTE,treats,0.997458699830735,"This finding was verified by Meschengieser and colleagues (4), who found that VTE events could be controlled by WARFARIN with lower target INR plus low dose aspirin.",VTE,WARFARIN
9840,DALTEPARIN treats MYOCARDIAL INFARCTION,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9841,DALTEPARIN treats MYOCARDIAL INFARCTION,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9842,DALTEPARIN treats MYOCARDIAL INFARCTION,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9843,no_relation,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9844,DALTEPARIN treats MYOCARDIAL INFARCTION,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9845,no_relation,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9846,DALTEPARIN treats MYOCARDIAL INFARCTION,treats,0.98058067569092,"CONCLUSION  In patients who received noninvasive management for unstable coronary disease, DALTEPARIN reduced death and MYOCARDIAL INFARCTION at 1 month but not at 3 months.",MYOCARDIAL INFARCTION,DALTEPARIN
9847,no_relation,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9848,no_relation,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9849,no_relation,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9850,no_relation,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9851,no_relation,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9852,no_relation,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9853,PV treats THROMBOSIS,treats,0.33333333333333304,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
9854,PROMETHAZINE treats VOMITING,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9855,PROMETHAZINE treats VOMITING,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9856,PROMETHAZINE treats VOMITING,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9857,PROMETHAZINE treats VOMITING,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9858,no_relation,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9859,PROMETHAZINE treats VOMITING,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9860,PROMETHAZINE treats VOMITING,treats,0.927172649945531,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and VOMITING in the emergency department  Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.",VOMITING,PROMETHAZINE
9861,DOPAMINE treats SHOCK,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9862,DOPAMINE treats SHOCK,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9863,DOPAMINE treats SHOCK,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9864,DOPAMINE treats SHOCK,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9865,DOPAMINE treats SHOCK,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9866,SHOCK treats DOPAMINE,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9867,DOPAMINE treats SHOCK,treats,0.9760921603577252,Current guidelines recommend that norepinephrine or dopamine be used as the initial vasopressor in patients with septic shock and that epinephrine be used as the first chosen alternative agent if SHOCK is poorly responsive to norepinephrine or DOPAMINE ( 39.,SHOCK,DOPAMINE
9868,no_relation,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9869,no_relation,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9870,SERTRALINE treats DEPRESSION,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9871,SERTRALINE treats DEPRESSION,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9872,SERTRALINE treats DEPRESSION,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9873,SERTRALINE treats DEPRESSION,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9874,SERTRALINE treats DEPRESSION,treats,0.938314863256837,"Bupropion SR, SERTRALINE or venlafaxine XR after failure of SSRIs for depression  Medication augmentation after the failure of SSRIs for DEPRESSION.",DEPRESSION,SERTRALINE
9875,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9876,no_relation,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9877,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9878,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9879,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9880,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9881,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
9882,NOCARDIA treats NOCARDIA INFECTIONS,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9883,no_relation,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9884,no_relation,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9885,NOCARDIA treats NOCARDIA INFECTIONS,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9886,no_relation,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9887,no_relation,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9888,NOCARDIA treats NOCARDIA INFECTIONS,treats,0.606779876216918,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
9889,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9890,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9891,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9892,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9893,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9894,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9895,IBUPROFEN treats INFLAMMATION,treats,0.993127066322842,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
9896,no_relation,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9897,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY treats HYPERTENSION,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9898,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY treats HYPERTENSION,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9899,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY treats HYPERTENSION,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9900,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY treats HYPERTENSION,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9901,HYPERTENSION treats ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9902,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY treats HYPERTENSION,treats,0.994134846772434,1  >     ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY for Dyslipidemias and Prevention of Cardiovascular Events (Atorvastatin) and for HYPERTENSION and/or CAD (Amlodipine)  Oral:  Use the fixed combination as a  substitute  for the individually titrated drugs.,HYPERTENSION,ATORVASTATIN/AMLODIPINE FIXED COMBINATION THERAPY
9903,SERTRALINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9904,SERTRALINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9905,SERTRALINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9906,SERTRALINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9907,SERTRALINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9908,SERTRALINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9909,OBSESSIVE COMPULSIVE DISORDER treats SERTRALINE,treats,1.0,"Wolkow R, Alderman J, Johnston J et alSERTRALINE treatment of children and adolescents with OBSESSIVE COMPULSIVE DISORDER or depression.",OBSESSIVE COMPULSIVE DISORDER,SERTRALINE
9910,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9911,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9912,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9913,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9914,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9915,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9916,ACEBUTOLOL treats HYPERTENSION,treats,0.9970544855015808,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
9917,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9918,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9919,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9920,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9921,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9922,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9923,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,treats,0.9830783046228492,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
9924,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9925,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9926,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9927,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9928,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9929,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9930,TUM treats ACID REFLUX,treats,0.9950371902,"antacids - nexium, [TUM]s, Pepcid AC, rolaids, etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,TUM
9931,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9932,no_relation,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9933,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9934,CHRONIC MYELOGENOUS LEUKEMIA treats BUSULFAN,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9935,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9936,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9937,BUSULFAN treats CHRONIC MYELOGENOUS LEUKEMIA,treats,0.964901281354015,"Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of BUSULFAN and hydroxyurea in CHRONIC MYELOGENOUS LEUKEMIA: prolongation of survival by hydroxyurea",CHRONIC MYELOGENOUS LEUKEMIA,BUSULFAN
9938,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9939,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9940,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9941,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9942,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9943,MALIGNANT HYPERTHERMIA treats INTRAVENOUS DANTROLENE,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9944,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,treats,0.42426406871192895,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
9945,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9946,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9947,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9948,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9949,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9950,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9951,[RIBOFLAVIN] treats [MIGRAINE],treats,0.997458699830735,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of [MIGRAINE] days and hours by 44%, although with no reduction in intensity of the headache.",[MIGRAINE],[RIBOFLAVIN]
9952,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9953,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9954,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9955,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9956,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9957,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9958,SULFASALAZINE treats JUVENILE RHEUMATOID ARTHRITIS,treats,1.0,146  Adverse effects observed in children receiving SULFASALAZINE for management of JUVENILE RHEUMATOID ARTHRITIS generally are similar to those observed in adults with rheumatoid arthritis.,JUVENILE RHEUMATOID ARTHRITIS,SULFASALAZINE
9959,no_relation,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9960,no_relation,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9961,no_relation,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9962,no_relation,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9963,no_relation,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9964,no_relation,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9965,MIGRAINE treats HEADACHE,treats,0.346410161513775,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
9966,ARICEPT treats ALZHEIMER'S DISEASE,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9967,ARICEPT treats ALZHEIMER'S DISEASE,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9968,ARICEPT treats ALZHEIMER'S DISEASE,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9969,ARICEPT treats ALZHEIMER'S DISEASE,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9970,ALZHEIMER'S DISEASE treats ARICEPT,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9971,ARICEPT treats ALZHEIMER'S DISEASE,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9972,ARICEPT treats ALZHEIMER'S DISEASE,treats,0.9974586998,"[ARICEPT], normally used for [ALZHEIMER'S DISEASE], has been shown to improve executive functioning in CADASIL patients.",ALZHEIMER'S DISEASE,ARICEPT
9973,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9974,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9975,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9976,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9977,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9978,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9979,BAPINEUZUMAB treats ALZHEIMER'S DISEASE,treats,0.9138115486,title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of [BAPINEUZUMAB] for [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,BAPINEUZUMAB
9980,ATROPINE treats BRADYCARDIA,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9981,ATROPINE treats BRADYCARDIA,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9982,BRADYCARDIA treats ATROPINE,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9983,no_relation,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9984,BRADYCARDIA treats ATROPINE,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9985,ATROPINE treats BRADYCARDIA,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9986,ATROPINE treats BRADYCARDIA,treats,0.9282791216329142,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
9987,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9988,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9989,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9990,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9991,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9992,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9993,[ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9282791216329142,Topical corticosteroids and [ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[ORAL ANTIHISTAMINES]
9994,no_relation,treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
9995,no_relation,treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
9996,no_relation,treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
9997,[GEMTUZUMAB OZOGAMICIN MYLOTARG] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
9998,no_relation,treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
9999,no_relation,treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
10000,no_relation,treats,0.43301270189221897,[GEMTUZUMAB OZOGAMICIN MYLOTARG] 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG]
10001,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10002,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10003,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10004,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10005,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10006,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10007,no_relation,treats,0.3779644730092271,"COMMENTARY  In a very diverse group of patients, with equally diverse risks for seizure recurrence, Marson and colleagues compared early and deferred AED treatment after a first SEIZURE or an early diagnosis of EPILEPSY",SEIZURE,EPILEPSY
10008,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10009,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10010,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10011,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10012,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10013,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10014,1 MG DEXAMETHASONE SUPPRESSION treats CUSHING'S SYNDROME,treats,0.34874291623145803,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
10015,PIRACETAM treats APHASIA,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10016,PIRACETAM treats APHASIA,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10017,PIRACETAM treats APHASIA,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10018,no_relation,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10019,PIRACETAM treats APHASIA,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10020,PIRACETAM treats APHASIA,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10021,PIRACETAM treats APHASIA,treats,0.968495997,"[PIRACETAM] has been found to improve cognition after stroke, and reduce symptoms, such as [APHASIA].",APHASIA,PIRACETAM
10022,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10023,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10024,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10025,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10026,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10027,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10028,ZIDOVUDINE treats ADVANCED AIDS RELATED COMPLEX,treats,0.9878291611472622,"Fischl MA, Richman DD, Causey DM et al. Prolonged ZIDOVUDINE therapy in patients with AIDS and ADVANCED AIDS RELATED COMPLEX.",ADVANCED AIDS RELATED COMPLEX,ZIDOVUDINE
10029,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10030,S PANAMA BACTEREMIA treats BACTERIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10031,no_relation,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10032,BACTERIA treats S PANAMA BACTEREMIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10033,no_relation,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10034,BACTERIA treats S PANAMA BACTEREMIA,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10035,no_relation,treats,0.3651483716701111,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA
10036,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10037,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10038,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10039,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10040,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10041,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10042,no_relation,treats,0.9166984970282108,"For example, any form of [NICOTINE] hinders the process of [BONE HEALING], and adequate nutrition will help the bone healing process.",BONE HEALING,NICOTINE
10043,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10044,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10045,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10046,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10047,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10048,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10049,SODIUM OXYBATE treats CATAPLEXY,treats,0.9918365981341752,"SODIUM OXYBATE which is more commonly known as Œ≥ hydroxybutyrate (GHB), was once classified as a schedule I control substance but has been approved recently by the Food and Drug Administration (FDA) for the treatment of CATAPLEXY.",CATAPLEXY,SODIUM OXYBATE
10050,no_relation,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10051,no_relation,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10052,PPD treats TB,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10053,PPD treats TB,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10054,PPD treats TB,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10055,PPD treats TB,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10056,PPD treats TB,treats,0.361157559257308,"If TB is a concern, a PPD is performed.",TB,PPD
10057,[2 HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10058,[2 HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10059,[2 HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10060,[2 HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10061,[2 HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10062,[STROKE] treats [2 HOMOCYSTEINE LOWERING VITAMINS],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10063,[2 HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.8660254037844392,"A trial with [2 HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[2 HOMOCYSTEINE LOWERING VITAMINS]
10064,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10065,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10066,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10067,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10068,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10069,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10070,CONCOMITANT DROTRECOGIN ALFA treats SEPSIS,treats,0.889000889001333,"Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of CONCOMITANT DROTRECOGIN ALFA (activated) and prophylactic heparin use in patients with severe SEPSIS",SEPSIS,CONCOMITANT DROTRECOGIN ALFA
10071,no_relation,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10072,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10073,no_relation,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10074,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10075,no_relation,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10076,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10077,BASAL INSULIN GLARGINE treats TYPE 2 DIABETES,treats,0.924500327042048,2010 06 26  Prandial inhaled insulin plus BASAL INSULIN GLARGINE versus twice daily biaspart insulin for TYPE 2 DIABETES: a multicentre randomised trial.,TYPE 2 DIABETES,BASAL INSULIN GLARGINE
10078,ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10079,ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10080,no_relation,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10081,ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10082,ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10083,ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10084,no_relation,treats,1.0,"Dabigatran etexilate versus ENOXAPARIN for prevention of VENOUS THROMBOEMBOLISM after total hip replacement: a randomised, double blind, non inferiority trial.",VENOUS THROMBOEMBOLISM,ENOXAPARIN
10085,no_relation,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10086,no_relation,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10087,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10088,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10089,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10090,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10091,no_relation,treats,0.37210420376762493,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
10092,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10093,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10094,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10095,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10096,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10097,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10098,LUPEOL treats TUMOR,treats,1.0,"Recent clinical studies have verified that red alder contains betulin and [LUPEOL], compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,LUPEOL
10099,no_relation,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10100,PROCAINAMIDE treats HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10101,PROCAINAMIDE treats HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10102,PROCAINAMIDE treats HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10103,PROCAINAMIDE treats HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10104,PROCAINAMIDE treats HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10105,PROCAINAMIDE treats HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,treats,0.9970544855015808,"Alternative to other antiarrhythmic drugs (e.g., amiodarone, PROCAINAMIDE sotalol) for the acute treatment of HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY (e.g., VPCs) that occurs following myocardial ischemia or infarction or during cardiac manipulative procedures such as cardiac surgery or cardiac catheterization.",HEMODYNAMICALLY COMPROMISING VENTRICULAR ECTOPY,PROCAINAMIDE
10106,no_relation,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10107,no_relation,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10108,FLUORIDE ION treats CARIES,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10109,FLUORIDE ION treats CARIES,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10110,FLUORIDE ION treats CARIES,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10111,FLUORIDE ION treats CARIES,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10112,FLUORIDE ION treats CARIES,treats,0.993127066322842,"The results show that the FLUORIDE ION concentration is sufficient (0.7 1.0 ppm F ) to prevent CARIES only in very few parts of Lower Austria, Upper Austria, Salzburg, Tirol, Carinthia, and Styria.",CARIES,FLUORIDE ION
10113,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10114,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10115,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10116,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10117,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10118,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10119,ANTIBIOTIC treats STREP THROAT,treats,0.9630868247,[ANTIBIOTIC]s are prescribed for [STREP THROAT] at a higher rate than would be expected from its prevalence.,STREP THROAT,ANTIBIOTIC
10120,CARVEDILOL treats MI,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10121,no_relation,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10122,CARVEDILOL treats MI,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10123,CARVEDILOL treats MI,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10124,CARVEDILOL treats MI,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10125,no_relation,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10126,CARVEDILOL treats MI,treats,0.970494958830946,"PubMed ID: 11356434  QUESTION  In patients with left ventricular dysfunction, does adding CARVEDILOL to the management of myocardial infarction (MI) reduce mortality and nonfatal MI",MI,CARVEDILOL
10127,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10128,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10129,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10130,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10131,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10132,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10133,no_relation,treats,0.985329278164293,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
10134,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10135,no_relation,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10136,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10137,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10138,STATUS EPILEPTICUS treats FOSPHENYTOIN,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10139,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10140,FOSPHENYTOIN treats STATUS EPILEPTICUS,treats,0.9578262852211508,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
10141,no_relation,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10142,no_relation,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10143,no_relation,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10144,CIPROFLOXACIN treats HEPATITIS,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10145,CIPROFLOXACIN treats HEPATITIS,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10146,no_relation,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10147,no_relation,treats,0.9113223768657672,"Case reports of [HEPATITIS] have been published for the older fluoroquinolones including [CIPROFLOXACIN], ofloxacin, and norfloxacin.",HEPATITIS,CIPROFLOXACIN
10148,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE treats SYSTEMIC INFECTION",treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10149,no_relation,treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10150,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE treats SYSTEMIC INFECTION",treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10151,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE treats SYSTEMIC INFECTION",treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10152,no_relation,treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10153,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE treats SYSTEMIC INFECTION",treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10154,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE treats SYSTEMIC INFECTION",treats,0.99654575824488,"SYSTEMIC INFECTION:  Parenteral therapy is required, generally with an aminoglycoside plus an antipseudomonal β lactam, anti PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME. CEFOPERAZONE or meropenem.",SYSTEMIC INFECTION,"PSEUDOMONAL CEPHALOSPORIN (EG), CEFEPIME, CEFOPERAZONE"
10155,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10156,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10157,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10158,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10159,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10160,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10161,no_relation,treats,0.538815906080325,A nonselective β blocker did not prevent gastroesophageal varices in cirrhosis and portal hypertension  Gastroenterology  About Star Ratings  Keywords: Adrenergic beta antagonists Esophageal and GASTRIC VARICES HYPERTENSION PORTAL LIVER CIRRHOSIS TIMOLOL  ACP Journal Club.,GASTRIC VARICES HYPERTENSION,PORTAL LIVER CIRRHOSIS TIMOLOL
10162,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10163,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10164,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10165,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10166,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10167,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10168,[ZOLINZA] treats [LATENTLY HIV INFECTED T CELLS],treats,0.995893206467704,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against [LATENTLY HIV INFECTED T CELLS].,[LATENTLY HIV INFECTED T CELLS],[ZOLINZA]
10169,GABAPENTIN treats PAIN,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10170,GABAPENTIN treats PAIN,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10171,GABAPENTIN treats PAIN,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10172,GABAPENTIN treats PAIN,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10173,GABAPENTIN treats PAIN,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10174,no_relation,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10175,GABAPENTIN treats PAIN,treats,0.9970544855015808,"Wiffen PJ, McQuay HJ, Edwards JE et alGABAPENTIN for acute and chronic PAIN",PAIN,GABAPENTIN
10176,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10177,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10178,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10179,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10180,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10181,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10182,no_relation,treats,0.346410161513775,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
10183,ARRHYTHMIA treats ANTIARRHYTHMIC,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10184,ARRHYTHMIA treats ANTIARRHYTHMIC,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10185,no_relation,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10186,ANTIARRHYTHMIC treats ARRHYTHMIA,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10187,ANTIARRHYTHMIC treats ARRHYTHMIA,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10188,no_relation,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10189,no_relation,treats,0.744208407535251,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
10190,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10191,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10192,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10193,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10194,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10195,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10196,RECOMBINANT HUMAN ACTIVATED PROTEIN C treats SEPSIS,treats,0.650944554904119,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
10197,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10198,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10199,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10200,no_relation,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10201,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10202,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10203,MECHANICALLY INDUCED HYPERVENTILATION treats RESPIRATORY ALKALOSIS,treats,0.7504787743864558,MECHANICALLY INDUCED HYPERVENTILATION is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce RESPIRATORY ALKALOSIS which may attenuate their pulmonary vasoconstriction.,RESPIRATORY ALKALOSIS,MECHANICALLY INDUCED HYPERVENTILATION
10204,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10205,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10206,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10207,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10208,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10209,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10210,no_relation,treats,0.9838699100999068,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
10211,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10212,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10213,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10214,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10215,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10216,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10217,LINDANE 1% treats SCABIES,treats,0.939912539985549,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
10218,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10219,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10220,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10221,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10222,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10223,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10224,[SUNSCREENS AND ORAL VITAMIN C] treats [FLARES],treats,1.0,Some patients are able to prevent [FLARES] with use of topical [SUNSCREENS AND ORAL VITAMIN C].,[FLARES],[SUNSCREENS AND ORAL VITAMIN C]
10225,no_relation,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10226,no_relation,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10227,no_relation,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10228,no_relation,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10229,no_relation,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10230,OSTEOPENIA treats FRACTURE,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10231,no_relation,treats,0.4803844614,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,OSTEOPENIA,FRACTURE
10232,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10233,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10234,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10235,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10236,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10237,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10238,CAPSAICIN treats INTERCOURSE RELATED PAIN,treats,1.0,• Topical application of CAPSAICIN for 12 weeks may reduce daily and INTERCOURSE RELATED PAIN; adjunctive treatment with topical lidocaine is often necessary.,INTERCOURSE RELATED PAIN,CAPSAICIN
10239,no_relation,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10240,MSM treats SEASONAL ALLERGIC RHINITIS,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10241,MSM treats SEASONAL ALLERGIC RHINITIS,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10242,MSM treats SEASONAL ALLERGIC RHINITIS,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10243,no_relation,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10244,no_relation,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10245,MSM treats SEASONAL ALLERGIC RHINITIS,treats,0.9878291611472622,[SEASONAL ALLERGIC RHINITIS]: Barrager et al. evaluated the efficacy of [MSM] for hayfever.,SEASONAL ALLERGIC RHINITIS,MSM
10246,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10247,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10248,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10249,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10250,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10251,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10252,no_relation,treats,0.400891862868637,Rationale • PTSD may be underdiagnosed in patients reporting depression or ANXIETY resulting in unsatisfactory treatment outcomes.,ANXIETY,PTSD
10253,[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] treats [VEIN THROMBUS],treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10254,[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] treats [VEIN THROMBUS],treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10255,[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] treats [VEIN THROMBUS],treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10256,[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] treats [VEIN THROMBUS],treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10257,no_relation,treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10258,[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] treats [VEIN THROMBUS],treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10259,no_relation,treats,0.971285862357264,"[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION] Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL ADMINISTRATION]
10260,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10261,no_relation,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10262,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10263,no_relation,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10264,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10265,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10266,OVERT STATUS EPILEPTICUS treats DIAZEPAM,treats,0.99654575824488,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
10267,NICOTINE ADDICTION treats NICOTINE,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10268,NICOTINE treats NICOTINE ADDICTION,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10269,no_relation,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10270,no_relation,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10271,no_relation,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10272,no_relation,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10273,NICOTINE treats NICOTINE ADDICTION,treats,0.307793505625546,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
10274,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10275,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10276,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10277,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10278,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10279,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10280,POLYMYXIN B treats EXTERNAL OTITIS,treats,0.9918365981341752,Localized infection:  EXTERNAL OTITIS is treated with 1% acetic acid irrigations or topical agents such as POLYMYXIN B or colistin.,EXTERNAL OTITIS,POLYMYXIN B
10281,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10282,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10283,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10284,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10285,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10286,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10287,DOXYCYCLINE treats MALARIA,treats,0.9578262852211508,"For nonimmune people traveling in areas where MALARIA is due to chloroquine resistant  P. falciparum  and  P. vivax , mefloquine, DOXYCYCLINE or atovaquone plus proguanil hydrochloride may be recommended.",MALARIA,DOXYCYCLINE
10288,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10289,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10290,no_relation,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10291,no_relation,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10292,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10293,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10294,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.9045340337332908,"REVIEW SCOPE  Included studies compared glucosamine sulfate, glucosamine hydrochloride, CHONDROITIN SULFATE or a combination of 2 of the drugs with each other or placebo and included ≥ 100 patients with OSTEOARTHRITIS of the hip or knee in each treatment group.",OSTEOARTHRITIS,CHONDROITIN SULFATE
10295,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10296,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10297,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10298,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10299,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10300,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10301,no_relation,treats,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
10302,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10303,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10304,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10305,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10306,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10307,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10308,IMIPRAMINE treats DEPRESSION,treats,0.8660254037844392,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
10309,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10310,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10311,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10312,no_relation,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10313,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10314,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10315,FACTOR VIII treats VON WILLEBRAND DISEASE,treats,1.0,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
10316,no_relation,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10317,no_relation,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10318,DIMENHYDRINATE MECLIZINE ANTI EMETICS treats VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10319,no_relation,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10320,DIMENHYDRINATE MECLIZINE ANTI EMETICS treats VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10321,DIMENHYDRINATE MECLIZINE ANTI EMETICS treats VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10322,DIMENHYDRINATE MECLIZINE ANTI EMETICS treats VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,treats,0.9539980920057242,"e.g., DIMENHYDRINATE MECLIZINE ANTI EMETICS that suppress nausea and vomiting of VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS of vestibular ototoxicity [ 23 ]    Bacitracin Possible increased incidence of nephrotoxicity and/or neurotoxicity [ 1 , 2 ] Avoid concurrent or sequential use, if possible [ 1 , 2 ]   β Lactam antibiotics (cephalosporins, penicillins.",VESTIBULAR ORIGIN AND VERTIGO MAY MASK SYMPTOMS,DIMENHYDRINATE MECLIZINE ANTI EMETICS
10323,INCREASED BLOOD PRESSURE treats HYPERTENSION,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10324,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10325,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10326,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10327,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10328,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10329,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
10330,Α (HUMAN LEUKOCYTE INTERFERON) treats RENAL CELL CARCINOMA,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10331,no_relation,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10332,Α (HUMAN LEUKOCYTE INTERFERON) treats RENAL CELL CARCINOMA,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10333,Α (HUMAN LEUKOCYTE INTERFERON) treats RENAL CELL CARCINOMA,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10334,Α (HUMAN LEUKOCYTE INTERFERON) treats RENAL CELL CARCINOMA,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10335,no_relation,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10336,Α (HUMAN LEUKOCYTE INTERFERON) treats RENAL CELL CARCINOMA,treats,0.9578262852211508,"Figlin RA, deKernlon JB, Maldazys J et al. Treatment of RENAL CELL CARCINOMA with Α (HUMAN LEUKOCYTE INTERFERON) and vinblastine in combination: a phase I II trial.",RENAL CELL CARCINOMA,Α (HUMAN LEUKOCYTE INTERFERON)
10337,IV AMPHOTERICIN B treats SEVERE DISSEMINATED HISTOPLASMOSIS,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10338,IV AMPHOTERICIN B treats SEVERE DISSEMINATED HISTOPLASMOSIS,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10339,SEVERE DISSEMINATED HISTOPLASMOSIS treats IV AMPHOTERICIN B,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10340,IV AMPHOTERICIN B treats SEVERE DISSEMINATED HISTOPLASMOSIS,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10341,IV AMPHOTERICIN B treats SEVERE DISSEMINATED HISTOPLASMOSIS,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10342,IV AMPHOTERICIN B treats SEVERE DISSEMINATED HISTOPLASMOSIS,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10343,IV AMPHOTERICIN B treats SEVERE DISSEMINATED HISTOPLASMOSIS,treats,0.9950371902099888,"441  HIV infected infants and children with moderately severe to SEVERE DISSEMINATED HISTOPLASMOSIS: Initial regimen of IV AMPHOTERICIN B given for at least 1 2 weeks, followed by itraconazole (oral solution) 2 5 mg/kg (up to 200 mg) 3 times daily for 3 days, then 2 5 mg/kg (up to 200 mg) twice daily for 12 months.",SEVERE DISSEMINATED HISTOPLASMOSIS,IV AMPHOTERICIN B
10344,[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] treats [RHEUMATOID ARTHRITIS],treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10345,[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] treats [RHEUMATOID ARTHRITIS],treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10346,[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] treats [RHEUMATOID ARTHRITIS],treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10347,no_relation,treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10348,[RHEUMATOID ARTHRITIS] treats [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE],treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10349,no_relation,treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10350,[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] treats [RHEUMATOID ARTHRITIS],treats,0.95257934441568,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE: A RANDOMISED PHASE] III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE: A RANDOMISED PHASE]
10351,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10352,no_relation,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10353,no_relation,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10354,CYCLOSPORINE treats GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10355,no_relation,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10356,GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS treats CYCLOSPORINE,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10357,no_relation,treats,0.342997170285018,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
10358,PROPRANOLOL treats SUPRAVENTRICULAR TACHYCARDIA,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10359,PROPRANOLOL treats SUPRAVENTRICULAR TACHYCARDIA,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10360,PROPRANOLOL treats SUPRAVENTRICULAR TACHYCARDIA,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10361,PROPRANOLOL treats SUPRAVENTRICULAR TACHYCARDIA,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10362,no_relation,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10363,PROPRANOLOL treats SUPRAVENTRICULAR TACHYCARDIA,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10364,no_relation,treats,0.737209780774486,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
10365,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10366,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10367,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10368,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10369,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10370,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10371,PEGINTERFERON treats CHRONIC HEPATITIS C,treats,0.9918365981341752,"cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol dependent patients with liver cirrhosis: randomised, double blind controlled study  Non peptide arginine vasopressin antagonists: the vaptans  New England Journal of Medicine  Prolonged therapy of advanced CHRONIC HEPATITIS C with low dose PEGINTERFERON",CHRONIC HEPATITIS C,PEGINTERFERON
10372,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10373,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10374,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10375,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10376,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10377,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10378,CEFTRIAXONE treats NEUROLOGIC LYME DISEASE,treats,0.995893206467704,• CEFTRIAXONE is the most well studied antibiotic for treatment of patients with more severe NEUROLOGIC LYME DISEASE ( 13 ;  60 ;  61.,NEUROLOGIC LYME DISEASE,CEFTRIAXONE
10379,[CAPHOSOL] treats [ORAL MUCOSITIS],treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10380,[CAPHOSOL] treats [ORAL MUCOSITIS],treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10381,[CAPHOSOL] treats [ORAL MUCOSITIS],treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10382,[CAPHOSOL] treats [ORAL MUCOSITIS],treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10383,no_relation,treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10384,[CAPHOSOL] treats [ORAL MUCOSITIS],treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10385,[CAPHOSOL] treats [ORAL MUCOSITIS],treats,1.0,Patients at risk of [ORAL MUCOSITIS] were given [CAPHOSOL] and instructed to rinse 4 10 times daily depending on the severity of the mucositis.,[ORAL MUCOSITIS],[CAPHOSOL]
10386,no_relation,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10387,PANTOPRAZOLE treats GASTRO OESOPHAGEAL REFLUX DISEASE,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10388,PANTOPRAZOLE treats GASTRO OESOPHAGEAL REFLUX DISEASE,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10389,PANTOPRAZOLE treats GASTRO OESOPHAGEAL REFLUX DISEASE,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10390,PANTOPRAZOLE treats GASTRO OESOPHAGEAL REFLUX DISEASE,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10391,PANTOPRAZOLE treats GASTRO OESOPHAGEAL REFLUX DISEASE,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10392,PANTOPRAZOLE treats GASTRO OESOPHAGEAL REFLUX DISEASE,treats,0.920574617898323,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
10393,NEUROLEPTIC AGENTS treats NMS,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10394,no_relation,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10395,NEUROLEPTIC AGENTS treats NMS,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10396,no_relation,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10397,NEUROLEPTIC AGENTS treats NMS,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10398,NEUROLEPTIC AGENTS treats NMS,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10399,NEUROLEPTIC AGENTS treats NMS,treats,0.953462589245592,"Some patients who have recovered from NMS have subsequently received NEUROLEPTIC AGENTS without suffering recurrences of NMS, but recurrent NMS does develop in 30% of patients who are rechallenged with neuroleptics.",NMS,NEUROLEPTIC AGENTS
10400,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10401,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10402,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10403,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10404,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10405,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10406,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
10407,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10408,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10409,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10410,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10411,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10412,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10413,no_relation,treats,0.34815531191139604,"The term MSA has supplanted the former terms Shy Drager syndrome, striatonigral degeneration, and OLIVOPONTOCEREBELLAR ATROPHY because it has come to be understood that these seemingly distinctive diseases are simply different expressions of the same condition.",OLIVOPONTOCEREBELLAR ATROPHY,MSA
10414,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10415,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10416,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10417,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10418,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10419,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10420,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated HEPARIN in the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10421,no_relation,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10422,SALMONELLA ISOLATES treats AMPICILLIN,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10423,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10424,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10425,no_relation,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10426,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10427,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
10428,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10429,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10430,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10431,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10432,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10433,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10434,PATIENT INITIATED FAMCICLOVIR THERAPY treats RECURRENT GENITAL HERPES,treats,0.946729262406258,"Aoki F, Tyring S, Diaz Mitoma F et al. Single day, PATIENT INITIATED FAMCICLOVIR THERAPY for RECURRENT GENITAL HERPES: a randomized, double blind, placebo controlled trial.",RECURRENT GENITAL HERPES,PATIENT INITIATED FAMCICLOVIR THERAPY
10435,[TOPICAL AND SYSTEMIC CORTICOSTEROIDS] treats [HALOGENODERMA],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10436,[TOPICAL AND SYSTEMIC CORTICOSTEROIDS] treats [HALOGENODERMA],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10437,[HALOGENODERMA] treats [TOPICAL AND SYSTEMIC CORTICOSTEROIDS],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10438,[TOPICAL AND SYSTEMIC CORTICOSTEROIDS] treats [HALOGENODERMA],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10439,[TOPICAL AND SYSTEMIC CORTICOSTEROIDS] treats [HALOGENODERMA],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10440,[TOPICAL AND SYSTEMIC CORTICOSTEROIDS] treats [HALOGENODERMA],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10441,[TOPICAL AND SYSTEMIC CORTICOSTEROIDS] treats [HALOGENODERMA],treats,0.953462589245592,"Medications given for [HALOGENODERMA] may include [TOPICAL AND SYSTEMIC CORTICOSTEROIDS] diuretics, and cyclosporine.",[HALOGENODERMA],[TOPICAL AND SYSTEMIC CORTICOSTEROIDS]
10442,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10443,no_relation,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10444,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10445,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10446,BRONCHIAL HYPERREACTIVITY treats METHACHOLINE,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10447,BRONCHIAL HYPERREACTIVITY treats METHACHOLINE,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10448,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.6933752452815359,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
10449,METHOTREXATE treats MOLE,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10450,METHOTREXATE treats MOLE,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10451,METHOTREXATE treats MOLE,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10452,METHOTREXATE treats MOLE,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10453,METHOTREXATE treats MOLE,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10454,METHOTREXATE treats MOLE,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10455,no_relation,treats,0.9773555549,Invasive or metastatic [MOLE]s may require chemotherapy and often respond well to [METHOTREXATE].,MOLE,METHOTREXATE
10456,PHARMACOKINETICS OF TERBINAFINE treats TINEA CAPITIS,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10457,PHARMACOKINETICS OF TERBINAFINE treats TINEA CAPITIS,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10458,no_relation,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10459,TINEA CAPITIS treats PHARMACOKINETICS OF TERBINAFINE,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10460,PHARMACOKINETICS OF TERBINAFINE treats TINEA CAPITIS,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10461,no_relation,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10462,PHARMACOKINETICS OF TERBINAFINE treats TINEA CAPITIS,treats,0.979957887012223,"Abdel Rahman SM, Herron J, Fallon Friedlander S et al. PHARMACOKINETICS OF TERBINAFINE in young children treated for TINEA CAPITIS.",TINEA CAPITIS,PHARMACOKINETICS OF TERBINAFINE
10463,no_relation,treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10464,no_relation,treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10465,no_relation,treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10466,[ARTEMISININ BASED ANTIMALARIALS] treats [P FALCIPARUM],treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10467,[ARTEMISININ BASED ANTIMALARIALS] treats [P FALCIPARUM],treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10468,[ARTEMISININ BASED ANTIMALARIALS] treats [P FALCIPARUM],treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10469,[P FALCIPARUM] treats [ARTEMISININ BASED ANTIMALARIALS],treats,0.9000703207408192,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED ANTIMALARIALS] became available.,[P FALCIPARUM],[ARTEMISININ BASED ANTIMALARIALS]
10470,SODIUM BICARBONATE treats HYPERKALEMIA,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10471,SODIUM BICARBONATE treats HYPERKALEMIA,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10472,SODIUM BICARBONATE treats HYPERKALEMIA,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10473,SODIUM BICARBONATE treats HYPERKALEMIA,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10474,no_relation,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10475,SODIUM BICARBONATE treats HYPERKALEMIA,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10476,SODIUM BICARBONATE treats HYPERKALEMIA,treats,0.9838699100999068,"256  If HYPERKALEMIA occurs, immediately discontinue and treat as indicated with parenteral calcium chloride, SODIUM BICARBONATE and/or oral or parenteral glucose with a rapid acting insulin preparation.",HYPERKALEMIA,SODIUM BICARBONATE
10477,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10478,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10479,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10480,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10481,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10482,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10483,OLANZAPINE treats BIPOLAR DISORDER,treats,1.0,"Section 17.14, Need for comprehensive Treatment Program in Pediatric Patients: OLANZAPINE is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and BIPOLAR DISORDER that may include other measures (psychological, educational, social) for patients with the disorder.",BIPOLAR DISORDER,OLANZAPINE
10484,[ACYCLOVIR] treats [NEONATAL HERPES SIMPLEX VIRUS INFECTION],treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10485,no_relation,treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10486,[ACYCLOVIR] treats [NEONATAL HERPES SIMPLEX VIRUS INFECTION],treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10487,[ACYCLOVIR] treats [NEONATAL HERPES SIMPLEX VIRUS INFECTION],treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10488,[ACYCLOVIR] treats [NEONATAL HERPES SIMPLEX VIRUS INFECTION],treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10489,no_relation,treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10490,[ACYCLOVIR] treats [NEONATAL HERPES SIMPLEX VIRUS INFECTION],treats,0.923380516876639,title=A controlled trial comparing vidarabine with [ACYCLOVIR] in [NEONATAL HERPES SIMPLEX VIRUS INFECTION],[NEONATAL HERPES SIMPLEX VIRUS INFECTION],[ACYCLOVIR]
10491,ANTIARRHYTHMIC treats VENTRICULAR ARRHYTHMIAS,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10492,no_relation,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10493,ANTIARRHYTHMIC treats VENTRICULAR ARRHYTHMIAS,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10494,ANTIARRHYTHMIC treats VENTRICULAR ARRHYTHMIAS,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10495,VENTRICULAR ARRHYTHMIAS treats ANTIARRHYTHMIC,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10496,no_relation,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10497,no_relation,treats,0.9918365981341752,"b  Ventricular Arrhythmias (General)  Treatment of VENTRICULAR ARRHYTHMIAS (e.g., sustained VT) that in the judgment of the clinician are life threatening, but the drug usually is not the ANTIARRHYTHMIC of first choice.",VENTRICULAR ARRHYTHMIAS,ANTIARRHYTHMIC
10498,YCLOPHOSPHAMIDE W treats PROLIFERATIVE SLE NEPHRITIS T,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10499,YCLOPHOSPHAMIDE W treats PROLIFERATIVE SLE NEPHRITIS T,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10500,YCLOPHOSPHAMIDE W treats PROLIFERATIVE SLE NEPHRITIS T,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10501,YCLOPHOSPHAMIDE W treats PROLIFERATIVE SLE NEPHRITIS T,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10502,no_relation,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10503,YCLOPHOSPHAMIDE W treats PROLIFERATIVE SLE NEPHRITIS T,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10504,YCLOPHOSPHAMIDE W treats PROLIFERATIVE SLE NEPHRITIS T,treats,1.0,"Evidence:  In a randomized controlled trial, monthly intravenous cYCLOPHOSPHAMIDE Was more effective for treatment of PROLIFERATIVE SLE NEPHRITIS Than monthly intravenous glucocorticoid therapy; combination therapy may be superior ( 52.",PROLIFERATIVE SLE NEPHRITIS T,YCLOPHOSPHAMIDE W
10505,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10506,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10507,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10508,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10509,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10510,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10511,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,1.0,"Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
10512,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10513,PAIN RELATED TO OSTEOARTHROSIS treats 900 MG OF IBUPROFEN,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10514,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10515,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10516,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10517,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10518,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.9918365981341752,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
10519,[MSM] treats [MELASMA],treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10520,no_relation,treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10521,[MSM] treats [MELASMA],treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10522,no_relation,treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10523,[MSM] treats [MELASMA],treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10524,no_relation,treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10525,[MSM] treats [MELASMA],treats,0.994134846772434,[MSM] for [MELASMA]   Megadoses of sulphur helps some sufferers.,[MELASMA],[MSM]
10526,no_relation,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10527,no_relation,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10528,REFLUX TO THE STOMACH treats PATHOGENESIS OF RESIDUAL GASTRITIS,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10529,no_relation,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10530,no_relation,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10531,REFLUX TO THE STOMACH treats PATHOGENESIS OF RESIDUAL GASTRITIS,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10532,REFLUX TO THE STOMACH treats PATHOGENESIS OF RESIDUAL GASTRITIS,treats,0.474341649025257,Bile REFLUX TO THE STOMACH is believed as one of the important PATHOGENESIS OF RESIDUAL GASTRITIS however the prevention for bile reflux cannot always heal the gastritis.,REFLUX TO THE STOMACH,PATHOGENESIS OF RESIDUAL GASTRITIS
10533,no_relation,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10534,no_relation,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10535,no_relation,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10536,no_relation,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10537,no_relation,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10538,no_relation,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10539,NEURALGIA treats NEUROPATHIC PAIN,treats,0.390566732942472,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
10540,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10541,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10542,no_relation,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10543,no_relation,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10544,no_relation,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10545,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10546,NASAL NAFARELIN treats ENDOMETRIOSIS,treats,0.9434563530497272,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
10547,no_relation,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10548,DEXAMETHASONE treats DEPRESSION,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10549,DEXAMETHASONE treats DEPRESSION,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10550,no_relation,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10551,DEXAMETHASONE treats DEPRESSION,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10552,no_relation,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10553,DEXAMETHASONE treats DEPRESSION,treats,0.680413817439772,"The aim of the present study was to investigate how DEXAMETHASONE, a synthetic glucocorticoid, and norepinephrine, both of which are involved in DEPRESSION, interact to affect aspects of neuronal plasticity",DEPRESSION,DEXAMETHASONE
10554,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10555,MALARIA treats PLASMODIUM FALCIPARUM INFECTION,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10556,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10557,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10558,MALARIA treats PLASMODIUM FALCIPARUM INFECTION,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10559,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10560,no_relation,treats,0.32444284226152503,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
10561,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10562,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10563,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10564,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10565,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10566,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10567,LITHIUM treats BIPOLAR DISORDER,treats,0.984731927834662,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to LITHIUM valproic acid, or divalproex in the management of patients with rapid cycling BIPOLAR DISORDER   +   , particularly in those with the bipolar 2 form of rapid cycling.",BIPOLAR DISORDER,LITHIUM
10568,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10569,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10570,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10571,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10572,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10573,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10574,AMOXICILLIN treats SOFT TISSUE INFECTIONS,treats,1.0,AMOXICILLIN combined with clavulanic acid for the treatment of SOFT TISSUE INFECTIONS in children.,SOFT TISSUE INFECTIONS,AMOXICILLIN
10575,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10576,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10577,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10578,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10579,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10580,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10581,TRIMETHOPRIM SULFAMETHOXAZOLE treats SYMPTOMATIC URINARY TRACT INFECTIONS,treats,0.997458699830735,"Norrby SR, Rylander M, Sandberg T et al. Coordinated multicenter study of norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE treatment of SYMPTOMATIC URINARY TRACT INFECTIONS",SYMPTOMATIC URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
10582,no_relation,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10583,no_relation,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10584,TOURETTE SYNDROME treats SCHIZOPHRENIA,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10585,no_relation,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10586,no_relation,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10587,TOURETTE SYNDROME treats SCHIZOPHRENIA,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10588,no_relation,treats,0.3,"Its main usefulness is the treatment of hyperkinetic movement disorders such as Huntington's disease and [TOURETTE SYNDROME], rather than for conditions such as [SCHIZOPHRENIA].",SCHIZOPHRENIA,TOURETTE SYNDROME
10589,[IV AMPHOTERICIN B] treats [CULTURE PROVEN CANDIDEMIA],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10590,[CULTURE PROVEN CANDIDEMIA] treats [IV AMPHOTERICIN B],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10591,[IV AMPHOTERICIN B] treats [CULTURE PROVEN CANDIDEMIA],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10592,[IV AMPHOTERICIN B] treats [CULTURE PROVEN CANDIDEMIA],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10593,[IV AMPHOTERICIN B] treats [CULTURE PROVEN CANDIDEMIA],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10594,[IV AMPHOTERICIN B] treats [CULTURE PROVEN CANDIDEMIA],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10595,[IV AMPHOTERICIN B] treats [CULTURE PROVEN CANDIDEMIA],treats,0.9838699100999068,Voriconazole has proven to be as effective as a regimen of [IV AMPHOTERICIN B] followed by oral fluconazole in patients with [CULTURE PROVEN CANDIDEMIA],[CULTURE PROVEN CANDIDEMIA],[IV AMPHOTERICIN B]
10596,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10597,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10598,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10599,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10600,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10601,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10602,KOJIC ACID treats HYPERPIGMENTATION,treats,0.9878291611,"Treatment of [HYPERPIGMENTATION] may include hydroquinone, [KOJIC ACID], alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin , topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,KOJIC ACID
10603,CLOMIPRAMINE treats PANIC DISORDER,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10604,PANIC DISORDER treats CLOMIPRAMINE,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10605,CLOMIPRAMINE treats PANIC DISORDER,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10606,CLOMIPRAMINE treats PANIC DISORDER,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10607,CLOMIPRAMINE treats PANIC DISORDER,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10608,CLOMIPRAMINE treats PANIC DISORDER,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10609,no_relation,treats,0.970494958830946,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
10610,EYE DROPS treats ALLERGIC CONJUNCTIVITIS,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10611,EYE DROPS treats ALLERGIC CONJUNCTIVITIS,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10612,no_relation,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10613,no_relation,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10614,no_relation,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10615,EYE DROPS treats ALLERGIC CONJUNCTIVITIS,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10616,EYE DROPS treats ALLERGIC CONJUNCTIVITIS,treats,0.9970544855015808,"as [EYE DROPS] , Crolom) for [ALLERGIC CONJUNCTIVITIS].",ALLERGIC CONJUNCTIVITIS,EYE DROPS
10617,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10618,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10619,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10620,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10621,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10622,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10623,LONG ACTING CHLORAMPHENICOL treats MENINGOCOCCAL MENINGITIS,treats,1.0,"1]  Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as LONG ACTING CHLORAMPHENICOL in short course treatment of MENINGOCOCCAL MENINGITIS during epidemics: a randomised non inferiority study.",MENINGOCOCCAL MENINGITIS,LONG ACTING CHLORAMPHENICOL
10624,ACEBUTOLOL treats HYPERTENSION,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10625,ACEBUTOLOL treats HYPERTENSION,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10626,ACEBUTOLOL treats HYPERTENSION,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10627,ACEBUTOLOL treats HYPERTENSION,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10628,HYPERTENSION treats ACEBUTOLOL,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10629,ACEBUTOLOL treats HYPERTENSION,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10630,ACEBUTOLOL treats HYPERTENSION,treats,0.9918365981341752,ACEBUTOLOL in the treatment of patients with HYPERTENSION and renal functional impairment.,HYPERTENSION,ACEBUTOLOL
10631,[INTERFERON] treats [MULTIPLE SCLEROSIS],treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10632,no_relation,treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10633,no_relation,treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10634,[INTERFERON] treats [MULTIPLE SCLEROSIS],treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10635,no_relation,treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10636,[INTERFERON] treats [MULTIPLE SCLEROSIS],treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10637,[INTERFERON] treats [MULTIPLE SCLEROSIS],treats,0.987878339907213,Participants were nine patients with [MULTIPLE SCLEROSIS] not controlled with [INTERFERON],[MULTIPLE SCLEROSIS],[INTERFERON]
10638,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10639,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10640,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10641,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10642,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10643,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10644,ACETAMINOPHEN treats PAIN,treats,0.9901475429766742,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
10645,no_relation,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10646,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10647,no_relation,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10648,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10649,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10650,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10651,FLUORIDE SUPPLEMENTS treats CARIES,treats,0.968495996958186,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
10652,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10653,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10654,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10655,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10656,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10657,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10658,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9491579957524988,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
10659,no_relation,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10660,no_relation,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10661,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10662,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10663,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10664,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10665,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
10666,BERBERINE treats DIABETES MELLITUS,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10667,BERBERINE treats DIABETES MELLITUS,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10668,BERBERINE treats DIABETES MELLITUS,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10669,DIABETES MELLITUS treats BERBERINE,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10670,BERBERINE treats DIABETES MELLITUS,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10671,BERBERINE treats DIABETES MELLITUS,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10672,BERBERINE treats DIABETES MELLITUS,treats,1.0,[BERBERINE] has been tested and used successfully in experimental and human [DIABETES MELLITUS].,DIABETES MELLITUS,BERBERINE
10673,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10674,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10675,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10676,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10677,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10678,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10679,IV AMPHOTERICIN B treats SYMPTOMATIC CYSTITIS,treats,0.938314863256837,"425   When fluconazole resistant  Candida  (e.g.,  C. glabrata ,  C. krusei ) are likely, IV AMPHOTERICIN B or oral flucytosine is recommended for SYMPTOMATIC CYSTITIS, IV AMPHOTERICIN B (with or without flucytosine) or oral flucytosine alone is recommended for pyelonephritis, and IV amphotericin B (with or without flucytosine) is recommended for fungus balls.",SYMPTOMATIC CYSTITIS,IV AMPHOTERICIN B
10680,CLINDAMYCIN VS PYRIMETHAMINE treats TOXOPLASMIC ENCEPHALITIS,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10681,CLINDAMYCIN VS PYRIMETHAMINE treats TOXOPLASMIC ENCEPHALITIS,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10682,CLINDAMYCIN VS PYRIMETHAMINE treats TOXOPLASMIC ENCEPHALITIS,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10683,CLINDAMYCIN VS PYRIMETHAMINE treats TOXOPLASMIC ENCEPHALITIS,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10684,no_relation,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10685,TOXOPLASMIC ENCEPHALITIS treats CLINDAMYCIN VS PYRIMETHAMINE,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10686,TOXOPLASMIC ENCEPHALITIS treats CLINDAMYCIN VS PYRIMETHAMINE,treats,0.9970544855015808,"Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine CLINDAMYCIN VS PYRIMETHAMINE sulfadiazine as acute and long term therapy for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,CLINDAMYCIN VS PYRIMETHAMINE
10687,ENCAINIDE treats VENTRICULAR ARRHYTHMIA SUPPRESSION,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10688,ENCAINIDE treats VENTRICULAR ARRHYTHMIA SUPPRESSION,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10689,VENTRICULAR ARRHYTHMIA SUPPRESSION treats ENCAINIDE,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10690,ENCAINIDE treats VENTRICULAR ARRHYTHMIA SUPPRESSION,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10691,no_relation,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10692,no_relation,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10693,VENTRICULAR ARRHYTHMIA SUPPRESSION treats ENCAINIDE,treats,0.7624928516630229,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
10694,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10695,SCHIZOPHRENIA treats CLOZAPINE,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10696,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10697,SCHIZOPHRENIA treats CLOZAPINE,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10698,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10699,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10700,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9901475429766742,"Barrett N, Ormiston S, Molyneux VCLOZAPINE: a new drug for SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
10701,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10702,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10703,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10704,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10705,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10706,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10707,METHYLDOPA treats HYPERTENSION,treats,0.99654575824488,Treatment of HYPERTENSION in pregnancy with METHYLDOPA: a randomized double blind study.,HYPERTENSION,METHYLDOPA
10708,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10709,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10710,no_relation,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10711,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10712,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10713,VASOPRESSIN treats DIABETES INSIPIDUS,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10714,no_relation,treats,0.404061017820884,Results of restriction of liquids followed by intravenous injection of VASOPRESSIN (Miller test) favoured a diagnosis of complete DIABETES INSIPIDUS,DIABETES INSIPIDUS,VASOPRESSIN
10715,no_relation,treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10716,[BOTOX INJECTIONS] treats [TARDIVE DYSKINESIA],treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10717,no_relation,treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10718,[BOTOX INJECTIONS] treats [TARDIVE DYSKINESIA],treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10719,no_relation,treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10720,[BOTOX INJECTIONS] treats [TARDIVE DYSKINESIA],treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10721,[BOTOX INJECTIONS] treats [TARDIVE DYSKINESIA],treats,0.441726104299386,[BOTOX INJECTIONS] are used for minor focal dystonia though not of use on for more advanced [TARDIVE DYSKINESIA],[TARDIVE DYSKINESIA],[BOTOX INJECTIONS]
10722,no_relation,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10723,FACTOR VIII treats HEMOPHILIA A,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10724,FACTOR VIII treats HEMOPHILIA A,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10725,FACTOR VIII treats HEMOPHILIA A,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10726,FACTOR VIII treats HEMOPHILIA A,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10727,HEMOPHILIA A treats FACTOR VIII,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10728,FACTOR VIII treats HEMOPHILIA A,treats,0.956182887467515,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
10729,FAMOTIDINE treats BENIGN GASTRIC ULCER,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10730,FAMOTIDINE treats BENIGN GASTRIC ULCER,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10731,FAMOTIDINE treats BENIGN GASTRIC ULCER,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10732,FAMOTIDINE treats BENIGN GASTRIC ULCER,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10733,BENIGN GASTRIC ULCER treats FAMOTIDINE,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10734,FAMOTIDINE treats BENIGN GASTRIC ULCER,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10735,FAMOTIDINE treats BENIGN GASTRIC ULCER,treats,1.0,"FAMOTIDINE once a day in the therapy of acute, BENIGN GASTRIC ULCER: a world wide experience.",BENIGN GASTRIC ULCER,FAMOTIDINE
10736,PIPERONYL BUTOXIDE treats LICE,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10737,PIPERONYL BUTOXIDE treats LICE,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10738,no_relation,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10739,PIPERONYL BUTOXIDE treats LICE,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10740,PIPERONYL BUTOXIDE treats LICE,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10741,PIPERONYL BUTOXIDE treats LICE,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10742,no_relation,treats,0.986393923832144,Pronto ®  plus LICE killing mousse shampoo kit (pyrethrins with PIPERONYL BUTOXIDE product information.,LICE,PIPERONYL BUTOXIDE
10743,ERYTHROMYCIN treats PERTUSSIS,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10744,PERTUSSIS treats ERYTHROMYCIN,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10745,ERYTHROMYCIN treats PERTUSSIS,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10746,ERYTHROMYCIN treats PERTUSSIS,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10747,ERYTHROMYCIN treats PERTUSSIS,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10748,ERYTHROMYCIN treats PERTUSSIS,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10749,ERYTHROMYCIN treats PERTUSSIS,treats,1.0,"Bergquist SO, Bernander S, Doahnsjo H et alERYTHROMYCIN in the treatment of PERTUSSIS: a study of bacteriologic and clinical effects.",PERTUSSIS,ERYTHROMYCIN
10750,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10751,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10752,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10753,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10754,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10755,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10756,ANTIDOTES treats OP POISONING,treats,0.99654575824488,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
10757,no_relation,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10758,no_relation,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10759,no_relation,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10760,no_relation,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10761,PLAGUE treats YERSINIA PESTIS,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10762,PLAGUE treats YERSINIA PESTIS,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10763,no_relation,treats,0.340502612303499,118  Plague  Has been used for treatment of PLAGUE   +    caused by  YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS
10764,ORAL CLONIDINE treats WITHDRAWAL SYNDROME,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10765,ORAL CLONIDINE treats WITHDRAWAL SYNDROME,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10766,no_relation,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10767,no_relation,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10768,no_relation,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10769,WITHDRAWAL SYNDROME treats ORAL CLONIDINE,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10770,ORAL CLONIDINE treats WITHDRAWAL SYNDROME,treats,0.640512615220349,"b  WITHDRAWAL SYNDROME (reported in about 1% of patients receiving ORAL CLONIDINE is more pronounced after abrupt cessation of long term therapy than after short term (1 2 months) therapy, and has usually been associated with previous administration of high oral dosages (>1.2 mg daily) and/or with continuation of concomitant β adrenergic blocking therapy.",WITHDRAWAL SYNDROME,ORAL CLONIDINE
10771,no_relation,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10772,no_relation,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10773,no_relation,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10774,no_relation,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10775,no_relation,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10776,YAWS treats TREPONEMA PERTENUE,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10777,YAWS treats TREPONEMA PERTENUE,treats,0.371390676354104,g  Yaws  Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
10778,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10779,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10780,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10781,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10782,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10783,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10784,CEFOTETAN treats INTRA ABDOMINAL SEPSIS,treats,0.99654575824488,CEFOTETAN in the treatment of serious INTRA ABDOMINAL SEPSIS: a controlled clinical trial.,INTRA ABDOMINAL SEPSIS,CEFOTETAN
10785,SODIUM OXYBATE treats CATAPLEXY,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10786,SODIUM OXYBATE treats CATAPLEXY,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10787,SODIUM OXYBATE treats CATAPLEXY,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10788,no_relation,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10789,SODIUM OXYBATE treats CATAPLEXY,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10790,SODIUM OXYBATE treats CATAPLEXY,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10791,CATAPLEXY treats SODIUM OXYBATE,treats,0.961074462327142,"• When discontinuing medications other than SODIUM OXYBATE for CATAPLEXY and other REM related symptoms, slowly taper dose over several weeks rather than stopping abruptly.",CATAPLEXY,SODIUM OXYBATE
10792,ORLISTAT treats TYPE 2 DIABETES,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10793,ORLISTAT treats TYPE 2 DIABETES,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10794,TYPE 2 DIABETES treats ORLISTAT,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10795,ORLISTAT treats TYPE 2 DIABETES,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10796,ORLISTAT treats TYPE 2 DIABETES,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10797,ORLISTAT treats TYPE 2 DIABETES,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10798,ORLISTAT treats TYPE 2 DIABETES,treats,0.995893206467704,The incidence of [TYPE 2 DIABETES] in an obese population over four years is decreased with [ORLISTAT] compared to placebo .,TYPE 2 DIABETES,ORLISTAT
10799,CYCLOPHOSPHAMIDE treats MANTLE CELL LYMPHOMA,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10800,CYCLOPHOSPHAMIDE treats MANTLE CELL LYMPHOMA,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10801,MANTLE CELL LYMPHOMA treats CYCLOPHOSPHAMIDE,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10802,CYCLOPHOSPHAMIDE treats MANTLE CELL LYMPHOMA,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10803,CYCLOPHOSPHAMIDE treats MANTLE CELL LYMPHOMA,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10804,CYCLOPHOSPHAMIDE treats MANTLE CELL LYMPHOMA,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10805,CYCLOPHOSPHAMIDE treats MANTLE CELL LYMPHOMA,treats,0.9760921603577252,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, procarbazine and [CYCLOPHOSPHAMIDE].",MANTLE CELL LYMPHOMA,CYCLOPHOSPHAMIDE
10806,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10807,MYXEDEMA treats INTRAVENOUS L THYROXINE,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10808,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10809,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10810,MYXEDEMA treats INTRAVENOUS L THYROXINE,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10811,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10812,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9113223768657672,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
10813,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10814,REFRACTORY REFLUX ESOPHAGITIS treats OMEPRAZOLE,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10815,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10816,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10817,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10818,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10819,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,0.995893206467704,"Klinkenberg Knol EC, Festen HPM, Jansen JBMJ et al. Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.",REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
10820,no_relation,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10821,no_relation,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10822,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10823,no_relation,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10824,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10825,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10826,NEURAL TUBE DEFECTS treats FOLIC ACID,treats,0.994134846772434,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
10827,TERBINAFINE treats TRICHOPHYTON TINEA CAPITIS,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10828,TRICHOPHYTON TINEA CAPITIS treats TERBINAFINE,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10829,TERBINAFINE treats TRICHOPHYTON TINEA CAPITIS,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10830,TERBINAFINE treats TRICHOPHYTON TINEA CAPITIS,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10831,TERBINAFINE treats TRICHOPHYTON TINEA CAPITIS,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10832,TERBINAFINE treats TRICHOPHYTON TINEA CAPITIS,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10833,TRICHOPHYTON TINEA CAPITIS treats TERBINAFINE,treats,1.0,"Friedlander SF, Aly R, Krafchik B et alTERBINAFINE in the treatment of TRICHOPHYTON TINEA CAPITIS: a randomized, double blind, parallel group, duration finding study.",TRICHOPHYTON TINEA CAPITIS,TERBINAFINE
10834,METHOTREXATE treats ECTOPIC PREGNANCY,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10835,METHOTREXATE treats ECTOPIC PREGNANCY,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10836,METHOTREXATE treats ECTOPIC PREGNANCY,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10837,METHOTREXATE treats ECTOPIC PREGNANCY,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10838,METHOTREXATE treats ECTOPIC PREGNANCY,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10839,no_relation,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10840,METHOTREXATE treats ECTOPIC PREGNANCY,treats,0.9615239476408228,1994 10 28  Transvaginal intra amniotic injection of METHOTREXATE in early ECTOPIC PREGNANCY,ECTOPIC PREGNANCY,METHOTREXATE
10841,ERGONOVINE treats VASOSPASTIC ANGINA,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10842,no_relation,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10843,ERGONOVINE treats VASOSPASTIC ANGINA,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10844,ERGONOVINE treats VASOSPASTIC ANGINA,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10845,no_relation,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10846,ERGONOVINE treats VASOSPASTIC ANGINA,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10847,ERGONOVINE treats VASOSPASTIC ANGINA,treats,0.936585811581694,"To investigate the mechanism of coronary spasm, we compared the action of acetylcholine with that of ERGONOVINE in 11 patients with VASOSPASTIC ANGINA and in 15 patients with chest pain (group 2",VASOSPASTIC ANGINA,ERGONOVINE
10848,ISLET CELL NEOGENESIS treats DIABETES,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10849,ISLET CELL NEOGENESIS treats DIABETES,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10850,ISLET CELL NEOGENESIS treats DIABETES,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10851,ISLET CELL NEOGENESIS treats DIABETES,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10852,no_relation,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10853,no_relation,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10854,no_relation,treats,0.993127066322842,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
10855,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10856,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10857,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10858,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10859,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10860,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10861,TERBINAFINE treats TINEA CAPITIS,treats,0.995893206467704,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
10862,no_relation,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10863,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10864,HEPATOCELLULAR CARCINOMA treats HYPERTHERMIA,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10865,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10866,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10867,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10868,HEPATOCELLULAR CARCINOMA treats HYPERTHERMIA,treats,0.953820966476532,"In view of acceptable toxicities and the current rate of survival, further evaluation of combined treatment of radiotherapy and HYPERTHERMIA for unresectable HEPATOCELLULAR CARCINOMA is warranted.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
10869,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10870,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10871,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10872,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10873,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10874,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10875,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,"Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with HEPARIN for the initial treatment of PULMONARY EMBOLISM",PULMONARY EMBOLISM,HEPARIN
10876,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10877,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10878,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10879,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10880,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10881,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10882,DRUG RESISTANT VISCERAL LEISHMANIASIS treats LIPOSOMAL AMPHOTERICIN B,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
10883,WARFARIN treats SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10884,WARFARIN treats SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10885,WARFARIN treats SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10886,WARFARIN treats SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10887,WARFARIN treats SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10888,WARFARIN treats SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10889,no_relation,treats,0.8846517369293829,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
10890,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10891,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10892,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10893,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10894,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10895,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10896,PILOCARPINE treats XEROSTOMIA,treats,0.9970544855015808,PILOCARPINE may be prescribed to treat XEROSTOMIA,XEROSTOMIA,PILOCARPINE
10897,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10898,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10899,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10900,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10901,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10902,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10903,TAZAROTENE treats PSORIASIS,treats,0.9754262200082652,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
10904,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10905,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10906,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10907,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10908,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10909,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10910,[ARIPIPRAZOLE] treats [ACUTE BIPOLAR MANIA],treats,0.9901475429766742,"title=A placebo controlled, double blind study of the efficacy and safety of [ARIPIPRAZOLE] in patients with [ACUTE BIPOLAR MANIA]",[ACUTE BIPOLAR MANIA],[ARIPIPRAZOLE]
10911,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10912,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10913,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10914,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10915,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10916,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10917,PAROXETINE treats PANIC DISORDER,treats,1.0,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
10918,CRYPTOCOCCAL MENINGITIS treats AMPHOTERICIN B,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10919,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10920,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10921,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10922,no_relation,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10923,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10924,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964763821237732,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
10925,WARFARIN treats THROMBOEMBOLIC STROKE,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10926,WARFARIN treats THROMBOEMBOLIC STROKE,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10927,WARFARIN treats THROMBOEMBOLIC STROKE,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10928,WARFARIN treats THROMBOEMBOLIC STROKE,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10929,no_relation,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10930,no_relation,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10931,WARFARIN treats THROMBOEMBOLIC STROKE,treats,0.8551861104941371,"Both warfarin groups had lower rates for the main composite measure, nonfatal reinfarction, and THROMBOEMBOLIC STROKE than the aspirin alone group (Table); the 2 WARFARIN groups did not differ for these outcomes.",THROMBOEMBOLIC STROKE,WARFARIN
10932,NIZATIDINE treats ACTIVE BENIGN GASTRIC ULCER DISEASE,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10933,NIZATIDINE treats ACTIVE BENIGN GASTRIC ULCER DISEASE,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10934,no_relation,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10935,no_relation,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10936,NIZATIDINE treats ACTIVE BENIGN GASTRIC ULCER DISEASE,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10937,no_relation,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10938,NIZATIDINE treats ACTIVE BENIGN GASTRIC ULCER DISEASE,treats,0.9950371902099888,"Cloud ML, Enas N, Offen WW et alNIZATIDINE versus placebo in ACTIVE BENIGN GASTRIC ULCER DISEASE: an eight week, multicenter, randomized, double blind comparison.",ACTIVE BENIGN GASTRIC ULCER DISEASE,NIZATIDINE
10939,no_relation,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10940,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10941,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10942,no_relation,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10943,no_relation,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10944,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10945,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9494253265550828,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
10946,AMPHOTERICIN B treats NEUTROPENIA,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10947,AMPHOTERICIN B treats NEUTROPENIA,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10948,AMPHOTERICIN B treats NEUTROPENIA,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10949,no_relation,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10950,no_relation,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10951,no_relation,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10952,AMPHOTERICIN B treats NEUTROPENIA,treats,0.936329177569045,"1]  Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with AMPHOTERICIN B as empiric anti fungal agents in cancer patients with prolonged fever and NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
10953,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10954,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10955,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10956,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10957,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10958,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10959,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
10960,VORICONAZOLE treats ASPERGILLOSIS,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10961,VORICONAZOLE treats ASPERGILLOSIS,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10962,VORICONAZOLE treats ASPERGILLOSIS,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10963,VORICONAZOLE treats ASPERGILLOSIS,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10964,VORICONAZOLE treats ASPERGILLOSIS,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10965,no_relation,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10966,VORICONAZOLE treats ASPERGILLOSIS,treats,0.9918365981341752,"Treatment  The current treatments include VORICONAZOLE and liposomal amphotericin B. Newer findings suggest use of mild oral steroids for a longer period of time, preferably for 6 9 months in ASPERGILLOSIS in pulmonary segment.",ASPERGILLOSIS,VORICONAZOLE
10967,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10968,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10969,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10970,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10971,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10972,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10973,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA treats COLESTIPOL,treats,0.99654575824488,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
10974,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10975,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10976,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10977,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10978,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10979,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10980,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"1]  Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
10981,WARFARIN treats VTE,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10982,WARFARIN treats VTE,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10983,WARFARIN treats VTE,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10984,no_relation,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10985,WARFARIN treats VTE,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10986,WARFARIN treats VTE,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10987,WARFARIN treats VTE,treats,1.0,"Low dose unfractionated heparin, low molecular weight heparin, fondaparinux, and WARFARIN have all been shown to be efficacious for VTE prevention in surgical patients.",VTE,WARFARIN
10988,MAINTENANCE CYCLOSPORINE THERAPY treats PSORIASIS,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10989,MAINTENANCE CYCLOSPORINE THERAPY treats PSORIASIS,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10990,MAINTENANCE CYCLOSPORINE THERAPY treats PSORIASIS,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10991,MAINTENANCE CYCLOSPORINE THERAPY treats PSORIASIS,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10992,no_relation,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10993,MAINTENANCE CYCLOSPORINE THERAPY treats PSORIASIS,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10994,MAINTENANCE CYCLOSPORINE THERAPY treats PSORIASIS,treats,0.995893206467704,"Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during MAINTENANCE CYCLOSPORINE THERAPY for PSORIASIS: relationship to maintenance dose and degree of improvement during initial therapy.",PSORIASIS,MAINTENANCE CYCLOSPORINE THERAPY
10995,[IBUPROFEN 400MG AND MORPHINE IR] treats [POST SURGERY DENTAL PAIN],treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
10996,[IBUPROFEN 400MG AND MORPHINE IR] treats [POST SURGERY DENTAL PAIN],treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
10997,[IBUPROFEN 400MG AND MORPHINE IR] treats [POST SURGERY DENTAL PAIN],treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
10998,[IBUPROFEN 400MG AND MORPHINE IR] treats [POST SURGERY DENTAL PAIN],treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
10999,[POST SURGERY DENTAL PAIN] treats [IBUPROFEN 400MG AND MORPHINE IR],treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
11000,[IBUPROFEN 400MG AND MORPHINE IR] treats [POST SURGERY DENTAL PAIN],treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
11001,no_relation,treats,0.933256525257383,"A phase II single dose trial of tapentadol 25mg 200mg, [IBUPROFEN 400MG AND MORPHINE IR] 60mg was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[IBUPROFEN 400MG AND MORPHINE IR]
11002,OMEPRAZOLE treats HEARTBURN,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11003,OMEPRAZOLE treats HEARTBURN,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11004,no_relation,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11005,OMEPRAZOLE treats HEARTBURN,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11006,OMEPRAZOLE treats HEARTBURN,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11007,no_relation,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11008,no_relation,treats,0.961074462327142,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
11009,VACCINE treats HEPATITIS B,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11010,VACCINE treats HEPATITIS B,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11011,VACCINE treats HEPATITIS B,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11012,no_relation,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11013,VACCINE treats HEPATITIS B,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11014,VACCINE treats HEPATITIS B,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11015,VACCINE treats HEPATITIS B,treats,0.9838699100999068,"This approach has been taken with [VACCINE]s for mumps, measles, rubella, and [HEPATITIS B] .",HEPATITIS B,VACCINE
11016,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11017,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11018,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11019,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11020,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11021,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11022,FUROSEMIDE treats EDEMA,treats,0.99654575824488,"34 ,   37 ,   54 ,   55 ,   56  Appears to be as effective as FUROSEMIDE in reducing EDEMA, body weight, and abdominal girth in patients with edema secondary to renal disease",EDEMA,FUROSEMIDE
11023,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11024,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11025,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11026,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11027,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11028,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11029,AMPHOTERICIN B LIPID COMPLEX treats FUNGAL INFECTIONS,treats,0.707106781186547,"Walsh TJ, Seibel JL, Arndt C et al. AMPHOTERICIN B LIPID COMPLEX in pediatric patients with invasive FUNGAL INFECTIONS",FUNGAL INFECTIONS,AMPHOTERICIN B LIPID COMPLEX
11030,no_relation,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11031,FLUOXETINE treats DEPERSONALIZATION DISORDER,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11032,no_relation,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11033,FLUOXETINE treats DEPERSONALIZATION DISORDER,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11034,no_relation,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11035,no_relation,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11036,no_relation,treats,0.6868028197,"However, a placebo-controlled trial failed to show benefit with [FLUOXETINE] in 54 patients with [DEPERSONALIZATION DISORDER].",DEPERSONALIZATION DISORDER,FLUOXETINE
11037,no_relation,treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11038,no_relation,treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11039,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11040,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11041,[VEIN THROMBUS] treats [INTRA ARTERIAL IODINE 131 LIPIODOL],treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11042,no_relation,treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11043,[VEIN THROMBUS] treats [INTRA ARTERIAL IODINE 131 LIPIODOL],treats,0.981980506061966,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
11044,SPIRONOLACTONE treats HEART FAILURE,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11045,SPIRONOLACTONE treats HEART FAILURE,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11046,SPIRONOLACTONE treats HEART FAILURE,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11047,SPIRONOLACTONE treats HEART FAILURE,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11048,SPIRONOLACTONE treats HEART FAILURE,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11049,no_relation,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11050,SPIRONOLACTONE treats HEART FAILURE,treats,0.9918365981341752,"138  Aldosterone antagonists   The aldosterone antagonists (i.e., SPIRONOLACTONE and eplerenone) are another relatively old class of drugs with new data to support use in HEART FAILURE",HEART FAILURE,SPIRONOLACTONE
11051,FLUTICASONE PROPIONATE AEROSOL treats MILD TO MODERATE ASTHMA,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11052,MILD TO MODERATE ASTHMA treats FLUTICASONE PROPIONATE AEROSOL,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11053,FLUTICASONE PROPIONATE AEROSOL treats MILD TO MODERATE ASTHMA,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11054,FLUTICASONE PROPIONATE AEROSOL treats MILD TO MODERATE ASTHMA,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11055,FLUTICASONE PROPIONATE AEROSOL treats MILD TO MODERATE ASTHMA,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11056,FLUTICASONE PROPIONATE AEROSOL treats MILD TO MODERATE ASTHMA,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11057,FLUTICASONE PROPIONATE AEROSOL treats MILD TO MODERATE ASTHMA,treats,1.0,FLUTICASONE PROPIONATE AEROSOL for the treatment of adults with MILD TO MODERATE ASTHMA,MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE AEROSOL
11058,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11059,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11060,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11061,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11062,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11063,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11064,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.963086824686154,"In general, CHONDROITIN SULFATE combined with these other agents was found to alleviate symptoms of OSTEOARTHRITIS compared to placebo.",OSTEOARTHRITIS,CHONDROITIN SULFATE
11065,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11066,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11067,DIAZEPAM treats OVERT STATUS EPILEPTICUS,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11068,no_relation,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11069,no_relation,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11070,no_relation,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11071,no_relation,treats,0.917662935482247,Treatment success of 4 drug therapies for status epilepticus at 12 hours  Drug therapies              Success rates OVERT STATUS EPILEPTICUS      Subtle status epilepticus Lorazepam                 67.0%                       26.1% Phenobarbital             63.0%                       24.4% Phenytoin                 51.0%                       19.5% DIAZEPAM and phenytoin    59.6%                       23.4%    COMMENTARY  Generalized convulsive status epilepticus requires prompt treatment to prevent death or serious brain injury.,OVERT STATUS EPILEPTICUS,DIAZEPAM
11072,CLOZAPINE treats TREATMENT RESISTANT PSYCHOSIS,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11073,no_relation,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11074,no_relation,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11075,CLOZAPINE treats TREATMENT RESISTANT PSYCHOSIS,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11076,CLOZAPINE treats TREATMENT RESISTANT PSYCHOSIS,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11077,CLOZAPINE treats TREATMENT RESISTANT PSYCHOSIS,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11078,CLOZAPINE treats TREATMENT RESISTANT PSYCHOSIS,treats,1.0,"Small JG, Milstein V, Marhenke JD et al. Treatment outcome with CLOZAPINE in tardive dyskinesia, neuroleptic sensitivity, and TREATMENT RESISTANT PSYCHOSIS",TREATMENT RESISTANT PSYCHOSIS,CLOZAPINE
11079,WARFARIN treats PE,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11080,WARFARIN treats PE,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11081,WARFARIN treats PE,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11082,WARFARIN treats PE,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11083,no_relation,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11084,WARFARIN treats PE,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11085,WARFARIN treats PE,treats,0.995893206467704,"Patients with transient risk factors for DVT (eg, immobilization, surgery) can discontinue warfarin after 3 to 6 mo. Patients with nonmodifiable risk factors (eg, hypercoagulability), spontaneous DVT with no known risk factors, or recurrent DVT and patients who have had PE should take WARFARIN for at least 6 mo and probably for life unless complications occur.",PE,WARFARIN
11086,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11087,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11088,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11089,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11090,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11091,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11092,ONDANSETRON treats ACUTE EMESIS,treats,0.9901475429766742,"Ondansetron was superior to high dose metoclopramide in controlling ACUTE EMESIS and nausea, and there was a significant patient preference for ONDANSETRON",ACUTE EMESIS,ONDANSETRON
11093,no_relation,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11094,no_relation,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11095,QUINIDINE treats PAROXYSMAL ATRIAL FIBRILLATION,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11096,QUINIDINE treats PAROXYSMAL ATRIAL FIBRILLATION,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11097,no_relation,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11098,PAROXYSMAL ATRIAL FIBRILLATION treats QUINIDINE,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11099,QUINIDINE treats PAROXYSMAL ATRIAL FIBRILLATION,treats,0.843274042711568,"2]  Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and PAROXYSMAL ATRIAL FIBRILLATION resistant to QUINIDINE therapy.",PAROXYSMAL ATRIAL FIBRILLATION,QUINIDINE
11100,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11101,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11102,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11103,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11104,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11105,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11106,SYSTEMIC HYPERTENSION treats SUBLINGUAL NIFEDIPINE,treats,0.985329278164293,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
11107,no_relation,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11108,A AND B VIRUS INFECTIONS treats INFLUENZA A VIRUS INFECTIONS,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11109,no_relation,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11110,no_relation,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11111,no_relation,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11112,A AND B VIRUS INFECTIONS treats INFLUENZA A VIRUS INFECTIONS,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11113,A AND B VIRUS INFECTIONS treats INFLUENZA A VIRUS INFECTIONS,treats,0.889000889001333,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
11114,no_relation,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11115,no_relation,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11116,no_relation,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11117,no_relation,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11118,no_relation,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11119,HYPERCELLULAR BONE MARROW treats MYELODYSPLASTIC SYNDROME,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11120,no_relation,treats,0.640512615220349,A study of 61 patients with MYELODYSPLASTIC SYNDROME and normocellular or HYPERCELLULAR BONE MARROW who received antithymocyte globulin found that 34% became transfusion independent after treatment ( 31.,HYPERCELLULAR BONE MARROW,MYELODYSPLASTIC SYNDROME
11121,no_relation,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11122,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS treats EXTRACTION OF BOTH LENSES,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11123,no_relation,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11124,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11125,no_relation,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11126,no_relation,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11127,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS treats EXTRACTION OF BOTH LENSES,treats,0.597614304667197,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
11128,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11129,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11130,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11131,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11132,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11133,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11134,DIVALPROEX treats BIPOLAR MANIA,treats,0.99654575824488,"1]  Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or DIVALPROEX for the treatment of BIPOLAR MANIA: a randomized, double blind, placebo controlled study.",BIPOLAR MANIA,DIVALPROEX
11135,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11136,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11137,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11138,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11139,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11140,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11141,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.707106781186547,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
11142,ASPIRIN treats MI,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11143,ASPIRIN treats MI,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11144,no_relation,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11145,ASPIRIN treats MI,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11146,ASPIRIN treats MI,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11147,no_relation,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11148,ASPIRIN treats MI,treats,0.995893206467704,"Clopidogrel decreases MI in patients treated with lytics and ASPIRIN  (4) , an accomplishment also claimed for the early invasive strategy with revascularization of the infarct artery.",MI,ASPIRIN
11149,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11150,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11151,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11152,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11153,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11154,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11155,MIDRIN treats MIGRAINE,treats,0.9965457582,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and [MIDRIN].",MIGRAINE,MIDRIN
11156,ALLEVIATE PAIN AND FATIGUE treats FEMALE PATIENTS WITH FMS,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11157,no_relation,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11158,ALLEVIATE PAIN AND FATIGUE treats FEMALE PATIENTS WITH FMS,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11159,no_relation,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11160,no_relation,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11161,no_relation,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11162,ALLEVIATE PAIN AND FATIGUE treats FEMALE PATIENTS WITH FMS,treats,0.6741998624632421,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
11163,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11164,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11165,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11166,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11167,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11168,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11169,ONDAPARINUX W treats ACUTE PROXIMAL DVT OR PE,treats,1.0," In two randomized trials with more than 2000 patients per trial, fONDAPARINUX Was shown to be as effective and safe in the initial treatment of ACUTE PROXIMAL DVT OR PE as LMWH or UFH, respectively ( 27 ;  28.",ACUTE PROXIMAL DVT OR PE,ONDAPARINUX W
11170,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11171,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11172,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11173,IBUPROFEN treats INFLAMMATION,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11174,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11175,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11176,no_relation,treats,0.9113223768657672,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
11177,[ORAL VITAMIN C] treats [FLARES],treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11178,[ORAL VITAMIN C] treats [FLARES],treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11179,[ORAL VITAMIN C] treats [FLARES],treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11180,[ORAL VITAMIN C] treats [FLARES],treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11181,no_relation,treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11182,[ORAL VITAMIN C] treats [FLARES],treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11183,[FLARES] treats [ORAL VITAMIN C],treats,0.9615239476408228,Some patients are able to prevent [FLARES] with use of topical sunscreens and [ORAL VITAMIN C].,[FLARES],[ORAL VITAMIN C]
11184,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11185,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11186,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11187,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11188,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11189,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11190,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832144,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
11191,FLUVOXAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11192,FLUVOXAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11193,FLUVOXAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11194,FLUVOXAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11195,no_relation,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11196,FLUVOXAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11197,FLUVOXAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Montgomery SA, Manceaux AFLUVOXAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUVOXAMINE
11198,no_relation,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11199,no_relation,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11200,VT treats REGULAR WIDE COMPLEX TACHYCARDIA,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11201,VT treats REGULAR WIDE COMPLEX TACHYCARDIA,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11202,no_relation,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11203,VT treats REGULAR WIDE COMPLEX TACHYCARDIA,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11204,no_relation,treats,0.328797974610715,◊ Often has characteristic ECG patterns that facilitate diagnosis • Avoid ICD placement in patients with Wolff Parkinson White syndrome with REGULAR WIDE COMPLEX TACHYCARDIA (a supraventricular arrhythmia resembling VT which should be treated with drug therapy or catheter ablation.,REGULAR WIDE COMPLEX TACHYCARDIA,VT
11205,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11206,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11207,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11208,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11209,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11210,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11211,DRONABINOL treats ANOREXIA,treats,0.858955690387333,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
11212,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11213,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11214,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11215,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11216,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11217,PARKINSON'S DISEASE treats AMANTADINE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11218,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
11219,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11220,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11221,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11222,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11223,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11224,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11225,TERAZOSIN THERAPY treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"The safety, efficacy and compliance of TERAZOSIN THERAPY for BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN THERAPY
11226,no_relation,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11227,LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS treats LOW MOLECULAR WEIGHT HEPARIN,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11228,no_relation,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11229,LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS treats LOW MOLECULAR WEIGHT HEPARIN,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11230,LOW MOLECULAR WEIGHT HEPARIN treats LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11231,LOW MOLECULAR WEIGHT HEPARIN treats LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11232,no_relation,treats,0.4574957109978139,"LOW MOLECULAR WEIGHT HEPARIN for 7 days was more effective than compression stockings for preventing DVT in knee arthroscopy  Hematology/Thrombosis  About Star Ratings  Keywords: Arthroplasty, replacement, knee Fibrinolytic agents Heparin, LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS compression Venous thromboembolism Venous Thrombosis  ACP Journal Club.",LOW MOLECULAR WEIGHT PULMONARY EMBOLISM STOCKINGS,LOW MOLECULAR WEIGHT HEPARIN
11233,IV AMPHOTERICIN B LIPOSOMAL treats INVASIVE ASPERGILLOSIS,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11234,IV AMPHOTERICIN B LIPOSOMAL treats INVASIVE ASPERGILLOSIS,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11235,IV AMPHOTERICIN B LIPOSOMAL treats INVASIVE ASPERGILLOSIS,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11236,IV AMPHOTERICIN B LIPOSOMAL treats INVASIVE ASPERGILLOSIS,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11237,INVASIVE ASPERGILLOSIS treats IV AMPHOTERICIN B LIPOSOMAL,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11238,no_relation,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11239,IV AMPHOTERICIN B LIPOSOMAL treats INVASIVE ASPERGILLOSIS,treats,0.938314863256837,"244 ,   248 ,   268 ,   269 ,   288 ,   396 ,   379 ,   420 ,   423 ,   436  IDSA considers voriconazole the drug of choice for primary treatment of INVASIVE ASPERGILLOSIS in most patients and IV AMPHOTERICIN B LIPOSOMAL the preferred alternative.",INVASIVE ASPERGILLOSIS,IV AMPHOTERICIN B LIPOSOMAL
11240,MAJOR DEPRESSION treats PAROXETINE,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11241,PAROXETINE treats MAJOR DEPRESSION,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11242,PAROXETINE treats MAJOR DEPRESSION,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11243,PAROXETINE treats MAJOR DEPRESSION,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11244,PAROXETINE treats MAJOR DEPRESSION,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11245,PAROXETINE treats MAJOR DEPRESSION,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11246,PAROXETINE treats MAJOR DEPRESSION,treats,0.9970544855015808,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
11247,INTERFERON treats HEPATOCELLULAR CANCER,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11248,INTERFERON treats HEPATOCELLULAR CANCER,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11249,INTERFERON treats HEPATOCELLULAR CANCER,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11250,no_relation,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11251,INTERFERON treats HEPATOCELLULAR CANCER,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11252,INTERFERON treats HEPATOCELLULAR CANCER,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11253,INTERFERON treats HEPATOCELLULAR CANCER,treats,0.9878291611472622,Review: Interferon and nucleoside/tide analogues reduce risk for HEPATOCELLULAR CANCER in patients with chronic hepatitis B  Gastroenterology Infectious Disease  About Star Ratings  Keywords: Hepatitis B INTERFERONs Nucleosides Nucleotides Neoplasms  ACP Journal Club.,HEPATOCELLULAR CANCER,INTERFERON
11254,no_relation,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11255,INTERFERON treats CHRONIC HEPATITIS C,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11256,CHRONIC HEPATITIS C treats INTERFERON,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11257,INTERFERON treats CHRONIC HEPATITIS C,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11258,INTERFERON treats CHRONIC HEPATITIS C,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11259,CHRONIC HEPATITIS C treats INTERFERON,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11260,INTERFERON treats CHRONIC HEPATITIS C,treats,1.0,"Evidence: • In large cohort studies, survival and complication free survival were significantly better in patients who received treatment with INTERFERON for CHRONIC HEPATITIS C ( 8 ) and for chronic hepatitis B ( 9 ) as compared to patients who did not.",CHRONIC HEPATITIS C,INTERFERON
11261,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11262,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11263,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11264,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11265,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11266,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11267,SUBCUTANEOUS TERIPARATIDE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,0.9878291611472622,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
11268,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11269,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11270,STAPHYLOCOCCI treats STAPHYLOCOCCAL INFECTIONS,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11271,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11272,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11273,STAPHYLOCOCCI treats STAPHYLOCOCCAL INFECTIONS,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11274,STAPHYLOCOCCI treats STAPHYLOCOCCAL INFECTIONS,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
11275,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11276,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11277,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11278,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11279,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11280,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11281,ACETAMINOPHEN treats PAIN,treats,0.99654575824488,PAIN without inflammation is usually more safely treated with ACETAMINOPHEN,PAIN,ACETAMINOPHEN
11282,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11283,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11284,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11285,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11286,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11287,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11288,PRIMAQUINE treats BENIGN TERTIAN MALARIA,treats,0.98058067569092,"The inadequacy of the 4 aminoquinolines for protection against latent BENIGN TERTIAN MALARIA is noted, and the use of PRIMAQUINE is recommended.",BENIGN TERTIAN MALARIA,PRIMAQUINE
11289,MESNA treats HAEMATURIA,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11290,MESNA treats HAEMATURIA,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11291,no_relation,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11292,MESNA treats HAEMATURIA,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11293,HAEMATURIA treats MESNA,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11294,no_relation,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11295,no_relation,treats,0.9970544855015808,[MESNA] is used therapeutically to reduce the incidence of haemorrhagic cystitis and [HAEMATURIA] when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy.,HAEMATURIA,MESNA
11296,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11297,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11298,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11299,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11300,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11301,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11302,METFORMIN treats TYPE 2 DIABETES,treats,0.995893206467704,"STUDY SELECTION  Clinical trials and cohort studies were selected if they included patients with TYPE 2 DIABETES lasted ≥ 1 month, compared METFORMIN alone or combined with other treatments with placebo or any other hypoglycemic therapy, and reported the number of patients and duration of treatment.",TYPE 2 DIABETES,METFORMIN
11303,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11304,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11305,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11306,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11307,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11308,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11309,ORLISTAT treats OBESITY,treats,0.99654575824488,ORLISTAT in the long term treatment of OBESITY in primary care settings.,OBESITY,ORLISTAT
11310,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11311,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11312,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11313,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11314,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11315,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11316,MIDODRINE (PROAMATINE treats ORTHOSTATIC HYPOTENSION,treats,0.993127066322842,MIDODRINE (PROAMATINE is approved by the U.S. Food and Drug Administration (FDA) to treat ORTHOSTATIC HYPOTENSION a condition related to POTS.,ORTHOSTATIC HYPOTENSION,MIDODRINE (PROAMATINE
11317,no_relation,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11318,no_relation,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11319,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11320,ACUTE MYELOCYTIC LEUKEMIA treats CYTOSINE ARABINOSIDE,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11321,no_relation,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11322,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11323,CYTOSINE ARABINOSIDE treats ACUTE MYELOCYTIC LEUKEMIA,treats,0.881917103688197,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
11324,ARSENIC TRIOXIDE treats APL,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11325,no_relation,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11326,ARSENIC TRIOXIDE treats APL,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11327,ARSENIC TRIOXIDE treats APL,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11328,APL treats ARSENIC TRIOXIDE,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11329,ARSENIC TRIOXIDE treats APL,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11330,ARSENIC TRIOXIDE treats APL,treats,1.0,"17 ,   20 ,   25  Combination therapy with ARSENIC TRIOXIDE and tretinoin has been used as an alternative to chemotherapy for induction and postremission therapy in newly diagnosed APL   +   ; may consider use of these regimens in select patients who cannot tolerate standard anthracycline containing chemotherapy (e.g., geriatric patients with poor performance or patients with cardiac dysfunction.",APL,ARSENIC TRIOXIDE
11331,RIFAMPIN treats TUBERCULOSIS,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11332,no_relation,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11333,RIFAMPIN treats TUBERCULOSIS,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11334,TUBERCULOSIS treats RIFAMPIN,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11335,no_relation,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11336,no_relation,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11337,no_relation,treats,0.6030226891555269,258 •   MTUBERCULOSIS  resistant to both isoniazid and RIFAMPIN (MDR TB) occurs.,TUBERCULOSIS,RIFAMPIN
11338,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11339,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11340,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11341,no_relation,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11342,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11343,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11344,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
11345,no_relation,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11346,MIDODRINE treats SYNCOPE,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11347,MIDODRINE treats SYNCOPE,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11348,no_relation,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11349,no_relation,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11350,MIDODRINE treats SYNCOPE,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11351,MIDODRINE treats SYNCOPE,treats,0.625,"Other medications which may be effective include: fludrocortisone, [MIDODRINE], SSRIs such as paroxetine or sertraline, disopyramide, and, in health-care settings where a [SYNCOPE] is anticipated, atropine.",SYNCOPE,MIDODRINE
11352,HYOSCYAMINE treats PANCREATITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11353,HYOSCYAMINE treats PANCREATITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11354,HYOSCYAMINE treats PANCREATITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11355,HYOSCYAMINE treats PANCREATITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11356,no_relation,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11357,HYOSCYAMINE treats PANCREATITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11358,HYOSCYAMINE treats PANCREATITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, [PANCREATITIS], colic and cystitis.",PANCREATITIS,HYOSCYAMINE
11359,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11360,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11361,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11362,no_relation,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11363,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11364,no_relation,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11365,no_relation,treats,0.492365963917331,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
11366,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11367,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11368,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11369,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11370,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11371,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11372,5 AMINOSALICYLIC ACID treats ULCERATIVE COLITIS,treats,0.995893206467704,"Austin CA, Cann PA, Jones TH et al. Exacerbation of diarrhea and pain in patients treated with 5 AMINOSALICYLIC ACID for ULCERATIVE COLITIS",ULCERATIVE COLITIS,5 AMINOSALICYLIC ACID
11373,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11374,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11375,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11376,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11377,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11378,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11379,PROPOFOL treats REFRACTORY STATUS EPILEPTICUS,treats,0.9838699100999068,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
11380,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11381,HYPERCORTISOLISM treats DEXAMETHASONE,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11382,no_relation,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11383,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11384,no_relation,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11385,no_relation,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11386,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.737209780774486,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
11387,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11388,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11389,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11390,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11391,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11392,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11393,PARACETAMOL treats MIGRAINE,treats,0.9970544855015808,"In combination with [PARACETAMOL] and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including Epidrin and Midrin.",MIGRAINE,PARACETAMOL
11394,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11395,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11396,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11397,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11398,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11399,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11400,SERTRALINE treats PEDIATRIC OCD,treats,1.0,"Wolkow R, March JS, Safferrman AZ et al. A placebo controlled trial of SERTRALINE treatment for PEDIATRIC OCD",PEDIATRIC OCD,SERTRALINE
11401,INSULIN treats TYPE 2 DIABETES,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11402,no_relation,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11403,INSULIN treats TYPE 2 DIABETES,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11404,INSULIN treats TYPE 2 DIABETES,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11405,INSULIN treats TYPE 2 DIABETES,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11406,no_relation,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11407,no_relation,treats,0.7378647873726221,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
11408,ASTHMA treats MONTELUKAST,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11409,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11410,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11411,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11412,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11413,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11414,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,One randomized controlled trial (RCT) in children showed that MONTELUKAST plus budesonide improved ASTHMA control better than budesonide alone  (1).,ASTHMA,MONTELUKAST
11415,[COMBINATION THERAPY] treats [COMPLICATED INFLUENZA],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11416,[COMPLICATED INFLUENZA] treats [COMBINATION THERAPY],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11417,[COMBINATION THERAPY] treats [COMPLICATED INFLUENZA],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11418,[COMBINATION THERAPY] treats [COMPLICATED INFLUENZA],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11419,[COMBINATION THERAPY] treats [COMPLICATED INFLUENZA],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11420,[COMBINATION THERAPY] treats [COMPLICATED INFLUENZA],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11421,[COMBINATION THERAPY] treats [COMPLICATED INFLUENZA],treats,0.994936676326182,A 1984 study on [COMPLICATED INFLUENZA] had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for influenza.,[COMPLICATED INFLUENZA],[COMBINATION THERAPY]
11422,no_relation,treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11423,[INSULIN GLARGINE] treats [SEVERE HYPOGLYCAEMIA],treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11424,[INSULIN GLARGINE] treats [SEVERE HYPOGLYCAEMIA],treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11425,[INSULIN GLARGINE] treats [SEVERE HYPOGLYCAEMIA],treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11426,no_relation,treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11427,[INSULIN GLARGINE] treats [SEVERE HYPOGLYCAEMIA],treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11428,no_relation,treats,0.559016994374947,"However, [INSULIN GLARGINE] was associated with a lower incidence of [SEVERE HYPOGLYCAEMIA] compared with NPH insulin.",[SEVERE HYPOGLYCAEMIA],[INSULIN GLARGINE]
11429,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11430,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11431,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11432,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11433,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11434,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11435,METRONIDAZOLE treats MYOSITIS,treats,0.943456353,"Agents that have been used include albendazole, [METRONIDAZOLE] and cotrimoxazole for [MYOSITIS].",MYOSITIS,METRONIDAZOLE
11436,[DOSE TRIAL OF TAPENTADOL 25MG 200MG] treats [POST SURGERY DENTAL PAIN],treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11437,[DOSE TRIAL OF TAPENTADOL 25MG 200MG] treats [POST SURGERY DENTAL PAIN],treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11438,no_relation,treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11439,[DOSE TRIAL OF TAPENTADOL 25MG 200MG] treats [POST SURGERY DENTAL PAIN],treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11440,[DOSE TRIAL OF TAPENTADOL 25MG 200MG] treats [POST SURGERY DENTAL PAIN],treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11441,[DOSE TRIAL OF TAPENTADOL 25MG 200MG] treats [POST SURGERY DENTAL PAIN],treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11442,[DOSE TRIAL OF TAPENTADOL 25MG 200MG] treats [POST SURGERY DENTAL PAIN],treats,0.979957887012223,A phase II single [DOSE TRIAL OF TAPENTADOL 25MG 200MG] ibuprofen 400mg and morphine IR 60mg was evaluated in [POST SURGERY DENTAL PAIN],[POST SURGERY DENTAL PAIN],[DOSE TRIAL OF TAPENTADOL 25MG 200MG]
11443,ORAL CYCLOPHOSPHAMIDE treats GENERALIZED WEGENER'S GRANULOMATOSIS,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11444,ORAL CYCLOPHOSPHAMIDE treats GENERALIZED WEGENER'S GRANULOMATOSIS,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11445,ORAL CYCLOPHOSPHAMIDE treats GENERALIZED WEGENER'S GRANULOMATOSIS,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11446,ORAL CYCLOPHOSPHAMIDE treats GENERALIZED WEGENER'S GRANULOMATOSIS,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11447,ORAL CYCLOPHOSPHAMIDE treats GENERALIZED WEGENER'S GRANULOMATOSIS,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11448,ORAL CYCLOPHOSPHAMIDE treats GENERALIZED WEGENER'S GRANULOMATOSIS,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11449,GENERALIZED WEGENER'S GRANULOMATOSIS treats ORAL CYCLOPHOSPHAMIDE,treats,0.9716656205775172,"1]  Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and ORAL CYCLOPHOSPHAMIDE in the treatment of GENERALIZED WEGENER'S GRANULOMATOSIS",GENERALIZED WEGENER'S GRANULOMATOSIS,ORAL CYCLOPHOSPHAMIDE
11450,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11451,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11452,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11453,no_relation,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11454,no_relation,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11455,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11456,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.9494253265550828,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN
11457,INTERLEUKIN 2 PLUS INTERFERON ALPHA treats RENAL CELL CARCINOMA,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11458,no_relation,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11459,INTERLEUKIN 2 PLUS INTERFERON ALPHA treats RENAL CELL CARCINOMA,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11460,no_relation,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11461,INTERLEUKIN 2 PLUS INTERFERON ALPHA treats RENAL CELL CARCINOMA,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11462,INTERLEUKIN 2 PLUS INTERFERON ALPHA treats RENAL CELL CARCINOMA,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11463,INTERLEUKIN 2 PLUS INTERFERON ALPHA treats RENAL CELL CARCINOMA,treats,0.696310623822791,"Boccardo F, Rubagotti A, Canobbio L et al. Interleukin 2, interferon alpha and INTERLEUKIN 2 PLUS INTERFERON ALPHA in RENAL CELL CARCINOMA",RENAL CELL CARCINOMA,INTERLEUKIN 2 PLUS INTERFERON ALPHA
11464,WARFARIN treats STROKE,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11465,WARFARIN treats STROKE,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11466,WARFARIN treats STROKE,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11467,no_relation,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11468,WARFARIN treats STROKE,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11469,WARFARIN treats STROKE,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11470,WARFARIN treats STROKE,treats,0.9615239476408228,"January 2010   Volume 152, Number 1  Therapeutics  Higher dose dabigatran reduced STROKE but not major hemorrhage, more than WARFARIN in atrial fibrillation.",STROKE,WARFARIN
11471,FOSCARNET treats CMV INFECTIONS,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11472,FOSCARNET treats CMV INFECTIONS,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11473,FOSCARNET treats CMV INFECTIONS,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11474,FOSCARNET treats CMV INFECTIONS,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11475,no_relation,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11476,FOSCARNET treats CMV INFECTIONS,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11477,no_relation,treats,0.98058067569092,"For long term therapy of CMV retinitis in patients with HIV infection Valganciclovir  900 mg p.o., b.i.d., for 21 days, then 900 mg p.o., q.d., for maintenance  First choice  For CMV retinitis and other advanced CMV INFECTIONS in immunocompromised patients FOSCARNET  90 mg/kg I.V. b.i.d.",CMV INFECTIONS,FOSCARNET
11478,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11479,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11480,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11481,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11482,ACETAMINOPHEN treats MIGRAINE HEADACHE PAIN,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11483,MIGRAINE HEADACHE PAIN treats ACETAMINOPHEN,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11484,no_relation,treats,0.9901475429766742,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
11485,no_relation,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11486,no_relation,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11487,no_relation,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11488,ENDOMETRIOSIS treats PAIN,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11489,no_relation,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11490,no_relation,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11491,no_relation,treats,0.369800130816819,Evidence: • Four studies reported on evidence suggesting that the LNG IUS reduces PAIN associated with ENDOMETRIOSIS which may last up to 3 years ( 48 ;  49 ;  50 ;  51.,PAIN,ENDOMETRIOSIS
11492,MELPHALAN treats MULTIPLE MYELOMA,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11493,MELPHALAN treats MULTIPLE MYELOMA,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11494,MELPHALAN treats MULTIPLE MYELOMA,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11495,MELPHALAN treats MULTIPLE MYELOMA,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11496,MELPHALAN treats MULTIPLE MYELOMA,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11497,no_relation,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11498,MELPHALAN treats MULTIPLE MYELOMA,treats,0.993127066322842,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
11499,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11500,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11501,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11502,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11503,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11504,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11505,ENOXACIN treats ACUTE UNCOMPLICATED URETHRA GONORRHEA,treats,1.0,"Van der Willigen AH, van der Hoek JCS, Wagenvoort JHT et al. Comparative double blind study of 200  and 400 mg ENOXACIN given orally in the treatment of ACUTE UNCOMPLICATED URETHRA GONORRHEA in males.",ACUTE UNCOMPLICATED URETHRA GONORRHEA,ENOXACIN
11506,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11507,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11508,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11509,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11510,TYPE 1 DIABETES treats INSULIN GLARGINE,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11511,TYPE 1 DIABETES treats INSULIN GLARGINE,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11512,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.8219949365267859,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
11513,PITAVASTATIN treats HYPERCHOLESTEROLAEMIA,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11514,PITAVASTATIN treats HYPERCHOLESTEROLAEMIA,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11515,PITAVASTATIN treats HYPERCHOLESTEROLAEMIA,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11516,PITAVASTATIN treats HYPERCHOLESTEROLAEMIA,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11517,PITAVASTATIN treats HYPERCHOLESTEROLAEMIA,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11518,PITAVASTATIN treats HYPERCHOLESTEROLAEMIA,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11519,HYPERCHOLESTEROLAEMIA treats PITAVASTATIN,treats,0.9958932065,"Like the other statins, [PITAVASTATIN] is indicated for [HYPERCHOLESTEROLAEMIA] and for the prevention of cardiovascular disease.",HYPERCHOLESTEROLAEMIA,PITAVASTATIN
11520,no_relation,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11521,BABESIA MICROTI treats BABESIOSIS,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11522,BABESIOSIS treats BABESIA MICROTI,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11523,no_relation,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11524,no_relation,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11525,BABESIOSIS treats BABESIA MICROTI,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11526,BABESIOSIS treats BABESIA MICROTI,treats,0.485642931178632,164  Babesiosis  Treatment of BABESIOSIS   +    caused by  BABESIA MICROTI.,BABESIOSIS,BABESIA MICROTI
11527,FOMEPIZOLE treats ETHYLENE GLYCOL POISONING,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11528,FOMEPIZOLE treats ETHYLENE GLYCOL POISONING,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11529,FOMEPIZOLE treats ETHYLENE GLYCOL POISONING,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11530,ETHYLENE GLYCOL POISONING treats FOMEPIZOLE,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11531,FOMEPIZOLE treats ETHYLENE GLYCOL POISONING,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11532,FOMEPIZOLE treats ETHYLENE GLYCOL POISONING,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11533,FOMEPIZOLE treats ETHYLENE GLYCOL POISONING,treats,0.9970544855015808,[FOMEPIZOLE] has been shown to be highly effective as an antidote for [ETHYLENE GLYCOL POISONING].,ETHYLENE GLYCOL POISONING,FOMEPIZOLE
11534,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11535,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11536,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11537,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11538,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11539,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11540,NYSTATIN treats ORAL CANDIDIASIS,treats,0.994134846772434,"Treatment  ORAL CANDIDIASIS can be treated with topical anti fungal drugs, such as NYSTATIN miconazole, Gentian violet or amphotericin B. Topical therapy is given as an oral suspension which is washed around the mouth and then swallowed by the patient.",ORAL CANDIDIASIS,NYSTATIN
11541,ATORVASTATIN treats TYPE 2 DIABETES,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11542,ATORVASTATIN treats TYPE 2 DIABETES,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11543,ATORVASTATIN treats TYPE 2 DIABETES,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11544,no_relation,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11545,no_relation,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11546,no_relation,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11547,ATORVASTATIN treats TYPE 2 DIABETES,treats,0.9113223769,"title=Reduction in cardiovascular events with [ATORVASTATIN] in 2,532 patients with [TYPE 2 DIABETES]: Anglo-Scandinavian Cardiac Outcomes Triallipid-lowering arm .",TYPE 2 DIABETES,ATORVASTATIN
11548,AMPHOTERICIN B treats NEUTROPENIA,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11549,NEUTROPENIA treats AMPHOTERICIN B,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11550,AMPHOTERICIN B treats NEUTROPENIA,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11551,AMPHOTERICIN B treats NEUTROPENIA,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11552,AMPHOTERICIN B treats NEUTROPENIA,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11553,AMPHOTERICIN B treats NEUTROPENIA,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11554,AMPHOTERICIN B treats NEUTROPENIA,treats,0.9918365981341752,"The study by Boogaerts and colleagues, although limited by its open design and a slightly older amphotericin B patient group, showed that empiric itraconazole was as effective as empiric AMPHOTERICIN B for eliminating fever and NEUTROPENIA in patients with hematologic cancer.",NEUTROPENIA,AMPHOTERICIN B
11555,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11556,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11557,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11558,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11559,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11560,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11561,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT treats ANAL FISSURES,treats,0.994134846772434,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT for ANAL FISSURES: long term efficacy in routine clinical practice.,ANAL FISSURES,TOPICAL 0.2% GLYCERYL TRINITRATE OINTMENT
11562,CLOMIPRAMINE treats DEPRESSION,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11563,no_relation,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11564,CLOMIPRAMINE treats DEPRESSION,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11565,CLOMIPRAMINE treats DEPRESSION,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11566,CLOMIPRAMINE treats DEPRESSION,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11567,CLOMIPRAMINE treats DEPRESSION,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11568,CLOMIPRAMINE treats DEPRESSION,treats,0.9716656205775172,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
11569,[LOW MOLECULAR WEIGHT HEPARIN] treats [WARFARIN'S TERATOGENICITY],treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11570,no_relation,treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11571,[LOW MOLECULAR WEIGHT HEPARIN] treats [WARFARIN'S TERATOGENICITY],treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11572,no_relation,treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11573,no_relation,treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11574,no_relation,treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11575,no_relation,treats,0.437594974493684,"During pregnancy, [LOW MOLECULAR WEIGHT HEPARIN] and low dose aspirin are used instead of warfarin because of [WARFARIN'S TERATOGENICITY]",[WARFARIN'S TERATOGENICITY],[LOW MOLECULAR WEIGHT HEPARIN]
11576,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11577,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11578,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11579,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11580,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11581,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11582,AMPHOTERICIN B treats SPOROTRICHOSIS,treats,0.9838699100999068,"146 ,   429 ,   436  IV AMPHOTERICIN B is the drug of choice for initial treatment of severe, life threatening sporotrichosis and whenever SPOROTRICHOSIS is disseminated or has CNS involvement.",SPOROTRICHOSIS,AMPHOTERICIN B
11583,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11584,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11585,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11586,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11587,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11588,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11589,PROPANTHELINE treats IBS,treats,0.961074462327142,"Antispasmodics, primarily anticholinergic agents (e.g., dicyclomine hydrochloride, clidinium bromide, hyoscyamine, PROPANTHELINE or belladonna alkaloids), can treat cramping abdominal discomfort or the symptoms of IBS that accompany UC and CD.",IBS,PROPANTHELINE
11590,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11591,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11592,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11593,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11594,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11595,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11596,AMOXICILLIN treats ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,treats,1.0,"Russell MD, Nolen T, Allen JM et al. Cefprozil versus AMOXICILLIN/clavulanate in the treatment of ACUTE UNCOMPLICATED MAXILLARY SINUSITIS in adults; a randomized, prospective clinical trial.",ACUTE UNCOMPLICATED MAXILLARY SINUSITIS,AMOXICILLIN
11597,NAPROXEN treats OSTEOARTHRITIS,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11598,NAPROXEN treats OSTEOARTHRITIS,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11599,NAPROXEN treats OSTEOARTHRITIS,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11600,OSTEOARTHRITIS treats NAPROXEN,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11601,no_relation,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11602,NAPROXEN treats OSTEOARTHRITIS,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11603,NAPROXEN treats OSTEOARTHRITIS,treats,0.993127066322842,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
11604,DERMATOPHYTE TOE ONYCHOMYCOSIS treats CICLOPIROX NAIL LACQUER SOLUTION,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11605,DERMATOPHYTE TOE ONYCHOMYCOSIS treats CICLOPIROX NAIL LACQUER SOLUTION,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11606,CICLOPIROX NAIL LACQUER SOLUTION treats DERMATOPHYTE TOE ONYCHOMYCOSIS,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11607,CICLOPIROX NAIL LACQUER SOLUTION treats DERMATOPHYTE TOE ONYCHOMYCOSIS,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11608,CICLOPIROX NAIL LACQUER SOLUTION treats DERMATOPHYTE TOE ONYCHOMYCOSIS,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11609,CICLOPIROX NAIL LACQUER SOLUTION treats DERMATOPHYTE TOE ONYCHOMYCOSIS,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11610,DERMATOPHYTE TOE ONYCHOMYCOSIS treats CICLOPIROX NAIL LACQUER SOLUTION,treats,0.9970544855015808,Pharmacoeconomic analysis of CICLOPIROX NAIL LACQUER SOLUTION 8% and the new oral antifungal agents used to treat DERMATOPHYTE TOE ONYCHOMYCOSIS in the United States.,DERMATOPHYTE TOE ONYCHOMYCOSIS,CICLOPIROX NAIL LACQUER SOLUTION
11611,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11612,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11613,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11614,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11615,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST treats OPIOID DEPENDENCE,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11616,OPIOID DEPENDENCE treats BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11617,no_relation,treats,0.986393923832144,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST is being investigated as a treatment for OPIOID DEPENDENCE,BUPRENORPHINE A MIXED OPIOID AGONIST ANTAGONIST,OPIOID DEPENDENCE
11618,[DADLE] treats [MEAN ARTERIAL BLOOD PRESSURE],treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11619,[DADLE] treats [MEAN ARTERIAL BLOOD PRESSURE],treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11620,[DADLE] treats [MEAN ARTERIAL BLOOD PRESSURE],treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11621,[DADLE] treats [MEAN ARTERIAL BLOOD PRESSURE],treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11622,[DADLE] treats [MEAN ARTERIAL BLOOD PRESSURE],treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11623,[DADLE] treats [MEAN ARTERIAL BLOOD PRESSURE],treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11624,no_relation,treats,0.722315118514615,Treatment with [DADLE] results in transient depression of [MEAN ARTERIAL BLOOD PRESSURE] and heart rate.,[MEAN ARTERIAL BLOOD PRESSURE],[DADLE]
11625,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11626,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11627,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11628,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11629,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11630,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11631,ANTIEPILEPTIC DRUG TREATMENT treats EPILEPSY,treats,0.99654575824488,"Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred ANTIEPILEPTIC DRUG TREATMENT for early EPILEPSY and single seizures: a randomised controlled trial.",EPILEPSY,ANTIEPILEPTIC DRUG TREATMENT
11632,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11633,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11634,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11635,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11636,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11637,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11638,FORSKOLIN treats GLAUCOMA,treats,0.9970544855015808,[FORSKOLIN] may be helpful to control the underlying cause of [GLAUCOMA].,GLAUCOMA,FORSKOLIN
11639,no_relation,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11640,INTRAARTICULAR HYALURONATE INJECTION treats PAIN,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11641,INTRAARTICULAR HYALURONATE INJECTION treats PAIN,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11642,no_relation,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11643,no_relation,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11644,PAIN treats INTRAARTICULAR HYALURONATE INJECTION,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11645,no_relation,treats,0.43301270189221897,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
11646,no_relation,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11647,no_relation,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11648,no_relation,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11649,ENTEROTOXIGENIC  ESCHERICHIA COLI treats TRAVELERS' DIARRHEA,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11650,ENTEROTOXIGENIC  ESCHERICHIA COLI treats TRAVELERS' DIARRHEA,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11651,no_relation,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11652,ENTEROTOXIGENIC  ESCHERICHIA COLI treats TRAVELERS' DIARRHEA,treats,0.340502612303499,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
11653,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11654,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11655,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11656,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11657,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11658,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11659,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9830783046228492,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
11660,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11661,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11662,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11663,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11664,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11665,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11666,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
11667,DIPHTHERIA TOXOID IMMUNIZATION treats DIPHTHERIA,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11668,DIPHTHERIA TOXOID IMMUNIZATION treats DIPHTHERIA,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11669,DIPHTHERIA TOXOID IMMUNIZATION treats DIPHTHERIA,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11670,DIPHTHERIA TOXOID IMMUNIZATION treats DIPHTHERIA,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11671,no_relation,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11672,no_relation,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11673,DIPHTHERIA TOXOID IMMUNIZATION treats DIPHTHERIA,treats,0.9970544855015808,3  DIPHTHERIA TOXOID IMMUNIZATION prevents the serious complications of DIPHTHERIA alleviating the clinical manifestations of the disease by blocking the toxin's ability to enter cells.,DIPHTHERIA,DIPHTHERIA TOXOID IMMUNIZATION
11674,no_relation,treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11675,no_relation,treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11676,no_relation,treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11677,[HOSPITALIZATIONS] treats [INFLUENZA],treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11678,[HOSPITALIZATIONS] treats [INFLUENZA],treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11679,[HOSPITALIZATIONS] treats [INFLUENZA],treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11680,no_relation,treats,0.493196961916072,full immunization against flu provided about a 75 percent effectiveness rate in preventing [HOSPITALIZATIONS] from influenza complications in the 2005 6 and 2006 7 [INFLUENZA] seasons..,[INFLUENZA],[HOSPITALIZATIONS]
11681,LATENT TUBERCULOSIS INFECTION treats ISONIAZID THERAPY,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11682,ISONIAZID THERAPY treats LATENT TUBERCULOSIS INFECTION,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11683,ISONIAZID THERAPY treats LATENT TUBERCULOSIS INFECTION,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11684,ISONIAZID THERAPY treats LATENT TUBERCULOSIS INFECTION,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11685,ISONIAZID THERAPY treats LATENT TUBERCULOSIS INFECTION,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11686,ISONIAZID THERAPY treats LATENT TUBERCULOSIS INFECTION,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11687,ISONIAZID THERAPY treats LATENT TUBERCULOSIS INFECTION,treats,0.979957887012223,"2]  Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of ISONIAZID THERAPY for LATENT TUBERCULOSIS INFECTION: a randomized trial.",LATENT TUBERCULOSIS INFECTION,ISONIAZID THERAPY
11688,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11689,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11690,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11691,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11692,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11693,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11694,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
11695,no_relation,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11696,no_relation,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11697,POSTPRANDIAL BLOOD GLUCOSE CONTROL treats HYPOGLYCEMIA,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11698,no_relation,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11699,POSTPRANDIAL BLOOD GLUCOSE CONTROL treats HYPOGLYCEMIA,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11700,no_relation,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11701,no_relation,treats,0.480384461415261,"Roach P, Trautmann M, Arora V et al. Improved POSTPRANDIAL BLOOD GLUCOSE CONTROL and reduced nocturnal HYPOGLYCEMIA during treatment with two novel insulin lispro protamine formulations, insulin lispro mix25 and insulin lispro mix50.",HYPOGLYCEMIA,POSTPRANDIAL BLOOD GLUCOSE CONTROL
11702,DAPSONE treats LEPROMATOUS LEPROSY,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11703,DAPSONE treats LEPROMATOUS LEPROSY,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11704,DAPSONE treats LEPROMATOUS LEPROSY,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11705,LEPROMATOUS LEPROSY treats DAPSONE,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11706,DAPSONE treats LEPROMATOUS LEPROSY,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11707,DAPSONE treats LEPROMATOUS LEPROSY,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11708,DAPSONE treats LEPROMATOUS LEPROSY,treats,0.994134846772434,"In the US, LEPROMATOUS LEPROSY is usually treated with RIF 600 mg once/day for 2 to 3 yr plus DAPSONE 100 mg once/day for life.",LEPROMATOUS LEPROSY,DAPSONE
11709,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11710,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11711,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11712,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11713,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11714,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11715,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,treats,0.9970544855015808,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
11716,CANDIDA treats CANDIDEMIA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11717,no_relation,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11718,CANDIDA treats CANDIDEMIA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11719,no_relation,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11720,no_relation,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11721,no_relation,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11722,CANDIDEMIA treats CANDIDA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
11723,BRADYCARDIA treats NEOSTIGMINE,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11724,NEOSTIGMINE treats BRADYCARDIA,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11725,NEOSTIGMINE treats BRADYCARDIA,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11726,NEOSTIGMINE treats BRADYCARDIA,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11727,BRADYCARDIA treats NEOSTIGMINE,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11728,NEOSTIGMINE treats BRADYCARDIA,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11729,NEOSTIGMINE treats BRADYCARDIA,treats,0.8571428570999999,"It is also used in conjunction with [NEOSTIGMINE], a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as [BRADYCARDIA].",BRADYCARDIA,NEOSTIGMINE
11730,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11731,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11732,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11733,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11734,RECURRENT VENOUS THROMBOEMBOLISM treats CONVENTIONAL INTENSITY WARFARIN THERAPY,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11735,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11736,CONVENTIONAL INTENSITY WARFARIN THERAPY treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,Comparison of low intensity warfarin therapy with CONVENTIONAL INTENSITY WARFARIN THERAPY for long term prevention of RECURRENT VENOUS THROMBOEMBOLISM,RECURRENT VENOUS THROMBOEMBOLISM,CONVENTIONAL INTENSITY WARFARIN THERAPY
11737,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11738,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11739,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11740,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11741,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11742,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11743,FLUCONAZOLE treats NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,treats,1.0,"Catanzaro A, Galgiani JN, Levine BE, et al: FLUCONAZOLE in the treatment of chronic pulmonary and NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS",NONMENINGEAL DISSEMINATED COCCIDIOIDOMYCOSIS,FLUCONAZOLE
11744,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11745,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11746,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11747,no_relation,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11748,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11749,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11750,IMMEDIATE RELEASE LEVODOPA treats PD,treats,0.8660254037844392,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA
11751,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11752,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11753,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11754,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11755,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11756,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11757,[NICLOSAMIDE] treats [TAPEWORM INFECTIONS],treats,0.99654575824488,The drug of choice for [TAPEWORM INFECTIONS] is [NICLOSAMIDE],[TAPEWORM INFECTIONS],[NICLOSAMIDE]
11758,no_relation,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11759,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11760,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11761,no_relation,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11762,no_relation,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11763,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11764,no_relation,treats,0.7559289460184542,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
11765,ACYCLOVIR treats GENITAL HERPES,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11766,ACYCLOVIR treats GENITAL HERPES,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11767,ACYCLOVIR treats GENITAL HERPES,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11768,ACYCLOVIR treats GENITAL HERPES,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11769,ACYCLOVIR treats GENITAL HERPES,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11770,ACYCLOVIR treats GENITAL HERPES,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11771,no_relation,treats,0.9491579957524988,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
11772,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11773,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11774,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11775,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11776,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11777,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11778,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.971285862357264,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
11779,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11780,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11781,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11782,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11783,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11784,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11785,AZELAIC ACID treats ACNE VULGARIS,treats,0.997458699830735,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
11786,THALIDOMIDE treats GRAFT VERSUS HOST DISEASE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11787,THALIDOMIDE treats GRAFT VERSUS HOST DISEASE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11788,THALIDOMIDE treats GRAFT VERSUS HOST DISEASE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11789,GRAFT VERSUS HOST DISEASE treats THALIDOMIDE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11790,THALIDOMIDE treats GRAFT VERSUS HOST DISEASE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11791,THALIDOMIDE treats GRAFT VERSUS HOST DISEASE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11792,THALIDOMIDE treats GRAFT VERSUS HOST DISEASE,treats,1.0,"Parker PM, Chao N, Nademanee A et alTHALIDOMIDE as salvage therapy for chronic GRAFT VERSUS HOST DISEASE",GRAFT VERSUS HOST DISEASE,THALIDOMIDE
11793,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11794,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11795,no_relation,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11796,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11797,no_relation,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11798,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11799,no_relation,treats,0.8944271909999159,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
11800,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11801,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11802,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11803,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11804,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11805,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11806,DANTROLENE SODIUM treats MALIGNANT HYPERTHERMIA,treats,1.0,"Treatment     DANTROLENE SODIUM the only available medical treatment for MALIGNANT HYPERTHERMIA    The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction.",MALIGNANT HYPERTHERMIA,DANTROLENE SODIUM
11807,no_relation,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11808,GLYCEROL treats ESCHERICHIA COLI,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11809,GLYCEROL treats ESCHERICHIA COLI,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11810,no_relation,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11811,GLYCEROL treats ESCHERICHIA COLI,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11812,no_relation,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11813,GLYCEROL treats ESCHERICHIA COLI,treats,0.452267016866645,Terrific Broth is used with [GLYCEROL] in cultivating recombinant strains of [ESCHERICHIA COLI].,ESCHERICHIA COLI,GLYCEROL
11814,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11815,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11816,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11817,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11818,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11819,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11820,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.970494958830946,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
11821,DOCETAXEL treats FLUID RETENTION,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11822,DOCETAXEL treats FLUID RETENTION,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11823,DOCETAXEL treats FLUID RETENTION,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11824,DOCETAXEL treats FLUID RETENTION,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11825,DOCETAXEL treats FLUID RETENTION,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11826,no_relation,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11827,DOCETAXEL treats FLUID RETENTION,treats,0.964763821237732,Premedication with corticosteroids is recommended before each administration of [DOCETAXEL] to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,DOCETAXEL
11828,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11829,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11830,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11831,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11832,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11833,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11834,[NONI'S] treats [TUMORS],treats,0.878114079917523,Laboratory studies of [NONI'S] effect on [TUMORS] in mice include evidence for reduced growth of capillaries in tumor explants.,[TUMORS],[NONI'S]
11835,ATOPIC DERMATITIS treats ALLERGIC RHINITIS,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11836,ALLERGIC RHINITIS treats ATOPIC DERMATITIS,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11837,no_relation,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11838,no_relation,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11839,no_relation,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11840,no_relation,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11841,no_relation,treats,0.5656854249492379,"◊ Nonsedating agents during the daytime for concurrent ALLERGIC RHINITIS or conjunctivitis, noting that they may not be effective for treating itch and rash • See table  Drug Treatment for ATOPIC DERMATITIS",ALLERGIC RHINITIS,ATOPIC DERMATITIS
11842,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11843,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11844,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11845,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11846,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11847,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11848,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,treats,0.99654575824488,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
11849,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING PROPERTIES],treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11850,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING PROPERTIES],treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11851,no_relation,treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11852,no_relation,treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11853,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING PROPERTIES],treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11854,no_relation,treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11855,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING PROPERTIES],treats,0.679366220486757,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING PROPERTIES].",[TUMOR SHRINKING PROPERTIES],[CAFFEIC ACID PHENETHYL ESTER]
11856,no_relation,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11857,INDOMETHACIN treats PDA,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11858,INDOMETHACIN treats PDA,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11859,INDOMETHACIN treats PDA,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11860,INDOMETHACIN treats PDA,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11861,INDOMETHACIN treats PDA,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11862,no_relation,treats,0.970142500145332,"Zarfin Y, Koren G, Perlman M. Digoxin and INDOMETHACIN in preterm infants with PDA",PDA,INDOMETHACIN
11863,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11864,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11865,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11866,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11867,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11868,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11869,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
11870,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11871,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11872,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11873,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11874,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11875,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11876,ANTIOXIDANT treats FATIGUE,treats,0.979957887012223,It is an [ANTIOXIDANT] and helps reduce [FATIGUE].,FATIGUE,ANTIOXIDANT
11877,no_relation,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11878,ISOTRETINOIN treats ACNE,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11879,ISOTRETINOIN treats ACNE,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11880,ISOTRETINOIN treats ACNE,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11881,no_relation,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11882,ISOTRETINOIN treats ACNE,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11883,ISOTRETINOIN treats ACNE,treats,0.979957887012223,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
11884,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11885,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11886,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11887,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11888,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11889,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11890,FAMCICLOVIR treats ZOSTER,treats,1.0,Acyclovir or FAMCICLOVIR are treatments of choice for both ZOSTER and herpes simplex reactivation.,ZOSTER,FAMCICLOVIR
11891,no_relation,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11892,no_relation,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11893,no_relation,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11894,VANCOMYCIN treats NEUTROPENIA,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11895,no_relation,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11896,no_relation,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11897,no_relation,treats,0.9237604307034007,"NEUTROPENIA can occur during therapy with penicillins, cephalosporins, or VANCOMYCIN",NEUTROPENIA,VANCOMYCIN
11898,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11899,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11900,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11901,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11902,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11903,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11904,VITAMIN C treats COMMON COLD,treats,1.0,2007 07 18     VITAMIN C for preventing and treating the COMMON COLD,COMMON COLD,VITAMIN C
11905,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11906,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11907,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11908,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11909,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11910,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11911,CISPLATINUM treats OSTEOSARCOMA,treats,0.9918365981341752,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
11912,LOPRAZOLAM treats INSOMNIA,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11913,LOPRAZOLAM treats INSOMNIA,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11914,LOPRAZOLAM treats INSOMNIA,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11915,LOPRAZOLAM treats INSOMNIA,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11916,no_relation,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11917,LOPRAZOLAM treats INSOMNIA,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11918,LOPRAZOLAM treats INSOMNIA,treats,0.9970544855015808,The dose of [LOPRAZOLAM] for [INSOMNIA] is usually 1 mg but can be increased to 2 mg if necessary.,INSOMNIA,LOPRAZOLAM
11919,no_relation,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11920,no_relation,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11921,no_relation,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11922,no_relation,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11923,no_relation,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11924,no_relation,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11925,OSTEOPENIA treats FRACTURE,treats,0.314485451,Individuals already diagnosed with [OSTEOPENIA] or osteoporosis should discuss their exercise program with their physician to avoid [FRACTURE]s.,FRACTURE,OSTEOPENIA
11926,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11927,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11928,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11929,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11930,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11931,GALLSTONE DISSOLUTION treats URSODEOXYCHOLIC ACID,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11932,URSODEOXYCHOLIC ACID treats GALLSTONE DISSOLUTION,treats,0.9970544855015808,"The authors concluded that the combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for GALLSTONE DISSOLUTION because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long term cost of treatment.",GALLSTONE DISSOLUTION,URSODEOXYCHOLIC ACID
11933,no_relation,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11934,no_relation,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11935,no_relation,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11936,INSULIN ASPART treats PREPRANDIAL HYPERGLYCEMIA,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11937,no_relation,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11938,no_relation,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11939,no_relation,treats,0.979957887012223,Some patients may require more basal insulin and a greater total daily insulin dosage to prevent PREPRANDIAL HYPERGLYCEMIA when using INSULIN ASPART than when using insulin human (regular.,PREPRANDIAL HYPERGLYCEMIA,INSULIN ASPART
11940,[WARM COMPRESSES] treats [A GOOD HYGIENE OF THE EYE],treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11941,no_relation,treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11942,no_relation,treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11943,no_relation,treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11944,no_relation,treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11945,[A GOOD HYGIENE OF THE EYE] treats [WARM COMPRESSES],treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11946,[WARM COMPRESSES] treats [A GOOD HYGIENE OF THE EYE],treats,0.452267016866645,Treatment normally consists in maintaining [A GOOD HYGIENE OF THE EYE] and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[A GOOD HYGIENE OF THE EYE],[WARM COMPRESSES]
11947,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11948,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11949,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11950,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11951,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11952,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11953,INSULIN GLARGINE treats TYPE 1 DIABETES,treats,0.971285862357264,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
11954,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11955,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11956,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11957,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11958,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11959,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11960,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.9838699100999068,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN
11961,TRETINOIN 0.025% GEL treats FACIAL ACNE VULGARIS,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11962,TRETINOIN 0.025% GEL treats FACIAL ACNE VULGARIS,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11963,TRETINOIN 0.025% GEL treats FACIAL ACNE VULGARIS,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11964,TRETINOIN 0.025% GEL treats FACIAL ACNE VULGARIS,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11965,FACIAL ACNE VULGARIS treats TRETINOIN 0.025% GEL,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11966,TRETINOIN 0.025% GEL treats FACIAL ACNE VULGARIS,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11967,FACIAL ACNE VULGARIS treats TRETINOIN 0.025% GEL,treats,0.995893206467704,"Webster GF, Berson D, Stein LF et al. Efficacy and tolerability of once daily tazarotene 0.1% gel versus once daily TRETINOIN 0.025% GEL in the treatment of FACIAL ACNE VULGARIS: a randomized trial.",FACIAL ACNE VULGARIS,TRETINOIN 0.025% GEL
11968,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11969,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11970,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11971,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11972,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11973,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11974,GABAPENTIN treats PAIN,treats,0.971285862357264,GABAPENTIN was more effective than placebo for PAIN relief and improvement in sleep and quality of life (1 trial.,PAIN,GABAPENTIN
11975,SULFADIAZINE PYRIMETHAMINE treats RECURRENT TOXOPLASMIC ENCEPHALITIS,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11976,no_relation,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11977,SULFADIAZINE PYRIMETHAMINE treats RECURRENT TOXOPLASMIC ENCEPHALITIS,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11978,SULFADIAZINE PYRIMETHAMINE treats RECURRENT TOXOPLASMIC ENCEPHALITIS,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11979,SULFADIAZINE PYRIMETHAMINE treats RECURRENT TOXOPLASMIC ENCEPHALITIS,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11980,SULFADIAZINE PYRIMETHAMINE treats RECURRENT TOXOPLASMIC ENCEPHALITIS,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11981,no_relation,treats,0.995893206467704,"Podzamczer D, Miro JM, Bolao F, et al: Twice weekly maintenance therapy with SULFADIAZINE PYRIMETHAMINE to prevent RECURRENT TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",RECURRENT TOXOPLASMIC ENCEPHALITIS,SULFADIAZINE PYRIMETHAMINE
11982,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11983,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11984,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11985,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11986,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11987,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11988,ROSIGLITAZONE treats TYPE 2 DIABETES MELLITUS,treats,0.9578262852211508,"May be used in combination with metformin or a thiazolidinedione antidiabetic agent (e.g., pioglitazone, ROSIGLITAZONE) as an adjunct to diet and exercise for the management of TYPE 2 DIABETES MELLITUS in patients who do not achieve adequate glycemic control with diet, exercise, and monotherapy with metformin, a sulfonylurea, repaglinide, or a thiazolidinedione antidiabetic agent",TYPE 2 DIABETES MELLITUS,ROSIGLITAZONE
11989,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11990,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11991,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11992,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11993,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11994,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11995,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,1.0,Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.,VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
11996,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
11997,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
11998,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
11999,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12000,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12001,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12002,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,0.964901281354015,A long term trial with CLOFAZIMINE in reactive LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12003,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12004,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12005,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12006,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12007,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12008,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12009,ORAL ANTIFUNGAL (EG KETOCONAZOLE) treats CUTANEOUS OR PULMONARY BLASTOMYCOSIS,treats,1.0,424   Treatment failures have been reported when an ORAL ANTIFUNGAL (EG KETOCONAZOLE) was used in the treatment of CUTANEOUS OR PULMONARY BLASTOMYCOSIS in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.,CUTANEOUS OR PULMONARY BLASTOMYCOSIS,ORAL ANTIFUNGAL (EG KETOCONAZOLE)
12010,[PHOTODYNAMIC THERAPY] treats [TUMORS],treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12011,[TUMORS] treats [PHOTODYNAMIC THERAPY],treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12012,[PHOTODYNAMIC THERAPY] treats [TUMORS],treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12013,no_relation,treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12014,[PHOTODYNAMIC THERAPY] treats [TUMORS],treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12015,no_relation,treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12016,[PHOTODYNAMIC THERAPY] treats [TUMORS],treats,0.9072647087265552,[PHOTODYNAMIC THERAPY] controls tumors by using targeted dyes and bright light to illuminate [TUMORS].,[TUMORS],[PHOTODYNAMIC THERAPY]
12017,INSULIN LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12018,no_relation,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12019,INSULIN LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12020,INSULIN LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12021,INSULIN LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12022,INSULIN LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12023,INSULIN LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.936329177569045,"1  Pediatric Use  Safety and efficacy of insulin lispro in fixed combination with insulin lispro protamine not established in children   165  Insulin lispro has been used in children aged 3 18 years of age with TYPE 1 DIABETES MELLITUS  1 ,   51 ,   74   and preliminary data suggest no unusual effects of INSULIN LISPRO therapy in adolescents receiving the drug.",TYPE 1 DIABETES MELLITUS,INSULIN LISPRO
12024,HYPERTENSION treats AMLODIPINE,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12025,AMLODIPINE treats HYPERTENSION,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12026,AMLODIPINE treats HYPERTENSION,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12027,AMLODIPINE treats HYPERTENSION,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12028,no_relation,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12029,AMLODIPINE treats HYPERTENSION,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12030,HYPERTENSION treats AMLODIPINE,treats,0.977355554850442,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
12031,LAMOTRIGINE treats SEIZURES,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12032,LAMOTRIGINE treats SEIZURES,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12033,LAMOTRIGINE treats SEIZURES,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12034,no_relation,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12035,LAMOTRIGINE treats SEIZURES,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12036,LAMOTRIGINE treats SEIZURES,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12037,LAMOTRIGINE treats SEIZURES,treats,0.975900072948533,"Antiepileptic agents often include phenytoin or carbamazepine for partial seizures, valproic acid for absence seizures, and any of these agents or phenobarbital, with or without newer drugs, such as gabapentin or LAMOTRIGINE for generalized SEIZURES",SEIZURES,LAMOTRIGINE
12038,no_relation,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12039,no_relation,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12040,no_relation,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12041,no_relation,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12042,SLIPPING treats PERSPIRATION,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12043,no_relation,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12044,no_relation,treats,0.7378647873726221,"In gymnastics, rock-climbing, weight-lifting and tug of war, chalk-now usually magnesium carbonate-is applied to the hands to remove [PERSPIRATION] and reduce [SLIPPING].",SLIPPING,PERSPIRATION
12045,[SWAINSONINE'S] treats [TUMORS],treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12046,[SWAINSONINE'S] treats [TUMORS],treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12047,[SWAINSONINE'S] treats [TUMORS],treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12048,[SWAINSONINE'S] treats [TUMORS],treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12049,no_relation,treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12050,no_relation,treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12051,no_relation,treats,0.995687776374027,[SWAINSONINE'S] activity against [TUMORS] is attributed to its stimuation of macrophages.cite journal.,[TUMORS],[SWAINSONINE'S]
12052,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12053,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12054,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12055,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12056,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12057,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12058,[DEFLUX] treats [URINARY REFLUX],treats,1.0,[DEFLUX] is injected around the ureteral opening to create a mound that stops [URINARY REFLUX],[URINARY REFLUX],[DEFLUX]
12059,no_relation,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12060,no_relation,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12061,no_relation,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12062,METHOTREXATE treats PREGNANCY,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12063,no_relation,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12064,METHOTREXATE treats PREGNANCY,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12065,METHOTREXATE treats PREGNANCY,treats,0.6019292654288461,METHOTREXATE followed by misoprostol may also be used to terminate early PREGNANCY,PREGNANCY,METHOTREXATE
12066,no_relation,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12067,TRICHOSTRONGYLUS treats TRICHOSTRONGYLIASIS,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12068,no_relation,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12069,no_relation,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12070,no_relation,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12071,no_relation,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12072,no_relation,treats,0.4472135954999579,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
12073,no_relation,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12074,BOSENTAN treats PAH,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12075,no_relation,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12076,PAH treats BOSENTAN,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12077,no_relation,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12078,BOSENTAN treats PAH,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12079,BOSENTAN treats PAH,treats,0.9615239476408228,"Specifically, pulmonary edema has been reported to develop in patients with PVOD when treated with agents used in PAH including epoprostenol and BOSENTAN",PAH,BOSENTAN
12080,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12081,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12082,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12083,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12084,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12085,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12086,TRIMETHOPRIM SULFAME THOXAZOLE treats P CARINII,treats,0.9722718241315028,"Other Infections  Pneumocystis jiroveci  (formerly,  P CARINII ) has essentially been eliminated by routine prophylaxis with TRIMETHOPRIM SULFAME THOXAZOLE or an alternative agent.",P CARINII,TRIMETHOPRIM SULFAME THOXAZOLE
12087,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12088,MBOLISM AFTER MA treats LOW DOSE HEPARIN PROPHYLA,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12089,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12090,LOW DOSE HEPARIN PROPHYLA treats MBOLISM AFTER MA,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12091,LOW DOSE HEPARIN PROPHYLA treats MBOLISM AFTER MA,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12092,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12093,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
12094,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12095,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12096,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12097,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12098,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12099,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12100,SODIUM OXYBATE treats CATAPLEXY,treats,1.0,"Although this patient still required modafinil for daytime sleepiness after initation of sodium oxybate, in some patients both excessive daytime sleepiness and CATAPLEXY are adequately controlled with just SODIUM OXYBATE.",CATAPLEXY,SODIUM OXYBATE
12101,CHLORAMPHENICOL treats SALMONELLOSIS,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12102,SALMONELLOSIS treats CHLORAMPHENICOL,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12103,CHLORAMPHENICOL treats SALMONELLOSIS,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12104,CHLORAMPHENICOL treats SALMONELLOSIS,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12105,CHLORAMPHENICOL treats SALMONELLOSIS,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12106,CHLORAMPHENICOL treats SALMONELLOSIS,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12107,CHLORAMPHENICOL treats SALMONELLOSIS,treats,1.0,"CHLORAMPHENICOL    (                     audio )  A broad spectrum antibiotic employed internationally for the treatment of SALMONELLOSIS ricksettsial diseases, and meningitis.",SALMONELLOSIS,CHLORAMPHENICOL
12108,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12109,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12110,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12111,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12112,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12113,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12114,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.9594032236002472,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
12115,LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12116,LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12117,TYPE 1 DIABETES MELLITUS treats LISPRO,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12118,no_relation,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12119,LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12120,LISPRO treats TYPE 1 DIABETES MELLITUS,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12121,no_relation,treats,0.9901475429766742,"Insulin LISPRO reduced nocturnal hypoglycemic episodes in TYPE 1 DIABETES MELLITUS when used to achieve tight glycemic control  Keywords: Blood glucose Diabetes mellitus, insulin dependent Hypoglycemia Hypoglycemic agents Insulin.",TYPE 1 DIABETES MELLITUS,LISPRO
12122,LINDANE treats SCABIES,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12123,LINDANE treats SCABIES,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12124,LINDANE treats SCABIES,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12125,LINDANE treats SCABIES,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12126,no_relation,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12127,SCABIES treats LINDANE,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12128,LINDANE treats SCABIES,treats,0.8192880303729141,"3  Resistant SCABIES  Overuse and misuse of certain scabicides, notably LINDANE have decreased their efficacy.",SCABIES,LINDANE
12129,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12130,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12131,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12132,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12133,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12134,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12135,TOPICAL CAPSAICIN treats CHRONIC POSTHERPETIC NEURALGIA,treats,1.0,TOPICAL CAPSAICIN treatment of CHRONIC POSTHERPETIC NEURALGIA,CHRONIC POSTHERPETIC NEURALGIA,TOPICAL CAPSAICIN
12136,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12137,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12138,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12139,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12140,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12141,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12142,TRANDOLAPRIL treats OBSTRUCTIVE UROPATHY,treats,0.997458699830735,Combination therapy with paricalcitol and [TRANDOLAPRIL] has been found to reduce fibrosis in [OBSTRUCTIVE UROPATHY].,OBSTRUCTIVE UROPATHY,TRANDOLAPRIL
12143,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12144,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12145,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12146,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12147,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12148,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12149,L DOPA treats PARKINSON'S DISEASE,treats,0.9797958971132712,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
12150,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12151,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12152,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12153,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12154,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12155,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12156,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,1.0,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12157,CIDOFOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12158,CIDOFOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12159,no_relation,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12160,CIDOFOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12161,CIDOFOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12162,CIDOFOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12163,CIDOFOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.9950371902099888,"Rahhal FM, Arevalo JF, Chavez de la Paz E et al. Treatment of CYTOMEGALOVIRUS RETINITIS with intravitreous CIDOFOVIR in patients with AIDS.",CYTOMEGALOVIRUS RETINITIS,CIDOFOVIR
12164,[INHALED SALMETEROL] treats [ASTHMA ATTACKS],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12165,[INHALED SALMETEROL] treats [ASTHMA ATTACKS],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12166,[INHALED SALMETEROL] treats [ASTHMA ATTACKS],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12167,[INHALED SALMETEROL] treats [ASTHMA ATTACKS],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12168,[INHALED SALMETEROL] treats [ASTHMA ATTACKS],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12169,[INHALED SALMETEROL] treats [ASTHMA ATTACKS],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12170,[ASTHMA ATTACKS] treats [INHALED SALMETEROL],treats,1.0,"When used regularly every day as prescribed, [INHALED SALMETEROL] decreases the number and severity of [ASTHMA ATTACKS].",[ASTHMA ATTACKS],[INHALED SALMETEROL]
12171,DILTIAZEM treats PRINZMETAL'S ANGINA,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12172,DILTIAZEM treats PRINZMETAL'S ANGINA,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12173,DILTIAZEM treats PRINZMETAL'S ANGINA,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12174,DILTIAZEM treats PRINZMETAL'S ANGINA,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12175,no_relation,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12176,DILTIAZEM treats PRINZMETAL'S ANGINA,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12177,DILTIAZEM treats PRINZMETAL'S ANGINA,treats,0.963086824686154,"DILTIAZEM    (                audio )  A calcium channel blocker administered orally or intravenously to manage hypertension, angina pectoris, PRINZMETAL'S ANGINA supraventricular tachyarrhythmias, and rapid ventricular rates in atrial flutter or fibrillation.",PRINZMETAL'S ANGINA,DILTIAZEM
12178,ACETAMINOPHEN treats PAIN,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12179,ACETAMINOPHEN treats PAIN,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12180,ACETAMINOPHEN treats PAIN,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12181,no_relation,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12182,ACETAMINOPHEN treats PAIN,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12183,ACETAMINOPHEN treats PAIN,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12184,ACETAMINOPHEN treats PAIN,treats,1.0,"BACKGROUND:  ACETAMINOPHEN one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over the counter (OTC) products to reduce PAIN and fever.",PAIN,ACETAMINOPHEN
12185,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12186,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12187,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12188,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12189,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12190,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12191,SYNTHETIC SALMON CALCITONIN treats PAGET'S DISEASE,treats,0.964763821237732,"Kanis JA, Horn DB, Scott RDM et al. Treatment of PAGET'S DISEASE of bone with SYNTHETIC SALMON CALCITONIN",PAGET'S DISEASE,SYNTHETIC SALMON CALCITONIN
12192,no_relation,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12193,no_relation,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12194,no_relation,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12195,ORAL CONTRACEPTIVE treats TEMAZEPAM,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12196,no_relation,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12197,TEMAZEPAM treats ORAL CONTRACEPTIVE,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12198,ORAL CONTRACEPTIVE treats TEMAZEPAM,treats,0.3665083330689161,[ORAL CONTRACEPTIVE]s may decrease the effectiveness of [TEMAZEPAM] and speed up its elimination half life.,ORAL CONTRACEPTIVE,TEMAZEPAM
12199,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12200,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12201,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12202,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12203,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12204,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12205,[MELARSOPROL/NIFURTIMOX] treats [AFRICAN SLEEPING SICKNESS],treats,0.9707253433941508,Trials are awaited comparing [MELARSOPROL/NIFURTIMOX] against melarsoprol alone for [AFRICAN SLEEPING SICKNESS],[AFRICAN SLEEPING SICKNESS],[MELARSOPROL/NIFURTIMOX]
12206,ISOTRETINOIN treats CYSTIC ACNE,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12207,ISOTRETINOIN treats CYSTIC ACNE,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12208,ISOTRETINOIN treats CYSTIC ACNE,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12209,ISOTRETINOIN treats CYSTIC ACNE,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12210,ISOTRETINOIN treats CYSTIC ACNE,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12211,ISOTRETINOIN treats CYSTIC ACNE,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12212,no_relation,treats,0.986393923832144,"Peck GL, Olsen TG, Butkus D et alISOTRETINOIN versus placebo in the treatment of CYSTIC ACNE: a randomized double blind study.",CYSTIC ACNE,ISOTRETINOIN
12213,CLL treats LYMPHADENOPATHY,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12214,CLL treats LYMPHADENOPATHY,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12215,CLL treats LYMPHADENOPATHY,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12216,no_relation,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12217,CLL treats LYMPHADENOPATHY,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12218,CLL treats LYMPHADENOPATHY,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12219,CLL treats LYMPHADENOPATHY,treats,0.905821627315677,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
12220,ERGONOVINE treats VARIANT ANGINA,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12221,ERGONOVINE treats VARIANT ANGINA,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12222,ERGONOVINE treats VARIANT ANGINA,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12223,no_relation,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12224,ERGONOVINE treats VARIANT ANGINA,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12225,ERGONOVINE treats VARIANT ANGINA,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12226,ERGONOVINE treats VARIANT ANGINA,treats,0.801783725737273,The response of the coronary artery to a small dose of ERGONOVINE was observed in nine patients without VARIANT ANGINA and in 10 patients with variant angina,VARIANT ANGINA,ERGONOVINE
12227,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12228,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12229,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12230,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12231,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12232,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12233,[MORPHINE IR 60MG] treats [POST SURGERY DENTAL PAIN],treats,0.962250448649376,"A phase II single dose trial of tapentadol 25mg 200mg, ibuprofen 400mg and [MORPHINE IR 60MG] was evaluated in [POST SURGERY DENTAL PAIN]",[POST SURGERY DENTAL PAIN],[MORPHINE IR 60MG]
12234,CORTICOSTEROIDS (PREDNISOLONE) treats INFLAMMATION,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12235,CORTICOSTEROIDS (PREDNISOLONE) treats INFLAMMATION,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12236,CORTICOSTEROIDS (PREDNISOLONE) treats INFLAMMATION,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12237,CORTICOSTEROIDS (PREDNISOLONE) treats INFLAMMATION,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12238,no_relation,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12239,CORTICOSTEROIDS (PREDNISOLONE) treats INFLAMMATION,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12240,CORTICOSTEROIDS (PREDNISOLONE) treats INFLAMMATION,treats,0.987878339907213,"Salmeterol is a long acting controller medication, and albuterol is a quick reliever  Tachycardia, anxiety, theoretical hypertrophy of submucosal glands  Longitudinal studies of long acting b agonists are underway Oral CORTICOSTEROIDS (PREDNISOLONE)  Decrease airway INFLAMMATION  Varies 1 mg/kg po qod, dose noted in Cochrane review  Treat ABPA.",INFLAMMATION,CORTICOSTEROIDS (PREDNISOLONE)
12241,MYOCARDIAL INFARCTION treats ACETYLSALICYLIC ACID,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12242,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12243,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12244,no_relation,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12245,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12246,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12247,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,treats,0.997458699830735,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
12248,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12249,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12250,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12251,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12252,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12253,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12254,EPHEDRINE treats SEASICKNESS,treats,0.99654575824488,As a motion sickness or [SEASICKNESS] remedy when used with [EPHEDRINE] or Pseudoephedrine.,SEASICKNESS,EPHEDRINE
12255,no_relation,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12256,P AERUGINOSA treats ECTHYMA GANGRENOSUM,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12257,no_relation,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12258,no_relation,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12259,ECTHYMA GANGRENOSUM treats P AERUGINOSA,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12260,no_relation,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12261,no_relation,treats,0.412081691846067,ECTHYMA GANGRENOSUM in neutropenic patients is a skin lesion pathognomonic for  P AERUGINOSA,ECTHYMA GANGRENOSUM,P AERUGINOSA
12262,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12263,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12264,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12265,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12266,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12267,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12268,GRANISETRON treats EMESIS,treats,0.993127066322842,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
12269,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12270,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12271,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12272,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12273,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12274,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12275,MAGNESIUM SULPHATE treats TORSADES,treats,0.8955334711889901,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
12276,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12277,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12278,ACTINIC KERATOSIS treats SKIN CONDITIONS,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12279,ACTINIC KERATOSIS treats SKIN CONDITIONS,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12280,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12281,no_relation,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12282,ACTINIC KERATOSIS treats SKIN CONDITIONS,treats,0.78086880944303,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
12283,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12284,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12285,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12286,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12287,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12288,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12289,ASPIRIN treats INFARCTION (MI,treats,1.0,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as high dose ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI and death after CE.",INFARCTION (MI,ASPIRIN
12290,no_relation,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12291,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12292,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12293,no_relation,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12294,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12295,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12296,FUROSEMIDE treats CHRONIC RENAL FAILURE,treats,0.9237604307034007,"1]  Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and FUROSEMIDE alone and in combination in CHRONIC RENAL FAILURE",CHRONIC RENAL FAILURE,FUROSEMIDE
12297,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12298,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12299,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12300,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12301,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12302,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12303,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
12304,no_relation,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12305,no_relation,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12306,no_relation,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12307,TYPHOID FEVER treats SALMONELLA TYPHI,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12308,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12309,no_relation,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12310,SALMONELLA TYPHI treats TYPHOID FEVER,treats,0.948683298050514,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
12311,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [VOMITING],treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12312,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [VOMITING],treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12313,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [VOMITING],treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12314,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [VOMITING],treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12315,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [VOMITING],treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12316,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [VOMITING],treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12317,no_relation,treats,0.9594032236002472,"In nausea and [VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12318,PROPRANOLOL treats SEVERE HYPERTENSION,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12319,PROPRANOLOL treats SEVERE HYPERTENSION,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12320,no_relation,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12321,PROPRANOLOL treats SEVERE HYPERTENSION,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12322,PROPRANOLOL treats SEVERE HYPERTENSION,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12323,PROPRANOLOL treats SEVERE HYPERTENSION,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12324,PROPRANOLOL treats SEVERE HYPERTENSION,treats,0.993883734673619,"Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of SEVERE HYPERTENSION with intravenous labetalol: comparison with PROPRANOLOL",SEVERE HYPERTENSION,PROPRANOLOL
12325,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12326,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12327,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12328,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12329,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12330,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12331,INTRAVAGINAL 0.75% METRONIDAZOLE GEL treats BACTERIAL VAGINOSIS,treats,0.979957887012223,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
12332,NICOTINE treats ALZHEIMER'S DISEASE,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12333,NICOTINE treats ALZHEIMER'S DISEASE,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12334,no_relation,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12335,NICOTINE treats ALZHEIMER'S DISEASE,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12336,NICOTINE treats ALZHEIMER'S DISEASE,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12337,NICOTINE treats ALZHEIMER'S DISEASE,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12338,NICOTINE treats ALZHEIMER'S DISEASE,treats,0.993127066322842,"Consequently, this may also suggest that administration of [NICOTINE] itself may act against the effects of [ALZHEIMER'S DISEASE].",ALZHEIMER'S DISEASE,NICOTINE
12339,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12340,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12341,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12342,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12343,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12344,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12345,FLUCONAZOLE treats ORAL CANDIDIASIS,treats,1.0,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
12346,RUBELLA VACCINE treats RUBELLA,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12347,RUBELLA VACCINE treats RUBELLA,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12348,RUBELLA VACCINE treats RUBELLA,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12349,RUBELLA VACCINE treats RUBELLA,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12350,RUBELLA VACCINE treats RUBELLA,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12351,RUBELLA VACCINE treats RUBELLA,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12352,RUBELLA treats RUBELLA VACCINE,treats,0.9970544855015808,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
12353,NADOLOL treats BLEEDING,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12354,NADOLOL treats BLEEDING,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12355,NADOLOL treats BLEEDING,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12356,NADOLOL treats BLEEDING,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12357,NADOLOL treats BLEEDING,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12358,NADOLOL treats BLEEDING,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12359,BLEEDING treats NADOLOL,treats,1.0,[NADOLOL] and other non-selective beta-blockers are used in the prevention of re[BLEEDING] in the setting of bleeding secondary to portal hypertension.,BLEEDING,NADOLOL
12360,VALSARTAN treats IMPAIRED GLUCOSE TOLERANCE,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12361,VALSARTAN treats IMPAIRED GLUCOSE TOLERANCE,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12362,no_relation,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12363,no_relation,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12364,no_relation,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12365,VALSARTAN treats IMPAIRED GLUCOSE TOLERANCE,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12366,VALSARTAN treats IMPAIRED GLUCOSE TOLERANCE,treats,0.9561828875,"In patients with [IMPAIRED GLUCOSE TOLERANCE], [VALSARTAN] may decrease the incidence of developing type 2 diabetes mellitus.",IMPAIRED GLUCOSE TOLERANCE,VALSARTAN
12367,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12368,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12369,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12370,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12371,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12372,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12373,[NON OPIOID AND NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.963086824686154,Ziconotide is a [NON OPIOID AND NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON OPIOID AND NON NSAID ANALGESIC AGENT]
12374,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12375,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12376,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12377,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12378,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12379,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12380,AZITHROMYCIN treats PRESUMPTIVE CHLAMYDIAL INFECTION,treats,1.0,"Treatment for PRESUMPTIVE CHLAMYDIAL INFECTION in men with NGU is with AZITHROMYCIN in a single 1 g oral dose or doxycycline, 100 mg orally twice a day for 7 days.",PRESUMPTIVE CHLAMYDIAL INFECTION,AZITHROMYCIN
12381,ASPIRIN treats DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12382,ASPIRIN treats DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12383,ASPIRIN treats DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12384,ASPIRIN treats DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12385,no_relation,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12386,ASPIRIN treats DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12387,ASPIRIN treats DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,treats,0.984731927834662,The benefits from coumadin therapy were further supported by secondary analyses showing lower rates of DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE and revascularization in patients receiving coumadin or aspirin plus coumadin therapy than in those receiving ASPIRIN alone.,DEATH VASCULAR DEATH MI UNSTABLE ANGINA STROKE,ASPIRIN
12388,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12389,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12390,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12391,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12392,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12393,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12394,PARICALCITOL treats SECONDARY HYPERPARATHYROIDISM,treats,1.0,"The parenteral form of calcitriol, or vitamin D analogs such as PARICALCITOL may better prevent SECONDARY HYPERPARATHYROIDISM in such patients, because the higher attained plasma levels of 1,25(OH) 2 D directly suppress PTH release.",SECONDARY HYPERPARATHYROIDISM,PARICALCITOL
12395,no_relation,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12396,no_relation,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12397,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12398,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12399,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12400,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12401,no_relation,treats,0.9970544855015808,2007 11 01  Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
12402,LEUPROLIDE ACETATE treats UTERINE FIBROIDS,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12403,LEUPROLIDE ACETATE treats UTERINE FIBROIDS,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12404,LEUPROLIDE ACETATE treats UTERINE FIBROIDS,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12405,LEUPROLIDE ACETATE treats UTERINE FIBROIDS,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12406,LEUPROLIDE ACETATE treats UTERINE FIBROIDS,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12407,no_relation,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12408,LEUPROLIDE ACETATE treats UTERINE FIBROIDS,treats,0.9761870601839532,• A prospective open clinical trial evaluated the effects of 2 year treatment on 25 women with LEUPROLIDE ACETATE and tibolone for UTERINE FIBROIDS,UTERINE FIBROIDS,LEUPROLIDE ACETATE
12409,PRAZOSIN treats HYPERTENSION,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12410,no_relation,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12411,PRAZOSIN treats HYPERTENSION,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12412,no_relation,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12413,PRAZOSIN treats HYPERTENSION,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12414,no_relation,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12415,PRAZOSIN treats HYPERTENSION,treats,0.881917103688197,"Postsynaptic α 1  blockers (eg, PRAZOSIN terazosin, doxazosin) are no longer used for primary treatment of HYPERTENSION because evidence suggests no mortality benefit.",HYPERTENSION,PRAZOSIN
12416,FIXED DOSE SUBCUTANEOUS HEPARIN treats DEEP VEIN THROMBOSIS,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12417,FIXED DOSE SUBCUTANEOUS HEPARIN treats DEEP VEIN THROMBOSIS,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12418,FIXED DOSE SUBCUTANEOUS HEPARIN treats DEEP VEIN THROMBOSIS,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12419,FIXED DOSE SUBCUTANEOUS HEPARIN treats DEEP VEIN THROMBOSIS,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12420,FIXED DOSE SUBCUTANEOUS HEPARIN treats DEEP VEIN THROMBOSIS,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12421,no_relation,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12422,FIXED DOSE SUBCUTANEOUS HEPARIN treats DEEP VEIN THROMBOSIS,treats,1.0,"1]  Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus FIXED DOSE SUBCUTANEOUS HEPARIN in the prevention of DEEP VEIN THROMBOSIS after total hip replacement.",DEEP VEIN THROMBOSIS,FIXED DOSE SUBCUTANEOUS HEPARIN
12423,SCOPOLAMINE treats MOTION SICKNESS,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12424,SCOPOLAMINE treats MOTION SICKNESS,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12425,MOTION SICKNESS treats SCOPOLAMINE,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12426,SCOPOLAMINE treats MOTION SICKNESS,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12427,SCOPOLAMINE treats MOTION SICKNESS,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12428,SCOPOLAMINE treats MOTION SICKNESS,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12429,no_relation,treats,0.824163383692134,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
12430,no_relation,treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12431,[GEMTUZUMAB OZOGAMICIN] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12432,no_relation,treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12433,[GEMTUZUMAB OZOGAMICIN] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12434,no_relation,treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12435,[GEMTUZUMAB OZOGAMICIN] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12436,no_relation,treats,0.486664263392288,[GEMTUZUMAB OZOGAMICIN] Mylotarg 2000 humanized CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN]
12437,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12438,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12439,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12440,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12441,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12442,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12443,no_relation,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
12444,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12445,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12446,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12447,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12448,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12449,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12450,PHENTERMINE treats OBESITY,treats,1.0,"Agents Approved for Short Term Use  Benzphetamine, phendimetrazine, diethylpropion, mazindol, and PHENTERMINE are approved by the FDA for the short term treatment of OBESITY (weeks.",OBESITY,PHENTERMINE
12451,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12452,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12453,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12454,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12455,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12456,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12457,ANTIPYRINE treats EAR PAIN (OTALGIA EARACHE,treats,0.9950371902099888,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
12458,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12459,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12460,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12461,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12462,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12463,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12464,MEROPENEM treats FEBRILE NEUTROPENIA,treats,0.99654575824488,"1]  Feld R, DePauw B, Berman S, Keating A, Ho WMEROPENEM versus ceftazidime in the treatment of cancer patients with FEBRILE NEUTROPENIA: a randomized, double blind trial.",FEBRILE NEUTROPENIA,MEROPENEM
12465,no_relation,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12466,no_relation,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12467,MYCOBACTERIUM KANSASII treats MYCOBACTERIAL INFECTIONS,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12468,no_relation,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12469,no_relation,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12470,no_relation,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12471,no_relation,treats,0.337526370277807,MYCOBACTERIUM KANSASII and Other MYCOBACTERIAL INFECTIONS  Treatment of  M. kansasii    +    infections in conjunction with other antimycobacterials.,MYCOBACTERIAL INFECTIONS,MYCOBACTERIUM KANSASII
12472,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12473,no_relation,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12474,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12475,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12476,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12477,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12478,BALSALAZIDE treats ULCERATIVE COLITIS,treats,0.956182887467515,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
12479,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12480,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12481,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12482,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12483,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12484,no_relation,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12485,no_relation,treats,0.9970544855015808,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT
12486,no_relation,treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12487,[STATINS] treats [FRACTURES],treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12488,no_relation,treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12489,[STATINS] treats [FRACTURES],treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12490,no_relation,treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12491,no_relation,treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12492,no_relation,treats,0.993127066322842,"Since [STATINS] have a bone strengthening effect , combining a statin with an aromatase inhibitor may avoid both [FRACTURES] and possible cardiovascular risks without jaw osteonecrosis.",[FRACTURES],[STATINS]
12493,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12494,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12495,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12496,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12497,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12498,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12499,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
12500,no_relation,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12501,YAWS treats TREPONEMA PERTENUE,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12502,no_relation,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12503,no_relation,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12504,TREPONEMA PERTENUE treats YAWS,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12505,no_relation,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12506,no_relation,treats,0.31622776601683805,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
12507,no_relation,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12508,STATIN treats DIABETES,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12509,no_relation,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12510,STATIN treats DIABETES,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12511,STATIN treats DIABETES,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12512,STATIN treats DIABETES,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12513,no_relation,treats,0.5547001962,"The ARBITER 6-HALTS trial enrolled patients with coronary artery disease, or an equivalent risk condition such as [DIABETES], who were already taking [STATIN]s.",DIABETES,STATIN
12514,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12515,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12516,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12517,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12518,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12519,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12520,MEMANTINE treats ALZHEIMER'S DISEASE,treats,0.9138115486,[MEMANTINE] has been associated with a moderate decrease in clinical deterioration in [ALZHEIMER'S DISEASE].,ALZHEIMER'S DISEASE,MEMANTINE
12521,no_relation,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12522,no_relation,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12523,ABDOMINAL PAIN treats HEREDITARY ANGIOEDEMA,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12524,no_relation,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12525,HEREDITARY ANGIOEDEMA treats ABDOMINAL PAIN,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12526,no_relation,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12527,no_relation,treats,0.811107105653813,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
12528,no_relation,treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12529,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12530,no_relation,treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12531,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12532,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] treats [ACUTE MYELOGENOUS LEUKEMIA],treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12533,no_relation,treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12534,no_relation,treats,0.369610635477286,[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED] CD33 [ACUTE MYELOGENOUS LEUKEMIA] .,[ACUTE MYELOGENOUS LEUKEMIA],[GEMTUZUMAB OZOGAMICIN MYLOTARG 2000 HUMANIZED]
12535,DECOMPRESSION SICKNESS treats OXYGEN,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12536,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12537,no_relation,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12538,no_relation,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12539,no_relation,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12540,OXYGEN treats DECOMPRESSION SICKNESS,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12541,no_relation,treats,0.361157559257308,"If the oxygen is too low, the incidence of DECOMPRESSION SICKNESS increases; if the OXYGEN is too high, oxygen poisoning becomes a problem.",DECOMPRESSION SICKNESS,OXYGEN
12542,[ANTIHISTAMINES] treats [PSORIASIS],treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12543,[ANTIHISTAMINES] treats [PSORIASIS],treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12544,[ANTIHISTAMINES] treats [PSORIASIS],treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12545,[ANTIHISTAMINES] treats [PSORIASIS],treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12546,[ANTIHISTAMINES] treats [PSORIASIS],treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12547,no_relation,treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12548,[ANTIHISTAMINES] treats [PSORIASIS],treats,0.950255268139496,"Some [ANTIHISTAMINES] have sedative properties, thus might aid to improve sleep and reduce anxiety in [PSORIASIS] patients.",[PSORIASIS],[ANTIHISTAMINES]
12549,no_relation,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12550,no_relation,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12551,LESION treats ERYTHEMA NODOSUM LEPROSUM,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12552,no_relation,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12553,no_relation,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12554,ERYTHEMA NODOSUM LEPROSUM treats LESION,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12555,no_relation,treats,0.369800130816819,"On July 16, 1998, the FDA approved the use of thalidomide for the treatment of [LESION]s associated with [ERYTHEMA NODOSUM LEPROSUM] .",LESION,ERYTHEMA NODOSUM LEPROSUM
12556,no_relation,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12557,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12558,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12559,no_relation,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12560,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12561,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12562,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
12563,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12564,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12565,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12566,no_relation,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12567,no_relation,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12568,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12569,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
12570,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12571,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12572,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12573,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12574,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12575,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12576,AZITHROMYCIN treats NON GONOCOCCAL URETHRITIS,treats,1.0,"AZITHROMYCIN as the first line treatment of NON GONOCOCCAL URETHRITIS (NGU): a study of follow up rates, contact attendance and patients' treatment preference.",NON GONOCOCCAL URETHRITIS,AZITHROMYCIN
12577,[TDAP VACCINE] treats [PERTUSSIS VIRUS],treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12578,[TDAP VACCINE] treats [PERTUSSIS VIRUS],treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12579,no_relation,treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12580,no_relation,treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12581,[TDAP VACCINE] treats [PERTUSSIS VIRUS],treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12582,[TDAP VACCINE] treats [PERTUSSIS VIRUS],treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12583,[TDAP VACCINE] treats [PERTUSSIS VIRUS],treats,0.639602149066831,"In yet another application, glutaraldehyde, along with formaldehyde, is used to detoxify the [PERTUSSIS VIRUS] in the common [TDAP VACCINE] BOOSTERIX.",[PERTUSSIS VIRUS],[TDAP VACCINE]
12584,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12585,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12586,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12587,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12588,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12589,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12590,METHOTREXATE treats CROHN'S DISEASE,treats,0.9707253434,"Lower doses of [METHOTREXATE] have been shown to be very effective for the management of rheumatoid arthritis, [CROHN'S DISEASE], and psoriasis.",CROHN'S DISEASE,METHOTREXATE
12591,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12592,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12593,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12594,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12595,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12596,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12597,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
12598,LAMOTRIGINE treats BIPOLAR DISORDER,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12599,no_relation,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12600,LAMOTRIGINE treats BIPOLAR DISORDER,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12601,no_relation,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12602,LAMOTRIGINE treats BIPOLAR DISORDER,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12603,LAMOTRIGINE treats BIPOLAR DISORDER,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12604,LAMOTRIGINE treats BIPOLAR DISORDER,treats,0.8082903768654759,"1 ,   2 ,   6 ,   13 ,   22 ,   24  Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 0.05 or 0.16% of adults or children with seizure disorders who received lamotrigine, respectively,  1   and in no adults with BIPOLAR DISORDER who received LAMOTRIGINE",BIPOLAR DISORDER,LAMOTRIGINE
12605,VARIANT ANGINA treats ERGOMETRINE,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12606,ERGOMETRINE treats VARIANT ANGINA,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12607,ERGOMETRINE treats VARIANT ANGINA,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12608,ERGOMETRINE treats VARIANT ANGINA,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12609,no_relation,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12610,ERGOMETRINE treats VARIANT ANGINA,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12611,no_relation,treats,0.9594032236002472,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
12612,HIGH DOSE ASPIRIN treats INFARCTION (MI),treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12613,HIGH DOSE ASPIRIN treats INFARCTION (MI),treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12614,HIGH DOSE ASPIRIN treats INFARCTION (MI),treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12615,HIGH DOSE ASPIRIN treats INFARCTION (MI),treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12616,HIGH DOSE ASPIRIN treats INFARCTION (MI),treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12617,no_relation,treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12618,HIGH DOSE ASPIRIN treats INFARCTION (MI),treats,0.964901281354015,"PubMed ID: 10392981  QUESTION  In patients scheduled for carotid endarterectomy (CE), is low dose aspirin as effective as HIGH DOSE ASPIRIN for reducing perioperative stroke, myocardial INFARCTION (MI) and death after CE.",INFARCTION (MI),HIGH DOSE ASPIRIN
12619,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12620,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12621,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12622,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12623,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12624,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12625,NAPROXEN treats PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,treats,0.997458699830735,"Kvien TK, Hoyeraal HM, Sandstad BNAPROXEN and acetylsalicylic acid in the treatment of PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS: assessment of tolerance and efficacy in a single centre 24 week double blind parallel study.",PAUCIARTICULAR AND POLYARTICULAR JUVENILE RHEUMATOID ARTHRITIS,NAPROXEN
12626,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12627,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12628,no_relation,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12629,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12630,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12631,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12632,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
12633,[PHENAZOPYRIDINE] treats [ANALGESIC EFFECTS],treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12634,no_relation,treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12635,no_relation,treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12636,no_relation,treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12637,[PHENAZOPYRIDINE] treats [ANALGESIC EFFECTS],treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12638,[PHENAZOPYRIDINE] treats [ANALGESIC EFFECTS],treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12639,no_relation,treats,0.911684611677104,[PHENAZOPYRIDINE] is prescribed for its local [ANALGESIC EFFECTS] on the urinary tract.,[ANALGESIC EFFECTS],[PHENAZOPYRIDINE]
12640,no_relation,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12641,no_relation,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12642,no_relation,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12643,no_relation,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12644,HEMOLYSIS treats AUTOIMMUNE HEMOLYTIC ANEMIA,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12645,no_relation,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12646,no_relation,treats,0.875,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
12647,ALENDRONATE treats POSTMENOPAUSAL BONE LOSS,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12648,no_relation,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12649,ALENDRONATE treats POSTMENOPAUSAL BONE LOSS,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12650,ALENDRONATE treats POSTMENOPAUSAL BONE LOSS,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12651,ALENDRONATE treats POSTMENOPAUSAL BONE LOSS,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12652,ALENDRONATE treats POSTMENOPAUSAL BONE LOSS,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12653,ALENDRONATE treats POSTMENOPAUSAL BONE LOSS,treats,1.0,"McClung M, Clemmesen B, Daifotis A et al.: ALENDRONATE prevents POSTMENOPAUSAL BONE LOSS in women without osteoporosis: a double blind, randomized, controlled trial.",POSTMENOPAUSAL BONE LOSS,ALENDRONATE
12654,no_relation,treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12655,[PEMETREXED] treats [LARGE CELL LUNG CARCINOMA],treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12656,[PEMETREXED] treats [LARGE CELL LUNG CARCINOMA],treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12657,[PEMETREXED] treats [LARGE CELL LUNG CARCINOMA],treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12658,[PEMETREXED] treats [LARGE CELL LUNG CARCINOMA],treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12659,[PEMETREXED] treats [LARGE CELL LUNG CARCINOMA],treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12660,[PEMETREXED] treats [LARGE CELL LUNG CARCINOMA],treats,0.997785157856609,"[PEMETREXED] has been shown to improve survival in non squamous cell NSCLC, and is the first drug to reveal differential survival benefit in [LARGE CELL LUNG CARCINOMA]",[LARGE CELL LUNG CARCINOMA],[PEMETREXED]
12661,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12662,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12663,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12664,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12665,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12666,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12667,LOW DOSE THALIDOMIDE THERAPY treats SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,treats,0.993127066322842,"Duong DJ, Spigel GT, Moxley RT et al. American experience with LOW DOSE THALIDOMIDE THERAPY for SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS.",SEVERE CUTANEOUS LUPUS ERYTHEMATOSUS,LOW DOSE THALIDOMIDE THERAPY
12668,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12669,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12670,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12671,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12672,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12673,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12674,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.9830783046228492,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
12675,no_relation,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12676,no_relation,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12677,INULIN LISPRO THERAPY treats IDDM,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12678,INULIN LISPRO THERAPY treats IDDM,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12679,INULIN LISPRO THERAPY treats IDDM,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12680,INULIN LISPRO THERAPY treats IDDM,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12681,no_relation,treats,0.929981109950554,"Ebeling P, Lalli C, Jansson PA et al. Strategies toward improved control during INULIN LISPRO THERAPY in IDDM",IDDM,INULIN LISPRO THERAPY
12682,no_relation,treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12683,[GUAIFENESIN KETAMINE XYLAZINE] treats [EQUINE DYSTOCIA],treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12684,[GUAIFENESIN KETAMINE XYLAZINE] treats [EQUINE DYSTOCIA],treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12685,[GUAIFENESIN KETAMINE XYLAZINE] treats [EQUINE DYSTOCIA],treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12686,[GUAIFENESIN KETAMINE XYLAZINE] treats [EQUINE DYSTOCIA],treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12687,[GUAIFENESIN KETAMINE XYLAZINE] treats [EQUINE DYSTOCIA],treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12688,[GUAIFENESIN KETAMINE XYLAZINE] treats [EQUINE DYSTOCIA],treats,0.961074462327142,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE] anesthesia for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE]
12689,no_relation,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12690,no_relation,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12691,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12692,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12693,no_relation,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12694,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12695,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,treats,0.668153104781061,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
12696,no_relation,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12697,NALTREXONE treats OBESITY,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12698,NALTREXONE treats OBESITY,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12699,NALTREXONE treats OBESITY,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12700,no_relation,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12701,NALTREXONE treats OBESITY,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12702,no_relation,treats,0.875,Combinations of bupropion and zonisamide and of bupropion and [NALTREXONE] are currently being studied for [OBESITY].,OBESITY,NALTREXONE
12703,[RAPID DETOXIFICATION REGIMENS] treats [OPIOID DEPENDENCE],treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12704,no_relation,treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12705,[RAPID DETOXIFICATION REGIMENS] treats [OPIOID DEPENDENCE],treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12706,no_relation,treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12707,no_relation,treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12708,no_relation,treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12709,[RAPID DETOXIFICATION REGIMENS] treats [OPIOID DEPENDENCE],treats,0.984731927834662,Naltrexone is sometimes used for [RAPID DETOXIFICATION REGIMENS] for [OPIOID DEPENDENCE],[OPIOID DEPENDENCE],[RAPID DETOXIFICATION REGIMENS]
12710,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12711,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12712,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12713,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12714,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12715,no_relation,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12716,ISONIAZID treats PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,treats,0.9354143466934848,"b  Advanced PULMONARY AND EXTRAPULMONARY TUBERCULOSIS  Systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, ISONIAZID to suppress manifestations related to the host's inflammatory response to the bacillus ( Mycobacterium tuberculosis ) and ameliorate complications in severe pulmonary or extrapulmonary tuberculosis.",PULMONARY AND EXTRAPULMONARY TUBERCULOSIS,ISONIAZID
12717,no_relation,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12718,no_relation,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12719,SARCOIDOSIS treats COUGH,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12720,SARCOIDOSIS treats COUGH,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12721,no_relation,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12722,no_relation,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12723,no_relation,treats,0.363803437554499,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
12724,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12725,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12726,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12727,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12728,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12729,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12730,PERMETHRIN treats SCABIES,treats,1.0,"Taplin D, Meinking TL, Porcelain SL et alPERMETHRIN 5% dermal cream: a new treatment for SCABIES",SCABIES,PERMETHRIN
12731,CAMPYLOBACTER treats CAMPYLOBACTER INFECTIONS,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12732,CAMPYLOBACTER treats CAMPYLOBACTER INFECTIONS,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12733,no_relation,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12734,CAMPYLOBACTER treats CAMPYLOBACTER INFECTIONS,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12735,no_relation,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12736,CAMPYLOBACTER INFECTIONS treats CAMPYLOBACTER,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12737,CAMPYLOBACTER INFECTIONS treats CAMPYLOBACTER,treats,0.569651921139812,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
12738,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12739,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12740,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12741,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12742,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12743,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12744,CLOFAZIMINE treats LEPROMATOUS LEPROSY,treats,1.0,Daily dapsone and CLOFAZIMINE plus monthly doses of rifampin for 24 months are required to treat LEPROMATOUS LEPROSY,LEPROMATOUS LEPROSY,CLOFAZIMINE
12745,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12746,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12747,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12748,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12749,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12750,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12751,OMEPRAZOLE treats REFRACTORY REFLUX ESOPHAGITIS,treats,1.0,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
12752,no_relation,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12753,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12754,no_relation,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12755,no_relation,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12756,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12757,LOSARTAN INTERVENTION FOR ENDPOINT treats HYPERTENSION,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12758,no_relation,treats,0.913811548620257,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
12759,[INHALED CORTICOSTEROIDS] treats [EDEMA],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12760,[INHALED CORTICOSTEROIDS] treats [EDEMA],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12761,[INHALED CORTICOSTEROIDS] treats [EDEMA],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12762,[INHALED CORTICOSTEROIDS] treats [EDEMA],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12763,[INHALED CORTICOSTEROIDS] treats [EDEMA],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12764,[EDEMA] treats [INHALED CORTICOSTEROIDS],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12765,[INHALED CORTICOSTEROIDS] treats [EDEMA],treats,0.995893206467704,Inflammation and [EDEMA] of the respiratory epithelium may be reduced with [INHALED CORTICOSTEROIDS].,[EDEMA],[INHALED CORTICOSTEROIDS]
12766,RATIONALE • INTRALESIONAL VINBLASTINE treats AIDS ASSOCIATED KS,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12767,no_relation,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12768,RATIONALE • INTRALESIONAL VINBLASTINE treats AIDS ASSOCIATED KS,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12769,AIDS ASSOCIATED KS treats RATIONALE • INTRALESIONAL VINBLASTINE,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12770,RATIONALE • INTRALESIONAL VINBLASTINE treats AIDS ASSOCIATED KS,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12771,RATIONALE • INTRALESIONAL VINBLASTINE treats AIDS ASSOCIATED KS,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12772,RATIONALE • INTRALESIONAL VINBLASTINE treats AIDS ASSOCIATED KS,treats,1.0,RATIONALE • INTRALESIONAL VINBLASTINE has shown efficacy for the treatment of oral or cutaneous KS lesions in patients with AIDS ASSOCIATED KS,AIDS ASSOCIATED KS,RATIONALE • INTRALESIONAL VINBLASTINE
12773,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12774,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12775,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12776,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12777,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12778,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12779,AZATHIOPRINE treats RHEUMATOID ARTHRITIS,treats,0.964763821237732,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
12780,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12781,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12782,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12783,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12784,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12785,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12786,ISOTRETINOIN treats ACNE,treats,0.9899494936611658,"Plewig G, Braun Falco O, Klovekorn W et al. [Isotretinoin in local treatment of ACNE and rosacea and animal experiment studies on ISOTRETINOIN and arotinoid.",ACNE,ISOTRETINOIN
12787,CEFTRIAXONE RO 13 9904 treats ACUTE UNCOMPLICATED GONORRHOEA,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12788,CEFTRIAXONE RO 13 9904 treats ACUTE UNCOMPLICATED GONORRHOEA,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12789,CEFTRIAXONE RO 13 9904 treats ACUTE UNCOMPLICATED GONORRHOEA,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12790,CEFTRIAXONE RO 13 9904 treats ACUTE UNCOMPLICATED GONORRHOEA,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12791,CEFTRIAXONE RO 13 9904 treats ACUTE UNCOMPLICATED GONORRHOEA,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12792,CEFTRIAXONE RO 13 9904 treats ACUTE UNCOMPLICATED GONORRHOEA,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12793,ACUTE UNCOMPLICATED GONORRHOEA treats CEFTRIAXONE RO 13 9904,treats,0.9578262852211508,"Eichmann A, Weidmann G, Havas L. One dose treatment of ACUTE UNCOMPLICATED GONORRHOEA of male patients with CEFTRIAXONE RO 13 9904 a new parenteral cephalosporin: a dose range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.",ACUTE UNCOMPLICATED GONORRHOEA,CEFTRIAXONE RO 13 9904
12794,CHOLESTYRAMINE treats BILE ACID MALABSORPTION,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12795,CHOLESTYRAMINE treats BILE ACID MALABSORPTION,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12796,CHOLESTYRAMINE treats BILE ACID MALABSORPTION,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12797,CHOLESTYRAMINE treats BILE ACID MALABSORPTION,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12798,CHOLESTYRAMINE treats BILE ACID MALABSORPTION,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12799,CHOLESTYRAMINE treats BILE ACID MALABSORPTION,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12800,no_relation,treats,0.9838699100999068,Use of [CHOLESTYRAMINE] to bind bile acid will help reducing diarrhoea in [BILE ACID MALABSORPTION].,BILE ACID MALABSORPTION,CHOLESTYRAMINE
12801,no_relation,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12802,no_relation,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12803,TUBERCULIN treats TUBERCULOSIS,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12804,TUBERCULIN treats TUBERCULOSIS,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12805,no_relation,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12806,no_relation,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12807,TUBERCULIN treats TUBERCULOSIS,treats,0.437594974493684,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
12808,ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12809,ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12810,ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12811,ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12812,BACTERIAL VAGINOSIS treats ORAL METRONIDAZOLE,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12813,BACTERIAL VAGINOSIS treats ORAL METRONIDAZOLE,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12814,ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,1.0,"Schmitt C, Sobel JD, Meriwether CBACTERIAL VAGINOSIS: treatment with clindamycin cream versus ORAL METRONIDAZOLE",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE
12815,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12816,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12817,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12818,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12819,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12820,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12821,CLONIDINE HYDROCHLORIDE treats HYPERTENSION,treats,0.985329278164293,Class:  Thiazide like Diuretics 40:28.24; CV701 (VA)  Synonyms:  Chlorthalidone and Atenolol; Chlorthalidone and CLONIDINE HYDROCHLORIDE  Uses  Hypertension  Used alone or in combination with other antihypertensive agents for all stages of HYPERTENSION,HYPERTENSION,CLONIDINE HYDROCHLORIDE
12822,VITAMIN B 3 treats HYPERLIPIDEMIA,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12823,VITAMIN B 3 treats HYPERLIPIDEMIA,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12824,VITAMIN B 3 treats HYPERLIPIDEMIA,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12825,VITAMIN B 3 treats HYPERLIPIDEMIA,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12826,VITAMIN B 3 treats HYPERLIPIDEMIA,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12827,VITAMIN B 3 treats HYPERLIPIDEMIA,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12828,no_relation,treats,0.993883734673619,INDICATIONS  Introduction  • There are consensus recommendations supporting the use of vitamin therapy for the following conditions: ◊ Hyperlipidemia and VITAMIN B 3  (niacin): Niacin treatment of hyperlipidemia has been studied over the past 2 decades and continues to show broad positive effects on HYPERLIPIDEMIA management.,HYPERLIPIDEMIA,VITAMIN B 3
12829,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12830,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12831,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12832,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12833,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12834,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12835,LACTULOSE treats ACUTE HEPATIC ENCEPHALOPATHY,treats,1.0,"Morgan MY, Hawley KE : Lactitol vsLACTULOSE in the treatment of ACUTE HEPATIC ENCEPHALOPATHY in cirrhotic patients: a double blind, randomized trial.",ACUTE HEPATIC ENCEPHALOPATHY,LACTULOSE
12836,no_relation,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12837,TEGASEROD treats OBJECTIVELY DOCUMENTED IBS,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12838,TEGASEROD treats OBJECTIVELY DOCUMENTED IBS,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12839,TEGASEROD treats OBJECTIVELY DOCUMENTED IBS,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12840,TEGASEROD treats OBJECTIVELY DOCUMENTED IBS,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12841,TEGASEROD treats OBJECTIVELY DOCUMENTED IBS,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12842,no_relation,treats,0.9491579957524988,"Study selection and assessment:  Randomized controlled trials (RCTs) or quasirandomized controlled trials published in any language that compared TEGASEROD with placebo, no treatment, or any other intervention, and reported relevant outcomes in patients (≥ 12 y) with OBJECTIVELY DOCUMENTED IBS",OBJECTIVELY DOCUMENTED IBS,TEGASEROD
12843,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12844,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12845,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12846,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12847,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12848,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12849,FLUCONAZOLE treats BLASTOMYCOSIS OF THE BRAIN,treats,0.995893206467704,"Taillan B, Ferrari E, Cosnefroy JY et al. Favourable outcome of BLASTOMYCOSIS OF THE BRAIN stem with FLUCONAZOLE and flucytosine treatment.",BLASTOMYCOSIS OF THE BRAIN,FLUCONAZOLE
12850,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12851,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12852,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12853,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12854,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12855,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12856,CONVENTIONAL AMPHOTERICIN B treats MENINGEAL SPOROTRICHOSIS,treats,0.942809041582063,"429  CONVENTIONAL AMPHOTERICIN B in patients with MENINGEAL SPOROTRICHOSIS: 0.7 1 mg/kg daily can be used for initial therapy, but a lipid formulation is preferred.",MENINGEAL SPOROTRICHOSIS,CONVENTIONAL AMPHOTERICIN B
12857,no_relation,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12858,AMPHOTERICIN B treats FUNGAL INFECTIONS,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12859,AMPHOTERICIN B treats FUNGAL INFECTIONS,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12860,AMPHOTERICIN B treats FUNGAL INFECTIONS,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12861,AMPHOTERICIN B treats FUNGAL INFECTIONS,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12862,AMPHOTERICIN B treats FUNGAL INFECTIONS,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12863,AMPHOTERICIN B treats FUNGAL INFECTIONS,treats,0.979957887012223,Caspofungin was noninferior to amphotericin B for invasive FUNGAL INFECTIONS in persistent fever and neutropenia and was better tolerated  Hospitalists Hematology/Thrombosis Infectious Disease Critical Care Oncology  About Star Ratings  Keywords: AMPHOTERICIN B Antifungal agents Mycoses Peptides  ACP Journal Club.,FUNGAL INFECTIONS,AMPHOTERICIN B
12864,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12865,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12866,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12867,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12868,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12869,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12870,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.99654575824488,"1]  Manns MP, McHutchison JG, Gordon S, et al. Peginterferon α 2b plus ribavirin compared to interferon α 2b plus RIBAVIRIN for the treatment of CHRONIC HEPATITIS C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [Abstract.",CHRONIC HEPATITIS C,RIBAVIRIN
12871,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12872,HEPATITIS A VIRUS treats HEPATITIS A,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12873,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12874,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12875,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12876,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12877,no_relation,treats,0.3,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
12878,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12879,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12880,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12881,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12882,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12883,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12884,NITAZOXANIDE treats SYMPTOMATIC GIARDIASIS,treats,0.99654575824488,"Ortiz JJ, Ayoub A, Gargala G, et al: Randomized clinical study of NITAZOXANIDE compared to metronidazole in the treatment of SYMPTOMATIC GIARDIASIS in children from northern Peru.",SYMPTOMATIC GIARDIASIS,NITAZOXANIDE
12885,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12886,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12887,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12888,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12889,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12890,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12891,TRAZODONE treats SLEEP PROBLEM,treats,0.99654575824488,[TRAZODONE] can be useful against irritability and [SLEEP PROBLEM]s.,SLEEP PROBLEM,TRAZODONE
12892,TERAZOSIN treats BENIGN PROSTATIC HYPERPLASIA,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12893,TERAZOSIN treats BENIGN PROSTATIC HYPERPLASIA,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12894,TERAZOSIN treats BENIGN PROSTATIC HYPERPLASIA,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12895,TERAZOSIN treats BENIGN PROSTATIC HYPERPLASIA,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12896,TERAZOSIN treats BENIGN PROSTATIC HYPERPLASIA,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12897,no_relation,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12898,TERAZOSIN treats BENIGN PROSTATIC HYPERPLASIA,treats,0.98058067569092,"Lepor H, Williford WO, Barry MJ, et al: The efficacy of TERAZOSIN finasteride, or both in BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,TERAZOSIN
12899,no_relation,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12900,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12901,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12902,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12903,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12904,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12905,MONTELUKAST treats ASTHMA,treats,0.9970544855015808,MONTELUKAST moderately decreased asthma symptoms in children with persistent asthma  Keywords: Acetates Anti ASTHMAtic agents Asthma Leukotriene antagonists  ACP Journal Club.,ASTHMA,MONTELUKAST
12906,METHOTREXATE treats RECALCITRANT PLAQUE PSORIASIS,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12907,no_relation,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12908,RECALCITRANT PLAQUE PSORIASIS treats METHOTREXATE,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12909,no_relation,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12910,METHOTREXATE treats RECALCITRANT PLAQUE PSORIASIS,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12911,METHOTREXATE treats RECALCITRANT PLAQUE PSORIASIS,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12912,METHOTREXATE treats RECALCITRANT PLAQUE PSORIASIS,treats,0.878114079917523,"367 ,   369 ,   373 ,   374 ,   375 ,   376  Psoriasis  Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), RECALCITRANT PLAQUE PSORIASIS that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, METHOTREXATE PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.",RECALCITRANT PLAQUE PSORIASIS,METHOTREXATE
12913,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12914,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12915,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12916,no_relation,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12917,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12918,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12919,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
12920,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12921,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12922,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12923,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12924,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12925,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12926,INH treats TB,treats,0.9970544855015808,"INH currently the first line prevention agent for reactivation TB in persons with HIV infection is problematic because of poor adherence to 12 month therapy, hepatotoxity, and increasing resistance to INH therapy.",TB,INH
12927,no_relation,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12928,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12929,no_relation,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12930,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12931,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12932,no_relation,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12933,no_relation,treats,0.6324555320336761,TRIGEMINAL NEURALGIA involving the first ophthalmic division can be a consideration where trigger zones and a response to CARBAMAZEPINE may be present.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
12934,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12935,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12936,no_relation,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12937,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12938,no_relation,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12939,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12940,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
12941,no_relation,treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12942,no_relation,treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12943,no_relation,treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12944,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [NAUSEA AND VOMITING],treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12945,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [NAUSEA AND VOMITING],treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12946,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [NAUSEA AND VOMITING],treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12947,[EFFECTIVE 5 HT3 ANTAGONISTS] treats [NAUSEA AND VOMITING],treats,0.762000762001143,"In [NAUSEA AND VOMITING] associated with cancer chemotherapy, it has been superseded by the more [EFFECTIVE 5 HT3 ANTAGONISTS].",[NAUSEA AND VOMITING],[EFFECTIVE 5 HT3 ANTAGONISTS]
12948,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12949,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12950,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12951,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12952,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12953,HEPATOCELLULAR CARCINOMA treats HYPERTHERMIA,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12954,no_relation,treats,0.787838597158335,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
12955,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12956,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12957,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12958,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12959,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12960,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12961,no_relation,treats,0.320256307610174,"Unless the cause is obvious, patients with pronounced PHOTOSENSITIVITY should be evaluated for systemic or cutaneous lupus erythematosus (see  SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  and  Variant Forms of Lupus ) and perhaps porphyria (see  Porphyrias.",PHOTOSENSITIVITY,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
12962,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12963,BACTERIAL VAGINOSIS treats CREAM VERSUS ORAL METRONIDAZOLE,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12964,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12965,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12966,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12967,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12968,CREAM VERSUS ORAL METRONIDAZOLE treats BACTERIAL VAGINOSIS,treats,0.988371697650617,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
12969,DEXTROMETHORPHAN HYDROCHLORIDE treats COUGH,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12970,DEXTROMETHORPHAN HYDROCHLORIDE treats COUGH,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12971,DEXTROMETHORPHAN HYDROCHLORIDE treats COUGH,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12972,no_relation,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12973,DEXTROMETHORPHAN HYDROCHLORIDE treats COUGH,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12974,no_relation,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12975,DEXTROMETHORPHAN HYDROCHLORIDE treats COUGH,treats,0.774596669241483,"Alka Seltzer Plus ®  COUGH and Cold (acetaminophen, chlorpheniramine maleate, DEXTROMETHORPHAN HYDROCHLORIDE and phenylephrine hydrochloride) capsules patient information.",COUGH,DEXTROMETHORPHAN HYDROCHLORIDE
12976,[HIGH FOLATE DIETS] treats [LOW DOSE METHOTREXATE],treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12977,no_relation,treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12978,no_relation,treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12979,[HIGH FOLATE DIETS] treats [LOW DOSE METHOTREXATE],treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12980,[HIGH FOLATE DIETS] treats [LOW DOSE METHOTREXATE],treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12981,no_relation,treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12982,[HIGH FOLATE DIETS] treats [LOW DOSE METHOTREXATE],treats,0.966736489045664,Both [HIGH FOLATE DIETS] and supplemental folic acid may help reduce the toxic side effects of [LOW DOSE METHOTREXATE] without decreasing its effectiveness.,[HIGH FOLATE DIETS],[LOW DOSE METHOTREXATE]
12983,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA treats RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12984,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12985,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12986,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12987,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12988,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12989,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,treats,0.927172649945531,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
12990,no_relation,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12991,no_relation,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12992,no_relation,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12993,no_relation,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12994,no_relation,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12995,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12996,DEDIFFERENTIATION treats GLIOBLASTOMA,treats,0.31622776601683805,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
12997,no_relation,treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
12998,no_relation,treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
12999,[ARTEMISININ BASED] treats [P FALCIPARUM],treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
13000,no_relation,treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
13001,no_relation,treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
13002,[ARTEMISININ BASED] treats [P FALCIPARUM],treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
13003,no_relation,treats,0.7120689949163119,Usage declined in the 1980s as piperaquine resistant strains of [P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[P FALCIPARUM],[ARTEMISININ BASED]
13004,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13005,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13006,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13007,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13008,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13009,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13010,KETOCONAZOLE 2% SHAMPOO treats TINEA VERSICOLOR,treats,1.0,"Lange DS, Richards HM, Guarnieri J et al. KETOCONAZOLE 2% SHAMPOO in the treatment of TINEA VERSICOLOR: a multicenter, randomized, double blind, placebo controlled trial.",TINEA VERSICOLOR,KETOCONAZOLE 2% SHAMPOO
13011,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13012,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13013,no_relation,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13014,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13015,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13016,SUBCUTANEOUS ENOXAPARIN treats VENOUS THROMBOEMBOLISM,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13017,VENOUS THROMBOEMBOLISM treats SUBCUTANEOUS ENOXAPARIN,treats,1.0,Oral dabigatran etexilate vs. SUBCUTANEOUS ENOXAPARIN for the prevention of VENOUS THROMBOEMBOLISM after total knee replacement: the RE MODEL randomized trial.,VENOUS THROMBOEMBOLISM,SUBCUTANEOUS ENOXAPARIN
13018,[LUNG DISEASE] treats [POSTNATAL DEXAMETHASONE THERAPY],treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13019,[POSTNATAL DEXAMETHASONE THERAPY] treats [LUNG DISEASE],treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13020,[POSTNATAL DEXAMETHASONE THERAPY] treats [LUNG DISEASE],treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13021,[POSTNATAL DEXAMETHASONE THERAPY] treats [LUNG DISEASE],treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13022,[POSTNATAL DEXAMETHASONE THERAPY] treats [LUNG DISEASE],treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13023,[POSTNATAL DEXAMETHASONE THERAPY] treats [LUNG DISEASE],treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13024,no_relation,treats,0.994134846772434,title= Outcomes at school age after [POSTNATAL DEXAMETHASONE THERAPY] for [LUNG DISEASE] of prematurity.,[LUNG DISEASE],[POSTNATAL DEXAMETHASONE THERAPY]
13025,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13026,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13027,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13028,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13029,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13030,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13031,RALOXIFENE treats POSTMENOPAUSAL OSTEOPOROSIS,treats,1.0,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
13032,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13033,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13034,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13035,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13036,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13037,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13038,CLONAZEPAM treats PANIC DISORDER,treats,0.9970544855015808,The alprazolam to CLONAZEPAM switch for the treatment of PANIC DISORDER,PANIC DISORDER,CLONAZEPAM
13039,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13040,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13041,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13042,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13043,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13044,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13045,CHONDROITIN SULFATE treats OSTEOARTHRITIS,treats,0.8137334712067349,"1]  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, CHONDROITIN SULFATE and the two in combination for painful knee OSTEOARTHRITIS",OSTEOARTHRITIS,CHONDROITIN SULFATE
13046,HYPERTENSION treats ATENOLOL,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13047,ATENOLOL treats HYPERTENSION,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13048,ATENOLOL treats HYPERTENSION,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13049,ATENOLOL treats HYPERTENSION,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13050,ATENOLOL treats HYPERTENSION,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13051,ATENOLOL treats HYPERTENSION,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13052,ATENOLOL treats HYPERTENSION,treats,0.977139836403678,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
13053,CISAPRIDE treats FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13054,CISAPRIDE treats FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13055,CISAPRIDE treats FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13056,no_relation,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13057,CISAPRIDE treats FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13058,CISAPRIDE treats FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13059,CISAPRIDE treats FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,treats,0.4008918629,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
13060,no_relation,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13061,no_relation,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13062,no_relation,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13063,no_relation,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13064,no_relation,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13065,HYPOGLYCEMIA treats BLOOD GLUCOSE CONCENTRATIONS,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13066,no_relation,treats,0.474341649,"prolonged QT interval, torsades de pointes)  1  Concomitant use contraindicated  1    Digoxin Increased digoxin plasma concentrations  1  If used concomitantly, monitor digoxin plasma concentrations  1    Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism)  1  Concomitant use contraindicated  1    Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported  1  Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes  1    Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
13067,no_relation,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13068,no_relation,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13069,PRINDOLOL treats HYPERTENSION,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13070,PRINDOLOL treats HYPERTENSION,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13071,PRINDOLOL treats HYPERTENSION,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13072,PRINDOLOL treats HYPERTENSION,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13073,PRINDOLOL treats HYPERTENSION,treats,0.5570860145000001,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
13074,GLUCOSE treats HYPOGLYCEMIA,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13075,no_relation,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13076,no_relation,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13077,no_relation,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13078,no_relation,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13079,no_relation,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13080,GLUCOSE treats HYPOGLYCEMIA,treats,0.7330166661,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
13081,CLOMIPRAMINE treats OCD WITHOUT CONCOMITANT DEPRESSION,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13082,no_relation,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13083,CLOMIPRAMINE treats OCD WITHOUT CONCOMITANT DEPRESSION,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13084,CLOMIPRAMINE treats OCD WITHOUT CONCOMITANT DEPRESSION,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13085,CLOMIPRAMINE treats OCD WITHOUT CONCOMITANT DEPRESSION,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13086,CLOMIPRAMINE treats OCD WITHOUT CONCOMITANT DEPRESSION,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13087,CLOMIPRAMINE treats OCD WITHOUT CONCOMITANT DEPRESSION,treats,0.9058216273,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
13088,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13089,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13090,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13091,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13092,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13093,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13094,CLIDINIUM treats PEPTIC ULCER DISEASE,treats,0.990147543,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
13095,ISOTRETINOIN treats SEVERE NODULAR ACNE,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13096,no_relation,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13097,ISOTRETINOIN treats SEVERE NODULAR ACNE,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13098,ISOTRETINOIN treats SEVERE NODULAR ACNE,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13099,no_relation,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13100,ISOTRETINOIN treats SEVERE NODULAR ACNE,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13101,SEVERE NODULAR ACNE treats ISOTRETINOIN,treats,0.7559289459999999,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
13102,no_relation,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13103,INSULIN SECRETION treats TYPE 2 DIABETES,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13104,no_relation,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13105,no_relation,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13106,INSULIN SECRETION treats TYPE 2 DIABETES,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13107,no_relation,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13108,INSULIN SECRETION treats TYPE 2 DIABETES,treats,0.4472135955,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
13109,ACETAMINOPHEN treats OSTEOARTHRITIS PAIN,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13110,ACETAMINOPHEN treats OSTEOARTHRITIS PAIN,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13111,ACETAMINOPHEN treats OSTEOARTHRITIS PAIN,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13112,ACETAMINOPHEN treats OSTEOARTHRITIS PAIN,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13113,ACETAMINOPHEN treats OSTEOARTHRITIS PAIN,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13114,no_relation,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13115,ACETAMINOPHEN treats OSTEOARTHRITIS PAIN,treats,0.9853292782,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
13116,ESTROGEN treats HOT FLASHES,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13117,ESTROGEN treats HOT FLASHES,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13118,ESTROGEN treats HOT FLASHES,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13119,no_relation,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13120,ESTROGEN treats HOT FLASHES,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13121,ESTROGEN treats HOT FLASHES,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13122,ESTROGEN treats HOT FLASHES,treats,0.7302967432999999,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
13123,no_relation,treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13124,INSULIN treats LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13125,INSULIN treats LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13126,INSULIN treats LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13127,INSULIN treats LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13128,INSULIN treats LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13129,INSULIN treats LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),treats,0.8682431421,"plasma glucose levels (hypoglycemia or hyperglycemia)  1 , 26  Possible dosage adjustment  1 , 26    Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA)  1 , 26  Possible dosage adjustment  1 , 26    Quinidine Possible decreased quinidine clearance  1 , 26  Use concomitantly with caution  1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
13130,TIROFIBAN treats UNSTABLE ANGINA,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13131,TIROFIBAN treats UNSTABLE ANGINA,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13132,TIROFIBAN treats UNSTABLE ANGINA,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13133,no_relation,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13134,TIROFIBAN treats UNSTABLE ANGINA,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13135,TIROFIBAN treats UNSTABLE ANGINA,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13136,TIROFIBAN treats UNSTABLE ANGINA,treats,0.8616404369,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
13137,THEOPHYLLINE treats ASTHMA,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13138,THEOPHYLLINE treats ASTHMA,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13139,no_relation,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13140,THEOPHYLLINE treats ASTHMA,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13141,ASTHMA treats THEOPHYLLINE,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13142,THEOPHYLLINE treats ASTHMA,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13143,THEOPHYLLINE treats ASTHMA,treats,0.4264014327,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
13144,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13145,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13146,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13147,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13148,TYPE 2 DIABETES MELLITUS treats INSULIN,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13149,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13150,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.9647638212,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
13151,INSULIN STIMULATED GLUCOSE TRANSPORT treats HYPERGLYCEMIA,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13152,no_relation,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13153,INSULIN STIMULATED GLUCOSE TRANSPORT treats HYPERGLYCEMIA,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13154,no_relation,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13155,INSULIN STIMULATED GLUCOSE TRANSPORT treats HYPERGLYCEMIA,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13156,no_relation,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13157,no_relation,treats,0.3611575593,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
13158,ENDOCRINE HYPOGONADISM treats TESTOSTERONE,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13159,TESTOSTERONE treats ENDOCRINE HYPOGONADISM,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13160,no_relation,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13161,no_relation,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13162,no_relation,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13163,no_relation,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13164,TESTOSTERONE treats ENDOCRINE HYPOGONADISM,treats,0.3849001795000001,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
13165,no_relation,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13166,RILUZOLE treats ALS,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13167,RILUZOLE treats ALS,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13168,RILUZOLE treats ALS,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13169,RILUZOLE treats ALS,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13170,RILUZOLE treats ALS,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13171,RILUZOLE treats ALS,treats,0.9863939238,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
13172,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13173,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13174,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13175,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13176,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13177,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13178,ACETAMINOPHEN treats PAIN,treats,0.9950371902,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
13179,LORATADINE treats IDIOPATHIC URTICARIA (EG HIVES,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13180,no_relation,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13181,LORATADINE treats IDIOPATHIC URTICARIA (EG HIVES,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13182,LORATADINE treats IDIOPATHIC URTICARIA (EG HIVES,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13183,LORATADINE treats IDIOPATHIC URTICARIA (EG HIVES,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13184,LORATADINE treats IDIOPATHIC URTICARIA (EG HIVES,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13185,LORATADINE treats IDIOPATHIC URTICARIA (EG HIVES,treats,0.7811334659,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
13186,CORTISOL treats ADRENAL INSUFFICIENCY,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13187,CORTISOL treats ADRENAL INSUFFICIENCY,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13188,CORTISOL treats ADRENAL INSUFFICIENCY,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13189,CORTISOL treats ADRENAL INSUFFICIENCY,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13190,no_relation,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13191,no_relation,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13192,CORTISOL treats ADRENAL INSUFFICIENCY,treats,0.5222329679,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
13193,no_relation,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13194,SPIRONOLACTONE treats HYPERALDOSTERONISM,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13195,no_relation,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13196,SPIRONOLACTONE treats HYPERALDOSTERONISM,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13197,no_relation,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13198,no_relation,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13199,no_relation,treats,0.4264014327,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
13200,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13201,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13202,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13203,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13204,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13205,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13206,THAM treats ACIDOSIS,treats,0.9205746179,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
13207,no_relation,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13208,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13209,no_relation,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13210,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13211,HEPARIN treats MYOCARDIAL INFARCTION,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13212,no_relation,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13213,MYOCARDIAL INFARCTION treats HEPARIN,treats,0.4815434123,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
13214,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13215,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13216,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13217,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13218,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13219,no_relation,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13220,INSULIN treats TYPE 2 DIABETES MELLITUS,treats,0.7730206825,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
13221,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE treats LUPUS NEPHRITIS LXV,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13222,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE treats LUPUS NEPHRITIS LXV,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13223,no_relation,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13224,no_relation,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13225,no_relation,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13226,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE treats LUPUS NEPHRITIS LXV,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13227,LUPUS NEPHRITIS LXV treats PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE,treats,0.9176629355,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
13228,no_relation,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13229,HYDROCORTISONE treats ADRENAL FAILURE,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13230,no_relation,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13231,no_relation,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13232,HYDROCORTISONE treats ADRENAL FAILURE,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13233,HYDROCORTISONE treats ADRENAL FAILURE,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13234,HYDROCORTISONE treats ADRENAL FAILURE,treats,0.9000703206999999,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
13235,TRIAMCINOLONE ACETONIDE treats INFLAMMATION,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13236,TRIAMCINOLONE ACETONIDE treats INFLAMMATION,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13237,TRIAMCINOLONE ACETONIDE treats INFLAMMATION,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13238,TRIAMCINOLONE ACETONIDE treats INFLAMMATION,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13239,TRIAMCINOLONE ACETONIDE treats INFLAMMATION,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13240,no_relation,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13241,no_relation,treats,0.9058216273,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
13242,TISSUE PLASMINOGEN ACTIVATOR treats MYOCARDIAL INFARCTION,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13243,MYOCARDIAL INFARCTION treats TISSUE PLASMINOGEN ACTIVATOR,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13244,no_relation,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13245,no_relation,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13246,no_relation,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13247,TISSUE PLASMINOGEN ACTIVATOR treats MYOCARDIAL INFARCTION,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13248,no_relation,treats,0.4375949745,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
13249,SC INSULIN treats TYPE 2 DIABETES,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13250,SC INSULIN treats TYPE 2 DIABETES,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13251,no_relation,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13252,SC INSULIN treats TYPE 2 DIABETES,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13253,SC INSULIN treats TYPE 2 DIABETES,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13254,SC INSULIN treats TYPE 2 DIABETES,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13255,SC INSULIN treats TYPE 2 DIABETES,treats,1.0,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
13256,no_relation,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13257,ASPIRIN treats FEVER,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13258,ASPIRIN treats FEVER,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13259,ASPIRIN treats FEVER,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13260,ASPIRIN treats FEVER,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13261,no_relation,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13262,no_relation,treats,0.9428090416,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
13263,ROSIGLITAZONE treats TYPE 2 DIABETES,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13264,no_relation,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13265,ROSIGLITAZONE treats TYPE 2 DIABETES,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13266,ROSIGLITAZONE treats TYPE 2 DIABETES,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13267,ROSIGLITAZONE treats TYPE 2 DIABETES,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13268,ROSIGLITAZONE treats TYPE 2 DIABETES,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13269,no_relation,treats,0.762000762,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
13270,MAGNESIUM SULFATE treats PREECLAMPSIA,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13271,MAGNESIUM SULFATE treats PREECLAMPSIA,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13272,no_relation,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13273,MAGNESIUM SULFATE treats PREECLAMPSIA,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13274,MAGNESIUM SULFATE treats PREECLAMPSIA,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13275,MAGNESIUM SULFATE treats PREECLAMPSIA,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13276,MAGNESIUM SULFATE treats PREECLAMPSIA,treats,0.7624928517,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
13277,CHONDROITIN SULFATES OSTEOARTHRITIS treats HIP OSTEOARTHRITIS,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13278,no_relation,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13279,no_relation,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13280,no_relation,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13281,no_relation,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13282,no_relation,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13283,no_relation,treats,0.6488856845000001,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
13284,no_relation,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13285,INSULIN treats HYPERGLYCEMIA,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13286,INSULIN treats HYPERGLYCEMIA,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13287,INSULIN treats HYPERGLYCEMIA,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13288,INSULIN treats HYPERGLYCEMIA,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13289,no_relation,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13290,INSULIN treats HYPERGLYCEMIA,treats,0.314485451,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
13291,FUROSEMIDE treats EDEMA,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13292,FUROSEMIDE treats EDEMA,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13293,no_relation,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13294,FUROSEMIDE treats EDEMA,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13295,FUROSEMIDE treats EDEMA,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13296,no_relation,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13297,no_relation,treats,0.7811334659,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
13298,OLANZAPINE treats DEMENTIA RELATED PSYCHOSIS,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13299,OLANZAPINE treats DEMENTIA RELATED PSYCHOSIS,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13300,no_relation,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13301,OLANZAPINE treats DEMENTIA RELATED PSYCHOSIS,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13302,OLANZAPINE treats DEMENTIA RELATED PSYCHOSIS,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13303,OLANZAPINE treats DEMENTIA RELATED PSYCHOSIS,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13304,DEMENTIA RELATED PSYCHOSIS treats OLANZAPINE,treats,0.9332565253,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
13305,BIPOLAR DISORDER treats DIVALPROEX SODIUM,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13306,DIVALPROEX SODIUM treats BIPOLAR DISORDER,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13307,DIVALPROEX SODIUM treats BIPOLAR DISORDER,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13308,DIVALPROEX SODIUM treats BIPOLAR DISORDER,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13309,DIVALPROEX SODIUM treats BIPOLAR DISORDER,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13310,DIVALPROEX SODIUM treats BIPOLAR DISORDER,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13311,DIVALPROEX SODIUM treats BIPOLAR DISORDER,treats,0.8741572761,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
13312,OFLOXACIN treats CHLAMYDIAL INFECTION,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13313,OFLOXACIN treats CHLAMYDIAL INFECTION,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13314,no_relation,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13315,no_relation,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13316,OFLOXACIN treats CHLAMYDIAL INFECTION,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13317,OFLOXACIN treats CHLAMYDIAL INFECTION,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13318,OFLOXACIN treats CHLAMYDIAL INFECTION,treats,0.966736489,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
13319,PREDNISONE treats AIRWAY INFLAMMATION,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13320,PREDNISONE treats AIRWAY INFLAMMATION,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13321,PREDNISONE treats AIRWAY INFLAMMATION,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13322,no_relation,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13323,no_relation,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13324,PREDNISONE treats AIRWAY INFLAMMATION,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13325,no_relation,treats,0.5207556439,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
13326,ZEBRA ANTIBODY LEVELS treats IMMUNODEFICIENCY,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13327,no_relation,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13328,ZEBRA ANTIBODY LEVELS treats IMMUNODEFICIENCY,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13329,no_relation,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13330,no_relation,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13331,no_relation,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13332,no_relation,treats,0.3922322703,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
13333,LEVODOPA treats PARKINSON'S DISEASE,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
13334,no_relation,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
13335,no_relation,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
13336,no_relation,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
13337,LEVODOPA treats PARKINSON'S DISEASE,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
13338,no_relation,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
13339,LEVODOPA treats PARKINSON'S DISEASE,treats,0.8728715609000001,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
